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Abstract 
 
Here, we present a concise overview of selective chemical reactions that are suitable for 
application in biological systems. These bioorthogonal reactions are frequently employed for the 
modification of biomolecules in vitro and in vivo, to study e.g. their role in their native cellular 
environment or preparing diagnostic applications. We focus on the popular tetrazine ligation, 
which is the inverse electron-demand Diels-Alder reaction between tetrazines and alkenes or 
alkynes. The reactivity of the reported bioorthogonal tetrazines and dienophiles is discussed, 
whereof especially electron-poor tetrazines with strained dienophiles give incredibly high rate 
constants. In addition, we highlight the applications of tetrazine ligations in orthogonal 
bioorthogonal reactions for labeling of multiple biomolecules in a single system and in click-to-
release reactions for activation of protected biologically relevant molecules. Finally, we describe 
the outline of this thesis on a new bioorthogonal tetrazine ligation with vinylboronic acids. 
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Here, we present a concise overview of selective chemical reactions that are suitable for 
application in biological systems. These bioorthogonal reactions are frequently employed for the 
modification of biomolecules in vitro and in vivo, to study e.g. their role in their native cellular 
environment or preparing diagnostic applications. We focus on the popular tetrazine ligation, 
which is the inverse electron-demand Diels-Alder reaction between tetrazines and alkenes or 
alkynes. The reactivity of the reported bioorthogonal tetrazines and dienophiles is discussed, 
whereof especially electron-poor tetrazines with strained dienophiles give incredibly high rate 
constants. In addition, we highlight the applications of tetrazine ligations in orthogonal 
bioorthogonal reactions for labeling of multiple biomolecules in a single system and in click-to-
release reactions for activation of protected biologically relevant molecules. Finally, we describe 
the outline of this thesis on a new bioorthogonal tetrazine ligation with vinylboronic acids. 
 
1.1 Bioorthogonal Chemistry 
 
Chemical biology is a relatively new field that applies chemistry to study and manipulate 
biological systems. A large part of the field focusses on the modification of biomolecules to study 
their role in their native cellular environment. A frequently used method for tracking proteins in 
living systems is genetically encoding a fluorescent protein reporter (e.g. green fluorescent protein 
(GFP)) with the protein of interest (POI). As this method is not applicable to non-proteinaceous 
biomolecules like lipids, nucleic acids and glycans, an alternative strategy is developed that utilizes 
selective chemical labeling of the biomolecules.1–6 This strategy relies on the installation of a 
unique functional group into the biomolecule of interest, which is in a second step ligated with a 
detection or affinity handle (Figure 1.1). This so-called bioorthogonal reaction should be highly 
specific, fast and non-perturbing to the biological system. The small size of one of the reactants 
allows incorporation by the endogenous cellular machinery and minimizes steric interactions with 
the biomolecule.  
 
 
Figure 1.1 – Schematic overview of a bioorthogonal reaction.3 
 
The first reaction that was named bioorthogonal, was the aldehyde/ketone condensation 
with hydrazines/alkoxyamines (Figure 1.2).7–10 The carbonyl group forms relatively stable 
products with both hydrazines and alkoxyamines, pushing the reaction towards the 
bioconjugation product. Although the carbonyl group can also react with naturally occurring 
amines, this equilibrium is at physiological pH towards the carbonyl group. Additionally, both 
aldehyde and ketone functionalities are present in several small molecules in vivo, making the 
condensation reaction strictly not ‘bioorthogonal’, but only biocompatible with certain 
biomolecules.  
In 2000, the group of Bertozzi reported the bioorthogonal Staudinger ligation, which is a 
modification of the standard Staudinger reduction of an azide by a phosphine, yielding a stable 
amide-linked bioconjugation product.11 Although the Staudinger ligation is popular for biological 
applications, the low rate constants of this reaction limit their utilization in vivo. Soon after, the 
copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) was reported independently by the 
groups of Meldal and Sharpless, showing high rate constants and excellent functional group 
tolerance.12,13 In the last fifteen years, the field has expanded tremendously with many new 
bioorthogonal reactions and even more biological applications in vitro and in vivo. The most 
popular bioorthogonal reactions include the strain-promoted alkyne-azide cycloaddition 
(SPAAC)14 and the tetrazine ligation.15–17  
In fact, many of the developed reactions are not completely bioorthogonal, as some 
reagents appear unstable (e.g. phosphines are oxidation sensitive), toxic (e.g. copper(I) catalyst in 
the CuAAC reaction) or reactive towards biological functional groups (e.g. condensation of 
endogenous keto-metabolites with hydrazides or alkoxyamines, and thiol-ene or thiol-yne  
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Figure 1.2 – Overview of the bioorthogonal aldehyde/ketone condensation, Staudinger ligation, CuAAC, 
SPAAC and tetrazine ligation. Ranges of second-order rate constants (in M-1 s-1) are reported.17 
 
reactions of free intracellular cysteines with strained alkenes or alkynes). Therefore, the choice for 
a particular bioorthogonal reaction is dependent on the type of application and biological system 
of interest. Furthermore, even though many bioorthogonal reactions have been developed, the 
quest for a fast and selective reaction that is completely orthogonal to all biological functional 
groups continues. As the development and applications of bioorthogonal reactions have been 
extensively reviewed,1–6 we will in this chapter highlight recent developments concerning the 
tetrazine ligation that is used throughout this thesis. 
 
1.2 Reactants for Bioorthogonal Tetrazine Ligations 
 
The tetrazine ligation, also known as the Carboni-Lindsey reaction, refers to the inverse 
electron-demand Diels-Alder (iEDDA) reaction between a tetrazine and an alkene or alkyne.15–17 
In the iEDDA, the tetrazine reacts as electron-poor diene with an electron-rich or strained 
dienophile, in contrast to the normal-demand Diels-Alder reaction where an electron-rich diene 
reacts with an electron-poor dienophile (Figure 1.3A). The [4+2]-cycloaddition of the tetrazine 
with an alkyne yields an aromatic pyridazine product, whereas the reaction with an alkene yields a 
dihydropyridazine (Figures 1.3B, C). In Figure 1.3D the mechanism of the tetrazine ligation with 
an alkene is shown. The iEDDA cycloaddition of the electron-poor tetrazine and the alkene 
dienophile yields a bridged ring structure. Immediately, a retro-Diels-Alder reaction affords N2 
release and the 4,5-dihydropyridazine product, which usually tautomerizes to the corresponding 
1,4-dihydropyridazine derivative. The reaction rates of the reported bioorthogonal tetrazine 
ligation are rather diverse, with second-order rate constants (k2) between 10-2 and 106. The 
solvent has a large influence on the reaction rates of Diels-Alder reactions, which proceed notably 
faster in aqueous media, an effect that is beneficial for the intended biological applications.  
Both the structures of dienophile and tetrazine influence the rate of the bioorthogonal 
reaction significantly.18 The reactivity of the tetrazine is generally tuned using substituents on the  
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Figure 1.2 – Overview of the bioorthogonal aldehyde/ketone condensation, Staudinger ligation, CuAAC, 
SPAAC and tetrazine ligation. Ranges of second-order rate constants (in M-1 s-1) are reported.17 
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Figure 1.3 – A) Frontier molecular orbital diagram of normal-demand and inverse electron-demand 
Diels-Alder reaction. EDG = electron-donating group, EWG = electron-withdrawing group. B) The 
tetrazine ligation with an alkyne, yielding a pyridazine. C) The tetrazine ligation with an alkene, yielding a 
dihydropyridazine. D) Mechanism of the iEDDA of unsubstituted tetrazine with an alkene.  
 
3- and 6-positions. Although many different tetrazines have been developed and their kinetics 
have been studied, only a handful of tetrazines are frequently used for biological applications. In 
Figure 1.4A, these tetrazines (I – VII) are arranged in the order of relative reactivity towards 
common bioorthogonal dienophiles.19–23 In general, electron-donating and sterically demanding 
substituents, like phenyl and methyl, give a slower iEDDA reaction. Furthermore, electron-
withdrawing substituents, such as pyridyl and pyrimidyl, increase the reactivity of tetrazines 
towards alkenes and alkynes. Unfortunately, the fast electron-poor tetrazines are in general less 
stable in aqueous media compared to their slower reacting, more-electron-rich analogues.19,23 
The reactivity of the dienophile is significantly enhanced when embedded in a strained 
cyclic system, although electron-donating substituents on the alkene can also influence its 
reactivity positively. In Figure 1.4B we highlight the reported rate constants of the dienophiles A 
– L in the bioorthogonal tetrazine ligation as they give a good indication of their reactivity in 
biological systems. However, it should be noted that the k2 values of the dienophiles are measured 
with several tetrazines derivatives and in different solvents and temperatures, and therefore their 
comparison is not fully accurate.  
In 2008, norbornene A24 and trans-cyclooctene B (TCO)33 were reported as the first 
bioorthogonal reactants in the tetrazine ligation. Norbornene gave in an aqueous solution with 
phenyl-s-tetrazine IV a good rate constant (k2 = 1.9 M-1 s-1) for bioorthogonal application.24 
However, the reported k2 value of the tetrazine ligation with TCO was more impressive with 
2000 M-1 s-1 in 9:1 MeOH/PBS.33 Recently, it was shown that in pure water the rate constant of 
TCO was more than an order of magnitude higher, with the axial diastereomer B being ca. 3.5-
fold more reactive than the equatorial diastereomer.25 Unfortunately, transition metals can 
catalyze in vivo the isomerization of TCO towards cis-cyclooctene (CCO),34 which is 7 orders of 
magnitude less reactive towards tetrazines.33 The axial TCO B has, depending on its substituents, 
a stability half-live of up to 3 days in non-tumor bearing mice. As expected, the less reactive 
equatorial isomer of TCO is slightly more stable. Since the group of Fox reported the first  
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Figure 1.4 – A) Overview of relative reactivity of several common bioorthogonal tetrazines in the iEDDA 
reaction, based on several articles.19–22 B) Second-order rate constants (in M-1 s-1) of the bioorthogonal 
tetrazine ligation with several dienophiles. [a] PBS, 20 °C.24 [b] H2O, 25 °C.25 [c] phosphate buffer pH 
7.4.26 [d] 12% DMSO/H2O, 20 °C.27 [e] 1:1 CH3CN/PBS, rt.28 [f] acetate buffer pH 4.8, rt.29 [g] 1:3 
CH3OH/H2O, 21 °C.30 [h] PBS, rt.31 [i] 1% DMSO/PBS, 37 °C.32 
 
reactions between tetrazines and TCO, many TCO derivatives have been synthesized to create an 
optimized reactant in terms of stability, hydrophilicity and reactivity. The development of these 
derivatives is discussed in recent reviews15–17 and outside the scope of this introduction. However, 
we would like to highlight here the fastest tetrazine ligation (k2 = 3 300 000 M-1 s-1) to date, 
which is with s-TCO C, a TCO ring fused with a cis-cyclopropane to increase the strain of the 
system.25 Not surprisingly, s-TCO C showed increased instability compared to TCO B, with a 
half-live of 0.67 day in mice.34 Also the storage stability of s-TCO C is moderate, although this 
can be improved by complexation with AgNO3.35 
After the publication of the first bioorthogonal tetrazine ligation with TCO B and 
norbornene A, significant efforts were focused on the development of smaller strained alkenes. In 
2012, the groups of Devaraj and Prescher both reported 1,3-disubstituted cyclopropenes as 
bioorthogonal reactant in the tetrazine ligation.36,37 The fastest cyclopropene D, containing a 
methyl substituent on the alkene for stability, has a k2 of 13 M-1 s-1 in 12% DMSO/PBS36 and of 
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280 M-1 s-1 in phosphate buffer26. The rate constants of the developed four-membered ring 
reactants, N-acylazetine E27 and cyclobutene F28, are both one order of magnitude lower than 
those of cyclopropene D in a mixture of organic and aqueous solvent. The recently reported 
spirohexene G, a cyclopropene ring fused with a cyclobutane ring, appeared a surprisingly fast 
reactant in the tetrazine ligation with a dipyridyl-s-tetrazine derivative (k2 = 7900 M-1 s-1).26  
 Due to the small size, non-strained primary aliphatic alkenes like H are also a noteworthy 
class of bioorthogonal reactants, although they react only slowly with tetrazines (k2 values <10-1 
M-1 s-1).29,38 Styrene I gives comparable low rate constants in the tetrazine ligation30,39, although 
the reaction with dipyridyl-s-tetrazines is exceptional as it gives a slightly fluorescent product.30 
The reactivity of the non-strained dienophiles in the iEDDA can be enhanced by the 
introduction of electron-donating substituents on the alkene bond.40,41 It should be noted that 
after tetrazine ligations with these alkenes, certain electron-donating substituents can act as a 
leaving group yielding an aromatic pyridazine product (see Section 1.3.2).41 
Cyclooctynes, which have been extensively used as reactant in the SPAAC, show diverse 
reaction rates with tetrazines. Many cyclooctynes are reactive towards tetrazines, such as 
bicyclo[6.1.0]nonyne J (BCN) that gives a rate constant in the same order of magnitude as TCO 
B.31,42 Interestingly, the cyclooctyne SCO K, with a substituent on the 3-position, reacts not in an 
iEDDA, but in a normal-demand Diels-Alder reaction.43,44 The highest rate constant of SCO is 
observed with phenyl tetrazine IV (k2 = 1140 M-1 s-1), while the more electron-rich 3-phenyl-6-
methyl-s-tetrazine II is unreactive towards SCO due to the steric hindrance of the methyl 
substituent. The bulky dibenzocyclooctyne L (DBCO) is not reactive towards disubstituted 
tetrazines such as methyl phenyl tetrazine II and only slightly towards the single substituted 
phenyl tetrazine IV, giving a k2 of 0.06 M-1 s-1.32,45 
 
1.3 Applications of Bioorthogonal Tetrazine Ligations 
 
 Since the discovery of the bioorthogonal tetrazine ligation, its use in biological systems has 
increased tremendously.15–17 For these applications, the choice of reagents is based on the rate 
constants and selectivity of the reaction as well as on the size and hydrophilicity of the reagents. 
The exceptionally high reaction rates of TCO have made the tetrazine ligations rather popular for 
in vivo applications compared to other bioorthogonal reactions. The smaller dienophiles, such as 
cyclopropenes, are more suitable when the modification is introduced into the biomolecule by the 
endogenous cellular machinery. Furthermore, the developed fluorogenic tetrazine conjugates have 
been used extensively for imaging of biomolecules in living cells. As the tetrazine moiety acts as 
quencher, the conjugate becomes fluorescent only after reaction with a dienophile and therefore 
no washing steps are needed for clear visualization. Since the applications of the tetrazine ligation 
have already been extensively reviewed, e.g. in biomedicine,46 radiochemistry47 and proteomics,48 
we highlight in this section only the applications that are relevant for the research that is 
described in this thesis. 
 
1.3.1 Orthogonal bioorthogonal reactions 
In addition to following a single biomolecule using a bioorthogonal reaction, scientists 
may benefit from the possibility to simultaneously track multiple biomolecules to unravel the 
complexity of biological systems (Figure 1.5).49,50 As many bioorthogonal reactants are not fully 
selective toward their reaction counterpart, they can cross-react with other bioorthogonal 
1Bioorthogonal Tetrazine Ligations 13
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reactions. Therefore, it has been a challenge to find suitable mutually orthogonal reaction pairs 
that can be used simultaneously or in a tandem fashion. 
 
 
Figure 1.5 – Schematic overview of orthogonal bioorthogonal reactions. 
 
Tetrazines and (strained) alkenes are unreactive towards azides, non-strained alkynes and 
phosphines, and their iEDDA can therefore be used orthogonal to the Staudinger ligation and the 
CuAAC.51–53 In 2012, the first triple labeling using these three bioorthogonal reactions was 
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azide handle.57,58 Orthogonal to the tetrazine ligation, DBCO can also be used for labeling with 
sydnones instead of azides.60  
The group of Lemke developed the first orthogonal tetrazine ligations by making use of 
the unique reactivity of SCO K, which is especially reactive towards phenyl-s-tetrazines IV 
(Figure 1.6B).43,44 SCO K was combined with TCO* M, which is bearing a substituent on the 
allylic position and is reactive towards nearly all tetrazines, for two tandem tetrazine ligations 
whereby first TCO* M is reacted with a disubstituted tetrazine II before the phenyl-s-tetrazine IV 
is added to label SCO K. Using this method, two proteins were visualized in living cells using 
dual-color super-resolution microscopy.  
 
1.3.2 Bioorthogonal click-to-release reactions 
 Next to the bioorthogonal ligation reactions described above, a significant number of 
bioorthogonal bond cleavage reactions have been developed over the past years.61 The 
combination of a tetrazine ligation and a release reaction, also known as the ‘click-to-release 
reaction’, enables new applications in vitro and in vivo, such as the activation of prodrugs or 
fluorogenic compounds. Alkenes bearing a leaving group directly on the double bond undergo a 
subsequent release reaction after the iEDDA, yielding both the leaving group and the pyridazine 
product.41 A substituent on the allylic position of the alkene also confers a release reaction, 
although the amount is dependent on the tautomer and the substituents of the dihydropyridazine 
product. Positioning the release substituent on the allylic position, though, may be advantageous 
for the reaction due to decreased steric hindrance.40,41 
In 2013, the group of Robillard reported the first bioorthogonal click-to-release reaction 
based on the reaction of tetrazines and TCO* M that possesses a carbamate substituent on its 
allylic position (Figure 1.7A).23 After the iEDDA of the tetrazine and TCO* M, the 4,5-
dihydropyridazine eliminates the leaving group to liberate both CO2 and the amine. 
Unfortunately, a part of the dihydropyridazine tautomerizes to the 1,4-dihydropyidazine, which 
does not yield a release reaction. Of the tested tetrazines, the least reactive tetrazine dimethyl-s-
tetrazine I provided the highest release of a prodrug. Although this click-to-release reaction is 
rather slow and does not yield complete elimination, it has been frequently applied in biological 
systems for activation of prodrugs62,63 or caged proteins.64,65 Recently, it was found that 
asymmetric tetrazines containing both an electron-withdrawing substituent, that promotes the 
iEDDA, and an electron-donating substituent, that promotes the release reaction, give a faster 
ligation reaction (no k2 values determined) with higher release yields of up to 100%.66 In 
addition, as the tetrazine-TCO* click-to-release reaction was found to be pH sensitive, tetrazines 
containing a carboxylic acid did also enhance the release significantly.67 It should be noted that 
TCO* M has been applied in bioconjugation, instead of a click-to-release reaction, using 
tetrazines that did not or only slightly trigger a release reaction.43 
In 2016, the groups of Deveraj and Bernardes reported both the bioorthogonal click-to-
release reaction of tetrazines and vinyl ethers N (Figure 1.7B).68,71 These alkenes bear their leaving 
group directly on the alkene and give therefore full release of the alcohol after the iEDDA. The 
click-to-release reaction of vinyl ethers can be performed with any tetrazine although even with 
the highly reactive phenyl tetrazine IV only rather low rate constants were observed (k2 <10-3 M-1 
s-1).68 Additionally, the vinyl ethers appeared stable in aqueous solutions for at least 8 hours and 
suitable for applications in living cells. Recently, oxa- and azabenzonorbornadienes O were 
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reported as reactants in a click-to-release reaction with tetrazines (Figure 1.7C).69,70 After the 
iEDDA, an isoindole or isobenzofuran moiety is released directly, which can subsequently give a 
second release reaction of the leaving group that is attached to the allylic position. 
Azabenzonorbornadienes gave slightly lower rate constants (k2= 0.027 M-1 s-1) but higher 
conversions of the second release reaction (up to 96%) and are therefore more suitable for 
bioorthogonal application than the oxabenzonorbornadienes (k2 = 0.065 M-1 s-1, up to 71% 
release). 
 
 
Figure 1.7 – Tetrazine ‘click-to-release’ reaction with alkenes bearing a leaving group on the alkene with 
A) TCO* M, B) vinyl ether N and C) benzonorbornadienes O. Second-order rate constants (in M-1 s-1) 
and percentage of release are reported with/in [a] Tetrazine I, MeCN, 20 °C. Percentage of release after 4 
h in 1:1 serum/PBS, 37 °C.23 [b] Tetrazine IV, 9:1 DMF/H2O, 37 °C.68 [c] X = NAc with tetrazine VI, 
9:1 DMSO/H2O, 37 °C. Percentage of release after 6 h, 9:1 (CD3)2SO/D2O, 37 °C.69,70 Structures of the 
corresponding tetrazines are shown in Figure 1.4A. 
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reported as reactants in a click-to-release reaction with tetrazines (Figure 1.7C).69,70 After the 
iEDDA, an isoindole or isobenzofuran moiety is released directly, which can subsequently give a 
second release reaction of the leaving group that is attached to the allylic position. 
Azabenzonorbornadienes gave slightly lower rate constants (k2= 0.027 M-1 s-1) but higher 
conversions of the second release reaction (up to 96%) and are therefore more suitable for 
bioorthogonal application than the oxabenzonorbornadienes (k2 = 0.065 M-1 s-1, up to 71% 
release). 
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A) TCO* M, B) vinyl ether N and C) benzonorbornadienes O. Second-order rate constants (in M-1 s-1) 
and percentage of release are reported with/in [a] Tetrazine I, MeCN, 20 °C. Percentage of release after 4 
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1.4 Aim and Outline of this Thesis 
 
Up to this date, many bioorthogonal iEDDA reactions have been developed with various 
tetrazines and dienophiles, and have been successfully used for the modification of biomolecules 
in vitro and in vivo. Despite the fact that the tetrazine ligations are frequently applied, many 
reactants do not fulfill the requirements that render them fully bioorthogonal. Several reactants 
suffer from stability issues in aqueous solution (e.g. degradation of electron-poor tetrazines) or 
reactivity towards biological functional groups (e.g. isomerization of TCO to CCO by proteins 
containing transition metals, and thiol-ene or thiol-yne reactions of free intracellular cysteines 
with strained alkenes or alkynes). Furthermore, incorporation by the endogenous cellular 
machinery is most feasible when the modified biomolecules contain a small and hydrophilic 
handle. The large, hydrophobic tetrazines and dienophiles such as (s-)TCO and BCN are 
therefore less suitable for these applications and can, additionally, have solubility problems at 
high concentrations. 
So far, the reported dienophiles and tetrazines used in the iEDDA vary widely in size, 
hydrophilicity, stability and reactivity. As the properties of the reactants are often not ideal, it can 
be a challenge to choose the most suitable set for the application of interest. Also the ease of 
access of the reactants is important, as some of the fastest dienophiles, like TCO and 
cyclopropene, are known for a laborious synthesis or require specialized photoisomerization 
equipment. It should be noted, however, that many bioorthogonal reactants have become 
commercially available over the past years. Nevertheless, new reactants in the iEDDA reaction 
that are more stable, soluble and/or accessible will be attractive complements to the bioorthogonal 
molecular toolbox. In this work, we aimed to develop new hydrophilic and non-strained reactants 
for the tetrazine ligation and established that vinylboronic acids (VBAs) are suitable fast-reacting 
bioorthogonal candidates. 
In Chapter 2, we provide an overview of the exciting developments of boronic acids in 
bioconjugation reactions for in vitro and in vivo applications. It entails a description of the 
interesting properties of the boronic acid moiety as well as of its unique reactivity towards several 
customized molecules. The applications of the reported reactions with boronic acids have been 
reviewed as well as their biocompatibility towards biological systems. Additionally, the possible 
problems that may be encountered when using boronic acids in living systems are discussed.  
In Chapter 3, we describe our investigation into the influence of electronic factors on the 
slow reacting non-strained primary alkenes towards dipyridyl-s-tetrazine, which has resulted in 
the finding of the highly reactive vinylboronic acid. Next, using different substituents on both the 
tetrazine and the VBA, we have examined the scope of the tetrazine ligation with the vinylboronic 
acids. Additionally, the reactivity of VBA analogues such as boronic esters and a trifluoroborate 
salt is studied. In Chapter 4, we report our research on the biocompatibility of the VBAs in vitro 
in more detail. The stability of VBAs is investigated in aqueous media and in cell lysate, and the 
rate constants of the tetrazine ligation with VBAs in aqueous solution are determined. 
Furthermore, the in vitro protein modification using the tetrazine-VBA reaction is reported. Our 
investigations into the bioorthogonality of the tetrazine ligation with VBAs in living cells is 
described in Chapter 5. As model system, we have designed inhibitors bearing a norbornene or a 
VBA moiety for the proteasome that were modified with. The subsequent comparison of the 
uptake and labeling intensities of the two inhibitors showed that VBAs did not hamper cellular 
uptake and were bioorthogonal to all biological functionalities in living cells.  
During our research, we have found that VBAs are especially reactive towards tetrazines 
bearing a pyridyl substituent while they were unreactive towards tetrazines bearing Lewis basic 
substituent. Chapter 6 addresses the underlying mechanisms on the reactivity of the VBAs 
towards several tetrazines carrying Lewis basic as well as non-Lewis basic substituents. The unique 
reactivity of the VBAs towards pyridyl-substituted tetrazines opened doors to use two tetrazine 
ligations for dual protein labeling in a single system. In Chapter 7, we have expanded the scope 
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of the tetrazines that are suitable for reactions with VBAs with tetrazines bearing alternative Lewis 
basic substituents. Finally, in Chapter 8 we reflect on the applications of VBAs as bioorthogonal 
reactants in the tetrazine ligation and discuss the added value of the new reactants in the 
bioorthogonal toolbox. We address the potential applications of the vinylboronic acid reactants 
and the subsequent tetrazine ligation, and report preliminary results of a new click-to-release 
reaction.  
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Abstract 
 
Chemical modification of biomolecules using selective bioconjugation reactions has been 
employed extensively to elucidate, engineer or utilize their biomolecular function in vitro and in 
vivo. In this chapter, we present an overview of the bioconjugation reactions that use reactants 
containing a boronic acid functionality. Although boronic acid moieties do not occur in nature, 
they are suitable for biological applications and have been extensively used in medicine, as 
chemical sensor or reactive handle. We summarize the reversible and covalent reactions of 
boronic acids handles with their developed bioconjugation partners and discuss some 
considerations concerning the use of boronic acids in biological systems. In addition, we highlight 
the biological applications of the reported bioconjugation reaction and discuss, in case this has 
not yet been described, their potential suitability for application in vivo. 
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Abstract 
 
Chemical modification of biomolecules using selective bioconjugation reactions has been 
employed extensively to elucidate, engineer or utilize their biomolecular function in vitro and in 
vivo. In this chapter, we present an overview of the bioconjugation reactions that use reactants 
containing a boronic acid functionality. Although boronic acid moieties do not occur in nature, 
they are suitable for biological applications and have been extensively used in medicine, as 
chemical sensor or reactive handle. We summarize the reversible and covalent reactions of 
boronic acids handles with their developed bioconjugation partners and discuss some 
considerations concerning the use of boronic acids in biological systems. In addition, we highlight 
the biological applications of the reported bioconjugation reaction and discuss, in case this has 
not yet been described, their potential suitability for application in vivo. 
  
2.1 Introduction 
 
In the past years, the development of selective bioconjugation reactions has advanced 
tremendously, allowing modification of biomolecules in vitro or in vivo.1–3 These chemical 
modifications should be high yielding and proceed rapidly under physiological conditions. 
Furthermore, the reactants and product(s) should be soluble and stable in aqueous media and, if 
applicable, non-toxic to the biological system. The use of small reactants is preferred to minimize 
steric interactions with the biomolecule or to facilitate incorporation by the endogenous cellular 
machinery. The chemical modification of biomolecules is widely used, for example, to investigate 
the working mechanisms of a biomolecule or to engineer bioconjugates for improved medicinal 
and diagnostic applications.4–7  
A bioconjugation reaction is called ‘biocompatible’ when the reaction can be used to 
modify biomolecules, but is not suitable for in vivo applications as it concerns a reaction with 
naturally occurring functional groups such as amines, hydroxyls or thiols, or when a reactant 
involved is toxic or unstable in certain biological systems. In contrast, ‘bioorthogonal’ 
conjugations involve unique non-natural reactive groups that do not interfere with any naturally 
occurring biofunctionality.8–13 These bioorthogonal reactions are extremely useful as they enable 
the chemical modification of biomolecules in their native cellular environment and hence gain a 
better understanding of their role in a specific biological system or process (Figure 2.1).  
 
 
Figure 2.1 – Labeling of a biomolecule in a living cell with a bioconjugation handle and subsequent 
visualization using a suitable bioorthogonal reaction. 
 
Recently, several bioconjugation reactions have been developed making use of reactants 
that contain a boronic acid moiety. Boronic acids contain a trivalent boron atom bound to two 
hydroxyl groups and an alkyl/aryl moiety.14 They possess only six valence electrons, leaving them 
with an empty p-orbital and giving them a trigonal planar sp2-hybridized geometry. Boronic acids 
are mild organic Lewis acids that form a tetrahedral sp3-hybridized adduct when they coordinate 
to Lewis bases, such as fluoride, hydroxide, or amine. In aqueous media, boronic acids usually do 
not behave as Brønsted acids but acquire their acidity indirectly by coordinating an additional 
hydroxyl group to form the boronate anion and consequently generate a proton (Scheme 2.1A).15 
The reversible covalent complexes of boronic acids with Lewis acids are especially strong when di- 
or tri-functionalized molecules such as diols, hydroxamic acids, amino acids and amino alcohols 
are utilized.14 These molecules have been extensively used as protecting groups of boronic acids in 
organic reactions and may be especially useful as they can have a large influence on the 
nucleophilicity of the reagent.16 The use of (protected) boronic acids as synthetic intermediates 
and reagents has become very common in modern organic chemistry in the past few decades, 
especially since Akira Suzuki proved the effective use of boronic acids in Pd-catalyzed C-C 
formation (Nobel Prize in Chemistry 2010).17 Interestingly, many protected boronic acids 
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hydrolyze quickly in aqueous media and can therefore serve as precursor for their boronic acid 
analogues when applied in biological systems (Scheme 2.1B). 
 
  
Scheme 2.1 – A) Equilibrium of phenylboronic acid with its boronate anion in aqueous solution. B) 
Protected boronic acids as precursor for their boronic acid analogues in aqueous media. 
 
There are some boron-containing molecules that do exist in nature, but none of these 
structures possess a C-B bond.18–20 Nonetheless, boronic acids are suitable for application in 
biological systems, because they are chemically stable and show no or only benign toxicity.21 In 
vivo, metabolism of the boronic acids proceeds mainly by deboronation towards the oxidized 
boric acid, which has a low toxicity in humans with a median lethal dose comparable to sodium 
chloride.22 The toxicity of boronic acid containing compounds is also dependent on the nature of 
the substituents.  
Recently, boronic acids have found great use in medicinal applications. Boronic acids and 
other boron-containing compounds have demonstrated to be effective in boron neutron capture 
therapy for treating cancer.23–25 In this method, 10B-containing drugs are, when localized in a 
tumor cell, exposed to thermal neutrons. The resulting unstable 11B-isotopes undergo a nuclear 
fission reaction in the tumor, yielding cell death. As pharmaceutical agents, boronic acids have 
shown to be effective enzyme inhibitors, antibacterials, antifungals and antiestrogens.26,27 In 2003, 
Bortezomib (Velcade®), the first drug containing a boronic acid moiety as active element, was 
approved as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin’s 
lymphoma.28,29 Several other compounds containing a boronic acid are in clinical trials, 
illustrating the promise of boronic acids in medicinal chemistry.26,27 
Besides medicinal applications, boronic acids have also been extensively used in chemical 
biology and bioengineering as chemical reporter or bioconjugation reagent. This chapter provides 
an overview of the recent development for the use of boronic acids in bioconjugation reactions for 
chemical modification of biomolecules. In Section 2.2 we first shortly discuss several 
considerations that should be made when using boronic acids as bioconjugation handle in living 
systems. Next, we summarize the non-catalyzed (Section 2.3) as well as the metal-catalyzed 
(Section 2.4) bioconjugation reactions utilizing boronic acids in vitro and in vivo.  
 
2.2 Applying Boronic Acids in Living Systems 
 
Over the last years, boronic acids have been used extensively in living systems as sensors 
for small biological reagents. This is possible due to the fact that boronic acids are prone to 
oxidation by reactive oxygen and reactive nitrogen species (ROS and RNS) or to condensation 
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hydrolyze quickly in aqueous media and can therefore serve as precursor for their boronic acid 
analogues when applied in biological systems (Scheme 2.1B). 
 
  
Scheme 2.1 – A) Equilibrium of phenylboronic acid with its boronate anion in aqueous solution. B) 
Protected boronic acids as precursor for their boronic acid analogues in aqueous media. 
 
There are some boron-containing molecules that do exist in nature, but none of these 
structures possess a C-B bond.18–20 Nonetheless, boronic acids are suitable for application in 
biological systems, because they are chemically stable and show no or only benign toxicity.21 In 
vivo, metabolism of the boronic acids proceeds mainly by deboronation towards the oxidized 
boric acid, which has a low toxicity in humans with a median lethal dose comparable to sodium 
chloride.22 The toxicity of boronic acid containing compounds is also dependent on the nature of 
the substituents.  
Recently, boronic acids have found great use in medicinal applications. Boronic acids and 
other boron-containing compounds have demonstrated to be effective in boron neutron capture 
therapy for treating cancer.23–25 In this method, 10B-containing drugs are, when localized in a 
tumor cell, exposed to thermal neutrons. The resulting unstable 11B-isotopes undergo a nuclear 
fission reaction in the tumor, yielding cell death. As pharmaceutical agents, boronic acids have 
shown to be effective enzyme inhibitors, antibacterials, antifungals and antiestrogens.26,27 In 2003, 
Bortezomib (Velcade®), the first drug containing a boronic acid moiety as active element, was 
approved as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin’s 
lymphoma.28,29 Several other compounds containing a boronic acid are in clinical trials, 
illustrating the promise of boronic acids in medicinal chemistry.26,27 
Besides medicinal applications, boronic acids have also been extensively used in chemical 
biology and bioengineering as chemical reporter or bioconjugation reagent. This chapter provides 
an overview of the recent development for the use of boronic acids in bioconjugation reactions for 
chemical modification of biomolecules. In Section 2.2 we first shortly discuss several 
considerations that should be made when using boronic acids as bioconjugation handle in living 
systems. Next, we summarize the non-catalyzed (Section 2.3) as well as the metal-catalyzed 
(Section 2.4) bioconjugation reactions utilizing boronic acids in vitro and in vivo.  
 
2.2 Applying Boronic Acids in Living Systems 
 
Over the last years, boronic acids have been used extensively in living systems as sensors 
for small biological reagents. This is possible due to the fact that boronic acids are prone to 
oxidation by reactive oxygen and reactive nitrogen species (ROS and RNS) or to condensation 
with diols present on biomolecules providing the corresponding boronate ester. As these are 
possible side reactions that can occur with bioconjugation handles containing a boronic acid 
moiety when applied in living systems, we discuss these reactions here shortly. 
 
2.2.1 ROS and RNS 
One of the main reported applications of boronic acids and esters in cells is the use as 
sensor for reactive oxygen and nitrogen species.30–33 ROS and RNS, which include hydrogen 
peroxide (H2O2), hypochlorous acid (HOCl), peroxynitrite (ONOO-), nitric oxide (NO·), 
hydroxyl radicals (·OH), singlet oxygen (1O2) and superoxide anion radicals (O2·-), are formed as 
by-product of biochemical reactions in the cell. They have an active role in various physiological 
processes, including signal transduction and inflammation.34,35 Overproduction of these reactive 
species, however, can cause irreversible damage to biomolecules (e.g. lipids, DNA and proteins), 
either via direct oxidative reactions or indirect via radical-mediated mechanisms. These reactions 
can trigger apoptosis and contribute to aging and age-related diseases, such as chronic 
inflammatory diseases, cancer, cardiovascular and neurodegenerative disorders.36–39 Boronic acids 
are oxidized by ROS and RNS towards their alcohol derivative and boric acid, according to the 
mechanism shown in Scheme 2.2. 
 
 
Scheme 2.2 – Mechanism of the oxidation of phenylboronic acid by the reactive oxygen species hydrogen 
peroxide. 
 
Boronic acids and derivatives have been extensively applied as fluorogenic sensors to study 
the role of H2O240,41 and other ROS and RNS42–46 in living systems. While it was claimed that the 
first fluorogenic probes were selective for H2O2, later research showed that these probes are also 
reactive towards other ROS and RNS, especially towards ONOO-.47–49 So far, it has been a major 
effort to develop boronic acid sensors that are sensitive to levels of ROS and RNS in disease 
conditions and, up to now, none of the reported sensors are sensitive enough to detect 
endogenous levels of ROS and RNS in healthy tissue.40,42,45,50 In the last decade, however, 
nanoparticles bearing multiple boronic acids have been developed, that are sufficiently sensitive to 
be applied successfully for targeted drug delivery towards cells containing high levels of ROS and 
RNS.50–52 Therefore, the application of bioconjugation probes containing boronic acid moieties 
will possibly not be suitable in certain disease, but we anticipate that their application in healthy 
tissue will not be hindered by the possible oxidation by ROS and RNS. 
 
2.2.2 Diol-containing biomolecules 
An additional popular application of boronic acids as sensors is based on their ability to 
form reversible esters with diols, of which cis-1,2-diols react with the highest binding affinity 
towards boronic acids.53–56 The formation of the boronate ester is influenced by many factors such 
as the pH, the pKa of the boronic acid and the equilibrium constants of the diol with the boronic 
acid and its boronate anion (Figure 2.2).57,58 Generally, reactions of boronic acids with diols give 
the anionic tetrahedral boronate esters in water, which are more stable than their trigonal boronic 
ester analogues. In addition, the neutral boronic ester is more Lewis acidic than the parent 
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boronic acid, so the formation of the boronate ester is favored at a pH above the pKa of the 
boronic acid. However, it should be noted that the boronic acid-diol complexation is more 
complex and we refer to the excellent work of the group of Wang for more detailed 
information.57,58 
 
 
Figure 2.2 – The binding of a boronic acid with a diol-containing biomolecule in aqueous media, 
influenced by multiple equilibria. 
 
 Diols are fairly prominent segments in biological systems as they occur in saccharides, 
glycans, glycoproteins, nucleosides and nucleotides. Especially the development of boronic-acid 
containing chemosensors to study saccharides in living systems has advanced tremendously over 
the past decades.59–61 In vitro, this boronate ester formation has been applied for separation and 
immobilization of glycopeptides and glycoproteins.62–64 Additionally, the reversibility of the 
boronate ester bond has provoked the development of supramolecular systems with interesting 
characteristics, such as self-healing properties or triggered cargo delivery by a decrease in pH or an 
increase in diol concentration.65–68 One of the most exciting applications of these supramolecular 
systems is as selective and noninvasive molecular sensor for monitoring blood glucose in insulin-
releasing implants for diabetes patients.65 In these systems, an increase in glucose levels in the 
blood will yield release of insulin by e.g. exchanging the boronic acid-insulin complex for a 
boronic acid-glucose complex, and will subsequently promote the metabolism of glucose. 
Up to this date, it has been notoriously difficult to develop boronic acid sensors that bind 
a single diol in the diol-rich living systems, as the characteristics of the diol-fractions in many 
biomolecules differ only slightly. The selectivity of boronic acids towards a specific saccharide can 
be improved by addition of a substituent close to the boronic acid, for example a m-methylamino 
group on phenylboronic acid for selective sialic acid detection due to electrostatic interactions of 
the amine with the carbohydrate, forming complex 1 (Figure 2.3).69,70 Furthermore, bidentate 
and multidentate compounds have been developed for stronger binding to biomolecules 
containing multiple diol moieties such as (oligo)saccharides or glycans, e.g. forming glucose 
complex 2.71  
The biggest challenge in the development of the boronic acid sensors for diols is finding a 
boronic acid moiety with a pKa below the physiological pH, as then the condensation reaction 
will be favored in living systems. As most boronic acids possess a pKa that is far above the 
physiological pH, they are in general not suitable for binding diols in biological systems. For 
example, phenylboronic acid has a pKa of 8.814 and accordingly a low association constant of 160 
M-1 with D-fructose and only 4.6 M-1 with D-glucose at pH 7.4.73 Derivatives of phenylboronic 
acid are suitable as diol-sensor when their pKa is lowered and subsequently their binding constant 
improved by addition of electron-withdrawing substituents.74 Furthermore, the addition of an 
aminomethyl substituent on the ortho position of the boronic acid phenyl ring, such as present in 
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boronic acid, so the formation of the boronate ester is favored at a pH above the pKa of the 
boronic acid. However, it should be noted that the boronic acid-diol complexation is more 
complex and we refer to the excellent work of the group of Wang for more detailed 
information.57,58 
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Figure 2.3 – Examples of complexes of specific boronic acid sensors with the carbohydrate. A) Sialic acid-
phenylboronic acid complex 1 with electrostatic interactions of the m-methylamino group on the phenyl 
ring.69,70 B) Bisboronic acid for binding with glucose in glucofuranose complex 2.71,72 
 
2.3 Bioconjugation Reactions with Boronic Acids 
 
In this section we review the catalyst-free reversible and irreversible bioconjugation 
reactions involving boronic acids and highlight their applications in vitro and in vivo. We focus 
on the development of reactive handles that are bioorthogonal and react either irreversibly or with 
high affinity with boronic acids, as these can be applied in living systems.  
  
2.3.1 Salicylhydroxamic acid 
The first bioconjugations using boronic acids were based on condensation reactions with 
di- or tri-functionalized reactants. As biological diols give low association constants with most 
boronic acids at physiological pH, it is feasible to apply boronic acids in a biological system when 
formation of a stronger bond is possible. In 2001, the group of Wiley reported that 
salicylhydroxamic acid 4 has a higher affinity towards boronic acids than any known diol and 
forms a stable complex with phenylboronic acid 3 (Scheme 2.3).78 The binding of the two 
compounds is pH dependent, whereby solely the 6-membered ring 5 was formed at pH > 7, and 
a mixture of 5- and 6-membered products 5 and 6 was observed at reduced pH. The high 
 
 
Scheme 2.3 – Reaction of phenylboronic acid 3 with salicylhydroxamic acid 4, forming the boronate 
esters 5 and/or 6 at A) pH 7.4 and B) pH 4.5.78 [a] 100 mM phosphate buffer.79  
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binding affinity of 3 and 4 at physiological pH was reduced dramatically when the pH was 
lowered, making the reaction suitable for an “assemble and release” system. 
The bioconjugation reaction between 3 and 4 was first utilized to immobilize proteins 
containing a boronic acid moiety on salicylhydroxamic acid-modified sepharose beads, to 
investigate both the conjugation reaction at physiological pH and the dissociation reaction when 
the pH was lowered.78 The results of immobilization and dissociation of the proteins were 
promising, and slightly optimized in a second study by using 1,3-phenyldiboronic acid instead of 
phenylboronic acid.80,81 Depending on the ratio of 1,3-phenyldiboronic acid and the 
salicylhydroxamic acid, the diboronic acid was functionalized twice. In addition, the 
phenylboronic acid-salicylhydroxamic acid bioconjugation has been used in vitro and on skin 
tissue for the formation of self-healing supramolecular systems that are pH-dependent, such as 
hydrogels and polymer networks.82–86 
The group of Cristiano extended the work above for targeted gene delivery in vivo using 
the formation of a stable bioconjugate using the reaction of a 1,3-phenyldiboronic acid with a 
salicylhydroxamic acid (Figure 2.4A).87 For this application, the boronic acid moiety was 
modified with a tumor-specific CD13 targeting peptide, CNGRC, and coupled in vitro to a 
salicylhydroxamic acid modified polycationic vector, that was composed of polyethyleneimine 
and DNA. Next, the CNGRC modified vector was administered to mice and showed efficient 
tumor-specific delivery and expression of the DNA. When the vector contained the tumor 
suppressor gene p53, the targeted gene delivery resulted in a significant tumor regression.88 The 
bioconjugation reaction of the salicylhydroxamic acid vector and a monoclonal antibody bearing 
the phenylboronic acid moieties and its subsequent tumor targeting in vivo was also successful.89 
This data showed that the bioconjugation product of the reaction between salicylhydroxamic acid 
and phenylboronic acid is, although still reversible, sufficiently stable for in vivo applications. 
 
 
Figure 2.4 – Schematic overview of applications of the reaction between boronic acid and 
salicylhydroxamic acid. A) Formation of a gene delivery vector.87 B) Formation of a pH-responsive protein 
bearing dendrimers of PEG linkers.90,91 POI = protein of interest.  
 
 In 2010, the group of Jaffrey reported the first application of the bioconjugation reaction 
between phenylboronic acid and salicylhydroxamic acid inside living cells.79 First, they 
investigated the biocompatibility of the reaction of 3 with 4 in more detail, by measuring the 
kinetics of the reaction and the stability of the product in the presence of biomolecules. The 
highly favored association constant for the boronate ester formation at physiological pH and the 
extremely large third-order rate constant (k3) render the reaction suitable for biological 
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binding affinity of 3 and 4 at physiological pH was reduced dramatically when the pH was 
lowered, making the reaction suitable for an “assemble and release” system. 
The bioconjugation reaction between 3 and 4 was first utilized to immobilize proteins 
containing a boronic acid moiety on salicylhydroxamic acid-modified sepharose beads, to 
investigate both the conjugation reaction at physiological pH and the dissociation reaction when 
the pH was lowered.78 The results of immobilization and dissociation of the proteins were 
promising, and slightly optimized in a second study by using 1,3-phenyldiboronic acid instead of 
phenylboronic acid.80,81 Depending on the ratio of 1,3-phenyldiboronic acid and the 
salicylhydroxamic acid, the diboronic acid was functionalized twice. In addition, the 
phenylboronic acid-salicylhydroxamic acid bioconjugation has been used in vitro and on skin 
tissue for the formation of self-healing supramolecular systems that are pH-dependent, such as 
hydrogels and polymer networks.82–86 
The group of Cristiano extended the work above for targeted gene delivery in vivo using 
the formation of a stable bioconjugate using the reaction of a 1,3-phenyldiboronic acid with a 
salicylhydroxamic acid (Figure 2.4A).87 For this application, the boronic acid moiety was 
modified with a tumor-specific CD13 targeting peptide, CNGRC, and coupled in vitro to a 
salicylhydroxamic acid modified polycationic vector, that was composed of polyethyleneimine 
and DNA. Next, the CNGRC modified vector was administered to mice and showed efficient 
tumor-specific delivery and expression of the DNA. When the vector contained the tumor 
suppressor gene p53, the targeted gene delivery resulted in a significant tumor regression.88 The 
bioconjugation reaction of the salicylhydroxamic acid vector and a monoclonal antibody bearing 
the phenylboronic acid moieties and its subsequent tumor targeting in vivo was also successful.89 
This data showed that the bioconjugation product of the reaction between salicylhydroxamic acid 
and phenylboronic acid is, although still reversible, sufficiently stable for in vivo applications. 
 
 
Figure 2.4 – Schematic overview of applications of the reaction between boronic acid and 
salicylhydroxamic acid. A) Formation of a gene delivery vector.87 B) Formation of a pH-responsive protein 
bearing dendrimers of PEG linkers.90,91 POI = protein of interest.  
 
 In 2010, the group of Jaffrey reported the first application of the bioconjugation reaction 
between phenylboronic acid and salicylhydroxamic acid inside living cells.79 First, they 
investigated the biocompatibility of the reaction of 3 with 4 in more detail, by measuring the 
kinetics of the reaction and the stability of the product in the presence of biomolecules. The 
highly favored association constant for the boronate ester formation at physiological pH and the 
extremely large third-order rate constant (k3) render the reaction suitable for biological 
applications (Scheme 2.3). Furthermore, the formation of the ester was not affected by small 
biological nucleophiles, e.g. D-glucose and any of the molecules present in tissue culture medium. 
Finally, the bioorthogonality of the phenylboronic acid-salicylhydroxamic acid reaction was 
demonstrated by using precursors containing the reactants that assemble in a ligand for the 
thrombopoietin receptor. After addition of the precursors to living cells, the cellular response to 
the ligand confirmed the formation of the bioconjugation product and the suitability of the 
reaction for applications in living systems. 
The group of Weil investigated whether the disassembly reaction of the bioconjugation 
product was feasible for a triggered release response in acidic organelles of the cells (Figure 
2.4B).90,91 First, phenylboronic acid-functionalized enzymes were protected in vitro with a 
dendritic shell using the bioconjugation reaction with salicylhydroxamic acids. The protected 
enzymes gave efficient cellular uptake and co-localization with acidic organelles, where the 
enzymes were deprotected and induced cell death.90 The PEGylation of phenylboronic acid-
functionalized proteins was next investigated, because PEGylation is known to enhance 
pharmacokinetics of proteins, including their hydrophilicity, stability, and circulation time. The 
PEGylated constructs showed again pH-dependent assembly and disassembly behavior, also in 
acidic compartments of living cells (Figure 2.4B).91  
 
2.3.2 Iminoboronates 
Several biocompatible conjugation reactions involve the condensation of amines with 
aldehydes to form imines. As imine formation is reversible in aqueous solution, imines can only 
be employed for bioconjugation applications if the imine is reduced by reductive amination.92–94 
Interestingly, iminoboronates, imines that are coordinated to boronic acids, are stable in aqueous 
solution and therefore more suitable for bioconjugation applications.95,96 
2-Acetylphenylboronic acid 7 and 2-formylphenylboronic acid 8 gave both a moderately 
efficient reaction with aliphatic amines, yielding 71% and 61% of the conjugation product, 
respectively.95 Additionally, both boronic acids 7 and 8 were suitable for the modification of 
several proteins at the ε-amino group of lysine or the N-terminal amine in neutral aqueous media 
at low millimolar concentrations (Figure 2.5A). In follow-up work, the reactions towards 
iminoboronates proved to be suitable for the formation of protein-fluorophore conjugates97 and 
orthogonal towards the copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) as well as the 
strain-promoted alkyne-azide cycloaddition (SPAAC).98 Additionally, in vitro formed 
iminoboronate conjugates were sufficiently stable for applications in cell culture media. The 
conjugate of folic acid with the cytotoxic drug paclitaxel underwent selective-folate receptor 
mediated internalization of cancer cells and subsequently caused cell death. Unfortunately, the 
iminoboronates are not suitable for bioconjugation reactions in living cells or in vivo, because 
they are unstable in the presence of several biological small molecules such as fructose, dopamine 
and glutathione.95 As no rate constants have been reported, it is not possible to compare the 
formation of iminoboronates with the other biocompatible reactions that are described. 
Peptides or proteins containing N-terminal cysteines have been selectively modified on 
the N-terminus using o-aldehyde- or ketone-substituted phenylboronic acids, as the 
iminoboronate will cyclize with the thiol towards a stable thiazolidine in aqueous solution (Figure 
2.5B).99,100 Especially o-aldehyde 8 gave excellent conversion and an impressive second-order rate 
constant with a tripeptide containing an N-terminal cysteine (k2 = 5.5 × 103 M-1 s-1).99 Lower 
conversions and binding affinity were found for the cyclization of the N-terminal cysteine with 
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ketone 7 (37% and >99% yield for 8 and 7, respectively).100,101 The thiazolidine conjugation 
product was found to be more stable in the presence of most biological small molecules than the 
iminoboronates, however, the product proved unstable at low pH (2.5 – 5.0) and in the presence 
of e.g. free cysteine.99  
 
 
Figure 2.5 – A) Reactions of 2-acetylphenylboronic acid 7 and 2-formylphenylboronic acid 8 with the 
amine moiety present in a protein.95 B) Reaction of boronic acid 8 with an N-terminal cysteine. [a] 10 
mM phosphate buffer (pH = 7), rt.99 
 
 Follow-up research focused on the formation of more stable and selective conjugates using 
imines and boronic acids, receding from the primary amines. It was found that the boronic acids 
7 and 8 react also fast with α-nucleophiles such as alkoxyamines, hydrazides and hydrazines in 
aqueous solutions.102–105 The reactions of alkoxyamines103 and hydrazides gave again reversible 
product formation, similar to the reactions with the primary amines.102 Also the reaction of 2-
acetylphenylboronic acid 7 with hydrazines is reversible. Interestingly, the reaction of 2-
formylphenylboronic acid 8 with phenylhydrazine 9 irreversibly forms the aromatic 
borazaroisoquinoline 11 after a second cyclization reaction (Scheme 2.4A). The rate of the 
conjugation reaction was fast (k2 = 102 to 103 M-1 s-1), whereas the intramolecular cyclization was 
much slower (k = 10-2 – 10-3 s-1).104,105 Protein modification and visualization by SDS-PAGE gel 
showed the biocompatibility of the reaction.104 Unfortunately, this conjugation reaction is not 
fully bioorthogonal, as hydrazines were found to be cytotoxic and easily oxidize in biological 
aqueous environments.106 Recently, the group of Bane showed that the reaction of α-amino 
carbohydrazide 12 with phenylboronic acid 7 or 8 gave also formation of a covalent 
iminoboronate (13 or 14, respectively) that was stable at pH 4 – 9 and suitable for protein 
modification (Scheme 2.4B).107 In future work, the toxicity, stability and kinetics of the α-amino 
carbohydrazides should be evaluated to explore the suitability of this reactant for bioconjugation 
further. 
Semicarbazide 15 and thiosemicarbazide 16 were shown to be much less cytotoxic 
towards bacteria and living cells than phenylhydrazine 9 and therefore their applicability in the 
bioconjugation reaction with boronic acids to form iminoboronates was investigated.101 The 
(thio)semicarbazides 15 and 16 reacted with both boronic acids 7 and 8, and although the 
reaction rate of 7 was lower, its use for bioconjugation is preferred as 8 is more reactive towards 
N-terminal cysteines. Boronic acid 7 gave with the (thio)semicarbazides 15 and 16 direct 
formation of the irreversible ring-closed diazaborines 17 or 18 (Scheme 2.4C). Unfortunately, 
the reactions did not go to full conversion, although the yield of 15 was much higher than of 16  
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ketone 7 (37% and >99% yield for 8 and 7, respectively).100,101 The thiazolidine conjugation 
product was found to be more stable in the presence of most biological small molecules than the 
iminoboronates, however, the product proved unstable at low pH (2.5 – 5.0) and in the presence 
of e.g. free cysteine.99  
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towards bacteria and living cells than phenylhydrazine 9 and therefore their applicability in the 
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Scheme 2.4 – A) Reaction of 2-formylphenylboronic acid 8 with phenylhydrazine 9, yielding quickly the 
bioconjugation product 10 that slowly ring closes to borazaroisoquinoline 11. B) Reaction of 
phenylboronic acids 7 or 8 with α-amino carbohydrazides 12, yielding complex 13 or 14, respectively. C) 
Reaction of 2-acetylphenylboronic acid 7 with a semicarbazide 15 or thiosemicarbazide 16, yielding 
diazaborine 17 or 18, respectively. [a] 0.1 M Sodium phosphate buffer (pH = 7.0), 25 °C104 or 0.1 M 
potassium phosphate buffer (pH 7.2).105 [b] PBS.101 
 
(60% for 15 compared to 27% of 16 at 50 μM of the reagents in PBS). The reaction between 
semicarbazide 15 and 2-acetylphenylboronic acid 7 gave an excellent second-order rate constant 
of 1.1 × 103 M-1 s-1 and was compatible to fetal bovine serum and cell lysate from HEK cells and 
S. aureus bacteria. The biocompatibility was further examined by incorporation of non-natural 
amino acids in the cell membrane of bacteria using cell wall remodeling. Both 2-
acetylphenylboronic acid 7 and the semicarbazide 15 can be incorporated in the cell wall of 
bacteria using non-natural amino acids analogues, showing the stability of these moieties in living 
cells.101,108 Additionally, the fluorogenic 2-acetylphenylboronic acid derivate 19 was developed, 
which showed a significant enhanced fluorescence signal after the reaction of the bacteria 
containing the semicarbazide in the cell wall, without any washing steps needed (Figure 2.6).108 
Although the conversion of the reaction of 2-acetylphenylboronic acid 7 with semicarbazides 15 
 
 
Figure 2.6 – Schematic overview of the cell wall visualization of bacteria. First, an unnatural amino acid 
containing a semicarbazide was incorporated in bacteria by cell wall remodeling and subsequently the cell 
wall was visualized using the fluorogenic 2-acetylphenylboronic acid-containing coumarin 19.108 
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needs optimization, it is the first irreversible reaction forming iminoboronates that is suitable for a 
bioconjugation application in living cells. 
 
2.3.3 Condensation of boronic acids with diols 
The condensation reaction of boronic acids with diols, as described in Section 2.2.2, can 
be used for bioconjugation when the reactant containing the diol binds with much higher affinity 
to boronic acids compared to the naturally occurring diols present in living systems. As the 
boronate ester formation with naturally occurring diols can also be employed for bioconjugation 
in vitro, we refer back to the excellent reviews on this subject.59–68 Here, we only highlight the 
condensation reaction of boronic acids with non-generic diols that are potentially suitable for 
applications in living cells.  
The group of Schepartz investigated the binding of boronic acids with genetically 
engineered proteins containing several serines in close proximity. The fluorogenic bisboronic acid 
rhodamine 20 bound with high affinity to the tetraserine motive SSPGSS, yielding a 
fluorescently labeled protein (Figure 2.7).109 This method was based on fluorogenic biarsenical 
dyes that can recognize the non-proteomic tetracysteine motif via a thiol-arsenic exchange motif. 
Unfortunately, the biarsenical dyes are plagued by high background signals and cytotoxicity.110,111 
In contrast, the bisboronic acid 20 was found to be non-toxic and showed significant fluorescence 
increase after binding with the tetraserine motive at 10,000-fold lower concentrations when 
compared to binding of small carbohydrates as glucose and sialic acid, providing therefore low 
background signal on the cell.109 Unfortunately, this method is not completely bioorthogonal, as 
the SSPGSS sequence is expressed in more than 100 human proteins that may potentially 
interfere with the bisboronic acid profluorophore. 
 
 
Figure 2.7 – Protein containing the SSPGSS tag and its reaction with the fluorogenic bisboronic acid 
rhodamine dye 20 yielding the fluorescently labeled protein.109 
 
In 2016, the group of Hall looked in more detail into the esterification of boronic acids with 
non-natural diols for a potential new bioconjugation reaction.112 The formation of an ester using 
a pre-organized diol gives in general high association constants and it was found that pinanediol 
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needs optimization, it is the first irreversible reaction forming iminoboronates that is suitable for a 
bioconjugation application in living cells. 
 
2.3.3 Condensation of boronic acids with diols 
The condensation reaction of boronic acids with diols, as described in Section 2.2.2, can 
be used for bioconjugation when the reactant containing the diol binds with much higher affinity 
to boronic acids compared to the naturally occurring diols present in living systems. As the 
boronate ester formation with naturally occurring diols can also be employed for bioconjugation 
in vitro, we refer back to the excellent reviews on this subject.59–68 Here, we only highlight the 
condensation reaction of boronic acids with non-generic diols that are potentially suitable for 
applications in living cells.  
The group of Schepartz investigated the binding of boronic acids with genetically 
engineered proteins containing several serines in close proximity. The fluorogenic bisboronic acid 
rhodamine 20 bound with high affinity to the tetraserine motive SSPGSS, yielding a 
fluorescently labeled protein (Figure 2.7).109 This method was based on fluorogenic biarsenical 
dyes that can recognize the non-proteomic tetracysteine motif via a thiol-arsenic exchange motif. 
Unfortunately, the biarsenical dyes are plagued by high background signals and cytotoxicity.110,111 
In contrast, the bisboronic acid 20 was found to be non-toxic and showed significant fluorescence 
increase after binding with the tetraserine motive at 10,000-fold lower concentrations when 
compared to binding of small carbohydrates as glucose and sialic acid, providing therefore low 
background signal on the cell.109 Unfortunately, this method is not completely bioorthogonal, as 
the SSPGSS sequence is expressed in more than 100 human proteins that may potentially 
interfere with the bisboronic acid profluorophore. 
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In 2016, the group of Hall looked in more detail into the esterification of boronic acids with 
non-natural diols for a potential new bioconjugation reaction.112 The formation of an ester using 
a pre-organized diol gives in general high association constants and it was found that pinanediol 
provides one of the most hydrolytically robust boronic esters.113 Therefore, the speed and 
association of the ester formation of several boronic acids was tested with nopoldiol 22, a 
pinanediol derivative with an extra functional handle.112 The reaction of 2-tolylboronic acid 21 
provided the best conditions, i.e. a high rate constant combined with a very high association 
constant (Scheme 2.5A). The high affinity ensured that ester 23 was formed, even in de presence 
of biomolecules containing diols at biologically relevant concentrations. Finally, the reaction was 
shown to be biocompatible with proteins, by labeling a boronic acid-modified protein with a 
fluorescent nopoldiol in a sodium phosphate buffer. Unfortunately, the ester linker of 23 
appeared too labile in a tris buffer, which contains both competing hydroxyl and amine groups, 
and no protein conjugate was formed.  
 
 
Scheme 2.5 – A) Reaction of 2-tolylboronic acid 21 with nopoldiol 22, yielding ester 23. B) Reaction of 
2-acetylphenylboronic acid 24 with thiosemicarbazide nopoldiol 25, yielding the conjugation product 26. 
[a] 2:8 MeCN/0.1 M phosphate buffer (pH 7.4).112 [b] 9:1 PBS buffer/D2O (pH 7.4), 25 °C. 114 
 
The group of Hall continued the search for an irreversible ester and was inspired by the 
reaction of 2-acetylphenylboronic acid with (thio)semicarbazides (Scheme 2.4C)108 and a three 
component reaction that formed a boronate ester that was coordinated to an imine.115,116 
Subsequently, they developed nopoldiol 25, bearing a thiosemicarbazide, that could react with 2-
acetylphenylboronic acid 24, yielding the covalent ester 26 (Scheme 2.5B).114 The reaction was 
established to be efficient, irreversible and not sensitive towards other diols, although, 
unfortunately, the rate constant of this ester-imine formation was almost 100-fold slower 
compared to the sole ester formation. To demonstrate the biocompatibility of the reaction, it was 
applied for site-selective protein labeling on mammalian cells (Figure 2.8). The 2-
acetylphenylboronic acid moiety was incorporated in a protein on the cell membrane using a 
SNAP-tag approach,117,118 which gave clear visualization of the cell surface after reacting with the 
nopoldiol-thiosemicarbazide bearing a fluorophore. Unfortunately, no applications of this 
irreversible reaction in the cytosol or in vivo have been described so far. 
 
 
Figure 2.8 – Schematic overview of visualization of the membrane of living HEK293T cells.114 First, 2-
acetylphenylboronic acid is labeled to a cell membrane protein using the SNAP-tag method, and 
subsequently fluorescently modified with nopoldiol bearing a thiosemicarbazide and fluorescein. 
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2.4 Metal-Catalyzed Bioconjugation Reactions with Boronic Acids 
 
In the last decades, several metal-catalyzed organic reactions have been explored for use as 
bioconjugation reactions in vitro and in vivo.119,120 Transition metal catalysis offers the possibility 
to perform new, non-natural, chemical transformations in biological systems, such as C-C bond 
formation. Unfortunately, transition metals show limited biocompatibility in living systems 
because they are prone to oxidation and show cytotoxicity, often at low concentration. The 
design of reactions containing metal catalysts, substrates and ligands that can cross the cell 
membrane and show high stability and low toxicity is a huge challenge that has only recently 
shown its first successes.121 So far, the boronic acid reagents have been successfully applied in the 
palladium-catalyzed Suzuki-Miyaura coupling, the oxidative Heck reaction and the copper-
catalyzed Chan-Lam reaction.  
 
2.4.1 The Suzuki-Miyaura coupling 
A reaction that proved suitable for multiple biological applications is the Suzuki-Miyaura 
coupling (SMC),17,122 which is the palladium-catalyzed C-C bond forming reaction between an 
aryl halide (or aryl triflate) and a boronic acid. In 2008, the first example of a biocompatible 
SMC was reported by the group of Hamachi. They applied a post-affinity labeling modification 
to introduce a phenyl iodide moiety on the protein, which was subsequently reacted with a 
fluorescent phenylboronic acid using Pd(OAc)2 (Figure 2.9A).123 This reaction gave a good 
conversion (80%), although lower conversions were found with phenylvinylboronic acid and a 
phenylboronic acid derivative modified with a PEG chain (0 and 40%, respectively). In addition, 
long reaction times were needed, possibly because no ligand was used in the SMC. The protein 
modification with the ligand-free SMC using Pd2(dba)3 provided comparable reaction rates as 
with Pd(OAc)2.124 However, the reaction rates of the SMC in aqueous solutions were increased 
significantly when the commercially available water-soluble 2-amino-4,6-dihydroxy-pyrimidine 
27 was employed as ligand for the Pd-catalyst.125 Subsequently, the group of Davis investigated 
the biocompatibility of this palladium-ligand combination for protein modification and showed 
that a protein bearing a phenyl iodide moiety was quickly converted into the coupling product 
utilizing several alkenyl- and arylboronic acids (>95% yield in 30 min) (Figure 2.9B). 
 
 
Figure 2.9 – A) First example of a biocompatible SMC between a protein modified with a phenyl iodide 
and a fluorescent phenylboronic acid. B) SMC of a protein bearing a phenyl iodide with boronic acids 
utilizing Pd(OAc)2 as catalyst and 2-amino-4,6-dihydroxy-pyrimidine 27 as ligand. [a] 8:1:1 HEPES 
buffer (pH = 8)/DMSO/glycerol. 37 °C, 7 h, 80%.123 [b] Phosphate buffer (pH = 8), 37 °C, 30 min, 
>95%.125 [c] KOH, H2O, 100 °C, 4 h, <5% – 100%.126  
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Next, the genetic incorporation of p-iodophenylalanine in proteins was employed by the 
group of Davis for the in vitro modification of a protein surface and the subsequent labeling using 
a boronic acid and their reported catalyst-ligand combination.127 The coupling was successful, 
despite the fact that non-specific binding of palladium to the protein was observed by mass 
spectrometry. Although addition of the scavenger 3-mercaptopropionic acid after the reaction 
removed the palladium from the protein, the non-specific binding of palladium could be 
problematic for applications in living cells. Follow-up work using p-iodophenylalanine 
demonstrated effective fluorescent labeling of an iodide-modified membrane protein on the 
surface of living E. coli cells using a fluorescent boronic acid conjugate.128 Visualization of the 
iodide-modified membrane proteins has also been performed in two steps, whereby first 
carbohydrates modified with vinylboronic acids were coupled to the p-iodophenylalanine using 
the SMC and subsequently visualized with a fluorescein-lectin conjugate that binds selectively to 
one of the coupled carbohydrates.129 These examples demonstrate the biocompatibility of the 
coupling reagents on living cells, despite the possible non-specific binding of the palladium 
catalyst. Recently, the scope of the possible catalyst-ligand systems was further expanded, as it was 
demonstrated that dimethylguanidine130 and N-heterocylic carbenes131 are also suitable ligands for 
the SMC bioconjugation. 
Although phosphine ligands have been frequently applied in Pd-catalyzed reactions in 
organic solvents, they tend to oxidize quickly in biological aqueous systems. Non-phosphine 
containing ligands are therefore preferred for bioconjugation using the SMC. Recently, however, 
several research groups showed that phosphine ligands can be successfully applied for a 
bioconjugation cross-coupling reactions using palladium.126,132 In 2016, the group of Clark used 
the palladium source 28 and phosphine ligand 29 in the SMC for the modification of DNA-
linked aryl chlorides in vitro (Figure 2.10A).126 The double stranded DNA analogues containing 
the chlorides were modified with several boronic acids and esters in acceptable to quantitative 
yields (30-100%), although elevated temperatures were needed for the cross-couplings to proceed. 
In 2018, the group of Cui reported the cross coupling of DNA bearing a bromine utilizing 
 
 
Figure 2.10 – A) SMC of DNA-linked aryl chlorides with arylboronic acids in vitro. B) SMC for 
visualization of DNA containing a bromide with a fluorescent phenylboronic acid in fixed cells under H2 
atmosphere. [a] Premix of POPd 28 and ligand 29, KOH, H2O, 100 °C, 4 h. [b] Premix of K2PdCl4 and 
ligand 30, sodium ascorbate, H2, 1:2 MeOH/H2O, 37 °C, 2 h. 
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2.4 Metal-Catalyzed Bioconjugation Reactions with Boronic Acids 
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coupling (SMC),17,122 which is the palladium-catalyzed C-C bond forming reaction between an 
aryl halide (or aryl triflate) and a boronic acid. In 2008, the first example of a biocompatible 
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fluorescent phenylboronic acid using Pd(OAc)2 (Figure 2.9A).123 This reaction gave a good 
conversion (80%), although lower conversions were found with phenylvinylboronic acid and a 
phenylboronic acid derivative modified with a PEG chain (0 and 40%, respectively). In addition, 
long reaction times were needed, possibly because no ligand was used in the SMC. The protein 
modification with the ligand-free SMC using Pd2(dba)3 provided comparable reaction rates as 
with Pd(OAc)2.124 However, the reaction rates of the SMC in aqueous solutions were increased 
significantly when the commercially available water-soluble 2-amino-4,6-dihydroxy-pyrimidine 
27 was employed as ligand for the Pd-catalyst.125 Subsequently, the group of Davis investigated 
the biocompatibility of this palladium-ligand combination for protein modification and showed 
that a protein bearing a phenyl iodide moiety was quickly converted into the coupling product 
utilizing several alkenyl- and arylboronic acids (>95% yield in 30 min) (Figure 2.9B). 
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K2PdCl4 and the commercially available phosphine ligand DTBPPS 30 (Figure 2.10B).132 The 
bromine nucleotide was genetically incorporated into the DNA by the addition of 5-bromo-2’-
deoxyuridine (BrdU) to the culture media of living cells before the cells were fixed and the SMC 
was performed with a phenylboronic acid containing a fluorophore. Initial attempts to use SMC 
was troublesome, however, successful labeling of the DNA was observed when the reaction was 
performed under oxygen-free conditions. Performing the SMC in the fixed cells under a 
hydrogen atmosphere yielded in the highest level of fluorescence. 
In 2011, the group of Bradley applied the SMC for the first time in living cells by making 
use of polystyrene microspheres containing Pd(0) trapped nanoparticles.133,134 The microspheres 
were cell permeable and not cytotoxic at concentrations necessary for the catalytic activity. Using 
these microspheres, a mitochondria-localized fluorophore was synthesized inside living cells using 
the non-fluorogenic triflate 31 and phenylboronic acid 32, carrying a mitochondria-targeting 
triphenylphosphonium moiety (Figure 2.11). The SMC was successful, demonstrated by the 
appearance of the fluorescent signal of probe 33 that co-localized with the MitoTracker signal for 
the mitochondria. More recently, the surface of the Pd(0) microspheres was modified with a 
ligand for cancer cell targeting and the subsequent formation of a cytotoxic drug at the tumor.135 
The ligand, cRGD, is a potent antagonist of the α2β3 receptor, which is overexpressed in many 
tumors. Addition of these microspheres and the precursors for the cytotoxic drug containing a 
boronic acid and iodide moiety to brain cancer cells, led to the formation of the anticancer agent 
and subsequent cell death. These examples utilizing the Pd(0) microspheres demonstrate the 
bioorthogonality of the SMC reactants and reagents for C-C bond formation. 
 
 
Figure 2.11 – The SMC of the fluorogenic probe 31 containing a triflate with a mitochondria-targeting 
signal 32 containing the boronic acid pinacol ester, catalyzed by palladium microspheres, to yield the 
mitochondria-localized fluorophore 33. A) Molecular level. B) Cellular level.133,134 
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K2PdCl4 and the commercially available phosphine ligand DTBPPS 30 (Figure 2.10B).132 The 
bromine nucleotide was genetically incorporated into the DNA by the addition of 5-bromo-2’-
deoxyuridine (BrdU) to the culture media of living cells before the cells were fixed and the SMC 
was performed with a phenylboronic acid containing a fluorophore. Initial attempts to use SMC 
was troublesome, however, successful labeling of the DNA was observed when the reaction was 
performed under oxygen-free conditions. Performing the SMC in the fixed cells under a 
hydrogen atmosphere yielded in the highest level of fluorescence. 
In 2011, the group of Bradley applied the SMC for the first time in living cells by making 
use of polystyrene microspheres containing Pd(0) trapped nanoparticles.133,134 The microspheres 
were cell permeable and not cytotoxic at concentrations necessary for the catalytic activity. Using 
these microspheres, a mitochondria-localized fluorophore was synthesized inside living cells using 
the non-fluorogenic triflate 31 and phenylboronic acid 32, carrying a mitochondria-targeting 
triphenylphosphonium moiety (Figure 2.11). The SMC was successful, demonstrated by the 
appearance of the fluorescent signal of probe 33 that co-localized with the MitoTracker signal for 
the mitochondria. More recently, the surface of the Pd(0) microspheres was modified with a 
ligand for cancer cell targeting and the subsequent formation of a cytotoxic drug at the tumor.135 
The ligand, cRGD, is a potent antagonist of the α2β3 receptor, which is overexpressed in many 
tumors. Addition of these microspheres and the precursors for the cytotoxic drug containing a 
boronic acid and iodide moiety to brain cancer cells, led to the formation of the anticancer agent 
and subsequent cell death. These examples utilizing the Pd(0) microspheres demonstrate the 
bioorthogonality of the SMC reactants and reagents for C-C bond formation. 
 
 
Figure 2.11 – The SMC of the fluorogenic probe 31 containing a triflate with a mitochondria-targeting 
signal 32 containing the boronic acid pinacol ester, catalyzed by palladium microspheres, to yield the 
mitochondria-localized fluorophore 33. A) Molecular level. B) Cellular level.133,134 
 
2.4.2 The oxidative Heck reaction 
The oxidative Heck reaction, or oxidative boron Heck, is the Pd(II)-catalyzed reaction 
between an alkene and a boronic acid.136 Alkenes are suitable as reactant in biological systems due 
to their low intrinsic reactivity and they have already been used in several bioconjugation 
reactions, e.g. the thiol-ene reaction,137,138 tetrazine ligation,139,140 tetrazole photoclick141 and olefin 
cross-metathesis.142 The traditional Mizoroki-Heck reaction,143 which is the Pd(0)-catalyzed 
reaction between a primary alkene and an unsaturated halide or triflate, has also been used as 
metal-catalyzed bioconjugation reaction.144 However, the oxidative Heck reaction does not 
require oxygen-free conditions and is therefore more suitable for bioconjugation applications. At 
the end of the catalytic cycle, the catalyst needs re-oxidation of Pd(0) to Pd(II), which can even 
be performed by O2.  
The group of Dekker was the first to use the oxidative Heck reaction for protein 
modification in vitro.145 The Pd-catalyzed reaction between a protein bearing a primary alkene 
and several phenylboronic acid derivatives using BIAN ligand 34 provided high yields at room 
temperature in a neutral buffer and in cell lysate (Figure 2.12A). Unfortunately, a high percentage 
of organic solvent (up to 25% DMF) was necessary, because the Pd-BIAN complex had low 
solubility in aqueous solution. Furthermore, non-specific binding of palladium(II) to certain 
amino acids in the protein, e.g. histidine, was observed, and therefore it was essential to use 
ethylenediaminetetraacetic acid (EDTA) for chelating palladium after the reaction. Both of these 
problems were circumvented by utilizing a water-soluble (EDTA)-Pd(II) complex for the 
biocompatible oxidative Heck reaction.146 The reaction of the alkene-modified protein with 
phenylboronic acid, bearing a biotin moiety, showed full conversion, although relatively long 
reaction times were required (Figure 2.12B). More recently, the oxidative Heck reaction was used 
for in vitro labeling of RNA147 and of proteins after activity-based protein profiling.148 Follow-up 
research must show whether the oxidative Heck reaction is suitable as bioconjugation reaction for 
in cell and in vivo applications. 
 
 
Figure 2.12 – A) The oxidative Heck reaction of a protein bearing a primary alkene with a boronic acid 
reagent, utilizing ligand 34 and Pd(OAc)2. B) The oxidative Heck reaction of a protein using an water-
soluble (EDTA)-Pd(II) complex [a] Na2HPO4 buffer (pH 7.0), DMF, rt, 24 h, 85% to 100%.145 [b] 
Ammonium formate buffer (pH 7.0), rt, 24 h, 100%.146 
 
2.4.3 Copper-catalyzed Chan-Lam coupling 
In 2016, the first example of a biocompatible copper-catalyzed Chan-Lam coupling 
between an aryl or alkenylboronic acid and a heteroatom, to form a carbon-heteroatom bond, was 
reported (Figure 2.13A).149 In a peptide backbone, it was found that the amide moiety preceding 
a histidine residue can selectively be modified with a boronic acid reagent using Cu(OAc)2. The 
copper catalyst coordinates to the histidine and deprotonates the backbone amide, directing the 
oxidative coupling. Several boronic acids were tested and alkenylboronic acids were found 
especially reactive for the modification of a peptide backbone. Attempts to modify the protein 
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lysozyme next to its single histidine residue with an arylboronic afforded only low yield, although 
selective modification was observed.  
 
 
Figure 2.13 – A) Copper-catalyzed Chan-Lam coupling of an amide in a peptide containing a histidine 
moiety with aryl and alkenyl boronic acids. B) Chan-Lam coupling of a protein containing N-terminal 
Glp-His with several functionalized vinylboronic acids. [a] 100 mM HEPES buffer (pH 7.4), rt, 
overnight, 0% to 100%.149 [b] 5 mM N-methylmorpholine buffer (pH 7.4), rt, 30 min.150 
 
Interestingly, the modification of peptides containing N-terminal pyroglutamate-histidine 
(Glp-His) residues was found to proceed much faster than of peptides containing e.g. proline or 
phenylalanine residues next to the histidine (Figure 2.13B).150 Pyroglutamate is a posttranslational 
modification of N-terminal glutamate, whose cyclization is catalyzed by a glutaminyl (QC) 
enzyme. The pyroglutamate modification occurs commonly in nature, although the Glp-His 
sequence is almost non-existent. Furthermore, as pyroglutamate can be engineered in a protein in 
the cell using natural posttranslational modification enzymes, it is readily accessible for 
bioconjugation reactions. The copper-catalyzed Chan-Lam reaction of alkenylboronic acids with 
Glp-His gave a good apparent second-order rate constant (k2 = ca. 4 M-1 s-1). The reaction was 
selective for the modified protein containing the Glp-His sequence in cell lysate, with only slight 
background labeling visible. So far, no bioorthogonal application of the Chan-Lam coupling is 
performed in living cells, possibly due to the toxicity of the copper catalyst. Fortunately, several 
non-toxic approaches have been developed involving use of a copper-catalyst in living systems, 
e.g. for the copper-catalyzed alkyne-azide cycloaddition,151 opening up the way for the Chan-Lam 
reaction in living cells and in vivo. 
 
2.5 Conclusions and Outlook  
 
The reactions reviewed in this chapter demonstrated that boronic acids are promising 
bioconjugation reagents for biological applications. The formation of iminoboronates from 2-
formyl- or 2-acetylphenylboronic and several amine derivatives was described, and so far the 
irreversible product formation utilizing the non-toxic semicarbazide seems most promising. The 
condensation reactions of boronic acids with diols or analogues appeared less suitable, as all esters 
were susceptible to hydrolysis in the presence of biological functional groups. The combination of 
nopoldiol with thiosemicarbazide, however, yielded a stable product with boronic acids that was 
suitable for labeling of the cell wall of bacteria. Unfortunately, none of the non-catalyzed 
bioconjugation reactions have yet been applied in the cytosol of living cells or in vivo.  
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lysozyme next to its single histidine residue with an arylboronic afforded only low yield, although 
selective modification was observed.  
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phenylalanine residues next to the histidine (Figure 2.13B).150 Pyroglutamate is a posttranslational 
modification of N-terminal glutamate, whose cyclization is catalyzed by a glutaminyl (QC) 
enzyme. The pyroglutamate modification occurs commonly in nature, although the Glp-His 
sequence is almost non-existent. Furthermore, as pyroglutamate can be engineered in a protein in 
the cell using natural posttranslational modification enzymes, it is readily accessible for 
bioconjugation reactions. The copper-catalyzed Chan-Lam reaction of alkenylboronic acids with 
Glp-His gave a good apparent second-order rate constant (k2 = ca. 4 M-1 s-1). The reaction was 
selective for the modified protein containing the Glp-His sequence in cell lysate, with only slight 
background labeling visible. So far, no bioorthogonal application of the Chan-Lam coupling is 
performed in living cells, possibly due to the toxicity of the copper catalyst. Fortunately, several 
non-toxic approaches have been developed involving use of a copper-catalyst in living systems, 
e.g. for the copper-catalyzed alkyne-azide cycloaddition,151 opening up the way for the Chan-Lam 
reaction in living cells and in vivo. 
 
2.5 Conclusions and Outlook  
 
The reactions reviewed in this chapter demonstrated that boronic acids are promising 
bioconjugation reagents for biological applications. The formation of iminoboronates from 2-
formyl- or 2-acetylphenylboronic and several amine derivatives was described, and so far the 
irreversible product formation utilizing the non-toxic semicarbazide seems most promising. The 
condensation reactions of boronic acids with diols or analogues appeared less suitable, as all esters 
were susceptible to hydrolysis in the presence of biological functional groups. The combination of 
nopoldiol with thiosemicarbazide, however, yielded a stable product with boronic acids that was 
suitable for labeling of the cell wall of bacteria. Unfortunately, none of the non-catalyzed 
bioconjugation reactions have yet been applied in the cytosol of living cells or in vivo.  
Of the metal-catalyzed reactions discussed, the studies of the biocompatibility of the 
oxidative Heck reaction and the Chan-Lam coupling are still preliminary. Both reactions showed 
promising labeling of proteins in vitro, and future research will hopefully provide more detail as 
to whether the catalyst and reactants are suitable for applications in living systems. In contrast, 
the palladium-catalyzed SMC of an aryl halide with a boronic acid has been employed in vitro 
and in living cells. The largest challenge of the SMC as bioconjugation reaction is the toxicity of 
the palladium and the solubility of the catalytic complex. Optimization of the palladium-ligand 
complex let to successful bioconjugation on the cell wall of bacteria, whereas the invention of 
non-toxic microspheres embedding the palladium catalyst provided the first boronic-acid based 
bioconjugation reactions in living cells.  
 Considering that boronic acids have been used extensively as sensors for biomolecules 
such as diols and reactive oxygen or nitrogen species, it needed to be seen whether boronic acids 
were suitable as bioconjugation reagents in these systems. However, whereas in certain diseases 
the levels of ROS and RNS are high enough for oxidation of boronic acids, in healthy tissue the 
levels of these reactive species are too low for a significant reaction. So far, no deactivation of 
boronic acid handles, which were applied for bioconjugation, by oxidation of ROS/RNS in living 
cells has been reported. Furthermore, only optimized boronic acids containing additional side 
groups or multivalent structures seem to have sufficiently high association constants with 
naturally occurring biological diols for applications as sensor. Most boronic acids will not or only 
slightly react with biological diols and are therefore suitable for bioconjugation reactions with 
non-natural compounds in living systems. Indeed, the described bioconjugation reactions with 
boronic acids that are applied in living systems, did not report on significant side reactions with 
diols, including the diol-rich cell membrane of bacteria and living cells.  
To summarize, boronic acids are excellent and promising bioconjugation reactants, due to 
their high solubility and stability in aqueous solutions and their low toxicity. Furthermore, the 
high rate constants of the bioconjugation reactions described (100 to 106 M-1 s-1) make them 
suitable for both in vitro and in vivo applications. Additionally, the unique reactivity as e.g. Lewis 
acids, render boronic acids attractive compliments to the bioconjugation toolbox. The 
development and use of boronic acids in medicine, as sensors or conjugation handles is only at its 
start and we believe that many opportunities and exciting developments are underway. 
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Abstract 
 
Bioorthogonal reactions are selective reactions that are not affected by any biological functional 
group and are widely used for chemical modification of biomolecules. One of the most widely 
used bioorthogonal reactions is the inverse electron-demand Diels-Alder (iEDDA) reaction 
between a tetrazine and a strained alkene or alkyne due to the high rates of reaction that can be 
achieved. Although non-strained alkenes have been shown to be suitable as bioorthogonal 
reactants, their reaction rates towards tetrazines, however, are relatively slow. As iEDDA reactions 
proceed faster with electron-rich alkenes, we investigated the reaction rates of a set of alkenes 
containing electron-donating substituents. We found that vinylboronic acids (VBAs) especially 
show impressive reaction rates with 3,6-dipyridiyl-s-tetrazine. The reaction of the dipyridyl 
tetrazine with the most reactive VBA gave fast and quantitative formation of the 
dihydropyridazine product as a single isomer, lacking the boronic acid. Derivatives of the boronic 
acid functionality, such as trifluoroborate and boronic esters, were not suitable as bioorthogonal 
reagents as they hydrolyze quickly in aqueous media to their boronic acid analogues.  
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Abstract 
 
Bioorthogonal reactions are selective reactions that are not affected by any biological functional 
group and are widely used for chemical modification of biomolecules. One of the most widely 
used bioorthogonal reactions is the inverse electron-demand Diels-Alder (iEDDA) reaction 
between a tetrazine and a strained alkene or alkyne due to the high rates of reaction that can be 
achieved. Although non-strained alkenes have been shown to be suitable as bioorthogonal 
reactants, their reaction rates towards tetrazines, however, are relatively slow. As iEDDA reactions 
proceed faster with electron-rich alkenes, we investigated the reaction rates of a set of alkenes 
containing electron-donating substituents. We found that vinylboronic acids (VBAs) especially 
show impressive reaction rates with 3,6-dipyridiyl-s-tetrazine. The reaction of the dipyridyl 
tetrazine with the most reactive VBA gave fast and quantitative formation of the 
dihydropyridazine product as a single isomer, lacking the boronic acid. Derivatives of the boronic 
acid functionality, such as trifluoroborate and boronic esters, were not suitable as bioorthogonal 
reagents as they hydrolyze quickly in aqueous media to their boronic acid analogues.  
 
 
  
3.1 Introduction 
 
In the last decades the development of selective reactions between two reactants that are 
unaffected by any of the naturally occurring biological functionalities has been a major research 
area in chemical biology.1–4 These bioorthogonal reactions (Figure 3.1A) make it possible to 
chemically modify biomolecules in their native cellular environment and gain a better 
understanding of their role in a specific biological system or process. The bioorthogonal reaction 
should be high yielding and rapid, and the reactants and product(s) should be soluble and stable 
in aqueous media and non-toxic to the biological system. The use of small reactants is preferred 
to minimize steric interactions with the biomolecule or to facilitate incorporation by the 
endogenous cellular machinery.  
 
 
Figure 3.1. A) Labeling of the protein of interest (POI) using the tetrazine ligation. B) Reagents of the 
tetrazine ligation. Tetrazine I, trans-cyclooctene II, norbornene III, cyclopropene IV, N-acylazetine V and 
terminal alkene VI. 
 
The inverse electron-demand Diels-Alder (iEDDA) reaction between an electron-poor 
tetrazine (Figure 3.1B – I) and an alkene, also known as the Carboni-Lindsey reaction, has gained 
considerable attention for use in bioorthogonal applications.5 As linear and unmodified alkenes 
(Figure 3.1B – VI) showed only poor reaction rates with tetrazines,6,7 most research has been 
directed to the development and use of strained alkenes such as trans-cyclooctene (TCO),8 
norbornene,9 cyclopropene,10,11 or N-acylazetine12 (Figure 3.1B – II-V). In addition to strain, the 
rate of these tetrazine ligations can be significantly enhanced by the introduction of electron-
donating substituents on the alkene bond.13,14 This aspect, however, has been poorly investigated 
in relation to bioorthogonal applications. 
Although the reaction of non-strained primary alkenes with tetrazines is slow (10-2 – 10-3 
M-1 s-1), the small alkenes have been used for genetic encoding using a non-natural amino acid 
containing the alkene and metabolic oligosaccharide engineering using a mannose derivative.6,7 
Here, we investigated whether the reaction rates of the non-strained alkenes with tetrazines could 
be improved by introducing electron-donating substituents on the alkene. We found that a 
boronic acid substituent gave a significant increase in reaction rate and investigated the scope of 
the ligation of dipyridyl-s-tetrazine with a set of vinylboronic acid (VBA) derivatives. 
 
N
N N
N
R
R'
I
R
R
N
H
N
N N
NN
POI POI
A
B
R
O
HN
O
R
N
H
O
RN
R
O
V
III
IV VI
O
O
H
N
R
II
Chapter 354
 
3.2 Results and Discussion 
 
3.2.1 Exploration of electron-donating substituents on non-strained primary alkenes to 
increase its reactivity towards dipyridyl-s-tetrazine 
We started our research by exploring the reaction rate of 3,6-dipyridyl-s-tetrazine 1 with 
primary alkenes containing hydrophilic, electron-donating substituents. These substituents 
should improve the reaction rate of the non-functionalized aliphatic alkene without diminishing 
the water-solubility of the compounds. The reaction progress of the tetrazine ligation was 
followed by UV/Vis spectroscopy, by measuring the decay of the tetrazine as the pink tetrazines 
react towards the colorless or slightly-yellow dihydropyridazines (Figures 3.2A and B). The 
reaction rates of the primary alkenes with dipyridyl-s-tetrazine 1 in 50% MeOH in PBS were 
compared to the rate of 1 with norbornene 2, a reagent that is used extensively in bioconjugation 
reactions (Figure 3.2C). 
 
 
Figure 3.2 – Reactions of dipyridyl-s-tetrazine 1 with norbornene 2 and primary alkenes 3 - 7. A) Scheme 
of the tetrazine ligation. B) Spectrum of the absorbance of the pink tetrazine 1 (1.25 mM) in MeOH/PBS 
1:1. C) The normalized decay of tetrazine 1 (500 μM) during the reaction with alkenes 2 - 7 (5 mM) in 
50% MeOH/PBS, measured at uncontrolled room temperature, followed at 540 nm. [a] Endo/exo = 2:1.  
 
Under the conditions used, the reaction of tetrazine 1 with norbornene 2 was completed 
within 30 minutes. The aliphatic primary alkene 3 showed around 50% conversion after four 
hours while alkene 4, containing an amide substituent, was slightly more reactive. The alkenes 5 
and 6, containing an ester and an ether substituent, respectively, both showed lower conversions 
after four hours than the aliphatic alkene 3. This was remarkable, as electron-rich alkenes, such as 
alkene 6, generally react faster in iEDDA reactions.13,14 Interestingly, introducing a boronic acid 
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of the tetrazine ligation. B) Spectrum of the absorbance of the pink tetrazine 1 (1.25 mM) in MeOH/PBS 
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Under the conditions used, the reaction of tetrazine 1 with norbornene 2 was completed 
within 30 minutes. The aliphatic primary alkene 3 showed around 50% conversion after four 
hours while alkene 4, containing an amide substituent, was slightly more reactive. The alkenes 5 
and 6, containing an ester and an ether substituent, respectively, both showed lower conversions 
after four hours than the aliphatic alkene 3. This was remarkable, as electron-rich alkenes, such as 
alkene 6, generally react faster in iEDDA reactions.13,14 Interestingly, introducing a boronic acid 
substituent on the alkene improved its reactivity in the tetrazine ligation significantly, giving an 
almost similar reaction rate as norbornene 2 with dipyridyl-s-tetrazine 1. 
 
3.2.2 Investigation of the second-order rate constants of VBAs with dipyridyl-s-tetrazine 
As we have found that a boronic acid substituent on a primary alkene gives an impressive 
increase in reaction rate with tetrazine 1, we further evaluated the effects of an additional 
substituent on the alkene. For future applications, this substituent is necessary for the possible 
functionalization of the VBA (Figure 3.3A). In order to properly compare the reactivity of the 
 
 
Figure 3.3 – Determination of the second-order rate constants of tetrazine 1 with alkenes 2 and 7 - 13 in 
50% MeOH/PBS at uncontrolled room temperature. A) Scheme of the tetrazine ligation. B) Data plot of 
(left) the decay of the tetrazine absorption (540 nm) over time in a reaction of 1 (500 μM) with 10 to 20 
equiv. of VBA 7, and (right) the pseudo-first-order rate constants to the concentration of VBA 7, the slope 
of which gives the k2. C) The k2 values of tetrazines 1 with alkenes 2 and 7 - 13, shown on a logarithmic 
scale. [a] Endo/exo = 2:1. [b] E/Z = 1:3. N.d. = not detectible at the measured conditions. 
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VBAs to other reported alkenes, we determined the second-order rate constant (k2) values for all 
reactions. First, the reaction of tetrazine 1 with varying amounts of excess alkene (10 to 20 equiv.) 
were followed by UV/Vis spectroscopy (Figure 3.3B, left). The pseudo-first-order rate constants 
(kobs) are given by the slope of the exponential decay of the tetrazine in time. Next, the pseudo-
first-order rate constants were plotted against the concentration of alkene used. The fit is linear if 
the reaction proceeds with second-order reaction kinetics and the slope provides the k2 for the 
reaction (Figure 3.3B, right). 
We examined the k2 of several commercially available VBAs with 3,6-dipyridyl-s-tetrazine 
1 in 50% MeOH in PBS and compared them to the k2 of norbornene 2 with 1 (Figure 3.3C, 
Table S3.1).5,9 Vinylboronic acid 7 reacted with tetrazine 1 with a k2 of 0.78 M-1 s-1, which is two 
times lower than the k2 of 1 with norbornene 2 and corresponds well with the slight difference in 
reaction rate observed in Figure 3.2C. A methyl substituent on the alkene reduced the rate 
constant at least one order of magnitude, although the (Z)-isomer was almost three times faster 
than the (E)-isomer of 8. Addition of a phenyl ring trans to the VBA increased the k2 
significantly, (E)-phenylvinylboronic acid 9 showed a five-fold higher rate constant than VBA 7. 
Introduction of an electron-donating methoxy substituent on the phenyl ring of (E)-9 further 
increased the reaction rate, giving a k2 of 3.2 M-1 s-1 for 12. 
As we observed a high reaction rate of the (Z)-isomer of 8 compared to the (E)-isomer, we 
additionally synthesized and evaluated the k2 of the (Z)-isomer of 9 (Scheme 3.1). Hydroboration 
of phenylacetylene with pinacolborane using a rhodium catalyst yielded alkene 14 solely as the 
(Z)-isomer in acceptable yield.15 Deprotection of the pinacol ester via the trifluoroborane salt 
15,16 yielded boronic acid (Z)-9. Unfortunately, the tetrazine ligation of dipyridyl-s-tetrazine 1 
with (Z)-9 gave a k2 of only 0.095 M-1 s-1, which was more than one order of magnitude lower 
than the k2 of (E)-9 with 1. 
 
 
Scheme 3.1 – Synthesis of (Z)-2-phenylvinylboronic acid (Z)-9. i) Pinacolborane, Rh(cod)Cl2, i-Pr3P, 
Et3N, cyclohexane, 4 h, 39%. ii) KHF2, H2O, MeOH, 0 °C to rt, 2 h, 58%. iii) SiO2, H2O, 2 h, 74%. 
 
To evaluate the effect of the boronic acid on the alkene’s reactivity, we next compared the 
rate constants of the fastest VBAs (E)-9 and 12 to the alkene derivatives lacking the boronic acid 
(Figure 3.3C). Under the measured conditions, we could estimate a decrease in rate constants of 
styrene 10 and p-methoxystyrene 13 of at least two orders of magnitude, although we could not 
determine the k2 accurately due to the low reaction rate and poor solubility of the unsubstituted 
alkene in the aqueous environment. Introduction of an electron-donating alkoxy substituent on 
the alkene, as in β-methoxystyrene 11, did not result in a significant increase in reaction rate, as 
was previously observed in Figure 3.2C. These results clearly indicate that the boronic acid has a 
large positive effect on the reactivity of the alkene. 
 
3.2.3 Evaluation of vinyl boronic esters in the iEDDA with dipyridyl-s-tetrazine  
Previously, it was shown that addition of substituents on the boron center has a large 
effect on the nucleophilicity.17 Ligands that hybridize boron to sp3 and form an anionic boronate 
give a large increase in nucleophilicity, whereas ligands containing electron-withdrawing 
substituents, like the MIDA ester, decrease the nucleophilicity. In organic reactions, such as the 
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constant at least one order of magnitude, although the (Z)-isomer was almost three times faster 
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Introduction of an electron-donating methoxy substituent on the phenyl ring of (E)-9 further 
increased the reaction rate, giving a k2 of 3.2 M-1 s-1 for 12. 
As we observed a high reaction rate of the (Z)-isomer of 8 compared to the (E)-isomer, we 
additionally synthesized and evaluated the k2 of the (Z)-isomer of 9 (Scheme 3.1). Hydroboration 
of phenylacetylene with pinacolborane using a rhodium catalyst yielded alkene 14 solely as the 
(Z)-isomer in acceptable yield.15 Deprotection of the pinacol ester via the trifluoroborane salt 
15,16 yielded boronic acid (Z)-9. Unfortunately, the tetrazine ligation of dipyridyl-s-tetrazine 1 
with (Z)-9 gave a k2 of only 0.095 M-1 s-1, which was more than one order of magnitude lower 
than the k2 of (E)-9 with 1. 
 
 
Scheme 3.1 – Synthesis of (Z)-2-phenylvinylboronic acid (Z)-9. i) Pinacolborane, Rh(cod)Cl2, i-Pr3P, 
Et3N, cyclohexane, 4 h, 39%. ii) KHF2, H2O, MeOH, 0 °C to rt, 2 h, 58%. iii) SiO2, H2O, 2 h, 74%. 
 
To evaluate the effect of the boronic acid on the alkene’s reactivity, we next compared the 
rate constants of the fastest VBAs (E)-9 and 12 to the alkene derivatives lacking the boronic acid 
(Figure 3.3C). Under the measured conditions, we could estimate a decrease in rate constants of 
styrene 10 and p-methoxystyrene 13 of at least two orders of magnitude, although we could not 
determine the k2 accurately due to the low reaction rate and poor solubility of the unsubstituted 
alkene in the aqueous environment. Introduction of an electron-donating alkoxy substituent on 
the alkene, as in β-methoxystyrene 11, did not result in a significant increase in reaction rate, as 
was previously observed in Figure 3.2C. These results clearly indicate that the boronic acid has a 
large positive effect on the reactivity of the alkene. 
 
3.2.3 Evaluation of vinyl boronic esters in the iEDDA with dipyridyl-s-tetrazine  
Previously, it was shown that addition of substituents on the boron center has a large 
effect on the nucleophilicity.17 Ligands that hybridize boron to sp3 and form an anionic boronate 
give a large increase in nucleophilicity, whereas ligands containing electron-withdrawing 
substituents, like the MIDA ester, decrease the nucleophilicity. In organic reactions, such as the 
Suzuki-Miyaura coupling, the more nucleophilic boronates have shown to give increased reaction 
rates.18 Therefore, we next evaluated the reaction rate of several alkenes containing various 
boronic esters or borate substituents with dipyridyl-s-tetrazine 1, and compared them to the 
reaction rate of their boronic acid analogues (Figure 3.4). 
Especially the negatively charged trifluoroborate 16 showed an increased reaction rate 
compared to phenylvinylboronic acid (E)-9. Unfortunately, the trifluoroborate was unstable in 
aqueous solution, and hydrolyzed quickly to its boronic acid analogue as evidenced by 1H NMR 
experiments (data not shown). Therefore, we synthesized a different negatively charged boron-
containing compound, triolborate 17, that we expected to be more stable in aqueous 
environments due to the bulky substituent surrounding the boron. Although 17 was indeed more 
stable than trifluoroborate 16, a similar reaction rate was observed as for VBA (E)-9 and slow 
hydrolysis in aqueous solution was still noticeable. The unsubstituted vinylboronic acid pinacol 
ester 18 reacted slightly slower with tetrazine 1 compared to vinylboronic acid 7, whereas the less 
electron-rich MIDA ester 19 reacted significantly slower than 18 and 7. Unfortunately, all tested 
boron-containing compounds hydrolyzed in aqueous environment and are therefore not suitable 
for application in an aqueous system, although they could possibly be used as precursor for their 
boronic acid derivatives. Important to note is that the observed reaction rates with tetrazine 1 in 
1:1 MeOH/H2O as depicted in Figure 3.4 are not accurate, due to the instability of the boron-
containing compounds. 
 
 
Figure 3.4 – The reaction between dipyridyl-s-tetrazine 1 (500 μM) and several boron-containing 
compounds 16 – 19 (5 mM) in 50% MeOH/H2O, measured at room temperature at 540 nm. A) 
Reactions of 1 with 16 and 17, compared to the reaction with VBA (E)-9. B) Reactions of 1 with 18 and 
19, compared to the reaction with VBA 7. The reaction rates are not accurate, because the boron-
containing compounds 16 - 19 hydrolyze in aqueous solvent to their boronic acid analogues.  
 
3.2.4 Evaluation of the reactivity of VBAs towards other tetrazines  
The reactions of VBAs 7, (E)-9 and 12 were additionally studied with 3-phenyl-s-
tetrazine 20 and 3-phenyl-6-methyl-s-tetrazine 21, and the reaction rates were compared with 
those with dipyridyl-s-tetrazine 1 (Figure 3.5). Interestingly, compared to the reaction rate of 
these tetrazines with norbornene 2, the reactions of the VBAs with tetrazines 20 and 21 are much 
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Figure 3.5 – The reaction between the tetrazines (500 μM) and alkenes (5 mM) in 50% MeOH/PBS were 
compared by measuring the absorbance at 540 nm of the tetrazines during the reaction over time. The 
normalized decrease of 3-methyl-6-phenyl-s-tetrazine 20 and 3-phenyl-s-tetrazine 21 for 2 hours and 3,6-
dipyridyl-s-tetrazine 1 for 30 min during the reaction with norbornene 2 and VBAs 7, (E)-9 and 12 is 
shown. [a] Endo/exo = 2:1. 
 
3.2.5 Formation of a single dihydropyridazine after the reaction of dipyridyl-s-tetrazine 1 
and VBA 12 
We then looked in more detail into the reaction of 3,6-dipyridyl-s-tetrazine 1 and the 
most reactive VBA 12 (Figure 3.6A). We observed quantitative formation of dihydropyridazine 
22 as the most abundant isomer, lacking the boronic acid. The dihydropyridazine product 22 is 
the same as found in the reaction of tetrazine 1 with p-methoxystyrene 13 (experimental 
section).19 We followed the tetrazine ligation in 9:1 CD3OD/D2O over time by 1H NMR, which 
showed the formation of dihydropyridazine 22 within 2 minutes and full conversion within 24 
hours (Figures 3.6B and S3.1). No intermediates were observed in 1H-NMR during the reaction 
between 1 and 12, showing that the protodeborylation of boric acid is fast. We therefore propose 
a mechanism whereby boric acid is released immediately after the iEDDA cycloaddition and 
subsequent dinitrogen release by a retro-Diels-Alder reaction (Figure 3.6C). 
During our NMR studies, we observed slow oxidation of the dihydropyridazine 22 to the 
pyridazine product 23 (~35% after 14 days in 9:1 CD3OD/D2O, 5 mM, data not shown). As 
defined product formation is essential for some experimental applications, for example in mass 
spectrometry analysis, we examined the stability of the dihydropyridazine 22 in more detail. The 
following observations were made: 1) The oxidation of 100 μM of 22 in aqueous solution (1% 
DMSO in PBS) was complete after 7 days (data not shown). 2) 22 was stable during purification 
by normal and reversed phase column chromatography (experimental section). 3) In a possible 
acidic HPLC solvent (MeCN/H2O with 0.1% TFA) no oxidation but tautomerization of 22 was 
observed (see experimental section). The oxidation of dihydropyridazines can be accelerated using 
an oxidation reagent, which was previously performed to eliminate tautomers and facilitate regio-
isomeric characterization of the final product.14 Indeed, 22 could be oxidized nearly 
quantitatively to pyridazine 23 by simple addition of chloranil to the reaction mixture (Figure 
3.6A). It should be emphasized though, that for many bioorthogonal applications, the oxidation 
of the dihydropyridazine is insignificant, whereas both 22 and 23 are covalent ligation products 
of the reaction of VBA 12 with tetrazine 1. 
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Figure 3.6 – The reaction of tetrazine with vinylboronic acids. A) Scheme of the reaction of 3,6-dipyridyl-
s-tetrazine 1 with VBA 12. i) MeOH/H2O 1:1, 8 h, quant. ii) Oxidation in time or by using chloranil, 
MeOH/H2O 1:1, 2 h, 96%. B) 1H-NMR study (500 MHz) of the reaction between 3,6-dipyridyl-s-
tetrazine 1 (∎) and VBA 12 () (1:1, both 5 mM) yielding dihydropyridazine 22 (▲) in CD3OD/D2O 
9:1. C) Proposed reaction mechanism.  
 
3.3 Conclusions and Outlook 
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substituents on the non-strained alkene in the tetrazine ligation with dipyridyl-s-tetrazine and 
found that a boronic acid moiety gives a large increase in reactivity. 
Vinylboronic acids (VBAs) are an interesting class of compounds with unique electronic 
properties due to their vacant p-orbital. As a result of the inductive effect that is caused by the 
electronegativity difference of boron and carbon, the electronic deficiency of boron and the 
electron-donating oxygens attached to boron, the boronic acid is considered a weak electron-
donor.20 Furthermore, boronic acids are mild organic Lewis acids, which in basic aqueous media 
are in equilibrium with their boronate anion, which is a strong electron-donor.20 Although Diels-
Alder reactions are known to proceed faster in aqueous media, the tetrazine ligations of 
vinylboronic acids and alkylboronic acids were reported only in organic solvents, and high 
temperatures were often needed for the reactions to proceed.21–23 Although boron-containing 
organic compounds are rarely found in nature, they are extremely suitable for chemical biological 
applications due to their hydrophilicity, stability and low toxicity. Their use in cellular systems 
has increased over the past years as, for example, protease inhibitor24, biosensor25, fluorescent 
sensor26, activating reagent27 or reactant in a metal-catalyzed bioconjugation reaction28. 
We showed that vinylboronic acids give, depending on the substituents, second-order rate 
constants up to 3.2 M-1 s-1 in the tetrazine ligation in 50% MeOH/PBS at room temperature. 
Other boron-containing compounds that were investigated, e.g. trifluoroborate and boronic 
esters, all hydrolyzed in aqueous media towards their boronic acid analogues, making them 
unsuitable for biological application. The reaction of 3,6-dipyridyl-s-tetrazine and the most 
reactive VBA, (E)-(4-methoxyphenyl)vinylboronic acid, gave quantitative formation of the 
dihydropyridazine product as a single isomer, lacking the boronic acid. The hydrophilic 
properties and the small size of the synthetically accessible VBAs make them attractive for use in 
protein modifications and other biomolecular labeling applications. Therefore, we next 
investigated whether the VBAs are biocompatible with biological functional groups and suitable 
for protein modification, which is described in Chapter 4. 
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3.5 Experimental Section 
 
3.5.1 Synthetic procedures 
Unless stated otherwise, all chemicals were obtained commercially and used without further purification, 
whereof 5-norbornene-2-methanol 2 was a mixture of endo/exo isomers (2:1), and β-methoxystyrene 11 a 
mixture of E/Z isomers (1:3). If no further details are given, the reaction was performed under nitrogen 
atmosphere and temperature. Analytical thin layer chromatography (TLC) was performed on silica gel-
coated plates (Merck, 60 F254) with the indicated solvent mixture, visualization was done using ultraviolet 
(UV) irradiation (λ = 254 nm) and/or staining with aqueous KMnO4, ninhydrin, or alizarin29. Purification 
by column chromatography was carried out using silica gel 60 (Merck, 0.040-0.063 mm), reversed-phase 
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(UV) irradiation (λ = 254 nm) and/or staining with aqueous KMnO4, ninhydrin, or alizarin29. Purification 
by column chromatography was carried out using silica gel 60 (Merck, 0.040-0.063 mm), reversed-phase 
column chromatography was carried out using C18 Functional, Irregular Silica (Screening Devices, 0.040-
0.063 mm. 60 Å, 12% functionalization). 
 
1H NMR spectra were recorded on a Bruker DMX 300 (300 MHz) or a Bruker Avance III 400 (400 
MHz) or 500 (500 MHz) spectrometer. TMS (δH 0.00) or the residual peak of (CD3)2CO ((C3HD5O) 
δH 2.05), CDCl3 ((CHCl3) δH 7.26), (CD3)2SO ((C2HD5SO) δH 2.50), CD3CN ((CHD2CN) δH 
1.94), CD3OD ((CHD3O) δH 3.31) or D2O ((HDO) δH 4.79) were used as the internal reference. 13C 
NMR spectra were recorded on a Bruker DMX 300 (75 MHz), or a Bruker Advance III 400 (100 MHz) 
or 500 (125 MHz) spectrometer in (CD3)2CO (δC 29.8), CDCl3 (δC 77.2), (CD3)2SO (δC 39.5), 
CD3CN (δC 1.3 and 118.3), or CD3OD (δC 49.0), using their central resonance as the internal 
reference. All 13C NMR spectra were proton decoupled. In 13C NMR spectra the signal belonging to the 
carbon next to boron is broadened and as a result often becomes undetectable in the baseline.20 11B NMR 
spectra were measured on the Bruker Avance III 400 (128 MHz) and calibrated with BF3·Et2O (0.0 ppm) 
as external reference. A blank spectrum (same type of tube, same parameters, containing only the solvent) 
was detracted from the recorded spectrum in order to remove the 11B background signal of the tube and 
NMR probe. 19F spectra were measured on the Bruker Avance III 400 (377 MHz) and referenced from 
the 1H spectrum using the Unified Chemical Shift Scale.  
 
Absorbance measurements were performed at the Infinite M200 Pro plate reader (Tecan), if not stated 
otherwise. UV/Vis spectra were recorded on a Cary 50 Cone UV-visible spectrophotometer (Varian). 
Low-resolution mass spectra (LRMS) were recorded on Thermo LCQ Advantage Max (Electrospray 
Ionization (ESI)). A Thermo Finnigan LCQ Fleet ESI ion-trap mass spectrometer, which is equipped with 
a Shimadzu HPLC (C18-column, 150 × 3 mm, particle size 3 μm, linear gradient 5 to 100% MeCN in 
H2O (0.1% TFA), 1 - 35 minutes and a ﬂow of 0.2 mL/min) and a PDA detector, was used to separated 
organic compounds and record a low-resolution mass spectra. GCMS spectra were recorded on a Thermo 
Finnigan Trace GC PolarisQ with a HP-5MS capillary column (30 m × 0.25 mm × 0.25 μm) using 
method 100°C (3 min) [15°C/min] 300°C (4 min). High-resolution mass spectra (HRMS) of small 
molecules were recorded on a JEOL AccuTOF JMS-T100CS (ESI). Not surprisingly, the boron-
containing compounds were not found using mass spectroscopy, they are notorious for being difficult to 
detect with mass spectrometry due to low volatility and boroxine formation.20,30 
 
(Z)-2-Phenylvinylboronic acid pinacol ester (14) is synthesized according to a modified literature 
procedure.15 A schlenk flask was loaded with [Rh(cod)Cl2] (7 mg, 0.015 mmol, 0.015 
equiv.) and flushed with argon. Cyclohexane (3 mL) and Et3N (0.7 mL, 5.0 mmol, 5.0 
equiv.) were added, after which the mixture was stirred with molecular sieves (4 Å) and 
bubbled with argon for 15 min. Then, triisopropylphosphine (11 μL, 0.06 mmol, 0.06 
equiv.) and pinacolborane (0.15 mL, 1.0 mmol, 1.0 equiv.) were added, followed after 30 min by 
ethynylbenzene (0.22 mL, 2.0 mmol, 2.0 equiv.). The reaction mixture was stirred for 4 h, after which 
MeOH was added and stirred for 2 min, then the volatiles were evaporated. The mixture was purified by 
column chromatography (2.5% Et2O in pentane) yielding product 14 as a green oil (90 mg, 39%). Rf = 
0.55 (10% Et2O in pentane). 1H NMR (400 MHz, (CD3)2CO) δ 7.58 (d, J = 7.3 Hz, 2H), 7.37 – 7.25 
(m, 3H), 7.19 (d, J = 15.0 Hz, 1H), 5.54 (d, J = 14.9 Hz, 1H), 1.27 (s, 12H). 13C NMR (100 MHz, 
(CD3)2CO) δ 148.4, 139.5, 129.4, 128.9, 128.8, 84.1, 25.1. No signal was observed for the carbon 
attached to boron. 11B NMR (128 MHz, (CD3)2CO) δ 30.1 (s). 
 
  
Chapter 362
Potassium (Z)-2-phenylvinyltrifluoroborate (15). Pinacol ester 14 (228 mg, 1.0 mmol, 1.0 equiv.) was 
dissolved in MeOH (2 mL) and cooled to 0 °C under ambient atmosphere. A solution of 
KHF2 (391 mg, 5.0 mmol, 5.0 equiv.) in H2O (1.1 mL) was added dropwise, whereupon 
the mixture was stirred at rt for 2 h. The volatiles were removed under reduced pressure, 
water was added and the mixture was lyophilized. The crude product was dissolved in minimal amounts of 
dry acetone (3 × 1 mL), filtered, and evaporated to yield trifluoroborate salt 15 as a white powder (130 
mg, 58%). 1H NMR (400 MHz, (CD3)2CO) δ 7.70 (d, J = 7.7 Hz, 2H), 7.11 (t, J = 7.7 Hz, 2H), 6.98 (t, 
J = 6.8 Hz, 1H), 6.57 – 6.42 (m, 1H), 5.80 – 5.72 (m, 1H). 13C NMR (100 MHz, (CD3)2CO) δ 143.6*, 
142.2, 136.4 (q, J = 5.5 Hz), 129.5 (q, J = 2.9 Hz), 128.0, 126.0. *Observed via 1H-13C HSQC NMR, 
while not visible in 13C NMR. 11B NMR (128 MHz, (CD3)2CO) δ 2.4 (q, J = 55 Hz). 19F NMR (377 
MHz, (CD3)2CO) δ -136.3 (1:1:1:1 quartet, J = 54 Hz). The data agrees with the reported literature 
values.16  
 
(Z)-2-Phenylvinylboronic acid ((Z)-9). Trifluoroborate 15 (130 mg, 0.6 mmol, 1.0 equiv.) was stirred 
with H2O (5 mL) and silica powder (0.4 g) under ambient atmosphere for 2 h. The 
product was extracted with Et2O, after which the organic layers were washed with brine 
and dried over Na2SO4. The volatiles were removed using a rotary evaporator at rt. 
Boronic acid (Z)-9 was obtained as a white powder (120 mg, 74%). 1H NMR (400 MHz, (CD3)2CO) δ 
7.50 – 7.45 (m, 2H), 7.36 – 7.27 (m, 2H), 7.26 – 7.20 (m, 1H), 7.03 (s, 2H), 6.94 (d, J = 14.8 Hz, 1H), 
5.68 (d, J = 15.0 Hz, 1H). 13C NMR (100 MHz, (CD3)2CO) δ 142.7, 140.1, 129.0, 128.7, 128.2. No 
signal was observed for the carbon attached to boron. 11B NMR (128 MHz, (CD3)2CO) δ 29.5 (s). 
Vinylboronic acid (Z)-9 was not visible on mass spectrometry. 
 
Potassium (E)-2-phenylvinyltriolborate (17). VBA (E)-9 (100 mg, 0.67 mmol, 1.0 equiv.) was 
dissolved in toluene (4 mL) and 1,1,1-tris(hydroxymethyl)ethane (81 mg, 0.67 
mmol, 1.0 equiv.) and molecular sieves (4 Å) were added. The reaction was stirred at 
90 °C overnight, before the mixture was filtrated and the volatiles were removed 
under reduced pressure. Next, the mixture was dissolved in toluene (2 mL), and KOH (38 mg, 0.67 
mmol, 1.0 equiv.) and molecular sieves (4 Å) were added. The reaction was stirred again at 90 °C 
overnight, before the mixture was filtrated and the volatiles were removed under reduced pressure, yielding 
triolborate 17 (108 mg, 59%) as a slightly yellow solid. 1H NMR (400 MHz, (CD3)2SO) δ 7.55 – 7.48 
(m, 2H), 7.39 – 7.27 (m, 3H), 7.20 (d, J = 18.3 Hz, 1H), 6.04 (d, J = 18.3 Hz, 1H), 3.60 (s, 6H), 0.83 
(s, 3H). 13C NMR (100 MHz, (CD3)2SO) δ 145.9, 137.4, 128.6, 128.5, 126.8, 66.2, 36.4, 17.1. No 
signal was observed for the carbon attached to boron. Vinylboronate 17 was not visible on mass 
spectrometry. 
 
3-Methyl-6-phenyl-1,2,4,5-tetrazine (20). Benzonitrile (400 μL, 3.88 mmol, 1.0 equiv.), acetonitrile 
(2.0 mL, 38.3 mmol, 10 equiv.) and Zn(OTf)2 (705 mg, 1.94 mmol, 0.5 equiv.) were mixed in 
dioxane (1.5 mL) and slowly hydrazine monohydrate (9.4 mL, 194 mmol, 50 equiv.) was added. 
After the mixture had stirred o/n at 60 °C, it was cooled down to rt and NaNO2 (5.35 g, 77.6 
mmol, 20 equiv.) in H2O (50 mL) was added. HCl (1 M) was dropwise added until the toxic gas 
evolution stopped, the pH < 3 and the solution turned red, whereupon the mixture was extracted 
with CH2Cl2 (3 ×). The combined organic layers were dried over Na2SO4, the volatiles were removed and 
the crude product was purified with column chromatography (5 to 10% EtOAc in heptane) yielding 
tetrazine 20 (284 mg, 42%) as purple crystals. Rf = 0.36 (10% EtOAc in heptane). 1H NMR (300 MHz, 
CDCl3) δ 8.62 – 8.55 (m, 2H), 7.67 – 7.55 (m, 3H), 3.10 (s, 3H). 13C NMR (75MHz, CDCl3) δ 197.5, 
194.3, 162.7, 162.0, 159.4, 158.1, 51.3. GCMS 9.14 min, m/z = 172 (M+·, calcd. for C9H8N4 172), 103 
[(M-C2H3N3)+, 100%], 76 [(M-C3H3N4)+, 40%]. Data agrees with the reported literature values.31 
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3-Phenyl-1,2,4,5-tetrazine (21) is synthesized according to a modified literature procedure.32 Ethyl 
iminobenzoate HCl (1.0 g, 5.4 mmol, 1.0 equiv.) was dissolved in hydrazine monohydrate (5.2 
mL, 108 mmol, 20 equiv.), formamidine acetate salt (2.24 g, 21.6 mmol, 4.0 equiv.) was added 
portionwise and the mixture was stirred o/n in open vessel. Then, AcOH (10 mL was added and 
the solution was cooled to 0 °C. Portionwise NaNO2 (1.49 g, 21.6 mmol, 4.0 equiv.) was added, 
whereupon H2O (10 mL) was added and the suspension was stirred for 1 h. Then, icewater (50 
mL) was added and the red solid was filtered off. Finally, the crude solid was purified by column 
chromatography (5 to 10% EtOAc in heptane) yielding tetrazine 21 (484 mg, 57%) as a red solid. Rf = 
0.41 (10% EtOAc in heptane). 1H NMR (300 MHz, CDCl3) δ 10.22 (s, 1H), 8.68 – 8.61 (m, 2H), 7.71 
– 7.57 (m, 3H). 13C NMR (75MHz, CDCl3) δ 166. 7, 158.0, 133.3, 131.8, 129.5, 128.5. GCMS (8.22 
min) m/z = 158 (M+·, 5%, calcd. for C8H6N4 158), 103 [(M-CHN3)+, 100%], 76 [(M-C2HN4)+, 50%].  
 
4-(4-Methoxyphenyl)-3,6-di(pyridin-2-yl)-1,4-dihydropyridazine (22). A) 3,6-Dipyridyl-s-tetrazine 1 
(24 mg, 0.10 mmol, 1.0 equiv.) and (E)-(4-methoxyphenyl)vinylboronic acid 12 (18 
mg, 0.10 mmol, 1.0 equiv.) were mixed in 1:1 MeOH/H2O (1 mL) under ambient 
atmosphere and stirred for 8 h. H2O was added and the mixture was extracted with 
CH2Cl2 (3 ×). The combined organic layers were washed with brine and dried over 
Na2SO4, whereupon the volatiles were removed yielding dihydropyridazine 22 as a 
yellow solid (36 mg, quant.) B) 3,6-Dipyridyl-s-tetrazine 1 (25 mg, 0.11 mmol, 1.0 
equiv.) and 4-methoxystyrene 13 (14 mg, 0.11 mmol, 1.0 equiv.) were mixed in 1:1 
MeOH/H2O (1 mL) and stirred for 16 h. Half-saturated NaCl solution (aq.) was added and the mixture 
was extracted with CH2Cl2 (3 ×). The combined organic layers were dried over Na2SO4, and the solvents 
were evaporated yielding dihydropyridazine 22 as a yellow solid (33.5 mg, 96%). The solid can be purified 
using column chromatography (25% EtOAc in heptane) yielding dihydropyridazine 22 (32 mg, 92%) or 
by reversed phase column chromatography (100% H2O to 100% MeOH) yielding 22 (26 mg, 75%) 
without notable formation of the oxidized pyridazine product 23. Rf = 0.35 (25% EtOAc in heptane). 1H 
NMR (400 MHz, CDCl3) δ 9.31 (s, 1H), 8.59 – 8.55 (m, 1H), 8.54 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 
8.09 – 8.05 (m, 1H), 7.70 – 7.66 (m, 2H), 7.65 – 7.58 (m, 1H), 7.36 – 7.30 (m, 2H), 7.25 – 7.19 (m, 
1H), 7.17 – 7.12 (m, 1H), 6.79 – 6.73 (m, 2H), 5.80 (dd, J = 6.3, 2.3 Hz, 1H), 5.48 (d, J = 6.3 Hz, 1H), 
3.72 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 158.4, 155.3, 150.6, 148.53, 148.50, 142.4, 136.6, 136.5, 
136.2, 136.0, 129.2, 123.1, 122.7, 121.2, 119.0, 114.1, 99.4, 55.3, 36.0. HRMS (ESI+) m/z calcd. for 
C21H18N4O [M+H]+ 343.15589, found: 343.15625.  
 
4-(4-Methoxyphenyl)-3,6-di(pyridin-2-yl) pyridazine (23). Dihydropyridazine 22 slowly oxidizes over 
time in solution to pyridazine 23. Dihydropyridazine 22 can also be oxidized using 
chloranil (49 mg, 0.20 mmol, 2.0 equiv.), which was added after the reaction of 3,6-
dipyridyl-s-tetrazine 1 (24 mg, 0.10 mmol, 1.0 equiv.) and (E)-(4-
methoxyphenyl)vinylboronic acid 12 (18 mg, 0.10 mmol, 1.0 equiv.) in 1:1 
MeOH/H2O (1 mL). The mixture was stirred for 2 h under ambient atmosphere, then 
H2O was added and the mixture was extracted with CH2Cl2 (3 ×). The combined 
organic layers were dried over Na2SO4 and the solvents were evaporated. The crude 
mixture was purified using column chromatography (60% EtOAc in heptane) yielding pyridazine 23 (33 
mg, 96%) as a yellow solid. Rf = 0.30 (60% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 8.84 – 
8.76 (m, 1H), 8.78 – 8.71 (m, 1H), 8.65 (s, 1H), 8.57 – 8.50 (m, 1H), 7.92 (td, J = 7.7, 1.8 Hz, 1H), 
7.87 – 7.78 (m, 2H), 7.42 (ddd, J = 7.6, 4.8, 1.3 Hz, 1H), 7.30 (ddd, J = 7.2, 4.9, 1.6 Hz, 1H), 7.24 – 
7.18 (m, 2H), 6.86 – 6.81 (m, 2H), 3.82 (s, 3H). LCMS (ESI+), rt. 21.54 min, m/z calcd. for C21H18N4O 
[M+H]+ 341.1, found: 341.5. HRMS (ESI+) m/z calcd. for C21H16N4O [M+H]+ 341.14024, found: 
341.14088. 
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4-(4-Methoxyphenyl)-3,6-di(pyridin-2-yl)-1,4-dihydropyridazine (22) and 5-(4-methoxyphenyl)-
3,6-di(pyrid-in-2-yl)-1,4-dihydropyridazine (S1). To determine 
which isomer was formed in the possible HPLC solvent, 
dihydropyridazine 22 was dissolved in CH3CN/H2O 1:1 with 1% 
TFA at 5 mM under ambient atmosphere. After 24 h the solution 
was lyophilized, yielding a 1:1 mixture of isomers 22 and S1. 
Dihydropyridazine 22: 1H NMR (500 MHz, CD3CN) δ 10.18 (s, 
1H), 8.62 – 8.59 (m, 1H), 8.57 (ddd, J = 5.9, 1.7, 0.7 Hz, 1H), 
8.38 (td, J = 8.0, 1.6 Hz, 1H), 7.89 (dt, J = 8.3, 0.9 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.78 – 7.70 (m, 2H), 
7.40 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.30 – 7.25 (m, 2H), 6.92 – 6.87 (m, 2H), 6.00 (dd, J = 5.7, 2.3 
Hz, 1H), 4.95 (d, J = 5.7 Hz, 1H), 3.73 (s, 3H). 13C NMR (125 MHz, CD3CN) δ 160.4, 149.9, 149.3, 
148.5, 148.2, 143.0, 138.8, 136.2, 133.9, 131.7, 129.7, 126.0, 125.1, 124.3, 120.4, 115.6, 103.2, 56.0, 
37.1. LCMS (ESI+) Rt = 19.59 min, m/z calcd. for C21H18N4O [M+H]+ 343.2, found: 343.2. Isomer S1: 
1H NMR (500 MHz, CD3CN) δ 9.79 (s, 1H), 8.66 (ddd, J = 5.2, 1.8, 0.9 Hz, 1H), 8.62 – 8.59 (m, 1H), 
8.50 (td, J = 7.9, 1.6 Hz, 1H), 8.06 (dt, J = 8.3, 1.0 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.78 – 7.70 (m, 1H), 
7.45 (ddd, J = 7.6, 5.1, 1.2 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.17 – 7.11 (m, 2H), 6.85 – 6.80 (m, 2H), 
3.77 (s, 3H), 3.69 (s, 2H). 13C NMR (125 MHz, CD3CN) δ 160.5, 151.3, 148.7, 148.5, 148.0, 142.7, 
139.6, 132.1, 131.2, 130.8, 129.5, 127.3, 125.9, 125.4, 124.4, 114.8, 108.9, 56.0, 27.4. 37.1. LCMS 
(ESI+) Rt = 18.70 min, m/z calcd. for C21H18N4O [M+H]+ 343.2, found: 343.2. 
 
3.5.2 Determination of reaction rates 
Reaction rate of tetrazines 1 with primary alkenes 
The reactions between tetrazines 1 (500 μM) and the alkenes 2 - 7 (5 mM, 10 equiv.) in 50% 
MeOH/PBS were followed on a plate reader at uncontrolled rt, by measuring the absorbance decay of the 
tetrazine at 540 nm. The tetrazine and alkene were both dissolved in methanol, and then diluted with 1 × 
PBS. The reactions were followed on a plate reader which started the measurement after ±20 s and no 
shaking was performed before the measurement. The data was normalized and plotted in Figure 3.2C.  
 
Reaction rate of tetrazines 1 with different boron-containing compounds 
The reaction rates between tetrazines 1 (500 μM) and the different boron-containing compounds 16 - 19 
(5 mM, 10 equiv.) in 50% MeOH/H2O were determined with the same method as for the primary 
alkenes. Because the data was not accurate, since the boron-containing compounds hydrolyze in aqueous 
environment, the data was shown relative to boronic acid 7 or (E)-9 and shown in Figure 3.4. 
 
Reaction rate of tetrazines 1, 20 and 21, with several alkenes 
The reactions between tetrazines 1, 20 and 21, (500 μM) and the alkenes 2, 7, (E)-9 and 12 (5 mM, 10 
equiv.) was determined with the same method as for the primary alkenes. The data was normalized and 
plotted in Figure 3.5.  
 
3.5.3 Determination of second-order rate constants 
Tetrazine 1 with the non-aromatic alkenes in 50% MeOH/PBS 
The reactions between the non-aromatic alkenes 2, 7 or 8 (10-20 equiv.) and dipyridyl tetrazine 1 in 50% 
MeOH and 50% 1 × PBS were followed on a plate reader (Sunrise tm, Tecan) at uncontrolled rt, by 
measuring the absorbance decay of the tetrazine at 540 nm. The tetrazine and alkene were both dissolved 
in methanol, and then diluted with 1 × PBS. After addition of the tetrazine to the vinylboronic acid 
solution, the measurement was started after the 96-well plate was shaken for 5 sec. The final concentration 
of the tetrazine was 500 μM and of the excess of alkene was 5.0, 6.25, 7.5, 8.75 or 10 mM. The time 
between the addition of the tetrazine and the start of the measurement was ca. 10 s. All reactions were 
performed in triplo or in quadruplo. The second-order rate constants were determined using Prism 
(GraphPad Software, Inc).  
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4-(4-Methoxyphenyl)-3,6-di(pyridin-2-yl)-1,4-dihydropyridazine (22) and 5-(4-methoxyphenyl)-
3,6-di(pyrid-in-2-yl)-1,4-dihydropyridazine (S1). To determine 
which isomer was formed in the possible HPLC solvent, 
dihydropyridazine 22 was dissolved in CH3CN/H2O 1:1 with 1% 
TFA at 5 mM under ambient atmosphere. After 24 h the solution 
was lyophilized, yielding a 1:1 mixture of isomers 22 and S1. 
Dihydropyridazine 22: 1H NMR (500 MHz, CD3CN) δ 10.18 (s, 
1H), 8.62 – 8.59 (m, 1H), 8.57 (ddd, J = 5.9, 1.7, 0.7 Hz, 1H), 
8.38 (td, J = 8.0, 1.6 Hz, 1H), 7.89 (dt, J = 8.3, 0.9 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.78 – 7.70 (m, 2H), 
7.40 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.30 – 7.25 (m, 2H), 6.92 – 6.87 (m, 2H), 6.00 (dd, J = 5.7, 2.3 
Hz, 1H), 4.95 (d, J = 5.7 Hz, 1H), 3.73 (s, 3H). 13C NMR (125 MHz, CD3CN) δ 160.4, 149.9, 149.3, 
148.5, 148.2, 143.0, 138.8, 136.2, 133.9, 131.7, 129.7, 126.0, 125.1, 124.3, 120.4, 115.6, 103.2, 56.0, 
37.1. LCMS (ESI+) Rt = 19.59 min, m/z calcd. for C21H18N4O [M+H]+ 343.2, found: 343.2. Isomer S1: 
1H NMR (500 MHz, CD3CN) δ 9.79 (s, 1H), 8.66 (ddd, J = 5.2, 1.8, 0.9 Hz, 1H), 8.62 – 8.59 (m, 1H), 
8.50 (td, J = 7.9, 1.6 Hz, 1H), 8.06 (dt, J = 8.3, 1.0 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.78 – 7.70 (m, 1H), 
7.45 (ddd, J = 7.6, 5.1, 1.2 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.17 – 7.11 (m, 2H), 6.85 – 6.80 (m, 2H), 
3.77 (s, 3H), 3.69 (s, 2H). 13C NMR (125 MHz, CD3CN) δ 160.5, 151.3, 148.7, 148.5, 148.0, 142.7, 
139.6, 132.1, 131.2, 130.8, 129.5, 127.3, 125.9, 125.4, 124.4, 114.8, 108.9, 56.0, 27.4. 37.1. LCMS 
(ESI+) Rt = 18.70 min, m/z calcd. for C21H18N4O [M+H]+ 343.2, found: 343.2. 
 
3.5.2 Determination of reaction rates 
Reaction rate of tetrazines 1 with primary alkenes 
The reactions between tetrazines 1 (500 μM) and the alkenes 2 - 7 (5 mM, 10 equiv.) in 50% 
MeOH/PBS were followed on a plate reader at uncontrolled rt, by measuring the absorbance decay of the 
tetrazine at 540 nm. The tetrazine and alkene were both dissolved in methanol, and then diluted with 1 × 
PBS. The reactions were followed on a plate reader which started the measurement after ±20 s and no 
shaking was performed before the measurement. The data was normalized and plotted in Figure 3.2C.  
 
Reaction rate of tetrazines 1 with different boron-containing compounds 
The reaction rates between tetrazines 1 (500 μM) and the different boron-containing compounds 16 - 19 
(5 mM, 10 equiv.) in 50% MeOH/H2O were determined with the same method as for the primary 
alkenes. Because the data was not accurate, since the boron-containing compounds hydrolyze in aqueous 
environment, the data was shown relative to boronic acid 7 or (E)-9 and shown in Figure 3.4. 
 
Reaction rate of tetrazines 1, 20 and 21, with several alkenes 
The reactions between tetrazines 1, 20 and 21, (500 μM) and the alkenes 2, 7, (E)-9 and 12 (5 mM, 10 
equiv.) was determined with the same method as for the primary alkenes. The data was normalized and 
plotted in Figure 3.5.  
 
3.5.3 Determination of second-order rate constants 
Tetrazine 1 with the non-aromatic alkenes in 50% MeOH/PBS 
The reactions between the non-aromatic alkenes 2, 7 or 8 (10-20 equiv.) and dipyridyl tetrazine 1 in 50% 
MeOH and 50% 1 × PBS were followed on a plate reader (Sunrise tm, Tecan) at uncontrolled rt, by 
measuring the absorbance decay of the tetrazine at 540 nm. The tetrazine and alkene were both dissolved 
in methanol, and then diluted with 1 × PBS. After addition of the tetrazine to the vinylboronic acid 
solution, the measurement was started after the 96-well plate was shaken for 5 sec. The final concentration 
of the tetrazine was 500 μM and of the excess of alkene was 5.0, 6.25, 7.5, 8.75 or 10 mM. The time 
between the addition of the tetrazine and the start of the measurement was ca. 10 s. All reactions were 
performed in triplo or in quadruplo. The second-order rate constants were determined using Prism 
(GraphPad Software, Inc).  
Tetrazine 1 with the aromatic alkenes in 50% MeOH/PBS 
The data for the reactions between dipyridyl tetrazine 1 and the aromatic alkenes 9 – 13 were determined 
with the same method as for the non-aromatic alkenes. Not all aromatic alkenes dissolved well at the high 
concentrations needed to measure at 540 nm, therefore the product formation of the reaction was 
followed at 360 nm at a final concentration of 100 μM tetrazine and 10-20 equiv. of alkene. The reactions 
were followed on the plate reader which started the measurement after ±20 s and no shaking was 
performed before the measurement.  
 
Normalization 
For the measurements where the decay of the tetrazine was followed, the observed reactions were 
normalized by setting the plateau at the end of the reaction as 0% and the absorbance at t = 0 s as 100%. 
If the reactions did not end in a plateau after the set time, the plateau was set equal to the background 
absorbance of the dihydropyridazine absorption at the given wavelength. For the measurements where the 
increase of product was measured, the observed reactions were normalized by setting the plateau at the end 
of the reaction as 100% and the absorbance at t = 0 s as 0%. If necessary the plateau was set equal to the 
product absorbance at the given concentration. It was taken into account that the measurement started 
after a certain time (an example is shown in Figure 3.3B left).  
 
Pseudo-first-order rate constant 
The pseudo first-order rate constants kobs for the tetrazine reactions with an excess of alkene was 
determined. The decay of the absorbance of the tetrazine was plotted against time (s) for the 5 different 
concentrations of the alkene. The kobs was determined by fitting an exponential ‘one phase decay’ 
(nonlinear regression) using Prism GraphPad Software whereby Y = (Y0 - plateau) × exp(-kobs × time(s)) + 
plateau (an example is shown in Figure 3.3B right).  
 
Second-order rate constant 
To determine the second-order rate constant, the kobs of the reactions was plotted against the 
concentration of the vinylboronic acid. The line was fitted using linear regression and the slope then gives 
the k2 value. The goodness of the fit is shown by the coefficient of determination (R2). The data is shown 
in Figure 3.3C and Table S3.1.  
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3.7 Supplementary Table and Figure 
 
Table S3.1 – Second-order rate constants of tetrazine 1 with alkenes 2, 7 - 13 
 
 
 
Entry # Structure k2 (M-1 s-1) R2 
1 2[a] 1.4 ± 0.1 0.99 
2 7 0.78 ± 0.06 0.98 
3 (E)-8 0.070 ± 0.006 0.98 
4 (Z)-8 0.18 ± 0.02 0.97 
5 (E)-9 1.4 ± 0.1 
 
0.99 
6 (Z)-9 0.095 ± 0.012 0.96 
7 10 0.0094 ± 0.0010 0.97 
8 (E/Z)-11[b] < 0.01[c] - 
9 12 3.2 ± 0.2 0.99 
10 13 0.026 ± 0.002 0.98 
[a] Endo/exo = 2:1. [b] E/Z = 1:3. [c] k2 could not be determined accurately, due to the 
slow reaction rate and low solubility of the alkenes in water. 
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Figure S3.1 – The reaction of 3,6-dipyridyl-s-tetrazine 1 (5 mM) and (E)-(4-methoxyphenyl)vinylboronic 
acid 12 (5 mM) in CD3OD/D2O 9:1 followed by 1H NMR (500 MHz) for 24 h.  
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Abstract 
 
Bioorthogonal reactions are widely used for chemical modification of biomolecules in vitro and in 
vivo. One of the most popular bioorthogonal reactions is the inverse electron-demand Diels-Alder 
(iEDDA) reaction between a strained alkene and a tetrazine due to the high reaction rates 
observed. In Chapter 3, we described vinylboronic acids (VBAs) as non-strained, hydrophilic 
reaction partners with 3,6-dipyridyl-s-tetrazines and showed that, depending on the substituents, 
reaction rates could be obtained in the same order of magnitude as norbornene, a widely used 
strained alkene. Here we explore the suitability of VBAs for biological labeling applications in a 
more aqueous environment using a sufficiently water soluble 3,6-dipyridyl-s-tetrazine derivative. 
We show that VBAs give with this tetrazine high second-order rate constants of up to 27 M-1 s-1. 
The VBAS are highly stable in aqueous media, compatible to the biomolecules in cell lysate and 
suitable for protein modification. Furthermore, VBAs can be used orthogonally to the strain-
promoted alkyne-azide cycloaddition for protein modification, making them attractive 
complements to the bioorthogonal molecular toolbox.  
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Abstract 
 
Bioorthogonal reactions are widely used for chemical modification of biomolecules in vitro and in 
vivo. One of the most popular bioorthogonal reactions is the inverse electron-demand Diels-Alder 
(iEDDA) reaction between a strained alkene and a tetrazine due to the high reaction rates 
observed. In Chapter 3, we described vinylboronic acids (VBAs) as non-strained, hydrophilic 
reaction partners with 3,6-dipyridyl-s-tetrazines and showed that, depending on the substituents, 
reaction rates could be obtained in the same order of magnitude as norbornene, a widely used 
strained alkene. Here we explore the suitability of VBAs for biological labeling applications in a 
more aqueous environment using a sufficiently water soluble 3,6-dipyridyl-s-tetrazine derivative. 
We show that VBAs give with this tetrazine high second-order rate constants of up to 27 M-1 s-1. 
The VBAS are highly stable in aqueous media, compatible to the biomolecules in cell lysate and 
suitable for protein modification. Furthermore, VBAs can be used orthogonally to the strain-
promoted alkyne-azide cycloaddition for protein modification, making them attractive 
complements to the bioorthogonal molecular toolbox.  
 
 
4.1 Introduction 
 
Bioconjugates of proteins with small molecules or peptides are widely used to e.g. explore 
biosynthetic pathways1, enhance therapeutic properties like drug delivery2 and prepare diagnostic 
applications like surface immobilized biosensors3. Because proteins are often sensitive to the 
conditions employed in organic chemistry, such as high temperatures or organic solvents, 
biocompatible reactions that are high yielding at ambient conditions in aqueous media are needed 
for the preparation of these bioconjugates.4,5 Protein bioconjugates can be prepared by a selective 
reaction with a nucleophilic residue commonly residing on a protein such as lysine, cysteine or 
serine. However, when several of these residues are on the surface of the protein, this results in 
multiple labeling and heterogeneity of the product. Therefore, it is preferred to use a nucleophilic 
residue that is singly expressed on the surface of the protein, or to genetic encode a non-natural 
amino acid site-specifically on the surface of the protein.6-8 
In the last decades, the development of reactions that are unaffected by any of the 
molecular functionalities in a biological system, has been a major field of chemical biology 
research.9–12 The inverse electron-demand Diels-Alder reaction (iEDDA) between a tetrazine and 
an alkene or alkyne is one of the most popular so-called bioorthogonal reaction and is frequently 
used for the formation of protein bioconjugates (Figure 4.1A).13–16 These were developed by e.g. 
the incorporation of a non-natural amino acid containing one of the functional groups, or by 
reacting one of the native nucleophilic residues with a small molecule containing the 
bioorthogonal reagents. In Chapter 3 we described the fast and high-yielding tetrazine ligation 
with vinylboronic acids (VBAs) as non-strained and hydrophilic reaction partner (Figure 4.1B). 
Boronic acids contain a trivalent boron atom and behave as mild Lewis acids due to their vacant 
p-orbital. In aqueous solution, the weak electron-donating boronic acids are in equilibrium with 
their tetravalent, strong electron-donating boronate anion. We found that the non-strained VBAs 
give, depending on the substituents, second-order rate constants (k2) up to 3.2 M-1 s-1 in 50% 
MeOH/PBS with the biocompatible 3,6-dipyridyl-s-tetrazine. The reaction of the most reactive 
VBA, (E)-(4-methoxyphenyl)vinylboronic acid 2, with dipyridyl-s-tetrazine 1 gave full conversion 
 
 
Figure 4.1 – A) Labeling of the protein of interest (POI) using the tetrazine ligation. B) The tetrazine 
ligation with dipyridyl-s-tetrazine 1 with vinylboronic acid 2, providing dihydropyridazine 3 with a k2 of 
3.2 M-1 s-1 in 50% MeOH/PBS at room temperature.  
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to dihydropyridazine 3 as a single isomer, lacking the boronic acid functionality. In this chapter, 
we evaluate the VBAs as bioorthogonal reactants in a more aqueous environment and for protein 
modification in vitro. We evaluated its biocompatibility with several common biological 
functional groups, the stability in aqueous environment and the toxicity to living cells. 
 
4.2 Results and Discussion 
 
4.2.1 Evaluation of the reactivity of VBAs in aqueous conditions using a water soluble 
dipyridyl-s-tetrazine 
In Chapter 3, we explored the reaction of several vinylboronic acids with dipyridyl-s-
tetrazine 1 in 50% MeOH/PBS. Here, we investigate the application of VBAs as bioorthogonal 
reactant for labeling of biomolecules and therefore, the second-order rate constants of the VBAs 
and dipyridyl-s-tetrazine were further investigated in a more aqueous solution. As tetrazine 1 was 
poorly soluble in aqueous solutions, we synthesized a more water-soluble 3,6-dipyridyl-s-tetrazine 
derivative 7 (Scheme 4.1). In addition, we presumed that the free amine functionality of 7 could 
easily be equipped with a functional group that is needed for potential future bioconjugation 
applications.  
The reaction between an equimolar concentration of 2-pyridinecarbonitrile and 5-amino-
2-pyridinecarbonitrile in an excess of hydrazine hydrate provided the dihydrotetrazine 4 in 
acceptable yield.17,18 The amine was coupled to N-Boc-glycine and the dihydrotetrazine 5 was 
subsequently oxidized with NaNO2 to yield Boc-protected tetrazine 6.18 Finally, Boc 
deprotection of tetrazine 6 using 4 M HCl in dioxane yielded tetrazine 7 as its hydrochloride salt 
in excellent yield. 
 
 
Scheme 4.1 – Synthesis route towards tetrazine 7. i) Hydrazine monohydrate, 90 °C, 16 h, 24%. ii) Boc-
glycine, NMO, isobutyl chloroformate, THF, 16 h, 79%. iii) NaNO2, AcOH, 10 min, 51%. iv) 4 M HCl 
in dioxane, CH2Cl2, 30 min, quant.. 
 
Having tetrazine derivative 7 in hand, we evaluated the second-order rate constants of 7 
with the same set of alkenes as evaluated in Chapter 3 in a more biologically relevant solvent 
system (95% PBS and 5% MeOH). Compared to tetrazine 1, a similar trend in rate constants 
was found, although the constants were significantly increased for all VBAs under the measured 
conditions (Figure 4.2, Table S4.1). The rate constant of norbornene 8 was only marginally 
influenced by the change in tetrazine and solvent system, giving a small increase in k2 from 1.4 to 
2.2 M-1 s-1. However, under these conditions VBA 9 gave a slightly higher k2 than norbornene 8 
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to dihydropyridazine 3 as a single isomer, lacking the boronic acid functionality. In this chapter, 
we evaluate the VBAs as bioorthogonal reactants in a more aqueous environment and for protein 
modification in vitro. We evaluated its biocompatibility with several common biological 
functional groups, the stability in aqueous environment and the toxicity to living cells. 
 
4.2 Results and Discussion 
 
4.2.1 Evaluation of the reactivity of VBAs in aqueous conditions using a water soluble 
dipyridyl-s-tetrazine 
In Chapter 3, we explored the reaction of several vinylboronic acids with dipyridyl-s-
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and dipyridyl-s-tetrazine were further investigated in a more aqueous solution. As tetrazine 1 was 
poorly soluble in aqueous solutions, we synthesized a more water-soluble 3,6-dipyridyl-s-tetrazine 
derivative 7 (Scheme 4.1). In addition, we presumed that the free amine functionality of 7 could 
easily be equipped with a functional group that is needed for potential future bioconjugation 
applications.  
The reaction between an equimolar concentration of 2-pyridinecarbonitrile and 5-amino-
2-pyridinecarbonitrile in an excess of hydrazine hydrate provided the dihydrotetrazine 4 in 
acceptable yield.17,18 The amine was coupled to N-Boc-glycine and the dihydrotetrazine 5 was 
subsequently oxidized with NaNO2 to yield Boc-protected tetrazine 6.18 Finally, Boc 
deprotection of tetrazine 6 using 4 M HCl in dioxane yielded tetrazine 7 as its hydrochloride salt 
in excellent yield. 
 
 
Scheme 4.1 – Synthesis route towards tetrazine 7. i) Hydrazine monohydrate, 90 °C, 16 h, 24%. ii) Boc-
glycine, NMO, isobutyl chloroformate, THF, 16 h, 79%. iii) NaNO2, AcOH, 10 min, 51%. iv) 4 M HCl 
in dioxane, CH2Cl2, 30 min, quant.. 
 
Having tetrazine derivative 7 in hand, we evaluated the second-order rate constants of 7 
with the same set of alkenes as evaluated in Chapter 3 in a more biologically relevant solvent 
system (95% PBS and 5% MeOH). Compared to tetrazine 1, a similar trend in rate constants 
was found, although the constants were significantly increased for all VBAs under the measured 
conditions (Figure 4.2, Table S4.1). The rate constant of norbornene 8 was only marginally 
influenced by the change in tetrazine and solvent system, giving a small increase in k2 from 1.4 to 
2.2 M-1 s-1. However, under these conditions VBA 9 gave a slightly higher k2 than norbornene 8 
of 3.0 M-1 s-1, which is 4-fold higher than that observed with dipyridyl-s-tetrazine 1 in 50% 
MeOH/PBS. A same increase in k2 values was found for the methyl-substituted VBAs (E)-10 and 
(Z)-10. The rate constant of the phenyl-substituted VBA (E)-11 with 7 of 11 M-1 s-1 is 
comparable to the reported k2 of the fastest cyclopropene.19,20 The (Z)-isomer of VBA 11 gave 
again a lower rate constant. The reaction of 7 with VBA 2, with an electron-donating substituent 
on the phenyl ring, gave a k2 of 27 M-1 s-1, which exceeds the k2 of norbornene 8 with one order 
of magnitude. The alkenes 12, 13 and 14, lacking the boronic acid, gave again k2 values of at least 
two orders of magnitude lower compared to their VBA derivatives. 
 
 
Figure 4.2 – The second-order rate constants of tetrazine 7 with alkenes 2 and 8 – 14 in 5% MeOH and 
95% PBS, measured at uncontrolled room temperature, shown on a logarithmic scale. [a] Endo/exo = 2:1. 
[b] E/Z = 1:3. 
 
4.2.2 VBAs are suitable reactants for modification of purified proteins  
To evaluate the applicability of the VBA as bioorthogonal reactant for protein 
modification, we first examined the stability of the VBAs in aqueous media and in the presence of 
a set of common biological functional groups. Using 1H NMR, we observed that the most 
reactive VBA 2 was stable for at least one week in deuterated water and in the presence of amines, 
alcohols, carboxylic acids and thiols (Figure S4.1).  
Next, we designed the bifunctional molecule 19, containing a VBA on one end and an 
azide on the other end (Scheme 4.2A). We envisioned that this azide-functionalized VBA 19 
could be used to install the VBA onto a protein that is modified with a dibenzocyclooctyne 
(DBCO), a commonly used reactive group for the strain-promoted alkyne-azide cycloaddition 
(SPAAC).21 Vinylboronic acids can be easily synthesized as the protected ester in one step by, for 
example, cross-metathesis between an alkene and a vinylboronic ester22–25 or hydroboration of an 
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alkyne.26 Hydrolysis of the boronic ester occurs spontaneously in aqueous media, although many 
deprotection strategies to the boronic acid are also available.27 For the uniformity of our work on 
vinylboronic acids, we initially synthesized the free vinylboronic acid probe 19 containing the 
azide moiety.  
The synthesis started with a Sonogashira coupling of 4-iodophenol and TMS-acetylene to 
form TMS-protected 16 (Scheme 4.2A). 2-(2-(2-Chloroethoxy)ethoxy)ethan-1-ol was 
substituted with an azide and tosylated to give 15 in excellent yield. Etherification of phenol 16 
with tosylate 15 and deprotection of the TMS group yielded alkyne 17 in good yield. Next, 
hydroboration using a ruthenium catalyst provided the pinacol protected VBA 18 in good yield. 
We were especially wary of a possible azide-alkyne cycloaddition of 19, as certain Ru compounds 
(containing e.g. a pentamethylcycopentadiene (Cp*) ligand), have been reported to catalyze this 
reaction.28 The Ru(CO)ClH(PPh3)3 was found safe in this regard and we did not observe 
formation of a major side product. Finally, VBA 19 was obtained after removal of the ester of 18 
via its organotrifluoroborate intermediate. In order to visualize the VBA-modified protein by 
fluorescent SDS-PAGE, we modified dipyridyl-s-tetrazine with a fluorophore. Deprotection of 
the previously synthesized Boc-protected dipyridyl-s-tetrazine 6 and subsequent coupling of the 
amine to the commercially available BODIPY-FL NHS ester, yielded tetrazine-BODIPY 20 in 
very good yield (Scheme 4.2B). 
 
 
Scheme 4.2 – A) Synthesis route towards azide-VBA 19. i) (a) NaN3, DMF, 80 °C, 16 h. (b) p-TsCl, 
Me3N·HCl, Et3N, MeCN, 0 °C to rt, 1 h, 98%. ii) Ethynyltrimethylsilane, PdCl2(PPh3)2, CuI, Et3N, 16 
h, 84%. iii) (a) 15, K2CO3, MeCN, 70 °C, 16 h. (b) MeOH, 5 h, 83%. iv) pinacolborane, 
Ru(CO)ClH(PPh3)3, toluene, 50 °C, 16 h, 72%. v) KHF2, H2O, MeOH, 0 °C to rt, 1 h. (b) SiO2, H2O, 
1.5 h, 56%. B) Synthesis route towards tetrazine-BODIPY FL 20. vi) (a) 4 M HCl in dioxane, CH2Cl2, 1 
h. (b) BODIPY-FL NHS ester, DIPEA, DMF, 16 h, 87%. 
 
With the azide-functionalized VBA 19 and the fluorescent tetrazine 20 in hand, we 
evaluated the tetrazine ligation for the protein modification using the commercially available 
purified human serum albumin (HSA) (Figure 4.3B). First, we equipped the model protein HSA, 
containing one free cysteine, with a DBCO function using commercially available DBCO-
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alkyne.26 Hydrolysis of the boronic ester occurs spontaneously in aqueous media, although many 
deprotection strategies to the boronic acid are also available.27 For the uniformity of our work on 
vinylboronic acids, we initially synthesized the free vinylboronic acid probe 19 containing the 
azide moiety.  
The synthesis started with a Sonogashira coupling of 4-iodophenol and TMS-acetylene to 
form TMS-protected 16 (Scheme 4.2A). 2-(2-(2-Chloroethoxy)ethoxy)ethan-1-ol was 
substituted with an azide and tosylated to give 15 in excellent yield. Etherification of phenol 16 
with tosylate 15 and deprotection of the TMS group yielded alkyne 17 in good yield. Next, 
hydroboration using a ruthenium catalyst provided the pinacol protected VBA 18 in good yield. 
We were especially wary of a possible azide-alkyne cycloaddition of 19, as certain Ru compounds 
(containing e.g. a pentamethylcycopentadiene (Cp*) ligand), have been reported to catalyze this 
reaction.28 The Ru(CO)ClH(PPh3)3 was found safe in this regard and we did not observe 
formation of a major side product. Finally, VBA 19 was obtained after removal of the ester of 18 
via its organotrifluoroborate intermediate. In order to visualize the VBA-modified protein by 
fluorescent SDS-PAGE, we modified dipyridyl-s-tetrazine with a fluorophore. Deprotection of 
the previously synthesized Boc-protected dipyridyl-s-tetrazine 6 and subsequent coupling of the 
amine to the commercially available BODIPY-FL NHS ester, yielded tetrazine-BODIPY 20 in 
very good yield (Scheme 4.2B). 
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1.5 h, 56%. B) Synthesis route towards tetrazine-BODIPY FL 20. vi) (a) 4 M HCl in dioxane, CH2Cl2, 1 
h. (b) BODIPY-FL NHS ester, DIPEA, DMF, 16 h, 87%. 
 
With the azide-functionalized VBA 19 and the fluorescent tetrazine 20 in hand, we 
evaluated the tetrazine ligation for the protein modification using the commercially available 
purified human serum albumin (HSA) (Figure 4.3B). First, we equipped the model protein HSA, 
containing one free cysteine, with a DBCO function using commercially available DBCO-
maleimide 21 (Figure 4.3A). The HSA-DBCO was then reacted with azide 19, demonstrating 
that VBAs can be used orthogonally to the SPAAC reaction between a DBCO and an azide 
function. Of note, the VBA is not orthogonal to a Cu(I)-mediated reaction between an azide and 
an alkyne due to copper-mediated boronic acid degradation.29 We finally used tetrazine-BODIPY 
20 to visualize the VBA-modified HSA protein. Complete conversion to the dihydropyridazine 
(HSA-DHP) product was observed by mass spectroscopy (Figure S4.2) and appearance of a green 
fluorescent band was evidenced by fluorescence imaging of the SDS-PAGE gel (Figure 4.3C). 
While the addition of tetrazine-BODIPY 20 gave almost no background signal, the addition of 
both DBCO-maleimide 21 and tetrazine-BODIPY 20 gave a slightly visible band, possibly 
caused by the reaction of DBCO moiety with the large excess of tetrazine present. We then 
evaluated the rate of the tetrazine ligation in time using 10 equivalents tetrazine-BODIPY 20 
(Figure 4.3D). For this experiment we incubated HSA-VBA with 20 for indicated time points 
before addition of a 100-fold excess of non-fluorescent dipyridyl-s-tetrazine to quench potentially 
unreacted VBA, explaining the faint band observed at 0 min. Using this procedure, we observed 
full labeling of HSA-VBA after 30 minutes, although already a clear fluorescent signal was visible 
on SDS-PAGE gel within 5 minutes. 
 
 
Figure 4.3 - Evaluation of the tetrazine ligation with HSA functionalized with VBA probe 19. A) The 
structure DBCO-maleimide 21. B) The route used for HSA modification steps. C) SDS-PAGE analysis of 
the modification steps of HSA (50 μM) as shown in B with 21, 19 and 20 (2, 10 and 10 equiv., 
respectively) D) SDS-PAGE analysis of the time range of the tetrazine ligation of HSA-VBA (50 μM) and 
tetrazine 20 (10 equiv.). [a] At t = 0 min 1% labeling is expected, because a premix of fluorescent tetrazine 
20 and dipyridyl-s-tetrazine (1000 equiv.) is added. 
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4.2.3 The VBAs are highly stable and suitable for tetrazine ligations in cell lysate 
Having established that the VBAs can be used for modification of purified proteins, we 
next evaluated the stability and compatibility of VBAs in cell lysate. First, we incubated VBA 2 
(100 μM) in cell lysate up to 24 hours before addition of tetrazine 7. We compared the reaction 
rates to that observed in PBS by following the decay of absorbance of the tetrazine for 1 hour. 
Only marginal loss in reactivity was observed, with 85% of the initial observed rate constant 
retained after 24 hours (Figure 4.4A). Next, we evaluated the stability of the VBA moiety at 
much lower concentrations by incubating the previously prepared HSA-VBA (0.5 μM) in cell 
lysate up to 24 hours before addition of the tetrazine-BODIPY 20 (Figure 4.4B). Again, we did 
not observe any significant loss in signal as evidenced by fluorescence analysis of the SDS-PAGE 
gel These experiments indicate that the VBA functionality is highly stable in the presence of all 
biomolecules in the cell lysate and available for ligation with a tetrazine. A dilution series of HSA-
VBA in cell lysate followed by addition of tetrazine-BODIPY 20 showed that we could visualize 
the modified HSA protein by fluorescence imaging as low as 50 nM using standard scanning 
settings (Figure 4.4C). At this concentration, a clear HSA band could no longer be distinguished 
on the gel when stained with Coomassie, indicating the selectivity of the reaction and the 
sensitivity of the fluorophore under these conditions. 
 
 
Figure 4.4 – A) Pseudo-first-order reaction rate of tetrazine 7 (50 μM) and VBA 2 (2 equiv.) in 1% 
DMSO/cell lysate or PBS followed at 335 nm for 1 h. VBA 2 was incubated in 1% DMSO/cell lysate for 
0, 4 or 24 h before addition of 7. left) The normalized reaction kinetics of tetrazine 7 and VBA 2 and 
right) The normalized pseudo-first-order rate constants (kobs), in which the constant in PBS was 
normalized to 100%. B) The stability of HSA-VBA (0.5 μM) in cell lysate. C) A concentration range of 
HSA-VBA followed by the reaction with tetrazine 20 (10 equiv.) in cell lysate. 
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4.2.3 The VBAs are highly stable and suitable for tetrazine ligations in cell lysate 
Having established that the VBAs can be used for modification of purified proteins, we 
next evaluated the stability and compatibility of VBAs in cell lysate. First, we incubated VBA 2 
(100 μM) in cell lysate up to 24 hours before addition of tetrazine 7. We compared the reaction 
rates to that observed in PBS by following the decay of absorbance of the tetrazine for 1 hour. 
Only marginal loss in reactivity was observed, with 85% of the initial observed rate constant 
retained after 24 hours (Figure 4.4A). Next, we evaluated the stability of the VBA moiety at 
much lower concentrations by incubating the previously prepared HSA-VBA (0.5 μM) in cell 
lysate up to 24 hours before addition of the tetrazine-BODIPY 20 (Figure 4.4B). Again, we did 
not observe any significant loss in signal as evidenced by fluorescence analysis of the SDS-PAGE 
gel These experiments indicate that the VBA functionality is highly stable in the presence of all 
biomolecules in the cell lysate and available for ligation with a tetrazine. A dilution series of HSA-
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settings (Figure 4.4C). At this concentration, a clear HSA band could no longer be distinguished 
on the gel when stained with Coomassie, indicating the selectivity of the reaction and the 
sensitivity of the fluorophore under these conditions. 
 
 
Figure 4.4 – A) Pseudo-first-order reaction rate of tetrazine 7 (50 μM) and VBA 2 (2 equiv.) in 1% 
DMSO/cell lysate or PBS followed at 335 nm for 1 h. VBA 2 was incubated in 1% DMSO/cell lysate for 
0, 4 or 24 h before addition of 7. left) The normalized reaction kinetics of tetrazine 7 and VBA 2 and 
right) The normalized pseudo-first-order rate constants (kobs), in which the constant in PBS was 
normalized to 100%. B) The stability of HSA-VBA (0.5 μM) in cell lysate. C) A concentration range of 
HSA-VBA followed by the reaction with tetrazine 20 (10 equiv.) in cell lysate. 
 
4.2.4 The direct modification of HSA using maleimide-VBA gives similar results than the 
two-step procedure 
We next investigated if we could modify HSA with the VBA moiety in a single step using 
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Figure 4.5 – A) Hydrolysis of the pinacol boronic ester 18 to VBA 19. B) Absorbance scan of VBA 19 
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mM in DMSO) were diluted in PBS. C) Normalized decay of absorbance at 315 nm of pinacol ester 18 to 
boronic acid 19 at 100 μM in 1% DMSO/PBS.  
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Figure 4.6 – A) Overview of the one- and two-step protein modification approach towards HSA-VBA 
and the subsequent tetrazine ligation. The linkers formed in HSA-VBA and HSA-DHP after the one- or 
two-step modification are not similar. B) Comparison of the two-step modification of HSA (50 μM) 
towards HSA-VBA using pinacol ester 18 or boronic acid 19, analyzed by SDS-PAGE. C) Comparison of 
the one-step modification with maleimide-VBA 23 and the two-step approach maleimide-DBCO 21 and 
VBA-azide 19, analyzed by SDS-PAGE. 
 
hydrolyze quickly in aqueous solution, we did not attempt to deprotect VBA 23, but used it 
directly for our labeling reaction. Incubation of HSA with 23 and subsequently visualization 
using tetrazine-BODIPY 20 gave a strong fluorescent signal (Figures 4.6A and C). Similar 
labeling intensities were observed as in the two-step labeling approach using the SPAAC reaction 
of 21 and 19, showing the compatibility of the VBA with the maleimide coupling. 
 
 
Scheme 4.3 – Synthesis of maleimide-VBA 23. i) N-Hydroxysuccinimide, EDCI, CH2Cl2, 4 h, 75%. ii) 
(a) PMe3 in toluene, THF, 1 h. (b) 22, DIPEA, MeCN, 16 h, 50%.  
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4.2.5 VBAs are non-toxic towards living cells 
For possible future applications of VBAs on live cells we assessed the toxicity of the 
tetrazine ligation on NIH-3T3 cells in 1% DMSO (Figure 4.7). Next to tetrazine 7 and 
vinylboronic acid 2, we tested boric acid, the side product of the tetrazine ligation, and all the 
ligation products, by adding both 2 and 7 to the cells. No toxicity was observed after 24 hours up 
to 100 μM for VBA 2 and boric acid whereas tetrazine 7 and the reaction of 2 with 7 showed 
some toxicity at this concentration after 24 hours. 
 
 
Figure 4.7 – Results of cell viability studies of NIH-3T3 cells using boric acid, VBA 2, tetrazine 7 and the 
tetrazine ligation between tetrazine 7 and vinylboronic acid 2 at different concentrations for 4 and 24 h.  
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model protein in a single step using maleimide-functionalized VBA pinacol ester. Finally, no 
toxicity of the VBAs towards living cells was observed after 24 hours up to 100 μM for the VBA 
indicating that VBAs are suitable for in situ applications. 
With these results of successful protein modification in vitro and in cell lysate, we can add 
VBAs as bioorthogonal reactants to the molecular toolbox. Although reaction rates of tetrazines 
with TCO are still orders of magnitude faster,17 the use of VBAs may be advantageous due to 
their chemical properties, stability and accessibility while showing suitable rate constants required 
for modification and conjugation of biomolecules. The next step to demonstrate the suitability of 
the vinylboronic acid moiety as bioorthogonal reagent, is application of the tetrazine ligation with 
these moieties in living cells, which is described in Chapter 5. 
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4.5 Experimental Section 
 
4.5.1 Synthetic procedures 
General experimental for the synthesis of the small molecules is described in Section 3.5.1. If no further 
details are given, the reaction was performed under nitrogen atmosphere and temperature. Dry Et3N was 
distilled from CaH under N2, THF, CH2Cl2, Et2O, toluene and MeCN were dried by purging over an 
activated alumina column utilizing an MBraun MB SPS800 system under nitrogen atmosphere. FTIR-
ATR spectra were recorded using a Bruker TENSOR 27.  
 
6-(6-(Pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazin-3-yl)pyridin-3-amine (4). 5-Amino-2-
pyridinecarbonitrile (1.0 g, 8.39 mmol, 1.0 equiv.) and 2-cyanopyridine (0.87 g, 8.39 mmol, 
1.0 equiv.) were heated in hydrazine monohydrate (1.6 mL, 33.6 mmol, 4.0 equiv.) o/n at 90 
°C. The solvent was evaporated, and the mixture was purified twice using column 
chromatography, first a column with (40 to 80% EtOAc in heptane), then (0 to 5% MeOH in 
CH2Cl2) yielding dihydrotetrazine 4 as a yellow solid (520 mg, 24%). Rf = 0.25 (50% EtOAc 
in heptane). 1H NMR (400 MHz, (CD3)2SO) δ 8.70 (s, 1H), 8.65 (s, 1H), 8.62 (ddd, J = 4.9, 
1.7, 1.0 Hz, 1H), 7.98 – 7.88 (m, 3H), 7.64 (dd, J = 8.6, 0.7 Hz, 1H), 7.51 (ddd, J = 7.2, 4.9, 
1.5 Hz, 1H), 6.99 (dd, J = 8.6, 2.7 Hz, 1H), 5.88 (s, 2H). 13C NMR (100 MHz, (CD3)2SO) δ 
148.6, 147.5, 146.7, 146.64, 146.60, 137.3, 134.2, 134.1, 125.2, 121.8, 120.8, 120.3. LRMS (ESI+) m/z 
calcd. for C12H11N7 [M+H]+ 254.1, found: 254.1. The data agrees with the reported literature values.17,18 
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°C. The solvent was evaporated, and the mixture was purified twice using column 
chromatography, first a column with (40 to 80% EtOAc in heptane), then (0 to 5% MeOH in 
CH2Cl2) yielding dihydrotetrazine 4 as a yellow solid (520 mg, 24%). Rf = 0.25 (50% EtOAc 
in heptane). 1H NMR (400 MHz, (CD3)2SO) δ 8.70 (s, 1H), 8.65 (s, 1H), 8.62 (ddd, J = 4.9, 
1.7, 1.0 Hz, 1H), 7.98 – 7.88 (m, 3H), 7.64 (dd, J = 8.6, 0.7 Hz, 1H), 7.51 (ddd, J = 7.2, 4.9, 
1.5 Hz, 1H), 6.99 (dd, J = 8.6, 2.7 Hz, 1H), 5.88 (s, 2H). 13C NMR (100 MHz, (CD3)2SO) δ 
148.6, 147.5, 146.7, 146.64, 146.60, 137.3, 134.2, 134.1, 125.2, 121.8, 120.8, 120.3. LRMS (ESI+) m/z 
calcd. for C12H11N7 [M+H]+ 254.1, found: 254.1. The data agrees with the reported literature values.17,18 
 
  
2-(Boc-amino)-N-(6-(6-(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)acetamide (5). 
Boc-glycine (622 mg, 3.55 mmol, 2.0 equiv.) was dissolved in dry THF (9 mL) and 
cooled to 0 °C with an ice bath. N-Methylmorpholine (977 μL, 8.88 mmol, 5.0 equiv.) 
and isobutyl chloroformate (464 μL, 3.55 mmol, 2.0 equiv.) were added and the 
mixture was stirred for 5 min. Then, amine 4 (450 mg, 1.78 mmol, 1.0 equiv.) was 
added and the mixture was stirred o/n. Water and EtOAc were added, the layers were 
separated and the water layer was extracted with EtOAc (2 ×). The combined organic 
layers were washed with sat. NaHCO3, dried over Na2SO4, and the solvent was 
removed under reduced pressure. The product was purified using column 
chromatography (70% to 100% EtOAc in heptane) yielding amide 5 as a yellow solid 
(575 mg, 79%). Rf = 0.37 (70% EtOAc in heptane). 1H NMR (400 MHz, (CD3)2SO) δ 10.41 (s, 1H), 
8.93 (s, 1H), 8.88 (s, 1H), 8.82 (d, J = 2.5 Hz, 1H), 8.67 – 8.57 (m, 1H), 8.15 (dd, J = 8.7, 2.5 Hz, 1H), 
8.00 – 7.87 (m, 3H), 7.53 (ddd, J = 7.2, 4.9, 1.5 Hz, 1H), 7.13 (t, J = 6.1 Hz, 1H), 3.78 (d, J = 6.1 Hz, 
2H), 1.40 (s, 9H). 13C NMR (100 MHz, (CD3)2SO) δ 169.2, 155.9, 148.6, 147.3, 146.3, 146.1, 141.6, 
138.9, 137.4, 137.0, 126.8, 125.3, 121.4, 121.0, 78.2, 43.8, 28.2. LRMS (ESI+) m/z calcd. for 
C19H22N8O3 [M+H]+ 411.2, found: 411.1. The data agrees with the reported literature values.18  
 
2-(Boc-amino)-N-(6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)acetamide (6). Dihydro-
tetrazine 5 (300 mg, 0.73 mmol, 1.0 equiv.) was dissolved in acetic acid (15 mL) under 
ambient atmosphere. Sodium nitrite (93 mg, 1.10 mmol, 1.5 equiv.) was added and the 
solution was stirred for 10 min. The mixture was diluted with CH2Cl2, and washed with 
sat. NaHCO3 (3 ×). The organic layer was dried over Na2SO4 and the volatiles were 
removed under reduced pressure. Finally, the product was purified using column 
chromatography (0 to 8% MeOH in CH2Cl2) yielding tetrazine 6 as a pink solid (151 
mg, 51%). Rf = 0.45 (10% MeOH in CH2Cl2). 1H NMR (400 MHz, (CD3)2SO) δ 
10.62 (s, 1H), 9.05 (d, J = 2.5 Hz, 1H), 8.97 – 8.90 (m, 1H), 8.64 (d, J = 8.7 Hz, 1H), 
8.59 (td, J = 8.0, 1.1 Hz, 1H), 8.43 (dd, J = 8.7, 2.5 Hz, 1H), 8.16 (dt, J = 7.7, 1.7 Hz, 
1H), 7.73 (ddd, J = 7.7, 4.7, 1.2 Hz, 1H), 7.18 (t, J = 6.1 Hz, 1H), 3.84 (d, J = 6.1 Hz, 2H), 1.41 (s, 
9H). 13C NMR (100 MHz, (CD3)2SO) δ 169.5, 163.0, 162.8, 156.0, 150.6, 150.2, 144.0, 141.3, 138.2, 
137.8, 126.6, 126.3, 124.9, 124.2, 78.2, 43.9, 28.2. LRMS (ESI+) m/z calcd. for C19H20N8O3 [M+H]+ 
409.2, found: 409.1. The data agrees with the reported literature values.18 
 
2-Amino-N-(6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)acetamide hydrochloride (7). 
Boc-protected amine 6 (40 mg, 98 μmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (2.2 
mL). 4 M HCl in dioxane (735 μL, 2.94 mmol, 30 equiv.) was slowly added and the 
mixture was stirred for 30 min. The solvent was removed under reduced pressure, 
whereupon the pink solid was lyophilized yielding amine 7 (34 mg, quant.). 1H NMR 
(400 MHz, (CD3)2SO) δ 11.57 (s, 1H), 9.16 (d, J = 2.4 Hz, 1H), 8.98 – 8.91 (m, 1H), 
8.68 (d, J = 8.7 Hz, 1H), 8.61 (dt, J = 8.0, 1.1 Hz, 1H), 8.44 (dd, J = 8.7, 2.5 Hz, 1H), 
8.35 (br. t, J = 5.6 Hz, 2H), 8.18 (dt, J = 7.7, 1.8 Hz, 1H), 7.75 (ddd, J = 7.7, 4.7, 1.2 
Hz, 1H), 3.99 – 3.91 (m, 2H). 13C NMR (100 MHz, (CD3)2SO) δ 166.1, 163.0, 
162.7, 150.5, 150.0, 144.6, 141.3, 138.0, 137.6, 126.7, 126.6, 125.1, 124.3, 41.3. 
LRMS (ESI+) m/z calcd. for C14H12N8O [M+H]+ 309.1, found: 309.1. The data agrees with the reported 
literature values.18 
 
2-[2-(2-Azidoethoxy)ethoxy]ethyl-4-methylbenzenesulfonate (15). To a solution of 2-[2-(2-
chloroethoxy)-ethoxy]ethanol (5.8 mL, 29.7 mmol, 1.0 equiv.) in DMF (60 mL) was 
added NaN3 (2.89 g, 44.5 mmol, 1.5 equiv.) and the reaction mixture was heated o/n 
at 80 °C. After cooling, the reaction mixture was diluted with water and extracted with CH2Cl2 (3 ×). The 
N
HN
N
N N
N
N
O
NHBoc
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combined organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated to 
provide 2-[2-(2-azidoethoxy)ethoxy]ethan-1-ol. Without further purification, it was dissolved in dry 
acetonitrile (40 mL), and Et3N (8.3 mL, 59.4 mmol, 2.0 equiv.) and trimethylamine hydrochloride (280 
mg, 3.0 mmol, 0.1 equiv.) were added. The reaction mixture was cooled to 0 °C and p-toluenesulfonyl 
chloride (8.49 g, 44.6 mmol, 1.5 equiv.) was added slowly. The reaction mixture was stirred under argon 
for 30 min at 0 °C and another 30 min at rt. Water was added to the mixture before it was extracted with 
EtOAc (3 ×). The combined organic layers were washed with brine, dried over Na2SO4 and the solvent 
was evaporated. Purification by column chromatography (40% EtOAc in heptane) provided tosyl 15 
(9.61 g, 98%) as a colorless oil. Rf = 0.31 (40% EtOAc in heptane). 1H NMR (300 MHz, CDCl3) δ 7.80 
(m, 2H), 7.34 (m, 2H), 4.17 (m, 2H), 3.75 – 3.58 (m, 8H), 3.36 (t, J = 5.0 Hz, 2H), 2.45 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 145.0, 133.1, 130.0, 128.1, 71.0, 70.8, 70.2, 69.4, 69.0, 50.8, 21.8. LRMS 
(ESI+) m/z calcd. for C13H19N3O5S [M+H]+ 330.1, found 329.9. FTIR-ATR (cm-1): inter alia 2098 (N3). 
The data agrees with the reported literature values.31  
 
4-[(Trimethylsilyl)ethynyl]phenol (16) is synthesized according to a modified literature procedure.32 4-
Iodophenol (2.20 g, 10.0 mmol, 1.0 equiv.), PdCl2(PPh3)2 (140 mg, 0.20 mmol, 
0.02 equiv.) and CuI (19 mg, 0.10 mmol, 0.01 equiv.) were dissolved in dry Et3N 
(40 mL). Ethynyltrimethylsilane (1.7 mL, 12.0 mmol, 1.2 equiv.) was added and the reaction mixture was 
stirred o/n. After addition of H2O, the product was extracted with EtOAc (3 ×). The combined organic 
layers were washed with brine, dried over Na2SO4 and the solvent was removed under reduced pressure. 
The product was further purified by column chromatography (0 to 20% EtOAc in heptane) to afford 
TMS-protected alkyne 16 as brown crystals (1.61 g, 84%). Rf = 0.38 (20% EtOAc in heptane). 1H NMR 
(400 MHz, (CD3)2CO) δ 8.76 (br. s, 1H), 7.31 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 0.20 (s, 
9H). 13C NMR (100 MHz, (CD3)2CO) δ 158.9, 134.3, 116.3, 114.9, 106.6, 91.9, 0.1. LRMS (ESI+) 
m/z calcd. for C11H14OSi [M-H]- 189.1, found 189.3.  
 
1-{2-[2-(2-Azidoethoxy)ethoxy]ethoxy}-4-ethynylbenzene (17). TMS-protected ethynylphenol 16 
(376 mg, 1.97 mmol, 1.3 equiv.) and K2CO3 (420 mg, 3.04 mmol, 2.0 equiv.) were 
mixed in dry MeCN (10 mL). After tosylate 15 (500 mg, 1.52 mmol, 1.0 equiv.) 
was added, the reaction mixture was heated o/n at 70 °C to provide ((4-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)phenyl)ethynyl)-trimethylsilane. After cooling to rt, 
MeOH (5 mL) was added and the reaction mixture was stirred for 5 h under ambient atmosphere for 
desilylation. The deprotected alkyne was extracted with EtOAc (3 ×). The combined organic layers were 
washed with brine and dried over Na2SO4. The volatiles were removed under reduced pressure and the 
crude mixture was purified using column chromatography (20 to 30% EtOAc in heptane) yielding azido-
alkyne 17 (346 mg, 83%). Rf = 0.29 (30% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.46 – 
7.37 (m, 2H), 6.90 – 6.81 (m, 2H), 4.17 – 4.10 (m, 2H), 3.90 – 3.83 (m, 2H), 3.76 – 3.71 (m, 2H), 
3.71 – 3.64 (m, 4H), 3.38 (t, J = 5.1 Hz, 2H), 2.99 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 159.3, 
133.7, 114.7, 114.5, 83.8, 76.0, 71.1, 70.9, 70.3, 69.9, 67.6, 50.8. FTIR-ATR (cm-1): inter alia 2100 
(N3), 3286 (≡C-H). Alkyne 17 was not visible on mass spectrometry. 
 
(E)-2-(4-{2-[2-(2-Azidoethoxy)ethoxy]ethoxy}phenyl)vinylboronic acid pinacol ester (18). Alkyne 
17 (200 mg, 0.91 mmol, 1.0 equiv.) was dissolved in toluene (4 mL) and 
sparged with argon for 10 min. Pinacolborane (521 μL, 4.54 mmol, 5.0 
equiv.) and RuHClCO(PPh3)3 (34 mg, 0.045 mmol, 0.05 equiv.) were 
added, after which the mixture was heated o/n at 50 °C. After cooling 
down, the volatiles were removed under reduced pressure. The crude was 
diluted with Et2O, washed with sat. NaHCO3 and brine, dried over Na2SO4, and the solvent was removed 
under reduced pressure. The product was purified by column chromatography (0 to 30% EtOAc in 
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combined organic layers were washed with brine, dried over Na2SO4 and the solvent was evaporated to 
provide 2-[2-(2-azidoethoxy)ethoxy]ethan-1-ol. Without further purification, it was dissolved in dry 
acetonitrile (40 mL), and Et3N (8.3 mL, 59.4 mmol, 2.0 equiv.) and trimethylamine hydrochloride (280 
mg, 3.0 mmol, 0.1 equiv.) were added. The reaction mixture was cooled to 0 °C and p-toluenesulfonyl 
chloride (8.49 g, 44.6 mmol, 1.5 equiv.) was added slowly. The reaction mixture was stirred under argon 
for 30 min at 0 °C and another 30 min at rt. Water was added to the mixture before it was extracted with 
EtOAc (3 ×). The combined organic layers were washed with brine, dried over Na2SO4 and the solvent 
was evaporated. Purification by column chromatography (40% EtOAc in heptane) provided tosyl 15 
(9.61 g, 98%) as a colorless oil. Rf = 0.31 (40% EtOAc in heptane). 1H NMR (300 MHz, CDCl3) δ 7.80 
(m, 2H), 7.34 (m, 2H), 4.17 (m, 2H), 3.75 – 3.58 (m, 8H), 3.36 (t, J = 5.0 Hz, 2H), 2.45 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 145.0, 133.1, 130.0, 128.1, 71.0, 70.8, 70.2, 69.4, 69.0, 50.8, 21.8. LRMS 
(ESI+) m/z calcd. for C13H19N3O5S [M+H]+ 330.1, found 329.9. FTIR-ATR (cm-1): inter alia 2098 (N3). 
The data agrees with the reported literature values.31  
 
4-[(Trimethylsilyl)ethynyl]phenol (16) is synthesized according to a modified literature procedure.32 4-
Iodophenol (2.20 g, 10.0 mmol, 1.0 equiv.), PdCl2(PPh3)2 (140 mg, 0.20 mmol, 
0.02 equiv.) and CuI (19 mg, 0.10 mmol, 0.01 equiv.) were dissolved in dry Et3N 
(40 mL). Ethynyltrimethylsilane (1.7 mL, 12.0 mmol, 1.2 equiv.) was added and the reaction mixture was 
stirred o/n. After addition of H2O, the product was extracted with EtOAc (3 ×). The combined organic 
layers were washed with brine, dried over Na2SO4 and the solvent was removed under reduced pressure. 
The product was further purified by column chromatography (0 to 20% EtOAc in heptane) to afford 
TMS-protected alkyne 16 as brown crystals (1.61 g, 84%). Rf = 0.38 (20% EtOAc in heptane). 1H NMR 
(400 MHz, (CD3)2CO) δ 8.76 (br. s, 1H), 7.31 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 0.20 (s, 
9H). 13C NMR (100 MHz, (CD3)2CO) δ 158.9, 134.3, 116.3, 114.9, 106.6, 91.9, 0.1. LRMS (ESI+) 
m/z calcd. for C11H14OSi [M-H]- 189.1, found 189.3.  
 
1-{2-[2-(2-Azidoethoxy)ethoxy]ethoxy}-4-ethynylbenzene (17). TMS-protected ethynylphenol 16 
(376 mg, 1.97 mmol, 1.3 equiv.) and K2CO3 (420 mg, 3.04 mmol, 2.0 equiv.) were 
mixed in dry MeCN (10 mL). After tosylate 15 (500 mg, 1.52 mmol, 1.0 equiv.) 
was added, the reaction mixture was heated o/n at 70 °C to provide ((4-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)phenyl)ethynyl)-trimethylsilane. After cooling to rt, 
MeOH (5 mL) was added and the reaction mixture was stirred for 5 h under ambient atmosphere for 
desilylation. The deprotected alkyne was extracted with EtOAc (3 ×). The combined organic layers were 
washed with brine and dried over Na2SO4. The volatiles were removed under reduced pressure and the 
crude mixture was purified using column chromatography (20 to 30% EtOAc in heptane) yielding azido-
alkyne 17 (346 mg, 83%). Rf = 0.29 (30% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.46 – 
7.37 (m, 2H), 6.90 – 6.81 (m, 2H), 4.17 – 4.10 (m, 2H), 3.90 – 3.83 (m, 2H), 3.76 – 3.71 (m, 2H), 
3.71 – 3.64 (m, 4H), 3.38 (t, J = 5.1 Hz, 2H), 2.99 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 159.3, 
133.7, 114.7, 114.5, 83.8, 76.0, 71.1, 70.9, 70.3, 69.9, 67.6, 50.8. FTIR-ATR (cm-1): inter alia 2100 
(N3), 3286 (≡C-H). Alkyne 17 was not visible on mass spectrometry. 
 
(E)-2-(4-{2-[2-(2-Azidoethoxy)ethoxy]ethoxy}phenyl)vinylboronic acid pinacol ester (18). Alkyne 
17 (200 mg, 0.91 mmol, 1.0 equiv.) was dissolved in toluene (4 mL) and 
sparged with argon for 10 min. Pinacolborane (521 μL, 4.54 mmol, 5.0 
equiv.) and RuHClCO(PPh3)3 (34 mg, 0.045 mmol, 0.05 equiv.) were 
added, after which the mixture was heated o/n at 50 °C. After cooling 
down, the volatiles were removed under reduced pressure. The crude was 
diluted with Et2O, washed with sat. NaHCO3 and brine, dried over Na2SO4, and the solvent was removed 
under reduced pressure. The product was purified by column chromatography (0 to 30% EtOAc in 
heptane) to yield VBA pinacol ester 18 (212 mg, 72%). Rf = 0.25 (30% EtOAc in heptane). 1H NMR 
(400 MHz, (CD3)2CO) δ 7.51 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 18.4 Hz, 1H), 6.96 (d, J = 8.7 Hz, 2H), 
5.98 (d, J = 18.4 Hz, 1H), 4.18 (t, J = 4.6 Hz, 2H), 3.88 – 3.80 (m, 2H), 3.73 – 3.62 (m, 6H), 3.38 (t, J 
= 5.0 Hz, 2H), 1.27 (s, 12H). 13C NMR (100 MHz, (CD3)2CO) δ 160.8, 149.8, 131.3, 129.3, 115.5, 
83.7, 71.5, 71.2, 70.8, 70.3, 68.4, 51.4, 25.1. No signal was observed for the carbon attached to boron. 
11B NMR (128 MHz, (CD3)2CO) δ 30.3 (s). FTIR-ATR (cm-1): inter alia 2101 (N3). VBA pinacol ester 
18 was not visible on mass spectrometry. 
 
(E)-2-(4-{2-[2-(2-Azidoethoxy)ethoxy]ethoxy}phenyl)vinylboronic acid (19). Pinacol ester 18 (72 
mg, 0.18 mmol, 1.0 equiv.) was dissolved in MeOH (0.4 mL) under ambient 
atmosphere and cooled to 0 °C. A solution of KHF2 (70 mg, 0.90 mmol, 5.0 
equiv.) in H2O (0.2 mL) was added dropwise. The reaction mixture was 
stirred for 1 h, after which the volatiles were evaporated, water was added and 
the mixture was lyophilized. The residue was dissolved in minimal amounts of dry acetone and filtered. 
Evaporation of the solvent yielded the potassium trifluoroborate salt, which was stirred in H2O (2 mL) 
with silica powder (0.2 g) for 1.5 h. The product was extracted with EtOAc (3 ×), dried over Na2SO4 and 
the solvent was removed under reduced pressure, to yield boronic acid 19 as a white powder (32 mg, 
56%). 1H NMR (400 MHz, (CD3)2CO) δ 7.44 (d, J = 8.9 Hz, 2H), 7.32 (d, J = 18.3 Hz, 1H), 6.94 (d, J 
= 8.8 Hz, 2H), 6.82 (s, 2H), 6.05 (d, J = 18.3 Hz, 1H), 4.18 – 4.14 (m, 2H), 3.86 – 3.82 (m, 2H), 3.71 
– 3.63 (m, 6H), 3.38 (t, J = 4.9 Hz, 2H). 13C NMR (100 MHz, (CD3)2CO) δ 160.4, 147.2, 131.8, 
129.0, 115.5, 71.5, 71.2, 70.8, 70.4, 68.4, 51.4. No signal was observed for the carbon attached to boron. 
11B NMR (128 MHz, (CD3)2CO) δ 28.5 (s). FTIR -ATR (cm-1): inter alia 2102 (N3). VBA 19 was not 
visible on mass spectrometry. 
 
2-((BODIPY-FL)amino)-N-(6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)acetamide (20). 
Boc-protected tetrazine 6 (12 mg, 28 μmol, 1.1 equiv.) was dissolved in dry CH2Cl2 
(1 mL) and 4 M HCl in dioxane (211 μL, 85 μmol, 33 equiv.) was added dropwise. 
After the mixture was stirred for 1 h, the volatiles were removed under reduced 
pressure. The solid was dissolved in dry DMF (0.5 mL) under nitrogen and DIPEA 
(9 μL, 51 μmol, 2.0 equiv.) and BODIPY FL NHS ester (10 mg, 26 μmol, 1.0 
equiv.) were added. The mixture was stirred o/n, concentrated and purified by 
column chromatography (0 to 10% MeOH in CH2Cl2) yielding the fluorescent 
tetrazine 20 as a red solid (13 mg, 87%). Rf = 0.43 (10% MeOH in CH2Cl2). 1H 
NMR (500 MHz, (CD3)2SO) δ 10.71 (s, 1H), 9.08 (dd, J = 2.5, 0.6 Hz, 1H), 8.94 
(ddd, J = 4.7, 1.8, 0.9 Hz, 1H), 8.67 – 8.64 (m, 1H), 8.61 (dt, J = 7.9, 1.1 Hz, 1H), 8.46 (t, J = 5.8 Hz, 
1H), 8.43 (dd, J = 8.7, 2.5 Hz, 1H), 8.17 (td, J = 7.8, 1.8 Hz, 1H), 7.74 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H), 
7.71 (s, 1H), 7.12 (d, J = 4.0 Hz, 1H), 6.44 (d, J = 4.1 Hz, 1H), 6.32 (s, 1H), 4.03 (d, J = 5.8 Hz, 2H), 
3.13 (t, J = 7.9 Hz, 2H), 2.64 (t, J = 7.7 Hz, 2H), 2.48 (s, 3H), 2.27 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 11.0, 14.5, 23.6, 33.5, 43.3, 117.1, 121.1, 124.7, 125.3, 126.2, 126.9, 129.5, 133.4, 134.9, 
138.2, 141.8, 144.7, 151.6, 158.0, 159.6, 169.3, 171.9, determined by 1H-13C HSQC and HMBC 
NMR, 4 quaternary carbons are missing. 19F NMR (377 MHz, (CD3)2SO) δ -143.2 (1:1:1:1 q, J = 33.5 
Hz). 11B NMR (128 MHz, (CD3)2SO) δ -1.4 (q, J = 34.9 Hz). HRMS (ESI+) m/z calcd. for 
C28H25BF2N10O2 [M+H]+ 583.23013, found: 583.22986. 
 
N-[(3-Maleimidopropionyl)oxy]succinimide (22). 3-Maleimidopropionic acid (150 mg, 0.89 
mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (3 mL). N-
hydroxysuccinimide (122 mg, 1.06 mmol, 1.2 equiv.) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (204 mg, 1.06 mmol, 1.2 
equiv.) were added and the mixture was stirred for 4 h. The solution was filtered and 
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concentrated. The crude mixture was purified by column chromatography (0 to 6% acetone in 
CH2Cl2) yielding NHS ester 22 (176 mg, 75%) as a white solid. Rf = 0.38 (5% acetone in 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 6.73 (s, 2H), 3.94 (t, J = 7.0 Hz, 2H), 3.02 (t, J = 6.9 
Hz, 2H), 2.82 (s, 4H). 13C NMR (125 MHz, CDCl3) δ 170.2, 168.8, 166.1, 134.4, 33.2, 29.9, 
25.7. LRMS (ESI+) m/z calcd. for C11H10N2O6 [M+H]+ 267.1, found 266.9. Data agrees with 
the reported literature values.33 
 
(E)-2-(4-{2-[2-(2-[3-Maleimidopropionamido]ethoxy)ethoxy]ethoxy}phenyl)vinylboronic acid 
pinacol ester (23). Azide 18 (20 mg, 50 μmol, 1.2 equiv.) was 
dissolved in dry THF and PMe3 in toluene (1M, 100 μL, 100 
μmol, 2.4 equiv.) was added. The solution was stirred for 1 h, 
whereupon H2O (250 μL) was added and the solution was 
stirred for another 30 min. Then, Na2SO4 was added, the 
mixture was filtrated, washed with CH2Cl2. The solvent was evaporated at rt, the solid was dissolved in dry 
DMF (0.5 mL) and maleimide 22 (12 mg, 45 μmol, 1.0 equiv.) and DIPEA (16 μL, 90 μmol, 2.0 equiv.) 
were added and the mixture was stirred overnight. Finally, the solvent was evaporated at rt, and the 
mixture was purified by column chromatography (0 to 5% MeOH in CH2Cl2) yielding maleimide-VBA 
23 (12 mg, 50%) as a yellow oil. Rf = 0.28 (5% MeOH in CH2Cl2). 1H NMR (500 MHz, (CD3)2SO) δ 
8.01 (t, J = 5.7 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.24 (d, J = 18.4 Hz, 1H), 6.99 (s, 2H), 6.95 – 6.90 (m, 
2H), 5.95 (d, J = 18.4 Hz, 1H), 4.13 – 4.07 (m, 2H), 3.77 – 3.69 (m, 2H), 3.61 – 3.58 (m, 4H), 3.51 
(dd, J = 5.9, 3.6 Hz, 2H), 3.37 (t, J = 5.9 Hz, 2H), 3.15 (q, J = 5.8 Hz, 2H), 2.32 (t, J = 7.3 Hz, 2H), 
1.23 (s, 12H). 13C NMR (125 MHz, (CD3)2SO) δ 170.7, 169.5, 159.3, 148.9, 134.5, 128.6, 114.6, 82.9, 
69.8, 69.5, 69.0, 68.9, 67.2, 66.4, 38.5, 34.1, 33.9, 24.6. No signal was observed for the carbon attached 
to boron. HRMS (ESI+) m/z calcd. for C27H37BN2O8 [M+H]+ 551.25407, found 551.25460. 
 
4.5.2 Determination of second-order rate constants 
Tetrazine 7 with the non-aromatic alkenes in 5% MeOH/PBS 
The k2 values of the reactions between dipyridyl tetrazine derivative 7 and the non-aromatic alkenes 8 – 
10 were determined with the same method as for dipyridyl-s-tetrazine 1, described in Section 3.5.3. 
However, the decrease of the tetrazine absorption was measured at 320 nm at a final concentration of 50 
μM of tetrazine 7 and 10-20 equiv. of alkene 8 – 10 in 5% MeOH and 95% 1 × PBS. The reactions were 
followed on a plate reader which started the measurement after ±20 s and no shaking was performed 
before the measurement. The 10-fold lower concentration of the reagents was used, as not all reagents 
were readily soluble in the aqueous solution. At this low concentration, the absorption of the tetrazines at 
540 nm was too low to accurately follow the reaction, and a different wavelength was therefore chosen. 
 
Tetrazine 7 with the aromatic alkenes in 5% MeOH/PBS. 
The k2 values of the reactions between tetrazine 7 and the aromatic alkenes 2 and 11 – 14 were 
determined with the same method as for 7 and the non-aromatic alkenes described above. However, the 
aromatic alkenes absorbed also at 320 nm, and the decrease in tetrazine absorbance was therefore 
measured at 335 nm.  
 
4.5.3 Biocompatibility of VBA 2 by 1H-NMR 
The stability of VBA 2 in deuterated water, and in the presence of 6-aminohexanol or L-cysteine was 
determined by 1H NMR (400 MHz). A) VBA 2 (20 mM) in 1:1 (CD3)2SO/D2O. B) VBA 2 (300 μL, 40 
mM, 1.0 equiv.) and 6-aminohexanol (300 μL, 40 mM, 1.0 equiv.) in 1:1 (CD3)2SO/D2O were 
combined, for a final concentration of 20 mM. C) VBA 2 (200 μL, 15 mM in 30% (CD3)2SO in D2O, 
1.0 equiv.) and L-cysteine (200 μL, 15 mM in D2O, 1.0 equiv.) and tris(2-carboxyethyl)phosphine 
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concentrated. The crude mixture was purified by column chromatography (0 to 6% acetone in 
CH2Cl2) yielding NHS ester 22 (176 mg, 75%) as a white solid. Rf = 0.38 (5% acetone in 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 6.73 (s, 2H), 3.94 (t, J = 7.0 Hz, 2H), 3.02 (t, J = 6.9 
Hz, 2H), 2.82 (s, 4H). 13C NMR (125 MHz, CDCl3) δ 170.2, 168.8, 166.1, 134.4, 33.2, 29.9, 
25.7. LRMS (ESI+) m/z calcd. for C11H10N2O6 [M+H]+ 267.1, found 266.9. Data agrees with 
the reported literature values.33 
 
(E)-2-(4-{2-[2-(2-[3-Maleimidopropionamido]ethoxy)ethoxy]ethoxy}phenyl)vinylboronic acid 
pinacol ester (23). Azide 18 (20 mg, 50 μmol, 1.2 equiv.) was 
dissolved in dry THF and PMe3 in toluene (1M, 100 μL, 100 
μmol, 2.4 equiv.) was added. The solution was stirred for 1 h, 
whereupon H2O (250 μL) was added and the solution was 
stirred for another 30 min. Then, Na2SO4 was added, the 
mixture was filtrated, washed with CH2Cl2. The solvent was evaporated at rt, the solid was dissolved in dry 
DMF (0.5 mL) and maleimide 22 (12 mg, 45 μmol, 1.0 equiv.) and DIPEA (16 μL, 90 μmol, 2.0 equiv.) 
were added and the mixture was stirred overnight. Finally, the solvent was evaporated at rt, and the 
mixture was purified by column chromatography (0 to 5% MeOH in CH2Cl2) yielding maleimide-VBA 
23 (12 mg, 50%) as a yellow oil. Rf = 0.28 (5% MeOH in CH2Cl2). 1H NMR (500 MHz, (CD3)2SO) δ 
8.01 (t, J = 5.7 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.24 (d, J = 18.4 Hz, 1H), 6.99 (s, 2H), 6.95 – 6.90 (m, 
2H), 5.95 (d, J = 18.4 Hz, 1H), 4.13 – 4.07 (m, 2H), 3.77 – 3.69 (m, 2H), 3.61 – 3.58 (m, 4H), 3.51 
(dd, J = 5.9, 3.6 Hz, 2H), 3.37 (t, J = 5.9 Hz, 2H), 3.15 (q, J = 5.8 Hz, 2H), 2.32 (t, J = 7.3 Hz, 2H), 
1.23 (s, 12H). 13C NMR (125 MHz, (CD3)2SO) δ 170.7, 169.5, 159.3, 148.9, 134.5, 128.6, 114.6, 82.9, 
69.8, 69.5, 69.0, 68.9, 67.2, 66.4, 38.5, 34.1, 33.9, 24.6. No signal was observed for the carbon attached 
to boron. HRMS (ESI+) m/z calcd. for C27H37BN2O8 [M+H]+ 551.25407, found 551.25460. 
 
4.5.2 Determination of second-order rate constants 
Tetrazine 7 with the non-aromatic alkenes in 5% MeOH/PBS 
The k2 values of the reactions between dipyridyl tetrazine derivative 7 and the non-aromatic alkenes 8 – 
10 were determined with the same method as for dipyridyl-s-tetrazine 1, described in Section 3.5.3. 
However, the decrease of the tetrazine absorption was measured at 320 nm at a final concentration of 50 
μM of tetrazine 7 and 10-20 equiv. of alkene 8 – 10 in 5% MeOH and 95% 1 × PBS. The reactions were 
followed on a plate reader which started the measurement after ±20 s and no shaking was performed 
before the measurement. The 10-fold lower concentration of the reagents was used, as not all reagents 
were readily soluble in the aqueous solution. At this low concentration, the absorption of the tetrazines at 
540 nm was too low to accurately follow the reaction, and a different wavelength was therefore chosen. 
 
Tetrazine 7 with the aromatic alkenes in 5% MeOH/PBS. 
The k2 values of the reactions between tetrazine 7 and the aromatic alkenes 2 and 11 – 14 were 
determined with the same method as for 7 and the non-aromatic alkenes described above. However, the 
aromatic alkenes absorbed also at 320 nm, and the decrease in tetrazine absorbance was therefore 
measured at 335 nm.  
 
4.5.3 Biocompatibility of VBA 2 by 1H-NMR 
The stability of VBA 2 in deuterated water, and in the presence of 6-aminohexanol or L-cysteine was 
determined by 1H NMR (400 MHz). A) VBA 2 (20 mM) in 1:1 (CD3)2SO/D2O. B) VBA 2 (300 μL, 40 
mM, 1.0 equiv.) and 6-aminohexanol (300 μL, 40 mM, 1.0 equiv.) in 1:1 (CD3)2SO/D2O were 
combined, for a final concentration of 20 mM. C) VBA 2 (200 μL, 15 mM in 30% (CD3)2SO in D2O, 
1.0 equiv.) and L-cysteine (200 μL, 15 mM in D2O, 1.0 equiv.) and tris(2-carboxyethyl)phosphine 
(TCEP, 200 μL, 30 mM in D2O, 2.0 equiv.) were combined, for a final concentration of 5 mM of VBA 2 
and L-cysteine and 10 mM of TCEP in 1:9 (CD3)2SO/D2O. TCEP was added to reduce the oxidized 
L-cystine back to L-cysteine. All samples were shaken at 400 rpm (thermometer comfort, Eppendorf AG) 
and followed over time by 1H NMR for one week. VBA 2 was stable under all conditions, data is shown 
in Figure S4.1.  
 
4.5.4 Protein modification of purified protein HSA 
Protein modifications were performed at a Thermomixer comfort, Eppendorf AG. Characterization of 
protein mass was performed by electrospray ionization time-of-flight (ESI-TOF) on a JEOL AccuTOF 
with Agilent (1100 series HPLC). Deconvoluted mass spectra were obtained using MagTran 1.03b2. For 
both the small molecules and the protein, the boron-containing compounds were not found using mass 
spectroscopy.27,30 To the samples (10 μL of 1.0 or 0.5 μM in 1 × PBS) that were analyzed by SDS-PAGE, 
5 × sample buffer (2.5 L) was added and the samples were subsequently heated at 95 C for 5 min and 
loaded (10 L) and analyzed on 15% SDS-PAGE gels. The fluorescent signal of the BODIPY dye (488 
nm) was measured on a Typhoon TRIO+ imager (GE Healthcare) and the proteins on the gel were 
visualized by staining with Coomassie Brilliant Blue. 
 
Modification of human serum albumin  
To a solution of recombinant HSA in 1 × PBS (50 μM, 1.0 mL) was added maleimide 21 (10 μL, 10 mM 
in DMSO, 2 equiv.). The mixture was incubated at 400 rpm (thermometer comfort, Eppendorf AG) at rt 
for 2 h, whereupon the protein was dialyzed to 1 × PBS (3 × 1 h, 12-14 kDa membrane, Spectra/Por 
Dialysis Membrane of Spectrum Laboratories, Inc.). Longer incubation or more equivalents of 21 yielded 
in double labeling of HSA. HSA-DBCO (800 μL) was incubated overnight with vinylboronic acid 19 (8 
μL, 50 mM in DMSO, 10 equiv.). After the SPAAC reaction, the HSA-VBA was dialyzed to 1 × PBS (3 × 
1 h, 12-14 kDa membrane). A part of HSA-VBA (100 μL) was incubated with tetrazine 20 (1 μL, 50 mM 
in DMSO, 10 equiv.) for 1 h. Furthermore HSA and HSA-DBCO (50 μL, 50 μM) were incubated with 
tetrazine 20 (0.5 μL, 50 mM in DMSO, 10 equiv.) for 1 h as a control. To samples were diluted to 1 μM 
with 1 × PBS and visualized with SDS-PAGE gel (Figure 4.3C). Mass spectra were recorded (Figure S4.2), 
the mass of the HSA-VBA was not found, the mass of the other modified proteins match the calculated 
mass. HRMS (ESI+) for HSA-DBCO calcd. 67002, found 67001 and for HSA-DHP calcd. 67833, found 
67833.  
 
Time range of tetrazine ligation of HSA-VBA 
HSA-VBA (20 μL, 50 μM) was incubated with tetrazine 20 (0.2 μL, 50 mM in DMSO, 10 equiv.) for 
120, 60, 30, 15, 5, 1 and 0 min, then 3,6-dipyridyl-s-tetrazine 1 (2 μL, 500 mM in DMSO, 1000 equiv.) 
was added to stop the reaction. The mixture was shaken for 1 h and centrifuged for 2 min at 13 000 rpm. 
Finally, the samples were diluted to 0.5 μM with 1 × PBS and visualized with SDS-PAGE gel (Figure 
4.3D).  
 
Protein modification with VBA pinacol ester 20 
To a solution of recombinant HSA in 1 × PBS (50 μM, 0.5 mL) was added maleimide-DBCO 21 (5 μL, 
10 mM in DMSO, 2 equiv.). The mixture was incubated at 400 rpm (thermometer comfort, Eppendorf 
AG) at rt for 2 h, whereupon the protein was dialyzed to 1 × PBS 3 × 30 min (12-14 kDa membrane, 
Spectra/Por Dialysis Membrane of Spectrum Laboratories, Inc.). HSA-DBCO (400 μL) was incubated 
overnight with vinylboronic acid pinacol ester 18 (4 μL, 50 mM in DMSO, 10 equiv.). After the SPAAC 
reaction, the HSA-VBA was dialyzed to 1 × PBS (o/n, 12-14 kDa membrane, Spectra/Por Dialysis 
Membrane of Spectrum Laboratories, Inc.). A part of HSA-VBA (50 μL) was incubated with tetrazine 20 
(0.5 μL, 50 mM in DMSO, 10 equiv.) for 1 h. Finally, the samples were diluted to 1 μM with 1 × PBS 
and visualized with SDS-PAGE gel (Figure 4.6B).  
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Protein modification with VBA-maleimide 23 
To a solution of recombinant HSA in 1 × PBS (50 μM, 250 μL) was added maleimide 23 (2.5 μL, 10 
mM in DMSO, 2 equiv.). The mixture was incubated at 400 rpm (thermometer comfort, Eppendorf AG) 
at rt for 2 h, whereupon the protein was dialyzed to 1 × PBS o/n (12-14 kDa membrane, Spectra/Por 
Dialysis Membrane of Spectrum Laboratories, Inc.). HSA-VBA (50 μL) was incubated with tetrazine 20 
(0.5 μL, 50 mM in DMSO, 10 equiv.) for 1 h. Finally, the samples were diluted to 1 μM with 1 × PBS 
and visualized with SDS-PAGE gel (Figure 4.6C). 
 
4.5.5 Stability of VBA in cell lysate and toxicity  
NIH/3T3 mouse embryonic fibroblast cells were maintained in DMEM supplemented with 10% heat-
inactivated donor bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin (all purchased at 
Life Technologies). All cells were incubated at 37 °C in a humidified atmosphere of 5% CO2. Cells were 
passaged every 2 to 3 days. Cell lysates were prepared from NIH/3T3 mouse embryonic fibroblast cells 
cultured in T75 tissue flasks containing 8 mL (100 000 cells/mL) for one day. The cells were washed with 
1 × PBS and harvested with trypsin (0.5 mL, from porcine pancreas). To remove the trypsin as much as 
possible, cells were washed 3 × by addition of 1 × PBS (5 mL), centrifugation for 5 min at 1000 rpm at rt 
and careful removal of the supernatant. Then, the pellet was resuspended in lysis buffer (4 mL, 20 mM 
Hepes 7.8, 150 mM NaCl and 0.1% Triton X-100) and rotated for 10 min at 4 °C, whereupon the cells 
were sonicated (Labsonic P, Sartorius). Finally, the sample was centrifuged for 20 min at 10 000 rpm and 
4 °C, the supernatant was transferred into a clean tube. The protein concentration (0.5 mg/mL) was 
determined using a Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific).  
 
The tetrazine ligation in cell lysate 
First (E)-(4-methoxyphenyl)vinylboronic acid 2 (100 mM in DMSO) was diluted 100 × in 1 × PBS or cell 
lysate. The sample in 1 × PBS was directly reacted with dipyridyl-s-tetrazine derivative 7 (0.1 mM in 1% 
DMSO/PBS). The samples in 1% DMSO/cell lysate were incubated first for 4 or 24 hour, or directly 
reacted with a freshly prepared sample of tetrazine 7 (0.1 mM in 1% DMSO/cell lysate). The reactions, 
with final concentrations of 50 μM tetrazine 7 and 500 μM VBA 2 (10 equiv.) in 1% DMSO/PBS or cell 
lysate were followed on a plate reader at uncontrolled rt, by measuring the absorbance decay of the 
tetrazine at 335 nm for 1 h. All reactions were performed in triplo or in quadruplo. The pseudo-first-order 
reaction rates were determined using Prism (GraphPad Software, Inc) using a non-linear regression fit. 
The kinetic data was normalized using the plateau at the end of the reaction as 0% and the absorbance at t 
= 0 s as 100%, taking into account that the measurement started after 20 s. The pseudo-first-order 
reaction rates were normalized by setting the reaction rate in 1 × PBS at 100% (Figure 4.4A).  
 
Stability of HSA-VBA in cell lysate  
To aliquots of 18 μL NIH 3T3 cell lysate (1 mg/mL) was added HSA-VBA (2 μL, 5 μM in 1 × PBS) for a 
final concentration of the functionalized HSA of 0.5 μM. The solution was shaken for 24, 4 or 1 h or 30, 
15, 0 min at 400 rpm (thermometer comfort, Eppendorf AG) at rt. Tetrazine 20 (0.2 μL, 0.5 mM, 10 
equiv.) was added and the reaction was shaken for 1 h. Finally, the reaction was visualized with SDS-
PAGE gel (Figure 4.4B) 
 
Concentrations range of the tetrazine ligation with HSA-VBA in cell lysate  
To NIH 3T3 cell lysate (18 μL, 1 mg/mL) were added different concentrations of HSA-VBA (2 μL, 0.1 to 
10 μM) for final concentrations of 10, 25, 50, 100, 250, 500 and 1000 nM. Then, tetrazine 20 (0.2 μL, 
10 μM – 1 mM, 10 equiv.) was added and it was shaken at 400 rpm for 1 h. Finally, the reaction was 
visualized with SDS-PAGE gel (Figure 4.4C) 
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Protein modification with VBA-maleimide 23 
To a solution of recombinant HSA in 1 × PBS (50 μM, 250 μL) was added maleimide 23 (2.5 μL, 10 
mM in DMSO, 2 equiv.). The mixture was incubated at 400 rpm (thermometer comfort, Eppendorf AG) 
at rt for 2 h, whereupon the protein was dialyzed to 1 × PBS o/n (12-14 kDa membrane, Spectra/Por 
Dialysis Membrane of Spectrum Laboratories, Inc.). HSA-VBA (50 μL) was incubated with tetrazine 20 
(0.5 μL, 50 mM in DMSO, 10 equiv.) for 1 h. Finally, the samples were diluted to 1 μM with 1 × PBS 
and visualized with SDS-PAGE gel (Figure 4.6C). 
 
4.5.5 Stability of VBA in cell lysate and toxicity  
NIH/3T3 mouse embryonic fibroblast cells were maintained in DMEM supplemented with 10% heat-
inactivated donor bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin (all purchased at 
Life Technologies). All cells were incubated at 37 °C in a humidified atmosphere of 5% CO2. Cells were 
passaged every 2 to 3 days. Cell lysates were prepared from NIH/3T3 mouse embryonic fibroblast cells 
cultured in T75 tissue flasks containing 8 mL (100 000 cells/mL) for one day. The cells were washed with 
1 × PBS and harvested with trypsin (0.5 mL, from porcine pancreas). To remove the trypsin as much as 
possible, cells were washed 3 × by addition of 1 × PBS (5 mL), centrifugation for 5 min at 1000 rpm at rt 
and careful removal of the supernatant. Then, the pellet was resuspended in lysis buffer (4 mL, 20 mM 
Hepes 7.8, 150 mM NaCl and 0.1% Triton X-100) and rotated for 10 min at 4 °C, whereupon the cells 
were sonicated (Labsonic P, Sartorius). Finally, the sample was centrifuged for 20 min at 10 000 rpm and 
4 °C, the supernatant was transferred into a clean tube. The protein concentration (0.5 mg/mL) was 
determined using a Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific).  
 
The tetrazine ligation in cell lysate 
First (E)-(4-methoxyphenyl)vinylboronic acid 2 (100 mM in DMSO) was diluted 100 × in 1 × PBS or cell 
lysate. The sample in 1 × PBS was directly reacted with dipyridyl-s-tetrazine derivative 7 (0.1 mM in 1% 
DMSO/PBS). The samples in 1% DMSO/cell lysate were incubated first for 4 or 24 hour, or directly 
reacted with a freshly prepared sample of tetrazine 7 (0.1 mM in 1% DMSO/cell lysate). The reactions, 
with final concentrations of 50 μM tetrazine 7 and 500 μM VBA 2 (10 equiv.) in 1% DMSO/PBS or cell 
lysate were followed on a plate reader at uncontrolled rt, by measuring the absorbance decay of the 
tetrazine at 335 nm for 1 h. All reactions were performed in triplo or in quadruplo. The pseudo-first-order 
reaction rates were determined using Prism (GraphPad Software, Inc) using a non-linear regression fit. 
The kinetic data was normalized using the plateau at the end of the reaction as 0% and the absorbance at t 
= 0 s as 100%, taking into account that the measurement started after 20 s. The pseudo-first-order 
reaction rates were normalized by setting the reaction rate in 1 × PBS at 100% (Figure 4.4A).  
 
Stability of HSA-VBA in cell lysate  
To aliquots of 18 μL NIH 3T3 cell lysate (1 mg/mL) was added HSA-VBA (2 μL, 5 μM in 1 × PBS) for a 
final concentration of the functionalized HSA of 0.5 μM. The solution was shaken for 24, 4 or 1 h or 30, 
15, 0 min at 400 rpm (thermometer comfort, Eppendorf AG) at rt. Tetrazine 20 (0.2 μL, 0.5 mM, 10 
equiv.) was added and the reaction was shaken for 1 h. Finally, the reaction was visualized with SDS-
PAGE gel (Figure 4.4B) 
 
Concentrations range of the tetrazine ligation with HSA-VBA in cell lysate  
To NIH 3T3 cell lysate (18 μL, 1 mg/mL) were added different concentrations of HSA-VBA (2 μL, 0.1 to 
10 μM) for final concentrations of 10, 25, 50, 100, 250, 500 and 1000 nM. Then, tetrazine 20 (0.2 μL, 
10 μM – 1 mM, 10 equiv.) was added and it was shaken at 400 rpm for 1 h. Finally, the reaction was 
visualized with SDS-PAGE gel (Figure 4.4C) 
 
  
Cell viability assay 
The toxicity of several compounds was tested with the cell proliferation and cytotoxicity assay using Cell 
Counting Kit-8 (CCK-8, Dojindo Laboratories). NIH/3T3 cells were seeded in a 96-well plate (20 000 
cells/well in 200 μL of medium). After one day of cell growth, the cells were washed once with 1 × PBS 
followed by addition of 100 μL of medium containing 1% DMSO and different concentrations of the 
compounds boric acid, VBA 2, tetrazine 7, and the tetrazine ligation of 2 with 7. After 4 or 24 h of 
incubation, the medium was removed, the cells were washed with growth medium (3 ×) and 100 μL of 
medium containing 10% CCK-8 was added. After incubation for 3 h, the absorbance at 450 nm using a 
microplate reader (Sunrise tm, Tecan) was measured. The background absorbance of cell medium 
containing 10% CCK-8 was abstracted from the measured values. The viability of the cells was 
determined to be 100% by measuring the absorbance of cells with CCK-8 that were first incubated with 
1% DMSO, without any other compound. The experiments were performed in triplo, mean values with 
SD are shown (Figure 4.7). 
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4.7 Supplementary Table and Figures 
 
Table S4.1 – Second-order rate constant of tetrazine 7 with alkenes 2 and 8 -14 
 
 
 
Entry # Structure k2 (M-1 s-1) R2 
1 8[a] 2.2 ± 0.1 0.99 
2 9 3.0 ± 0.1 > 0.99 
3 (E)-10 0.24 ± 0.01 > 0.99 
4 (Z)-10 0.65 ± 0.02 > 0.99 
5 (E)-11 11 ± 1 > 0.99 
6 (Z)-11 0.59 ± 0.03 0.99 
7 12 0.011 ± 0.001 0.96 
8 (E/Z)-13[b] 0.020 ± 0.001 > 0.99 
9 2 27 ± 2 0.99 
10 14 0.13 ± 0.01  0.97 
[a] Endo/exo = 2:1. [b] E/Z = 1:3.  
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Figure S4.1 – Stability of (E)-(4-methoxyphenyl)vinylboronic acid 2, measured by 1H NMR (400 MHz). 
A) VBA 2 (20 mM) in 1:1 (CD3)2SO/D2O. B) VBA 2 (20 mM) and 6-aminohexanol (20 mM) in 1:1 
(CD3)2SO/D2O. C) VBA 2 (5 mM), L-cysteine (5 mM) and tris(2-carboxyethyl)phosphine (TCEP, 10 
mM) in 1:9 (CD3)2SO/D2O. L-cysteine and TCEP oxidized over the time, giving tris(2-
carboxyethyl)phosphine oxide (□) and L-cystine (○). 
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Figure S4.2 – ESI-TOF mass spectrometry of HSA and functionalized HSA. A) Deconvoluted total mass 
spectrum of HSA, HSA-DBCO and HSA-DHP. B) Multiply charged ion series of HSA, HSA-DBCO and 
HSA-DHP.  
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Figure S4.2 – ESI-TOF mass spectrometry of HSA and functionalized HSA. A) Deconvoluted total mass 
spectrum of HSA, HSA-DBCO and HSA-DHP. B) Multiply charged ion series of HSA, HSA-DBCO and 
HSA-DHP.  
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Abstract 
 
The tetrazine ligation is a suitable bioorthogonal reaction because of its selectivity and high 
reaction rates with several alkenes and alkynes. In Chapter 4, we described vinylboronic acids 
(VBAs) as novel hydrophilic bioorthogonal moieties that react efficiently with dipyridyl-s-
tetrazines and used them for protein modification in cell lysate. It remained to be seen, however, 
whether VBAs are suitable for labeling experiments in living cells because of the possible 
coordination with, for example, carbohydrate diols. Here, we evaluated VBAs as bioorthogonal 
reactants for labeling of proteins in living cells using an irreversible inhibitor of the proteasome 
and compared the reactivity to that of an inhibitor containing norbornene, a widely used reactant 
for the tetrazine ligation. No large differences were observed between the VBA and norbornene 
probes in a two-step labeling approach with a cell-penetrable fluorescent tetrazine, indicating that 
the VBA gives little or no side reactions with diols and can be used efficiently for protein labeling 
in living cells. 
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Abstract 
 
The tetrazine ligation is a suitable bioorthogonal reaction because of its selectivity and high 
reaction rates with several alkenes and alkynes. In Chapter 4, we described vinylboronic acids 
(VBAs) as novel hydrophilic bioorthogonal moieties that react efficiently with dipyridyl-s-
tetrazines and used them for protein modification in cell lysate. It remained to be seen, however, 
whether VBAs are suitable for labeling experiments in living cells because of the possible 
coordination with, for example, carbohydrate diols. Here, we evaluated VBAs as bioorthogonal 
reactants for labeling of proteins in living cells using an irreversible inhibitor of the proteasome 
and compared the reactivity to that of an inhibitor containing norbornene, a widely used reactant 
for the tetrazine ligation. No large differences were observed between the VBA and norbornene 
probes in a two-step labeling approach with a cell-penetrable fluorescent tetrazine, indicating that 
the VBA gives little or no side reactions with diols and can be used efficiently for protein labeling 
in living cells. 
 
  
5.1 Introduction 
 
In the last years, the development of reactions that are unaffected by any of the molecular 
functionalities in a biological system has emerged as a major field of research in chemical 
biology.1–4 These bioorthogonal reactions are used for tagging biomolecules with a high reaction 
rate by a two-step approach in vitro and in vivo, without the need to attach these tags directly 
onto the biomolecule. The reactants should be non-toxic to the cellular environment and should 
not influence the function of the labeled biomolecule of interest, therefore a small hydrophilic 
reactant is often preferred. One of the most popular bioorthogonal reactions is the inverse 
electron-demand Diels-Alder (iEDDA) reaction between electron-poor tetrazines5–8 and electron-
rich or strained alkenes or alkynes, e.g. trans-cyclooctene,9,10 norbornene,11 or cyclopropene.12,13 In 
Chapters 3 and 4, we reported a new non-strained bioorthogonal reactant, vinylboronic acid 
(VBA), which reacts, depending on its substituents, with second-order rate constants (k2) up to 
27 M-1 s-1 with 3,6-dipyridyl-s-tetrazines. These VBAs are one order of magnitude faster than 
norbornene, a commonly used tetrazine reactant (Figure 5.1A). We further showed that the VBA 
moiety is biocompatible with cellular components, stable in cell lysate, and applicable for protein 
 
 
Figure 5.1 – A) The reported tetrazine ligation with vinylboronic acids and norbornene with k2 values 
determined in 5% MeOH in PBS. B) Two-step protein labeling protocol. Addition of an irreversible 
protein inhibitor containing a VBA was followed by cycloaddition with a dipyridyl-s-tetrazine containing a 
fluorophore. C) The equilibria of carbohydrate diols with a boronic acid in aqueous media.  
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modification. 
Over the last years, boronic acids have been used in living cells for various applications.14 
The concept that phenylboronic acid moieties can form reversible complexes with 1,2- and 1,3-
cis-diols in aqueous environments has been exploited in the development of chemosensors for 
carbohydrates (Figure 5.1C).15 The rate of this condensation reaction is dependent on the pKa of 
the phenylboronic acid, where electron-withdrawing substituents on the phenyl ring lower the 
pKa and thereby favor binding to the diols.16,17 Despite the potential condensation reaction with 
biological diols present in and on the cell, many boronic acid-containing compounds have been 
successfully used inside living cells such as protease inhibitors18, sensors for reactive oxygen 
species19 and reactants in bioconjugation reactions.20–22 It is not clear, however, if or to what 
extent the carbohydrate rich cellular environment interferes with the cellular uptake and 
distribution of these boronic-acid-containing compounds or with molecules containing our 
bioorthogonal VBA moiety.  
To investigate the uptake and bioorthogonality of the VBA moiety in living cells, we 
chose a two-step labeling strategy of the proteasome using a VBA-modified irreversible inhibitor, 
followed by visualization using a dipyridyl-s-tetrazine functionalized with a fluorophore (Figure 
5.1B). The proteasome is a large multi-subunit proteolytic complex that is mainly responsible for 
the degradation of proteins into small peptides by the ubiquitin-proteasome pathway.23–25 The 
proteolytic core contains seven distinct α and β subunits, whereas the β1, β2 and β5 subunits are 
responsible for the proteolytic activities of the proteasome. These proteolytic subunits act as N-
terminal threonine proteases, where the nucleophilic hydroxyl attacks the peptide carbonyl 
causing cleavage of the peptide bond. Recent progress in the development of inhibitors of the 
proteasome or of only one of the proteolytic subunits, has been extensively reviewed.26–28 The 
two-step labeling strategy of the proteolytic proteasome subunits using irreversible inhibitors 
followed by a bioorthogonal reaction with a fluorescent molecule has been previously performed 
using the copper-catalyzed alkyne-azide cycloaddition,29,30 strain-promoted alkyne-azide 
cycloaddition,31 the Staudinger ligation,29,32–35 and the tetrazine ligation29 and thereby serves as a 
well-established model system for our studies. 
The (6-aminohexanoyl)3(leucinyl)3vinyl(methyl)sulfone (Ahx3L3VS) moiety is found to 
give strong inhibition of the proteasome, without being selective for any of the three catalytic 
subunits.36 The three leucines are recognized by the proteasome and the vinylsulfone moiety 
reacts covalently and irreversibly with the -hydroxyl of the N-terminal threonine of the catalytic 
proteasome subunits. The long linker of the scaffold is built up by aminohexanoic acids that are 
beneficial for efficient binding to the proteasome36 and were thought to be an advantage for the 
two-step labeling of the proteasome as the bioorthogonal moiety could be placed far away from 
the active site. Here, we describe the synthesis and application of proteasome inhibitor VBA-
Ahx3L3VS 9, containing a protected vinylboronic acid moiety that hydrolyzes quickly in aqueous 
solution to the free boronic acid. We compared this compound to Nor-Ahx3L3VS 10, which 
contains the commonly used bioorthogonal norbornene moiety. 
 
5.2 Results and Discussion 
 
5.2.1 Synthesis of the VBA, norbornene and BODIPY proteasome inhibitors 
The proteasome inhibitors were synthesized using modified literature procedures as 
depicted in Scheme 5.1. In short, Boc-Leu-OH was first reduced to its corresponding aldehyde 3 
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5.2 Results and Discussion 
 
5.2.1 Synthesis of the VBA, norbornene and BODIPY proteasome inhibitors 
The proteasome inhibitors were synthesized using modified literature procedures as 
depicted in Scheme 5.1. In short, Boc-Leu-OH was first reduced to its corresponding aldehyde 3 
via Weinreb amide 2. A stabilized Wittig reaction gave trans-VS 4 containing a small amount of 
cis-VS that was removed using column chromatography. Next, a double round of Boc-
deprotection and coupling of Boc-Leu-OH yielded Boc-L3VS 6 via Boc-L2VS 5. Finally, Boc-
deprotection and then coupling of Fmoc-Ahx3-OH 7, yielded Fmoc-protected Ahx3L3VS 8. 
 
 
Scheme 5.1 – Synthesis of proteasome inhibitors 9 - 11. i) N,O-dimethyl hydroxylamine HCl, NMM, 
EDCI, CH2Cl2, 5 h, 95%. ii) LiAlH4, Et2O, 0 °C, 15 min, 81%. iii) 
Diethyl(methylsulfonylmethyl)phosphonate, NaH, THF, 0 °C, 1 h, 35%. iv) (a) 4 M HCl in dioxane, 
CH2Cl2, 2 h, (b) Boc-Leu-OH, EDCI, HOBt, Et3N, CH2Cl2, o/n, 94%. v) Same as iv, yielding 6 in 98%. 
vi) (a) 4 M HCl in dioxane, CH2Cl2, 2 h, (b) Fmoc-Ahx3-OH, EDCI, HOBt, Et3N, CH2Cl2, o/n, 54%. 
vii) (a) piperidine, DMF, 15 min (b) VBA-NHS 15, DIPEA, DMF, 1 h, yielding 9 in 73%. viii) same as 
vii, only (b) with norbornene-NHS 16, yielding 10 in 94%. ix) (a) DBU, DMF, 7 min, (b) BODIPY-FL 
NHS ester, HOBt, DIPEA, DMF, 1.5 h, yielding 11 in 44%.  
 
Next, we prepared the NHS ester of VBA and norbornene to ensure efficient coupling to 
scaffold 8, after deprotection of the Fmoc. For VBA-NHS 15, we used the alkoxy-substituted 
phenylvinylboronic acid, as we previously found that this electron-rich VBA gave the highest 
reaction rate with dipyridyl-s-tetrazine. First, etherification of 4-iodophenol using ethyl 
chloroacetate yielded ether 12 in excellent yield (Scheme 5.2A). Subsequently, a Sonagashira 
coupling of iodide 12 yielded TMS-protected alkyne 13. Deprotection of the TMS group and 
hydrolysis of the ester to its free acid, followed by coupling of the acid with N-
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hydroxysuccinimide yielded alkyne-NHS 14. Final hydroboration of the alkyne with 
pinacolborane yielded NHS-boronic ester 15. Norbornene-NHS 16 was prepared in one step 
from its corresponding alcohol in good yield (Scheme 5.2B). The VBA-NHS 15 and the 
norbornene-NHS 16 were finally coupled to the free amine of Fmoc-deprotected 8, yielding 
VBA-Ahx3L3VS 9 and Nor-Ahx3L3VS 10 in good yields (Scheme 5.1). In addition, the 
fluorescent BODIPY-Ahx3L3VS 11 was prepared by direct coupling of the commercially available 
BODIPY-FL NHS ester to deprotected 8. 
 
 
Scheme 5.2 – A) Synthesis of VBA-NHS 15. i) Ethyl chloroacetate, K2CO3, DMF, 16 h, 98%. ii) 
Trimethylsilylacetylene, CuI, PdCl2(PPh3)3, DIPEA, toluene, 30 °C, 24 h, 99%. iii) (a) LiOH, THF/H2O 
1:1, 2 h, (b) N-hydroxysuccinimide, EDCI, DMF, 16 h, 88%. iv) Pinacolborane, Ru(CO)ClH(PPh3)3, 
toluene, 50 °C, 16 h, 74%. B) Synthesis of norbornene-NHS 16. v) N,N-disuccimidyl carbonate, Et3N, 
CH2Cl2, 2 h, 74%. 
 
5.2.2 VBA containing inhibitors are suitable for proteasome inhibition in cell lysate and 
living cells 
Having VBA-Ahx3L3VS 9 and Nor-Ahx3L3VS 10 in hand, we initially evaluated the 
selectivity and potency of the inhibitors in cell lysate (Figures 5.2A, B). First, we established that a 
concentration of 0.3 μM of BODIPY-Ahx3L3VS 11 was essential for visualization of all 
proteasome subunits in cell lysate (Figure S5.1A). Then, compounds 9 or 10 were incubated for 
one hour at various concentrations in the protein lysate, after which BODIPY 11 was added to 
label all residual unbound proteasomal subunits (Figure 5.2B). Using this set-up, we observed 
that low micromolar concentrations of inhibitor 9 and 10 were essential for full inhibition of all 
subunits. In addition, we observed a slight selectivity of VBA 9 for β5 compared to the other 
subunits, whereas norbornene 10 was more selective for β2 as well as β5. 
We continued to evaluate the inhibition of the proteasome with the Ahx3L3VS probes 9 
and 10 in living cells. Here, performing a similar competition experiment as above, a 100-fold 
higher concentration of both 9 and 10 was essential to inhibit the proteasome subunits 
completely. Despite the moderate cell permeability of the probes this indicates that, similarly to 
the norbornene handle, the VBA moiety did not hamper membrane permeability of the inhibitor 
(Figure 5.2C). Elevated concentrations for complete proteasome inhibition and the observed  
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Figure 5.2 – A) Schematic figure of the competition assay of VBA 9 or norbornene 10 using BODIPY 11 
in cell lysate and living HeLa cells. B) SDS-PAGE analysis of the competition assay in cell lysate (10 μL of 
1 mg/mL), which was first incubated with 9 or 10 (indicated concentration) for 1 h at 37 °C and next 
with 11 (0.3 μM) for 1 h at 37 °C. C) Competition assay in living HeLa cells, which were first incubated 
with 9 or 10 (indicated concentration) for 3 h at 37 °C, whereupon the cells were lysed and the lysate (10 
μL of 1 mg/mL) was incubated with 11 (0.3 μM) for 1 h at 37 °C. In-gel fluorescence (top) was measured 
at 488 nm, followed by colloidal staining (bottom) as a loading control of the protein lysates. 
 
reduced labeling of the β1 subunit in living cells was also observed with BODIPY 11 (Figure 
S5.1B) and reported previously using a different Ahx3L3VS probe.36 Aside, significant cell death 
was visible when norbornene 10 was used at concentrations > 100 μM, while VBA 9 did not 
show any toxicity up to 1 mM concentration. 
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5.2.3 The tetrazine ligation with VBA is suitable for visualization of the proteasome in 
living cells 
Next, we investigated whether we could visualize the proteasome subunits with a two-step 
labeling strategy using VBA 9 or norbornene 10 followed by the tetrazine ligation with dipyridyl-
s-tetrazine 17, containing a BODIPY-FL fluorophore, in cell lysate as well as in living cells 
(Figure 5.3A). After inhibition of the subunits using VBA 9 and norbornene 10 in cell lysate at 
concentrations that showed full subunit inhibition as established above (3 M), about 3 M of 
tetrazine 17 was necessary to give a complete reaction (Figure S5.2). In living cells, after 
inhibition of the proteasome with 300 M VBA 9 and 100 M norbornene 10, a comparable 
concentration of 10 M tetrazine 17 was necessary to visualize the subunits (Figures 5.3B, C). To 
our delight, similar labeling intensities of the proteasome subunits were observed using the probes 
VBA 9 and norbornene 10 in lysate and in living cells, as evidenced by SDS-PAGE gel. 
 
 
Figure 5.3 – A) Structure of the cell-permeable tetrazine-BODIPY 17. B) Schematic figure of the two-
step labeling of the proteasome. C) SDS-PAGE fluorescence analysis of a concentration range of tetrazine 
17 in the two-step labeling of the proteasome subunits with VBA 9 (300 μM) or norbornene 10 (100 μM) 
in living cells. D) Confocal microscopy of the two-step labeling of the proteasome. HeLa cells were first 
incubated with DMSO, VBA 9 (300 μM) or norbornene 10 (100 μM) for 3 h at 37 °C, after which 
tetrazine 17 (3 μM) was applied. Scale bar = 50 μm. 
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5.2.3 The tetrazine ligation with VBA is suitable for visualization of the proteasome in 
living cells 
Next, we investigated whether we could visualize the proteasome subunits with a two-step 
labeling strategy using VBA 9 or norbornene 10 followed by the tetrazine ligation with dipyridyl-
s-tetrazine 17, containing a BODIPY-FL fluorophore, in cell lysate as well as in living cells 
(Figure 5.3A). After inhibition of the subunits using VBA 9 and norbornene 10 in cell lysate at 
concentrations that showed full subunit inhibition as established above (3 M), about 3 M of 
tetrazine 17 was necessary to give a complete reaction (Figure S5.2). In living cells, after 
inhibition of the proteasome with 300 M VBA 9 and 100 M norbornene 10, a comparable 
concentration of 10 M tetrazine 17 was necessary to visualize the subunits (Figures 5.3B, C). To 
our delight, similar labeling intensities of the proteasome subunits were observed using the probes 
VBA 9 and norbornene 10 in lysate and in living cells, as evidenced by SDS-PAGE gel. 
 
 
Figure 5.3 – A) Structure of the cell-permeable tetrazine-BODIPY 17. B) Schematic figure of the two-
step labeling of the proteasome. C) SDS-PAGE fluorescence analysis of a concentration range of tetrazine 
17 in the two-step labeling of the proteasome subunits with VBA 9 (300 μM) or norbornene 10 (100 μM) 
in living cells. D) Confocal microscopy of the two-step labeling of the proteasome. HeLa cells were first 
incubated with DMSO, VBA 9 (300 μM) or norbornene 10 (100 μM) for 3 h at 37 °C, after which 
tetrazine 17 (3 μM) was applied. Scale bar = 50 μm. 
In addition, we evaluated the stability of the VBA and norbornene handles in living cells 
and the efficiency of the tetrazine ligation by monitoring the protein labeling over the course of 
time. After inhibition of the proteasome with VBA 9 and norbornene 10 (300 M and 100 M, 
respectively), the cells were lysed and the subsequent tetrazine ligation was performed with 
tetrazine 17 for various amounts of time. Complete labeling of the subunits was observed within 
2-5 minutes, indicating that both functionalities were intact and the reaction was very efficient 
(Figure S5.3). 
Finally, we used the same two-step labeling protocol to visualize the proteasome in living 
HeLa cells by confocal microscopy (Figures 5.3B, D). Again, similar intensities were observed 
using VBA 9 or norbornene 10 followed by addition of 3 μM of tetrazine-BODIPY 17, 
indicating successful labeling of the proteasome. For comparison, the labeling pattern of 
BODIPY 11 was measured, which was similar to that observed for 9 and 10, indicating that the 
VBA, norbornene and BODIPY labels did not significantly influence the cellular distribution of 
the inhibitors (Figure S5.4). Performing the ligation with a higher concentration of tetrazine 17 
using the same microscopy settings resulted in higher labeling intensities, however, in this case 
also an increased background signal was observed (Figure S5.5). 
 
5.3 Conclusions and Outlook 
 
In summary, we evaluated the use of the vinylboronic acid functionality for bioorthogonal 
labeling with tetrazines in living cells. The synthesized proteasome inhibitor containing a 
vinylboronic acid was successfully used for the two-step labeling of the proteasome in cell lysate 
and in living cells without showing diminished labeling efficiency with a dipyridyl-s-tetrazine 
compared to the proteasome inhibitor functionalized with a norbornene moiety. We have to 
emphasize that the potential condensation of the VBAs to biolocial diols would not be visible on 
SDS-PAGE gel or on confocal microscopy, as the boronic acid is released after the tetrazine 
ligation. However, if significant condensation would occur, a higher concentration of VBA 9 
would be essential to fully inhibit the proteasome subunits. Our results show that three times 
more VBA 9 compared to norbornene 10 was needed for complete inhibition of all subunits in 
vitro as well as in living cells, indicating that the vinylboronic acid handle does not significantly 
hamper cellular uptake of the probes into the cell. 
The number of bioorthogonal reactions that are suitable for labeling inside living cells is 
limited, because of the requirement of toxic reagents (e.g. copper(I)-catalyzed alkyne-azide 
cycloaddition) or possible side reactions of the reactants (e.g. the thiol-ene or thiol-yne side 
reactions of free intracellular cysteines with strained alkenes or alkynes). We have shown that the 
tetrazine ligation with vinylboronic acid is little or not affected by possible side reactions that can 
occur in the cell with biomolecules such as carbohydrates, making the reaction a valuable addition 
to the bioorthogonal toolbox. 
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5.5 Experimental Section 
 
5.5.1 Synthesis 
General experimental for the synthesis of the small molecules is described in Sections 3.5.1 and 4.5.1. 
BODIPY-FL dipyridyl-s-tetrazine 17 is synthesized as described in Chapter 3. 
 
Boc-leucine-N-methoxy-N-methylamide (2). Boc-Leu-OH 1 (1.07 g, 4.30 mmol, 1.0 equiv.) was 
dissolved in dry CH2Cl2 (20 mL) and cooled to 0 °C. N,O-dimethyl hydroxylamine (289 
mg, 4.73 mmol 1.1 equiv.) and N-methylmorpholine (0.52 mL, 4.73 mmol, 1.1 equiv.) 
were added, followed by EDCI hydrochloride (907 mg 4.73 mmol, 1.1 equiv.). The 
mixture was stirred at rt for 5 h, then 1 M HCl (50 mL) was added, the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 × 30 mL). The combined organic layers 
were washed with sat. NaHCO3 (50 mL) and brine (50 mL), dried over Na2SO4 and then the volatiles 
were removed under reduced pressure, which yielded the Weinreb amide 2 (1.16 g, 97%). Rf = 0.24 (10% 
MeOH in CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 4.99 (d, J = 9.5 Hz, 1H), 4.73 – 4.58 (m, 1H), 3.72 
(s, 3H), 3.13 (s, 3H), 1.72 – 1.59 (m, 1H), 1.41 – 1.33 (m, 11H), 0.90 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 
6.7 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 174.0, 155.8, 79.6, 61.7, 49.1, 42.2, 32.3, 28.5, 24.9, 
23.5, 21.7. LRMS (ESI+) m/z calcd. for C13H26N2O4 [M+H]+ 275.2, found: 274.7. The data agrees with 
the reported literature values.38 
 
Boc-leucinal (3). Weinreb amide 2 (500 mg, 1.82 mmol, 1.0 equiv.) was dissolved in dry Et2O (50 mL) 
and cooled to 0 °C. LiAlH4 (76 mg, 2.01 mmol, 1.1 equiv.) was added in portions over 
10 min, and the mixture was stirred for 20 min The reaction was quenched with 1 M HCl, 
filtered and the layers were separated. The organic layer was washed with sat. NaHCO3 and 
brine and dried over Na2SO4. Removal of the volatiles under reduced pressure yielded Boc-
leucinal 3 (316 mg, 81%). Rf = 0.46 (30% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 9.59 (s, 
1H), 4.91 (s, 1H), 4.29 – 4.19 (m, 1H), 1.82 – 1.72 (m, 1H), 1.70 – 1.61 (m, 1H), 1.45 (s, 9H), 1.38 
(ddd, J = 14.0, 9.3, 5.6 Hz, 1H), 0.97 (2 × d, J = 6.6 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 200.5, 
155.7, 80.2, 58.6, 38.3, 28.4, 24.8, 23.2, 22.1. Compound 3 was not visible on mass spectrometry. The 
data agrees with the reported literature values.38 
 
Boc-leucine-VS (4). Diethyl(methylsulfonylmethyl)phosphonate (321 mg, 1.40 mmol, 1.0 equiv.) was 
dissolved in dry THF (30 mL) and cooled to 0 °C. NaH (60% dispersion in mineral 
oil, 64 mg, 1.60 mmol, 1.15 equiv.) was added in portions over 10 min. After 5 min, 
aldehyde 3 (300 mg, 1.40 mmol, 1.0 equiv.) in dry THF (20 mL) was added and the 
mixture was stirred for 1 h at 0 °C. The reaction was quenched with HCl (1 M), 
EtOAc was added and the layers were separated. The organic phase was washed with sat. NaHCO3 (2 ×) 
and brine, dried over Na2SO4, and the volatiles were removed under reduced pressure, yielding vinyl 
sulfone 4 (194 mg, 73%) as a cis and trans mixture of 16:100. The product was purified using column 
chromatography (20 to 30% EtOAc in heptane) to yield trans-vinyl sulfone 4 (94 mg, 35%) as a slightly 
yellow oil. Rf = 0.13 (30% EtOAc in heptane). 1H NMR (500 MHz, CD3OD) δ 6.79 (dd, J = 15.2, 5.2 
Hz, 1H), 6.60 (d, J = 15.0 Hz, 1H), 4.33 (d, J = 8.3 Hz, 1H), 2.97 (s, 3H), 1.75 – 1.63 (m, 1H), 1.51 – 
1.36 (m, 11H), 0.99 – 0.91 (m, 6H). 13C NMR (125 MHz, CD3OD) δ 157.8, 149.7, 130.3, 80.5, 50.7, 
43.8, 42.8, 28.7, 26.0, 23.3, 22.0. LRMS (ESI+) m/z calcd. for C13H25NO4S [M+Na]+ 314.1, found: 
314.0. The data agrees with the reported literature values.39 
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5.5 Experimental Section 
 
5.5.1 Synthesis 
General experimental for the synthesis of the small molecules is described in Sections 3.5.1 and 4.5.1. 
BODIPY-FL dipyridyl-s-tetrazine 17 is synthesized as described in Chapter 3. 
 
Boc-leucine-N-methoxy-N-methylamide (2). Boc-Leu-OH 1 (1.07 g, 4.30 mmol, 1.0 equiv.) was 
dissolved in dry CH2Cl2 (20 mL) and cooled to 0 °C. N,O-dimethyl hydroxylamine (289 
mg, 4.73 mmol 1.1 equiv.) and N-methylmorpholine (0.52 mL, 4.73 mmol, 1.1 equiv.) 
were added, followed by EDCI hydrochloride (907 mg 4.73 mmol, 1.1 equiv.). The 
mixture was stirred at rt for 5 h, then 1 M HCl (50 mL) was added, the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (2 × 30 mL). The combined organic layers 
were washed with sat. NaHCO3 (50 mL) and brine (50 mL), dried over Na2SO4 and then the volatiles 
were removed under reduced pressure, which yielded the Weinreb amide 2 (1.16 g, 97%). Rf = 0.24 (10% 
MeOH in CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 4.99 (d, J = 9.5 Hz, 1H), 4.73 – 4.58 (m, 1H), 3.72 
(s, 3H), 3.13 (s, 3H), 1.72 – 1.59 (m, 1H), 1.41 – 1.33 (m, 11H), 0.90 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 
6.7 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 174.0, 155.8, 79.6, 61.7, 49.1, 42.2, 32.3, 28.5, 24.9, 
23.5, 21.7. LRMS (ESI+) m/z calcd. for C13H26N2O4 [M+H]+ 275.2, found: 274.7. The data agrees with 
the reported literature values.38 
 
Boc-leucinal (3). Weinreb amide 2 (500 mg, 1.82 mmol, 1.0 equiv.) was dissolved in dry Et2O (50 mL) 
and cooled to 0 °C. LiAlH4 (76 mg, 2.01 mmol, 1.1 equiv.) was added in portions over 
10 min, and the mixture was stirred for 20 min The reaction was quenched with 1 M HCl, 
filtered and the layers were separated. The organic layer was washed with sat. NaHCO3 and 
brine and dried over Na2SO4. Removal of the volatiles under reduced pressure yielded Boc-
leucinal 3 (316 mg, 81%). Rf = 0.46 (30% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 9.59 (s, 
1H), 4.91 (s, 1H), 4.29 – 4.19 (m, 1H), 1.82 – 1.72 (m, 1H), 1.70 – 1.61 (m, 1H), 1.45 (s, 9H), 1.38 
(ddd, J = 14.0, 9.3, 5.6 Hz, 1H), 0.97 (2 × d, J = 6.6 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 200.5, 
155.7, 80.2, 58.6, 38.3, 28.4, 24.8, 23.2, 22.1. Compound 3 was not visible on mass spectrometry. The 
data agrees with the reported literature values.38 
 
Boc-leucine-VS (4). Diethyl(methylsulfonylmethyl)phosphonate (321 mg, 1.40 mmol, 1.0 equiv.) was 
dissolved in dry THF (30 mL) and cooled to 0 °C. NaH (60% dispersion in mineral 
oil, 64 mg, 1.60 mmol, 1.15 equiv.) was added in portions over 10 min. After 5 min, 
aldehyde 3 (300 mg, 1.40 mmol, 1.0 equiv.) in dry THF (20 mL) was added and the 
mixture was stirred for 1 h at 0 °C. The reaction was quenched with HCl (1 M), 
EtOAc was added and the layers were separated. The organic phase was washed with sat. NaHCO3 (2 ×) 
and brine, dried over Na2SO4, and the volatiles were removed under reduced pressure, yielding vinyl 
sulfone 4 (194 mg, 73%) as a cis and trans mixture of 16:100. The product was purified using column 
chromatography (20 to 30% EtOAc in heptane) to yield trans-vinyl sulfone 4 (94 mg, 35%) as a slightly 
yellow oil. Rf = 0.13 (30% EtOAc in heptane). 1H NMR (500 MHz, CD3OD) δ 6.79 (dd, J = 15.2, 5.2 
Hz, 1H), 6.60 (d, J = 15.0 Hz, 1H), 4.33 (d, J = 8.3 Hz, 1H), 2.97 (s, 3H), 1.75 – 1.63 (m, 1H), 1.51 – 
1.36 (m, 11H), 0.99 – 0.91 (m, 6H). 13C NMR (125 MHz, CD3OD) δ 157.8, 149.7, 130.3, 80.5, 50.7, 
43.8, 42.8, 28.7, 26.0, 23.3, 22.0. LRMS (ESI+) m/z calcd. for C13H25NO4S [M+Na]+ 314.1, found: 
314.0. The data agrees with the reported literature values.39 
 
Boc-L2VS (5). Boc-leucine-VS 4 (343 mg, 1.18 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (15 mL), 
4.0 M HCl in dioxane (3.0 mL, 12.0 mmol, 10 equiv.) was added and the 
mixture was stirred for 2 h. After evaporation of the volatiles, the mixture was 
suspended in dry CH2Cl2 (15 mL) and Boc-Leu-OH (273 mg, 1.18 mmol, 1.0 
equiv.), HOBt (160 mg, 1.18 mmol, 1.0 equiv.) and Et3N (213 μL, 1.53 mmol, 
1.3 equiv.) were added. The mixture was cooled to 0 °C, EDCI hydrochloride 
(225 mg, 1.18 mmol, 1.0 equiv.) was added and the reaction was stirred at rt overnight. 1 M HCl (10 
mL) was added and the layers were separated, the organic layer was washed with sat. NaHCO3 and brine 
and dried over Na2SO4. The volatiles were removed under reduced pressure to yield Boc-L2VS 5 (447 mg, 
94%) as a slightly yellow solid. Rf = 0.47 (10% MeOH in CH2Cl2). 1H NMR (500 MHz, CD3OD) δ 
6.80 (dd, J = 15.1, 4.9 Hz, 1H), 6.59 (dd, J = 15.1, 1.6 Hz, 1H), 4.73 – 4.64 (m, 1H), 4.05 (t, J = 7.6 
Hz, 1H), 2.96 (s, 3H), 1.76 – 1.63 (m, 2H), 1.62 – 1.49 (m, 3H), 1.50 – 1.40 (m, 10H), 1.00 – 0.89 (m, 
12H). 13C NMR (125 MHz, CD3OD) δ 175.7, 157.9, 148.8, 130.6, 80.7, 55.1, 49.2*, 43.2, 42.8, 42.0, 
28.8, 26.0, 25.9, 23.4, 23.3, 22.0, 21.8. * Underneath the CD3OD peak, found with HSQC. HRMS 
(ESI+) m/z calcd. for C19H36N2O5S [M+Na]+ 427.22426, found: 427.22422. 
 
Boc-L3VS (6). Boc-L2VS 5 (447 mg, 1.10 mmol, 1 equiv.) was dissolved in dry CH2Cl2 (15 mL), 4.0 M 
HCl in dioxane (3.0 mL, 12.0 mmol, 11 equiv.) was added and the 
reaction was stirred for 2 h. After the volatiles were removed under 
reduced pressure and the mixture was suspended in dry CH2Cl2 (15 mL), 
Boc-Leu-OH (254 mg, 1.1 mmol, 1.0 equiv.), HOBt (148mg, 1.1 mmol, 
1.0 equiv.) and Et3N (230 μL, 1.7 mmol, 1.5 equiv.) were added. The 
mixture was cooled to 0 °C, EDCI hydrochloride (211 mg, 1.1 mmol, 1.0 equiv.) was added and the 
reaction was stirred at rt overnight. 1 M HCl (10 mL) was added, the layers were separated and the 
organic layer was washed with sat. NaHCO3 and brine and dried over Na2SO4. The volatiles were 
removed under reduced pressure to yield Boc-L3VS 6 (558 mg, 98%) as a slightly yellow solid. Rf = 0.51 
(10% MeOH in CH2Cl2). 1H NMR (500 MHz, CD3OD) δ 6.79 (dd, J = 15.1, 5.2 Hz, 1H), 6.62 (dd, J 
= 15.1, 1.7 Hz, 1H), 4.71 – 4.62 (m, 1H), 4.42 – 4.35 (m, 1H), 4.05 (t, J = 7.5 Hz, 1H), 2.97 (s, 3H), 
1.74 – 1.46 (m, 9H), 1.45 (s, 9H), 1.00 – 0.87 (m, 18H). 13C NMR (125 MHz, CD3OD) δ 175.8, 
174.3, 158.1, 148.4, 130.9, 80.7, 54.8, 53.4, 49.3*, 43.4, 42.8, 41.9, 41.7, 28.8, 25.9, 25.8, 23.4, 23.3, 
22.1, 21.98, 21.95. * Underneath the CD3OD peak, found with HSQC. HRMS (ESI+) m/z calcd. for 
C25H47N3O6S [M+Na]+ 540.30833, found: 540.30801. 
 
Fmoc-Ahx3-OH (7). Standard solid phase peptide synthesis (SPPS) was performed using a Barlos-resin 
(1.00 g, loading: 1.1 mmol/g). Fmoc deprotection was performed with 20% 
piperidine in DMF for 30 min, coupling of amino acids was performed with 
6-aminohexanoic acid (5.0 equiv.), DIPEA (10 equiv.) and HATU (5.0 equiv.) 
in DMF for 2 h. Cleavage of the peptide from the resin was performed by mixing the resin with 5 mL 
TFA/Milli-Q (95:5) for 1.5 h. After filtration, the solution was dissolved in diethyl ether and coevaporated 
with acetic acid (2 ×). Next, the peptide was dissolved in acetic acid and lyophilized to give Fmoc-Ahx3-
OH 7 (501 mg, 79%) as a white solid. 1H NMR (500 MHz, (CD3)2SO) δ 7.88 (d, J = 7.5 Hz, 2H), 7.71 
(br. t, J = 5.6 Hz, 2H), 7.68 (d, J = 7.4 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.32 (td, J = 7.5, 1.2 Hz, 2H), 
7.25 (br. t, J = 5.7 Hz, 1H), 4.28 (d, J = 7.0 Hz, 2H), 4.23 – 4.16 (m, 1H), 3.03 – 2.92 (m, 6H), 2.18 (t, 
J = 7.4 Hz, 2H), 2.04 – 1.99 (m, 4H), 1.53 – 1.42 (m, 6H), 1.42 – 1.31 (m, 6H), 1.28 – 1.14 (m, 6H). 
13C NMR (125 MHz, (CD3)2SO) δ 174.5, 171.85, 171.85, 156.1, 144.0, 140.8, 127.6, 127.1, 125.2, 
120.1, 65.2, 46.8, 40.2, 39.9, 38.33, 38.26, 35.4, 33.6, 29.2, 29.0, 28.9, 26.2, 25.99, 25.96, 25.1, 24.2. 
LCMS (ESI+) (linear gradient 5 to 100% MeCN in H2O, 0.1% TFA, 16 min): Rt = 14.65 min, m/z calcd. 
for C33H45N3O6 [M+H]+ 580.33, found: 580.60. The data agrees with the reported literature values.40 
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Fmoc-Ahx3L3VS (8). Boc-L3VS 6 (98 mg, 0.19 mmol, 1.1 equiv.) was dissolved in dry CH2Cl2 (2 mL), 
4.0 M HCl in dioxane (0.48 mL, 1.9 mmol, 11 equiv.) 
was added and the reaction was stirred for 2 h. The 
volatiles were removed under reduced pressure, the solid 
was dissolved in dry DMF (2 mL) and Fmox-Ahx3-OH 7 
(100 mg, 0.17 mmol, 1.0 equiv.), HATU (98 mg, 0.26 
mmol, 1.5 equiv.) and DIPEA (92 μL, 0.52 mmol, 3.0 equiv.) were added. After the reaction was stirred 
overnight, the product was precipitated in Et2O, washed with Et2O (2 ×) and purified using column 
chromatography (0 to 10% MeOH in EtOAc) yielding Fmoc-Ahx3L3VS 8 (90 mg, 54%) as a white solid. 
Rf = 0.37 (10% MeOH in EtOAc). 1H NMR (500 MHz, CD3OD) δ 7.80 (d, J = 7.5 Hz, 2H), 7.65 (d, J 
= 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 6.79 (dd, J = 15.2, 5.1 Hz, 1H), 6.60 
(dd, J = 15.2, 1.6 Hz, 1H), 4.70 – 4.61 (m, 1H), 4.39 – 4.30 (m, 4H), 4.20 (t, J = 6.9 Hz, 1H), 3.18 – 
3.11 (m, 4H), 3.10 (t, J = 6.9 Hz, 2H), 2.97 (s, 3H), 2.25 (td, J = 7.4, 1.8 Hz, 2H), 2.22 – 2.13 (m, 4H), 
1.71 – 1.45 (m, 21H), 1.40 – 1.27 (m, 6H), 0.99 – 0.88 (m, 18H). 13C NMR (125 MHz, CD3OD) δ 
176.4, 176.01, 175.96, 175.1, 174.3, 158.9, 148.5, 145.4, 142.6, 130.8, 128.8, 128.1, 126.2, 120.9, 
67.6, 53.5, 53.4, 49.3*, 48.7*, 43.3, 42.8, 41.61, 41.59, 41.5, 40.21, 40.20, 37.04, 37.00, 36.6, 30.6, 
30.1, 27.61, 27.56, 27.4, 26.8, 26.7, 26.6, 26.0, 25.9, 25.8, 23.43, 23.41, 23.40, 22.1, 22.0, 21.9. 
* Underneath the CD3OD peak, found with HSQC. HRMS (ESI+) m/z calcd. for C53H82N6O9S [M+Na]+ 
1001.57617, found: 1001.57212. 
 
VBA-Ahx3L3VS (9). Fmoc-Ahx3L3VS 8 (25 mg, 26 μmol, 1.1 equiv.) was dissolved in 20% piperidine in 
DMF and stirred for 15 min The 
product was precipitated in Et2O and 
the solid was washed with Et2O (2 ×), 
whereupon it was dissolved in DMF 
(1 mL) and VBA-NHS 15 (9.5 mg, 
24 μmol, 1.0 equiv.) and DIPEA (12 
μL, 71 μmol, 3.0 equiv.) were added. The reaction was stirred for 1 h, whereupon the solvents were 
removed under reduced pressure and the crude product was purified using column chromatography (0 to 
10% MeOH in EtOAc), yielding VBA-Ahx3L3VS 9 (18 mg, 73%) as a white solid. Rf = 0.39 (10% 
MeOH in EtOAc). 1H NMR (500 MHz, CD3OD) δ 7.41 – 7.35 (m, 2H), 7.21 (d, J = 18.4 Hz, 1H), 
6.91 – 6.85 (m, 2H), 6.69 (dd, J = 15.2, 5.1 Hz, 1H), 6.51 (dd, J = 15.2, 1.6 Hz, 1H), 5.89 (d, J = 18.3 
Hz, 1H), 4.59 – 4.53 (m, 1H), 4.42 (s, 2H), 4.29 – 4.19 (m, 2H), 3.17 (t, J = 7.1 Hz, 2H), 3.08 – 3.01 
(m, 4H), 2.87 (s, 3H), 2.15 (td, J = 7.4, 2.0 Hz, 2H), 2.10 – 2.02 (m, 4H), 1.62 – 1.37 (m, 21H), 1.30 – 
1.15 (m, 18H), 0.90 – 0.76 (m, 18H). 13C NMR (125 MHz, CD3OD) δ 176.4, 176.0, 175.1, 174.3, 
170.8, 159.9, 150.3, 148.5, 132.8, 130.8, 129.6, 116.0, 84.6, 68.3, 53.5, 53.4, 49.5*, 43.3, 42.8, 41.6, 
41.5, 40.21, 40.20, 40.0, 37.00, 36.99, 36.6, 30.1, 27.61, 27.57, 27.5, 26.72, 26.69, 26.6, 26.0, 25.9, 
25.8, 25.1, 23.43, 23.42, 23.40, 22.1, 22.0, 21.9. * Underneath the CD3OD peak, found with HSQC. In 
the 13C NMR, no signal was observed for the carbon attached to boron. HRMS (ESI+) m/z calcd. for 
C54H91BN6O11S [M+H]+ 1043.66378, found: 1043.66316. 
 
Nor-Ahx3L3VS (10). Fmoc-Ahx3L3VS 8 (25 mg, 26 μmol, 1.1 equiv.) was dissolved in 20% piperidine in 
DMF (400 μL) and stirred for 15 min The 
product was precipitated in Et2O and the solid 
was washed with Et2O (2 ×), whereupon it was 
dissolved in DMF (1 mL) and norbornene-NHS 
16 (6.2 mg, 23 μmol, 1.0 equiv.) and DIPEA (12 
μL, 70 μmol, 3.0 equiv.) were added. The reaction was stirred for 1 h, whereupon the solvents were 
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Fmoc-Ahx3L3VS (8). Boc-L3VS 6 (98 mg, 0.19 mmol, 1.1 equiv.) was dissolved in dry CH2Cl2 (2 mL), 
4.0 M HCl in dioxane (0.48 mL, 1.9 mmol, 11 equiv.) 
was added and the reaction was stirred for 2 h. The 
volatiles were removed under reduced pressure, the solid 
was dissolved in dry DMF (2 mL) and Fmox-Ahx3-OH 7 
(100 mg, 0.17 mmol, 1.0 equiv.), HATU (98 mg, 0.26 
mmol, 1.5 equiv.) and DIPEA (92 μL, 0.52 mmol, 3.0 equiv.) were added. After the reaction was stirred 
overnight, the product was precipitated in Et2O, washed with Et2O (2 ×) and purified using column 
chromatography (0 to 10% MeOH in EtOAc) yielding Fmoc-Ahx3L3VS 8 (90 mg, 54%) as a white solid. 
Rf = 0.37 (10% MeOH in EtOAc). 1H NMR (500 MHz, CD3OD) δ 7.80 (d, J = 7.5 Hz, 2H), 7.65 (d, J 
= 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 6.79 (dd, J = 15.2, 5.1 Hz, 1H), 6.60 
(dd, J = 15.2, 1.6 Hz, 1H), 4.70 – 4.61 (m, 1H), 4.39 – 4.30 (m, 4H), 4.20 (t, J = 6.9 Hz, 1H), 3.18 – 
3.11 (m, 4H), 3.10 (t, J = 6.9 Hz, 2H), 2.97 (s, 3H), 2.25 (td, J = 7.4, 1.8 Hz, 2H), 2.22 – 2.13 (m, 4H), 
1.71 – 1.45 (m, 21H), 1.40 – 1.27 (m, 6H), 0.99 – 0.88 (m, 18H). 13C NMR (125 MHz, CD3OD) δ 
176.4, 176.01, 175.96, 175.1, 174.3, 158.9, 148.5, 145.4, 142.6, 130.8, 128.8, 128.1, 126.2, 120.9, 
67.6, 53.5, 53.4, 49.3*, 48.7*, 43.3, 42.8, 41.61, 41.59, 41.5, 40.21, 40.20, 37.04, 37.00, 36.6, 30.6, 
30.1, 27.61, 27.56, 27.4, 26.8, 26.7, 26.6, 26.0, 25.9, 25.8, 23.43, 23.41, 23.40, 22.1, 22.0, 21.9. 
* Underneath the CD3OD peak, found with HSQC. HRMS (ESI+) m/z calcd. for C53H82N6O9S [M+Na]+ 
1001.57617, found: 1001.57212. 
 
VBA-Ahx3L3VS (9). Fmoc-Ahx3L3VS 8 (25 mg, 26 μmol, 1.1 equiv.) was dissolved in 20% piperidine in 
DMF and stirred for 15 min The 
product was precipitated in Et2O and 
the solid was washed with Et2O (2 ×), 
whereupon it was dissolved in DMF 
(1 mL) and VBA-NHS 15 (9.5 mg, 
24 μmol, 1.0 equiv.) and DIPEA (12 
μL, 71 μmol, 3.0 equiv.) were added. The reaction was stirred for 1 h, whereupon the solvents were 
removed under reduced pressure and the crude product was purified using column chromatography (0 to 
10% MeOH in EtOAc), yielding VBA-Ahx3L3VS 9 (18 mg, 73%) as a white solid. Rf = 0.39 (10% 
MeOH in EtOAc). 1H NMR (500 MHz, CD3OD) δ 7.41 – 7.35 (m, 2H), 7.21 (d, J = 18.4 Hz, 1H), 
6.91 – 6.85 (m, 2H), 6.69 (dd, J = 15.2, 5.1 Hz, 1H), 6.51 (dd, J = 15.2, 1.6 Hz, 1H), 5.89 (d, J = 18.3 
Hz, 1H), 4.59 – 4.53 (m, 1H), 4.42 (s, 2H), 4.29 – 4.19 (m, 2H), 3.17 (t, J = 7.1 Hz, 2H), 3.08 – 3.01 
(m, 4H), 2.87 (s, 3H), 2.15 (td, J = 7.4, 2.0 Hz, 2H), 2.10 – 2.02 (m, 4H), 1.62 – 1.37 (m, 21H), 1.30 – 
1.15 (m, 18H), 0.90 – 0.76 (m, 18H). 13C NMR (125 MHz, CD3OD) δ 176.4, 176.0, 175.1, 174.3, 
170.8, 159.9, 150.3, 148.5, 132.8, 130.8, 129.6, 116.0, 84.6, 68.3, 53.5, 53.4, 49.5*, 43.3, 42.8, 41.6, 
41.5, 40.21, 40.20, 40.0, 37.00, 36.99, 36.6, 30.1, 27.61, 27.57, 27.5, 26.72, 26.69, 26.6, 26.0, 25.9, 
25.8, 25.1, 23.43, 23.42, 23.40, 22.1, 22.0, 21.9. * Underneath the CD3OD peak, found with HSQC. In 
the 13C NMR, no signal was observed for the carbon attached to boron. HRMS (ESI+) m/z calcd. for 
C54H91BN6O11S [M+H]+ 1043.66378, found: 1043.66316. 
 
Nor-Ahx3L3VS (10). Fmoc-Ahx3L3VS 8 (25 mg, 26 μmol, 1.1 equiv.) was dissolved in 20% piperidine in 
DMF (400 μL) and stirred for 15 min The 
product was precipitated in Et2O and the solid 
was washed with Et2O (2 ×), whereupon it was 
dissolved in DMF (1 mL) and norbornene-NHS 
16 (6.2 mg, 23 μmol, 1.0 equiv.) and DIPEA (12 
μL, 70 μmol, 3.0 equiv.) were added. The reaction was stirred for 1 h, whereupon the solvents were 
removed under reduced pressure and the crude product was purified using column chromatography (0 to 
10% MeOH in EtOAc), yielding Nor-Ahx3L3VS 10 (20 mg, 94%), an endo/exo mixture of 2:1, as a white 
solid. Rf = 0.55 (10% MeOH in EtOAc). 1H NMR (500 MHz, CD3OD) δ 6.79 (dd, J = 15.2, 5.1 Hz, 
1H), 6.61 (dd, J = 15.2, 1.6 Hz, 1H), 6.16 (dd, J = 5.8, 3.0 Hz, 1H, Hendo-5), 6.11 – 6.06 (m, 1H, Hexo-5 
and 1H, Hexo-6), 5.95 (dd, J = 5.8, 2.9 Hz, 1H, Hendo-6), 4.70 – 4.62 (m, 1H), 4.40 – 4.30 (m, 2H), 4.12 
– 4.06 (m, 1H, OCH2CHexo), 3.92 (dd, J = 10.7, 9.1 Hz, 1H, OCH2CHexo), 3.78 (dd, J = 10.3, 6.6 Hz, 
1H, OCH2CHendo), 3.59 (t, J = 10.0 Hz, 1H, OCH2CHendo), 3.19 – 3.12 (m, 4H), 3.13 – 3.05 (m, 2H), 
3.00 – 2.95 (m, 3H), 2.89 – 2.85 (m, 1H, Hendo-1), 2.83 – 2.78 (m, 1H, Hendo-4 and 1H, Hexo-4), 2.72 – 
2.65 (m, 1H, Hexo-1), 2.41-2.33 (m, 1H, Hendo-2), 2.26 (td, J = 7.3, 2.0 Hz, 2H), 2.20 – 2.14 (m, 4H), 
1.89 – 1.80 (m, 1H, Hendo-3), 1.74 – 1.41 (m, 22H, whereof Hexo-2, Hexo-3, Hexo-7, Hendo-7), 1.41 – 1.16 
(m, 9H), 1.00 – 0.87 (m, 18H), 0.55 (ddd, J = 11.8, 4.6, 2.6 Hz, 1H, Hendo-3). 13C NMR (125 MHz, 
CD3OD) δ 176.4, 176.01, 175.96, 175.1, 174.3, 159.2, 148.5, 138.5, 137.9, 137.3, 133.2, 130.8, 69.8, 
69.1, 53.5, 53.4, 50.3, 49.9, 49.3*, 45.8, 45.1, 44.8, 43.5, 43.3, 42.8, 41.6, 41.5, 40.2, 40.2, 39.8, 39.5, 
37.04, 37.00, 36.6, 30.6, 30.4, 30.1, 29.8, 27.61, 27.57, 27.4, 26.8, 26.7, 26.6, 26.0, 25.9, 25.8, 23.43, 
23.42, 23.40, 22.1, 22.0, 21.9. * Underneath the CD3OD peak, found with HSQC. HRMS (ESI+) m/z 
calcd. for C47H82N6O9S [M+Na]+ 929.57617, found: 929.57485. 
 
BODIPY-Ahx3L3VS (11). Fmoc-Ahx3L3VS 8 (16.0 mg, 16 μmol, 1.0 equiv.) was dissolved in dry DMF 
(0.5 mL), DBU (240 μL, 16 μmol, 1.0 equiv.) was 
added and the Fmoc-deprotection was carefully 
monitored using TLC. After 7 min, HOBt (10 
mg, 73 μmol, 4.5 equiv.) was added, followed by 
BODIPY-FL NHS ester (8.0 mg, 21 μmol, 1.3 
equiv.) and DIPEA (17 μL, 98 μmol, 6.0 equiv.). 
The reaction mixture was stirred for 1.5 h, whereupon the volatiles were removed under reduced pressure. 
The product was purified using semi preparative HPLC with a H2O/MeCN gradient containing 1% 
trifluoroacetic acid (5% MeCN for 5 min, to 40% in 5 min, to 80% in 20 min, and then to 100% in 5 
min), yielding BODIPY-Ahx3L3VS 11 (7.3 mg, 44%) as an orange solid after lyophilisation. Rf = 0.53 
(10% MeOH in CH2Cl2). 1H NMR (500 MHz, (CD3)2SO) δ 7.97 – 7.86 (m, 4H), 7.74 – 7.69 (m, 2H), 
7.68 (s, 1H), 7.09 (d, J = 4.0 Hz, 1H), 6.66 (dd, J = 15.2, 4.8 Hz, 1H), 6.59 (dd, J = 15.2, 1.0 Hz, 1H), 
6.34 (d, J = 4.0 Hz, 1H), 6.30 (s, 1H), 4.59 – 4.49 (m, 1H), 4.29 – 4.20 (m, 2H), 3.08 – 2.95 (m, 9H), 
2.48 – 2.43 (m, 5H), 2.26 (s, 3H), 2.15 – 2.05 (m, 2H), 2.05 – 1.98 (m, 4H), 1.64 – 1.51 (m, 3H), 1.51 
– 1.32 (m, 21H), 1.25 – 1.18 (m, 6H), 0.91 – 0.79 (m, 18H). 13C NMR (125 MHz, (CD3)2SO) δ 172.5, 
172.2, 171.9, 171.8, 171.5, 170.6, 159.1, 157.9, 146.7, 144.1, 134.5, 133.0, 129.6, 129.0, 125.4, 120.3, 
116.6, 51.2, 46.9, 42.3, 42.0, 40.5, 40.4, 38.5, 38.3, 35.4, 35.2, 33.8, 30.5, 28.99, 28.97, 28.9, 26.2, 
26.1, 25.10, 25.07, 24.3, 24.2, 24.1, 22.99, 22.97, 22.9, 21.68, 21.65, 21.4, 14.5, 11.0. LCMS (ESI+) 
(linear gradient 5 to 100% MeCN in H2O, 0.1% TFA, 16 min): Rt = 14.26 min, m/z calcd. for 
C52H85BF2N8O8S [M+H]+ 1031.63, found: 1032.16. HRMS (ESI+) m/z calcd. for C52H85BF2N8O8S 
[M+H]+ 1031.63504, found: 1031.63382. 
 
Ethyl 2-(4-iodophenoxy)acetate (12). 4-Iodophenol (500 mg, 2.27 mmol, 1.0 equiv.) was dissolved in 
dry DMF (5 mL). K2CO3 (942 mg, 6.82 mmol, 3.0 equiv.) and ethyl chloroacetate 
(365 μL, 3.41 mmol, 1.5 equiv.) were added and the mixture was stirred at rt for 16 
h. Then, H2O was added and the mixture was extracted with EtOAc. The organic 
layer was washed with brine, dried over Na2SO4 and the volatiles were removed under 
reduced pressure. The crude mixture was purified using column chromatography (10% EtOAc in 
heptane) yielding ether 12 (682 mg, 98%) as a white solid. Rf = 0.29 (10% EtOAc in heptane). 1H NMR 
(500 MHz, CDCl3) δ 7.60 – 7.52 (m, 2H), 6.72 – 6.64 (m, 2H), 4.58 (s, 2H), 4.27 (q, J = 7.2 Hz, 2H), 
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1.29 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 168.7, 157.9, 138.5, 117.2, 84.2, 65.5, 61.6, 
14.3. Ether 12 was not visible on mass spectrometry. The data agrees with literature.41 
 
Ethyl 2-(4-((trimethylsilyl)ethynyl)phenoxy)acetate (13). Iodobenzene 12 (650 mg, 2.12 mmol, 1.0 
equiv.) was dissolved in dry toluene (5 mL) and PdCl2(PPh3)2 (41 mg, 0.059 
mmol, 3 mol%), CuI (37 mg, 0.20 mmol, 0.1 equiv.), trimethylsilylacetylene 
(332 μL, 2.35 mmol, 1.1 equiv.) and DIPEA (853 μL, 4.90 mmol, 2.3 equiv.) 
were added. After the mixture was stirred at 30 °C for 24 h, the volatiles were 
removed under reduced pressure. The crude product was purified using 
column chromatography (10% EtOAc in heptane) yielding ethynylbenzene 13 (578 mg, 99%) as a 
slightly yellow solid. Rf = 0.29 (10% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.38 (m, 
2H), 6.85 – 6.80 (m, 2H), 4.61 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H), 0.23 (s, 9H). 
13C NMR (125 MHz, CDCl3) δ 168.7, 158.0, 133.7, 116.6, 114.7, 104.9, 93.1, 65.5, 61.6, 14.3, 0.2. 
Ethynylbenzene 13 was not visible on mass spectrometry. The data agrees with literature.41 
 
2,5-Dioxopyrrolidin-1-yl 2-(4-ethynylphenoxy)acetate (14). Ethynylbenzene 13 (350 mg, 1.27 mmol, 
1.0 equiv.) was dissolved in THF/H2O (5 mL, 1:1) at ambient atmosphere and 
LiOH (121 mg, 5.07 mmol, 4.0 equiv.) was added. The mixture was stirred for 
2 h, whereupon it was neutralized with HCl (1 M) and extracted with EtOAc. 
The organic layer was washed with brine, dried over Na2SO4 and the volatiles 
were removed under reduced pressure. The solid was dissolved in dry DMF (5 
mL) and N-hydroxysuccinimide (175 mg, 1.52 mmol, 1.2 equiv.) and EDCI hydrochloride (292 mg, 
1.52 mmol, 1.2 equiv.) were added. The solution was stirred for 16 h, concentrated and purified with 
column chromatography (40% EtOAc in heptane) yielding alkyne-NHS 14 (305 mg, 88%) as a white 
solid. Rf = 0.26 (40% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 7.51 – 7.38 (m, 2H), 6.95 – 
6.81 (m, 2H), 4.98 (s, 2H), 3.01 (s, 1H), 2.87 (s, 4H). 13C NMR (125 MHz, CDCl3) δ 168.6, 164.4, 
157.5, 134.0, 116.3, 114.9, 83.2, 76.6, 63.3, 25.7. Alkyne 14 was not visible on mass spectrometry. 
 
 (E)-(4-(2-((2,5-Dioxopyrrolidin-1-yl)oxy)-2-oxoethoxy)styryl)boronic acid pinacol ester (15). 
Alkyne 14 (270 mg, 0.99 mmol, 1.0 equiv.) was dissolved in dry 
toluene (10 mL) and pinacolborane (717 μL, 4.94 mmol, 5.0 equiv.) 
and RuHClCO(PPh3)3 (47 mg, 0.049 mmol, 5 mol%) were added. 
The mixture was stirred at 50 °C for 16 h, whereupon the volatiles 
were removed under reduced pressure. Et2O was added and the 
solution was washed with sat. NaHCO3 and brine, dried over Na2SO4 and concentrated. The crude 
product was purified with column chromatography (40% EtOAc in heptane) yielding VBA-NHS 15 (292 
mg, 74%) as a white solid. Rf = 0.26 (40% EtOAc/heptane). 1H NMR (500 MHz, (CD3)2SO) δ 7.58 – 
7.52 (m, 2H), 7.26 (d, J = 18.4 Hz, 1H), 7.03 – 6.95 (m, 2H), 6.01 (d, J = 18.5 Hz, 1H), 5.35 (s, 2H), 
2.83 (s, 4H), 1.24 (s, 12H). 13C NMR (125 MHz, (CD3)2SO) δ 169.9, 165.4, 157.7, 148.5, 130.9, 
128.5, 114.8, 82.9, 62.9, 25.5, 24.6. In the 13C NMR, no signal was observed for the carbon attached to 
boron. VBA-NHS 15 was not visible on mass spectrometry. 
 
5-Norbornene-2-methyl-(2,5-dioxopyrolidin-1-yl) carbonate (16). 5-Norbornene-2-methanol (0.49 
mL, 4.0 mmol, 1.0 equiv.), Et3N (0.84 mL, 6.0 mmol, 1.5 equiv.) and 
N,N-disuccimidyl carbonate (1.53 g, 6.0 mmol, 1.5 equiv.) were dissolved in dry 
CH2Cl2 (20 mL) and stirred for 2 h. 1 M HCl (10 mL) was added and the phases 
were separated. The organic layer was washed with sat. NaHCO3 (30 mL) and 
brine (20 mL), dried over Na2SO4 and then the volatiles were removed under reduced pressure. The 
product was purified using column chromatography (20 to 30% EtOAc in heptane) to yield norbornene-
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1.29 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 168.7, 157.9, 138.5, 117.2, 84.2, 65.5, 61.6, 
14.3. Ether 12 was not visible on mass spectrometry. The data agrees with literature.41 
 
Ethyl 2-(4-((trimethylsilyl)ethynyl)phenoxy)acetate (13). Iodobenzene 12 (650 mg, 2.12 mmol, 1.0 
equiv.) was dissolved in dry toluene (5 mL) and PdCl2(PPh3)2 (41 mg, 0.059 
mmol, 3 mol%), CuI (37 mg, 0.20 mmol, 0.1 equiv.), trimethylsilylacetylene 
(332 μL, 2.35 mmol, 1.1 equiv.) and DIPEA (853 μL, 4.90 mmol, 2.3 equiv.) 
were added. After the mixture was stirred at 30 °C for 24 h, the volatiles were 
removed under reduced pressure. The crude product was purified using 
column chromatography (10% EtOAc in heptane) yielding ethynylbenzene 13 (578 mg, 99%) as a 
slightly yellow solid. Rf = 0.29 (10% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.38 (m, 
2H), 6.85 – 6.80 (m, 2H), 4.61 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H), 0.23 (s, 9H). 
13C NMR (125 MHz, CDCl3) δ 168.7, 158.0, 133.7, 116.6, 114.7, 104.9, 93.1, 65.5, 61.6, 14.3, 0.2. 
Ethynylbenzene 13 was not visible on mass spectrometry. The data agrees with literature.41 
 
2,5-Dioxopyrrolidin-1-yl 2-(4-ethynylphenoxy)acetate (14). Ethynylbenzene 13 (350 mg, 1.27 mmol, 
1.0 equiv.) was dissolved in THF/H2O (5 mL, 1:1) at ambient atmosphere and 
LiOH (121 mg, 5.07 mmol, 4.0 equiv.) was added. The mixture was stirred for 
2 h, whereupon it was neutralized with HCl (1 M) and extracted with EtOAc. 
The organic layer was washed with brine, dried over Na2SO4 and the volatiles 
were removed under reduced pressure. The solid was dissolved in dry DMF (5 
mL) and N-hydroxysuccinimide (175 mg, 1.52 mmol, 1.2 equiv.) and EDCI hydrochloride (292 mg, 
1.52 mmol, 1.2 equiv.) were added. The solution was stirred for 16 h, concentrated and purified with 
column chromatography (40% EtOAc in heptane) yielding alkyne-NHS 14 (305 mg, 88%) as a white 
solid. Rf = 0.26 (40% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 7.51 – 7.38 (m, 2H), 6.95 – 
6.81 (m, 2H), 4.98 (s, 2H), 3.01 (s, 1H), 2.87 (s, 4H). 13C NMR (125 MHz, CDCl3) δ 168.6, 164.4, 
157.5, 134.0, 116.3, 114.9, 83.2, 76.6, 63.3, 25.7. Alkyne 14 was not visible on mass spectrometry. 
 
 (E)-(4-(2-((2,5-Dioxopyrrolidin-1-yl)oxy)-2-oxoethoxy)styryl)boronic acid pinacol ester (15). 
Alkyne 14 (270 mg, 0.99 mmol, 1.0 equiv.) was dissolved in dry 
toluene (10 mL) and pinacolborane (717 μL, 4.94 mmol, 5.0 equiv.) 
and RuHClCO(PPh3)3 (47 mg, 0.049 mmol, 5 mol%) were added. 
The mixture was stirred at 50 °C for 16 h, whereupon the volatiles 
were removed under reduced pressure. Et2O was added and the 
solution was washed with sat. NaHCO3 and brine, dried over Na2SO4 and concentrated. The crude 
product was purified with column chromatography (40% EtOAc in heptane) yielding VBA-NHS 15 (292 
mg, 74%) as a white solid. Rf = 0.26 (40% EtOAc/heptane). 1H NMR (500 MHz, (CD3)2SO) δ 7.58 – 
7.52 (m, 2H), 7.26 (d, J = 18.4 Hz, 1H), 7.03 – 6.95 (m, 2H), 6.01 (d, J = 18.5 Hz, 1H), 5.35 (s, 2H), 
2.83 (s, 4H), 1.24 (s, 12H). 13C NMR (125 MHz, (CD3)2SO) δ 169.9, 165.4, 157.7, 148.5, 130.9, 
128.5, 114.8, 82.9, 62.9, 25.5, 24.6. In the 13C NMR, no signal was observed for the carbon attached to 
boron. VBA-NHS 15 was not visible on mass spectrometry. 
 
5-Norbornene-2-methyl-(2,5-dioxopyrolidin-1-yl) carbonate (16). 5-Norbornene-2-methanol (0.49 
mL, 4.0 mmol, 1.0 equiv.), Et3N (0.84 mL, 6.0 mmol, 1.5 equiv.) and 
N,N-disuccimidyl carbonate (1.53 g, 6.0 mmol, 1.5 equiv.) were dissolved in dry 
CH2Cl2 (20 mL) and stirred for 2 h. 1 M HCl (10 mL) was added and the phases 
were separated. The organic layer was washed with sat. NaHCO3 (30 mL) and 
brine (20 mL), dried over Na2SO4 and then the volatiles were removed under reduced pressure. The 
product was purified using column chromatography (20 to 30% EtOAc in heptane) to yield norbornene-
NHS 16 (745 mg, 74%), an endo/exo mixture of 3:1, as a white solid. Rf = 0.29 (30% EtOAc in heptane). 
1H-NMR (500 MHz, CDCl3) δ 6.19 (dd, J = 5.8, 3.1 Hz, 1H, Hendo-5), 6.13 – 6.08 (m, 1H, Hexo-5 and 
1H, Hexo-6), 5.98 (dd, J = 5.8, 2.9 Hz, 1H, Hendo-6), 4.40 (dd, J = 10.4, 6.4 Hz, 1H, OCH2CHexo), 4.23 
(dd, J = 10.4, 9.4 Hz, 1H, OCH2CHexo), 4.10 (dd, J = 10.3, 6.6 Hz, 1H, OCH2CHendo), 3.93 (dd, J = 
10.3, 9.5 Hz, 1H, OCH2CHendo), 2.98-2.94 (m, J = 2.4 Hz, 1H, Hendo-1), 2.89-2.86 (m, 1H, Hexo-4), 
2.86-2.84 (m, 1H, Hendo-4), 2.84 (s, 4H, CH2C=O), 2.80-2.78 (m, 1H, Hexo-1), 2.56 – 2.47 (m, 1H, 
Hendo-2), 1.89 (ddd, J = 11.9, 9.3, 3.8 Hz, 1H, Hendo-3), 1.87-1.82 (m, 1H, Hexo-2), 1.53 – 1.46 (m, 1H, 
Hendo-7), 1.40 (ddd, J = 8.9, 2.7, 1.6 Hz, 1H, Hexo-7) 1.31 – 1.27 (m, 1H, Hendo-7), 1.30-1.26 (m, 1H, 
Hexo-7), 1.19 (ddd, J = 11.9, 4.5, 3.4 Hz, 1H, Hexo-3), 0.90-0.82 (m, 1H, Hexo-3), 0.58 (ddd, J = 11.8, 4.5, 
2.6 Hz, 1H, Hendo-3). 13C-NMR (125 MHz, CDCl3) δ 168.8 (CH2C=O), 151.7 (O-C=O), 138.2 (Cendo-
5), 137.2, 136.2 (Cexo-5,6), 132.2 (Cendo-6), 75.5 (OCH2CHexo), 74.9 (OCH2CHendo), 49.6 (Cendo-7), 45.1 
(Cexo-7), 43.9 (Cendo-1), 43.6 (Cexo-1), 42.3 (Cendo-4), 41.8 (Cexo-4), 38.0 (Cexo-2), 37.8 (Cendo-2), 29.4 (Cexo-
3), 28.9 (Cendo-3), 25.6 (CH2C=O). Norbornene 16 was not visible on mass spectrometry. The data agrees 
with the reported literature values for both endo42 and exo products.43 
 
5.5.2 Proteasome inhibition and labeling in cell lysate and living cells 
HeLa cells were cultured in DMEM supplemented with 10% fetal calf serum, 100 units/mL penicillin and 
100 μg/mL streptomycin (all purchased at Life Technologies). The cells were grown at 37 °C in a 
humidified atmosphere of 5% CO2 and passaged every 2 to 3 days. Cell lysates were prepared by 
trypsinization, adding 1 × PBS to take up the cells, and centrifugation to form cell pellets (5 min at 2000 
rpm). Cell pellets were then resuspended in digitonin lysis buffer (50 mM Tris (pH = 7.5), 250 mM 
sucrose, 5 mM MgCl2, 1 mM DTT, 2 mM ATP, 0.025% digitonin; 5 × pellet volume) and incubation on 
ice for 60 min or by flash freezing the cell pellet before resuspension in the digitonin lysis buffer. After 
centrifugation (20 min, 16000 rcf, 4 °C), the supernatant was transferred to a clean Eppendorf tube and 
the protein concentration was determined by the Bradford assay.  
 
In lysate, proteasome labeling and tetrazine ligation was performed at a Thermomixer comfort (Eppendorf 
AG) at 400 rpm. In case of the tetrazine ligation, the excess of tetrazine 17 was removed by precipitating 
the proteins using a standard chloroform/methanol precipitation protocol37. To each lysate (10 L), 5 × 
sample buffer (2 L) was added and the samples were subsequently heated at 95 C for 5 min and loaded 
(10 L) and analyzed on 12% SDS-PAGE gels. The fluorescent signal of the SDS-PAGE gels was 
measured on a Typhoon TRIO+ imager (GE Healthcare) at 488 nm and as a loading control the SDS-
PAGE gels were stained with colloidal to visualize the protein lysate. Samples for confocal microscopy 
were imaged on a Leica SP 8 confocal microscope using 63 × magnification with 1.0 × digital zoom. 
Images were processed using ImageJ64 software. 
 
In lysate labeling of the proteasome with BODIPY 11 
The protein lysates harvested from HeLa cells (10 μL of 1 mg/mL protein) were incubated with the 
indicated concentrations of BODIPY 11 (0.1 μL of 100 × stock in DMSO) for 1 h at 37 °C and the 
samples were analyzed by SDS-PAGE as described in the general experimental (Figure S5.1A). 
 
Competition assay of proteasome inhibition in cell lysate 
HeLa protein lysate samples (10 μL of 1 mg/mL protein) were incubated with the indicated 
concentrations of VBA 9 or norbornene 10 (0.1 μL of 100 × stock in DMSO) for 1 h at 37 °C, before 
BODIPY 11 (0.1 μL of 30 μM stock in DMSO, 0.3 μM final concentration) was added and the lysate was 
mixed again for 1 h at 37 °C. Next, the samples were analyzed by SDS-PAGE (Figure 5.2B). 
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Inhibition of the proteasome in living cells followed by competition in cell lysate 
HeLa cells were seeded in a 12-well plate (0.5 × 106 cells/well in 500 μL of growth medium) and directly 
incubated with the indicated concentration of VBA 9 or norbornene 10 (5 μL of 100 × stock in DMSO) 
for 3 h at 37 °C. The cells were washed twice with 1 × PBS, and then lysed as described in the general 
experimental (~30 μL digitonin lysis buffer for 1 mg/mL protein lysate). Finally, the lysate (10 μL of 1 
mg/mL) was incubated with BODIPY 11 (0.1 μL of 30 μM stock in DMSO, 0.3 μM final concentration) 
for 1 h at 37 °C and the samples were analyzed by SDS-PAGE (Figure 5.2C).  
 
Labeling in living cell with BODIPY 11 
HeLa cells were seeded in a 12-well plate (0.5 × 106 cells/well in 500 μL of medium) and directly 
incubated with the indicated concentration of BODIPY 11 (5 μL of 100 × solution in DMSO) for 3 h at 
37 °C. The cells were washed twice with 1 × PBS, and cell lysates were prepared as described above in the 
general experimental (~15 μL digitonin lysis buffer for 1 mg/mL lysate) and analyzed by SDS-PAGE 
(Figure S5.1B). 
 
Proteasome inhibition and tetrazine ligation in lysate 
HeLa lysate samples (100 μL of 2 mg/mL) were incubated with VBA 9 or norbornene 10 (1.0 μL of 300 
μM stock in DMSO, 3 μM final concentration) for 1 h at 37 °C. Next, the excess of inhibitors was 
removed by dialysis against 1 × PBS using a spin filter (3 kDa) (3 × 10 min). The protein concentration 
was determined by the Bradford assay and the samples were diluted to 1 mg/mL. Then, the pretreated 
lysate samples (10 μL) were incubated with the indicated concentration of tetrazine 17 (0.1 μL of 100 × 
stock in DMSO) or DMSO only for 1 h at 20 °C. After a chloroform/methanol precipitation37 to remove 
the non-reacted tetrazine probe, the samples were dissolved in MQ (10 μL) and analyzed by SDS-PAGE 
(Figure S5.2). 
 
Labeling of the proteasome and tetrazine ligation in living cell 
HeLa cells were seeded in a 24-well plate (0.25 × 106 cells/well in 250 μL of medium) and directly 
incubated with the proteasome inhibitors VBA 9 (2.5 μL of 30 mM stock in DMSO, 300 M final 
concentration) or norbornene 10 (2.5 μL of 10 mM stock in DMSO, 100 M final concentration) for 3 h 
at 37 °C. The cells were washed once briefly with growth medium and once for 30 min at 37 °C. The 
tetrazine ligation was then performed by adding 250 L pre-warmed growth medium with the indicated 
concentration of tetrazine 17 (2.5 μL of 100 × stock in DMSO). The cells were incubated for 1 h at 37 
°C, washed briefly twice with 1 × PBS, and cell lysates were prepared as described above in the general 
experimental (~15 μL digitonin lysis buffer for 1 mg/mL lysate) and analyzed by SDS-PAGE (Figure 
5.3C). 
 
Labeling of the proteasome in living cell, followed by a time response of the tetrazine ligation in lysate 
HeLa cells were seeded in a T25 culture dish (4 × 106 cells in 4 mL of growth medium) and directly 
incubated with the proteasome inhibitors VBA 9 (40 μL of 30 mM stock in DMSO, 300 μM final 
concentration) or norbornene 10 (40 μL of 10 mM stock in DMSO, 100 μM final concentration) for 3 h 
at 37 °C. The cells were washed twice with 1 × PBS and cell lysates were prepared as described above in 
the general experimental (~150 μL digitonin lysis buffer for 1 mg/mL lysate) was added. The protein 
concentration was determined by the Bradford assay and the samples were diluted to 1 mg/mL. The pre-
treated lysates (20 μL of 1 mg/mL) were incubated with tetrazine 17 (0.2 μL of 1 mM stock in DMSO, 
10 μM final concentration) for the indicated time at 20 °C. After a chloroform/methanol precipitation37, 
the samples were dissolved in MQ (20 μL) and analyzed by SDS-PAGE (Figure S5.3). 
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Inhibition of the proteasome in living cells followed by competition in cell lysate 
HeLa cells were seeded in a 12-well plate (0.5 × 106 cells/well in 500 μL of growth medium) and directly 
incubated with the indicated concentration of VBA 9 or norbornene 10 (5 μL of 100 × stock in DMSO) 
for 3 h at 37 °C. The cells were washed twice with 1 × PBS, and then lysed as described in the general 
experimental (~30 μL digitonin lysis buffer for 1 mg/mL protein lysate). Finally, the lysate (10 μL of 1 
mg/mL) was incubated with BODIPY 11 (0.1 μL of 30 μM stock in DMSO, 0.3 μM final concentration) 
for 1 h at 37 °C and the samples were analyzed by SDS-PAGE (Figure 5.2C).  
 
Labeling in living cell with BODIPY 11 
HeLa cells were seeded in a 12-well plate (0.5 × 106 cells/well in 500 μL of medium) and directly 
incubated with the indicated concentration of BODIPY 11 (5 μL of 100 × solution in DMSO) for 3 h at 
37 °C. The cells were washed twice with 1 × PBS, and cell lysates were prepared as described above in the 
general experimental (~15 μL digitonin lysis buffer for 1 mg/mL lysate) and analyzed by SDS-PAGE 
(Figure S5.1B). 
 
Proteasome inhibition and tetrazine ligation in lysate 
HeLa lysate samples (100 μL of 2 mg/mL) were incubated with VBA 9 or norbornene 10 (1.0 μL of 300 
μM stock in DMSO, 3 μM final concentration) for 1 h at 37 °C. Next, the excess of inhibitors was 
removed by dialysis against 1 × PBS using a spin filter (3 kDa) (3 × 10 min). The protein concentration 
was determined by the Bradford assay and the samples were diluted to 1 mg/mL. Then, the pretreated 
lysate samples (10 μL) were incubated with the indicated concentration of tetrazine 17 (0.1 μL of 100 × 
stock in DMSO) or DMSO only for 1 h at 20 °C. After a chloroform/methanol precipitation37 to remove 
the non-reacted tetrazine probe, the samples were dissolved in MQ (10 μL) and analyzed by SDS-PAGE 
(Figure S5.2). 
 
Labeling of the proteasome and tetrazine ligation in living cell 
HeLa cells were seeded in a 24-well plate (0.25 × 106 cells/well in 250 μL of medium) and directly 
incubated with the proteasome inhibitors VBA 9 (2.5 μL of 30 mM stock in DMSO, 300 M final 
concentration) or norbornene 10 (2.5 μL of 10 mM stock in DMSO, 100 M final concentration) for 3 h 
at 37 °C. The cells were washed once briefly with growth medium and once for 30 min at 37 °C. The 
tetrazine ligation was then performed by adding 250 L pre-warmed growth medium with the indicated 
concentration of tetrazine 17 (2.5 μL of 100 × stock in DMSO). The cells were incubated for 1 h at 37 
°C, washed briefly twice with 1 × PBS, and cell lysates were prepared as described above in the general 
experimental (~15 μL digitonin lysis buffer for 1 mg/mL lysate) and analyzed by SDS-PAGE (Figure 
5.3C). 
 
Labeling of the proteasome in living cell, followed by a time response of the tetrazine ligation in lysate 
HeLa cells were seeded in a T25 culture dish (4 × 106 cells in 4 mL of growth medium) and directly 
incubated with the proteasome inhibitors VBA 9 (40 μL of 30 mM stock in DMSO, 300 μM final 
concentration) or norbornene 10 (40 μL of 10 mM stock in DMSO, 100 μM final concentration) for 3 h 
at 37 °C. The cells were washed twice with 1 × PBS and cell lysates were prepared as described above in 
the general experimental (~150 μL digitonin lysis buffer for 1 mg/mL lysate) was added. The protein 
concentration was determined by the Bradford assay and the samples were diluted to 1 mg/mL. The pre-
treated lysates (20 μL of 1 mg/mL) were incubated with tetrazine 17 (0.2 μL of 1 mM stock in DMSO, 
10 μM final concentration) for the indicated time at 20 °C. After a chloroform/methanol precipitation37, 
the samples were dissolved in MQ (20 μL) and analyzed by SDS-PAGE (Figure S5.3). 
 
  
Confocal microscopy of the proteasome labeling with BODIPY 11 
HeLa cells were seeded in a 48-well plate (1 × 105 cells per well in 500 μL medium) containing coverslips, 
precoated with poly-L-lysine, one day prior to the experiment. The cells were then incubated with the 
indicated concentration of BODIPY 11 (1.5 μL, 100 × stock in DMSO) or DMSO only (1.5 μL) in pre-
warmed growth medium (150 μL) at 37 °C for 3 h. The cells were washed with 1 × PBS (2 ×) and fixed 
for 15 min with paraformaldehyde (250 μL, 3.7% in 1 × PBS) at rt Then, the cells were washed with 1 × 
PBS (3 ×) and permeabilized for 5 min with ice cold MeOH (250 μL) followed by one wash with 1 × 
PBS. The cells were blocked with 3% BSA in 1 × PBS for 1 h at rt and next the nucleus was stained with 
150 L of DAPI (1 g/mL in 1 × PBS; Sigma-Aldrich) for 5 min, washed with 0.1% TWEEN20 in 1 × 
PBS (2 ×) and once with 1 × PBS. Mounting medium (Mowiol®4-88 from Sigma-Aldrich) was used to 
secure the coverslips to the glass plates. Finally, the cells were measured at the confocal microscope using 
the excitation wavelengths 408 nm (DAPI) and 488 nm (BODIPY-FL) (Figure S5.4). The pictures are 
measured with approximately 2 times less intensity of the laser of the confocal microscope, compared to 
3D and S5. 
 
Confocal microscopy of the proteasome labeling and tetrazine ligation in the cell 
HeLa cells were seeded in a 48-well plate (1 × 105 cells per well in 500 μL medium) containing coverslips, 
precoated with poly-L-lysine, one day prior to the experiment. The cells were then incubated with the 
indicated concentration of VBA 9 or norbornene 10 (1.5 μL, 100 × stock in DMSO) or DMSO only (1.5 
μL) in pre-warmed growth medium (150 μL) at 37 °C for 3 h. After treatment with the proteasome 
inhibitors, the medium was removed and the cells were washed once briefly with growth medium and 
once for 30 min at 37 °C. Subsequently, the cells were incubated with the indicated concentration of 
tetrazine 17 (1.5 μL, 100 × stock in DMSO) in pre-warmed growth medium (150 μL) for 1 h at 37 °C. 
The cells were washed with 1 × PBS (2 ×) and then fixed and treated as described above. Finally, the cells 
were measured at the confocal microscope using the excitation wavelengths 408 nm (DAPI) and 488 nm 
(BODIPY-FL) (Figure S5.5). The Figures 5.3D and S5.5 are measured using the same microscope 
settings, and in Figure S5.5 the pictures are shown with the same and lower contrast.  
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5.7 Supplementary Figures 
 
 
Figure S5.1 – SDS-PAGE analysis of labeling of the proteasome with BODIPY 11 in A) cell lysate and B) 
living HeLa cells. 
 
 
 
 
Figure S5.2 – In cell lysate labeling of the proteasome with VBA 9 or norbornene 10 and visualizing the 
labeled proteasome using the tetrazine ligation with tetrazine 17.  
 
 
 
 
Figure S5.3 – In living cell labeling of the proteasome in with VBA 9 or norbornene 10, followed by cell 
lysis and a time range with tetrazine 17 to determine the reaction rate of the tetrazine ligation. 
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Figure S5.3 – In living cell labeling of the proteasome in with VBA 9 or norbornene 10, followed by cell 
lysis and a time range with tetrazine 17 to determine the reaction rate of the tetrazine ligation. 
 
 
 
 
Figure S5.4 – Confocal microscopy of the labeling of the proteasome using BODIPY 11. HeLa cells were 
treated with DMSO or BODIPY 11 (10-100 μM) for 3 h at 37 °C, the cells were fixed and stained against 
DAPI (shown in grey). Scale bar = 50 m. 
 
Figure S5.5 – Confocal microscopy of the two-step labeling of the proteasome using a higher 
concentration of the tetrazine resulted in higher background. HeLa cells were treated first with either 
DMSO, VBA 9 (300 μM) or norbornene 10 (100 μM) for 3 h at 37 °C, followed by the tetrazine ligation 
in the cell with tetrazine 17 (10 μM; shown in green). Finally, the HeLa cells were fixed and stained 
against DAPI (shown in grey). [a] The high contrast settings are the same as used for Figure 5.3D. Scale 
bar = 50 m. 
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Abstract 
 
Bioorthogonal chemistry can be used for the selective modification of biomolecules without 
interfering with other functionalities that are present. Recent developments in the field include 
orthogonal bioorthogonal reactions to modify multiple biomolecules simultaneously. During our 
research, we observed that the reaction rates for the bioorthogonal inverse electron-demand Diels-
Alder (iEDDA) reactions between VBAs and dipyridyl-s-tetrazine were exceptionally higher than 
those between VBAs and tetrazines bearing a methyl or phenyl substituent. As VBAs are mild 
Lewis acids, we hypothesized that coordination of the pyridyl nitrogen atom to the boronic acid 
promoted the tetrazine ligation. Herein, we explore the scope of the VBA-tetrazine ligation in 
more detail and benefit from its unique reactivity in the simultaneous orthogonal tetrazine 
labeling of two proteins modified with VBA and norbornene, a widely used strained alkene. We 
further show that the two orthogonal iEDDA reactions can be carried out in living cells by 
labeling the proteasome using a nonselective probe equipped with a VBA and a subunit-selective 
one bearing a norbornene. 
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research, we observed that the reaction rates for the bioorthogonal inverse electron-demand Diels-
Alder (iEDDA) reactions between VBAs and dipyridyl-s-tetrazine were exceptionally higher than 
those between VBAs and tetrazines bearing a methyl or phenyl substituent. As VBAs are mild 
Lewis acids, we hypothesized that coordination of the pyridyl nitrogen atom to the boronic acid 
promoted the tetrazine ligation. Herein, we explore the scope of the VBA-tetrazine ligation in 
more detail and benefit from its unique reactivity in the simultaneous orthogonal tetrazine 
labeling of two proteins modified with VBA and norbornene, a widely used strained alkene. We 
further show that the two orthogonal iEDDA reactions can be carried out in living cells by 
labeling the proteasome using a nonselective probe equipped with a VBA and a subunit-selective 
one bearing a norbornene. 
 
 
 
 
  
6.1 Introduction 
 
In the last decades, bioorthogonal reactions that can be used for the selective chemical 
modification of biomolecules in vitro and in vivo have emerged.1–4 One of the most versatile 
bioorthogonal reactions is the inverse electron-demand Diels-Alder (iEDDA) reaction between 
electron-poor tetrazines and alkenes or alkynes owing to its selectivity and high reaction rates.5–8 
Several bioorthogonal reactants have been developed for the reaction with tetrazines, and they are 
generally based on strained alkenes, e.g. trans-cyclooctene (TCO),9,10 norbornene,11 and 
cyclopropene.12,13 Non-strained alkenes show lower reaction rates with tetrazines,14,15 although the 
reaction rate can be enhanced by using electron-donating substituents.16,17 In Chapters 3 and 4, 
we reported a large rate enhancement if boronic acid-substituted alkenes were used instead of 
their corresponding unsubstituted alkenes in reactions with 3,6-dipyridyl-s-tetrazines. These non-
strained vinylboronic acids (VBAs) showed, depending on the substituents, second-order rate 
constants (k2) of up to 27 M-1 s-1 in 5% MeOH/PBS. These alkenes are readily accessible, 
biocompatible with cellular components, highly soluble, and stable in aqueous media and in cell 
lysate. Furthermore, VBAs are suitable as bioorthogonal reactants in the tetrazine ligation shown 
by protein modification in vitro (Chapter 4) and in living cells (Chapter 5).  
 
 
Figure 6.1 – A) Schematic overview of orthogonal bioorthogonal chemistry. B) Schematic overview of the 
reactivity difference between VBA 1 and norbornene 2 with 3,6-dipyridyl-s-tetrazine 3a and 3-methyl-6-
phenyl-s-tetrazine 3b measured in 1:1 MeOH/PBS at 20 °C. C) The tetrazine ligation of dipyridyl-s-
tetrazine 3a and VBA 1 with the proposed coordination of the pyridyl nitrogen to the boronic acid. 
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To unravel the complexity of biological systems, scientists would benefit from the 
possibility to track multiple biomolecules simultaneously (Figure 6.1A).18,19 Since many 
bioorthogonal reactants are not fully selective toward their reaction counterpart, it is challenging 
to find mutual orthogonal reaction pairs. Tetrazine ligations have been used orthogonal to the 
Staudinger ligation, the copper-mediated alkyne-azide cycloaddition (CuAAC), and the strain-
promoted alkyne-azide cycloaddition (SPAAC) with benzoannulated cycloalkynes (e.g. 
dibenzocyclooctyne).12,18–22 In addition, orthogonal tetrazine ligations with a trans-cyclooct-2-ene 
(TCO*) and a cyclooctyne (SCO) were developed, whereby the latter showed selective 
cycloaddition with 3-phenyl-s-tetrazine, while being inactive towards the more hindered methyl 
phenyl tetrazine.23,24  
Although VBAs showed high reaction rates towards dipyridyl tetrazine 3a, we observed 
unexpectedly low reactivity of VBAs towards methyl phenyl tetrazine 3b when compared to the 
common bioorthogonal reactant norbornene 2 (Figure 6.1B). Boronic acids possess a vacant p 
orbital and are mild organic Lewis acids, which after coordination by a Lewis base form a more 
electron-rich boronate.25 We suggest that the nitrogen of the pyridyl ring of 3a promotes the rate 
of the iEDDA cycloaddition by coordinating to the boron atom, as this makes the VBA more 
reactive and the reaction favorable owing to the induced proximity (Figure 6.1C). A similar 
coordination and rate enhancement was previously reported between alkynyldifluoroboranes and 
N-heterocycle-substituted tetrazines.26 The large rate enhancement observed for VBAs with 
tetrazines possessing a Lewis basic heteroatom that is capable of coordinating to boron, would 
provide a unique angle to control the reactivity of iEDDA reactions and thereby opening the 
door towards an additional set of orthogonal bioorthogonal tetrazine ligations. 
 
6.2 Results and Discussion 
 
6.2.1 VBAs are highly reactive towards pyridyl-substituted tetrazines 
To explore the reactivity of the VBAs towards various tetrazines, we determined the 
second-order rate constants of tetrazines 3a – f with phenylvinylboronic acid 1 in 1:1 
MeOH/PBS at 20 °C. We compared these constants with the k2 values of the tetrazine ligations 
with non-substituted alkene 4 as well as those with norbornene 2 (Figure 6.2, Table S6.1). As 
previously reported, dipyridyl tetrazine 3a showed similar k2 values with VBA 1 and norbornene 
2 of 1.4 M-1 s-1 under the employed conditions, whereas styrene 4 gave a rate constant that was 
ca. 150 times lower using this tetrazine. Asymmetric phenyl pyridyl tetrazine 3c followed a 
similar trend as 3a, although all rate constants were approximately 10-fold lower. Methyl-pyridyl-
substituted tetrazine 3d gave k2 values of the same order of magnitude as 3c for norbornene 2 and 
styrene 4, while VBA 1 was less reactive to 3d than to 3c. 
We then examined tetrazine 3b, a derivative of 3d bearing a phenyl instead of a pyridyl 
substituent, as this substituent was expected not to coordinate readily to boron. This more 
electron-rich tetrazine was approximately 4-fold less reactive towards norbornene 2 and styrene 4 
than towards 3d. Interestingly, VBA 1 showed a 40-fold reduced rate constant, which is below 
those observed for norbornene 2 as well as styrene 4. Unfortunately, the diphenyl-substituted 
tetrazine was not soluble under the reaction conditions used and therefore its rate constant could 
not be determined. 
 
 
 
Figure 6.2 – The second-order rate constants of tetrazines 3a - f with 5-norbornene-2-methanol 2, 
phenylvinylboronic acid 1 and styrene 4 measured in 1:1 MeOH/PBS at 20 °C, shown on a logarithmic 
scale. [a] k2 values previously reported in Chapter 3. [b] Endo/exo 2:1.  
 
Next, tetrazines bearing a pyrimidyl substituent were investigated, as these have shown 
superior reaction rates in iEDDA reactions with (strained) alkenes compared to the phenyl- and 
pyridyl-substituted tetrazines.27 We were especially interested in this series because the pyrimidyl 
substituent possesses an additional potential boron-coordinating site. As expected, tetrazine 3e 
reacts 4-10 times faster with norbornene 2 and styrene 4 than its pyridyl-substituted derivative 3c 
while, unexpectedly, VBA 1 showed a rate constant that was 34-fold lower. The same trend was 
found for tetrazine 3f compared to its pyridyl-substituted counterpart 3d, providing 3-5 times 
higher rate constants for norbornene 2 and styrene 4, while a 6-fold lower k2 was found for 
VBA 1.  
The kinetic data of tetrazines 3a - f above indicate that coordination of the nitrogen atom 
of the pyridyl ring to the boronic acid positively influences the rate of the iEDDA cycloaddition. 
The pyrimidyl-substituted tetrazines 3e and 3f, however, do not seem to provoke efficient 
boronic acid coordination with VBA 1, which can reasonably be ascribed to the lower basicity of 
the pyrimidyl nitrogens.28 
To further establish whether the increase in reactivity of the VBAs towards pyridyl-
substituted tetrazines was indeed caused by coordination, we studied the reactions of VBA 1 and 
styrene 4 with asymmetric phenyl pyridyl tetrazine 3c in more detail (Scheme 6.1). We expected 
the formation of a single isomer when the pyridyl coordinates to the boronic acid during the 
reaction, yielding the phenyl-substituent of VBA 1 on the 4-position of the dihydropyridazine  
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Scheme 6.1 – The reaction of phenyl pyridyl tetrazine 3c with VBA 1 and styrene 4. Yield of the crude 
mixture is determined by 1H NMR, isolated yield is shown in brackets. i) MeOH, 16 h, >99% (96%). ii) 
chloranil, MeOH, 1 h, >99% (98%). iii) a) MeOH, 5 days. b) Chloranil, MeOH, 1 h, yielding 6 in 70% 
(57%) and 7 in 30% (23%).  
 
ring. Indeed, full conversion to the dihydropyridazine 5 as a single isomer was observed, which 
structure was elucidated after oxidation to the more stable pyridazine 6 using chloranil. In 
contrast, the reaction of styrene 4 yielded both isomers 6 and 7 in a 7:3 ratio, indicating modest 
regioselectivity due to inductive effects of the tetrazine substituents. 
 
6.2.2 Dual labeling of purified proteins using orthogonal tetrazine ligations  
We next examined if we could benefit from the unique reactivity of the VBAs towards 
pyridyl-substituted tetrazines in the simultaneous modification of two proteins by using two 
orthogonal tetrazine ligations with norbornene and VBA (Figure 6.3). First, we modified the 
model proteins human serum albumin (HSA, 66 kDa) and green fluorescent protein (GFP, 32 
kDa) with a vinylboronic acid and a norbornene moiety, respectively. After mixing of the two 
proteins, we applied two tetrazine ligations, whereof VBA will only react with the pyridyl-
substituted tetrazine, to specifically label the proteins with a different fluorophore. 
 
 
Figure 6.3 – The route used for the orthogonal protein modification of HSA and GFP using maleimides 
8 and 9, and tetrazines 10 and 11. Structures of the applied molecules are shown in Scheme 6.2. 
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The commercially available HSA was functionalized with a VBA moiety using the 
previously synthesized maleimide-VBA 8 (Scheme 6.2A), as described in Chapter 4. We chose 
the vinylboronic pinacol ester as we have previously established that this ester hydrolyzes quickly 
to its corresponding boronic acid derivative in an aqueous environment. For the functionalization 
of GFP, that we genetically modified so that it contains a single cysteine moiety at the C-
terminus, we synthesized norbornene-maleimide 9 (Scheme 6.2B). Single Boc protection of 2,2’-
(ethylenedioxy)diethylamine 12 yielded carbamate 13 in good yield. Subsequently, the free amine 
of 13 was coupled to norbornene-NHS, which was used previously in Chapter 5, yielding 
norbornene 14 containing the small PEG linker. Boc deprotection and subsequent peptide 
coupling of the free amine to 3-maleimidopropionic acid yielded norbornene-maleimide 9. Next, 
we functionalized GFP-cys with norbornene 9 using the previously developed method for the 
maleimide coupling of HSA. 
  
 
Scheme 6.2 – A) Structure of VBA-maleimide 8 and dipyridyl tetrazine 10 containing BODIPY FL. B) 
Synthesis of norbornene-maleimide 9. i) Boc2O, CH2aCl2, 1 h, 77%. ii) Norbornene-NHS, DIPEA, DMF, 
1 h, 80%. iii) a) 4 M HCl in dioxane, CH2Cl2, 1 h. b) 3-Maleimidopropionic acid, EDCI, HOBt, 
DIPEA, 16 h, 54%. C) Synthesis of phenyl pyrimidyl tetrazine 11 conataining Lissamine rhodamine B. 
iv) a) Hydrazine hydrate, EtOH, reflux, 16 h. b) NaNO2, AcOH, 1 h, 30%. v) 13, HATU, DIPEA, DMF, 
16 h, 30%. vi) a) 4 M HCl in dioxane, CH2Cl2, 1 h. b) Lissamine rhodamine B sulfonyl chloride, DIPEA, 
DMF, 16 h, 36%.  
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a large difference in reactivity towards VBA 1 (k2 = 1.4 and 0.0052 M-1 s-1) while maintaining 
high rate constants for norbornene 2 (k2 = 1.4 and 0.7 M-1 s-1). We prepared dipyridyl tetrazine 
10 containing the green fluorophore BODIPY FL, as described in Chapter 4, and phenyl 
pyrimidyl tetrazine 11 containing the red fluorophore Lissamine rhodamine B (Scheme 6.2C). 
First, phenyl pyrimidyl tetrazine 15, containing a free carboxylic acid, was synthesized from 2-
cyanopyrimidine and 4-cyanobenzoic acid, by following a literature procedure.29 Peptide coupling 
of the poorly soluble tetrazine 15 with the free amine of the small PEG-linker 13 yielded amide 
16 in acceptable yield. Next, Boc-deprotection and coupling to Lissamine rhodamine B sulfonyl 
chloride yielded tetrazine 11.  
The labeling efficiency of the modified proteins HSA-VBA and GFP-norbornene was 
explored by separately reacting the proteins with 10 equivalents of dipyridyl tetrazine-BODIPY 
10 or phenyl pyrimidyl tetrazine-rhodamine 11. Furthermore, the non-modified proteins HSA 
and GFP-cys were also incubated with the tetrazines to investigate the background of the 
modifications. The protein labeling was visualized by appearance of red and green fluorescent 
bands by fluorescence imaging on SDS-PAGE gel (Figure 6.4A). As expected, HSA-VBA showed 
strong labeling with dipyridyl tetrazine 10 and only minor labeling with phenyl pyrimidyl 
tetrazine 11, whereas GFP-norbornene showed equal labeling with both tetrazines 10 and 11. 
Furthermore, little to no background reaction was observed for both tetrazine ligations with the 
non-modified proteins. 
 
 
Figure 6.4 – Evaluation of the orthogonal tetrazine ligations for bioorthogonal protein modification. A) 
SDS-PAGE analysis of the tetrazine ligation of the non-modified or modified proteins (10 μM) in PBS 
with 10 or 11 (10 equiv.) for 60 min at 20 °C. B) SDS-PAGE analysis of the tandem tetrazine ligations of 
a mixture of HSA-VBA and GFP-norbornene (10 μM of both proteins) in PBS at 20 °C. First 11 (2 
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a large difference in reactivity towards VBA 1 (k2 = 1.4 and 0.0052 M-1 s-1) while maintaining 
high rate constants for norbornene 2 (k2 = 1.4 and 0.7 M-1 s-1). We prepared dipyridyl tetrazine 
10 containing the green fluorophore BODIPY FL, as described in Chapter 4, and phenyl 
pyrimidyl tetrazine 11 containing the red fluorophore Lissamine rhodamine B (Scheme 6.2C). 
First, phenyl pyrimidyl tetrazine 15, containing a free carboxylic acid, was synthesized from 2-
cyanopyrimidine and 4-cyanobenzoic acid, by following a literature procedure.29 Peptide coupling 
of the poorly soluble tetrazine 15 with the free amine of the small PEG-linker 13 yielded amide 
16 in acceptable yield. Next, Boc-deprotection and coupling to Lissamine rhodamine B sulfonyl 
chloride yielded tetrazine 11.  
The labeling efficiency of the modified proteins HSA-VBA and GFP-norbornene was 
explored by separately reacting the proteins with 10 equivalents of dipyridyl tetrazine-BODIPY 
10 or phenyl pyrimidyl tetrazine-rhodamine 11. Furthermore, the non-modified proteins HSA 
and GFP-cys were also incubated with the tetrazines to investigate the background of the 
modifications. The protein labeling was visualized by appearance of red and green fluorescent 
bands by fluorescence imaging on SDS-PAGE gel (Figure 6.4A). As expected, HSA-VBA showed 
strong labeling with dipyridyl tetrazine 10 and only minor labeling with phenyl pyrimidyl 
tetrazine 11, whereas GFP-norbornene showed equal labeling with both tetrazines 10 and 11. 
Furthermore, little to no background reaction was observed for both tetrazine ligations with the 
non-modified proteins. 
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To investigate the orthogonality of the two tetrazine reactions, we next used a 1:1 mixture 
of HSA-VBA and GFP-norbornene and incubated these with an equimolar concentration of 
tetrazines 10 and 11 (Figure 6.4B). As expected, selective labeling of HSA-VBA by 9 and dual 
labeling of GFP-norbornene by 10 and 11 was observed, as indicated by the green fluorescent 
band around 66 kDa and the green and red band around 32 kDa. To our satisfaction, complete 
orthogonal labeling could be achieved by incubating the protein mixture first with tetrazine 11 
for 30 minutes to ensure complete consumption of the norbornene, before addition of tetrazine 
10. Alternatively, full orthogonal protein modification with simultaneous addition of both 
tetrazines was also achieved, by increasing the amount of tetrazine 11 relative to 10 to a 5:1 ratio 
(Figure 6.4C). Any further increas the tetrazine ratio resulted in the undesired reaction between 
HSA-VBA and pyrimidyl tetrazine 11, likely due to the high concentration of tetrazine 11 
present.  
 
6.2.3 Dual labeling of the proteasome in living cells using orthogonal tetrazine ligations  
Next, we evaluated the orthogonal tetrazine ligations in living cells for labeling of the 
proteasome active sites modified with a VBA and a norbornene (Figure 6.5B). The 20S 
proteasome core is the main responsible cellular protein degradation machinery and consists of 
three different catalytic subunits (β1, β2 and β5), each having its own substrate specificity.30 In 
Chapter 5, we reported on the use of a nonselective irreversible inhibitor for the proteasome 
containing a VBA moiety, VBA-Ahx3L3VS 17, which was readily taken up by the cell and 
successfully bound to all catalytically active proteasomal subunits (Figure 6.5A). We further 
modified a previously reported inhibitor31 that was selective for the β5 subunit with a norbornene 
functionality (Nor-β5 18, experimental section). We reasoned that we could attain dual 
proteasome labeling by first incubating living HeLa cells with the β5 subunit-selective inhibitor 
18, after which the unbound β1 and β2 subunits could react with the nonselective inhibitor 
VBA-Ahx3L3VS 17. 
We first evidenced that 18 remained selective for the β5 subunit upon modification with 
a norbornene and that 30 μM of compound 18 was needed for full inhibition of the subunit in 
living cells (Figure S6.3). In Chapter 5, we determined that 300 μM of the VBA probe 17 was 
sufficient for full inhibition of all three subunits in living cells. Next, we incubated cells with 
VBA-Ahx3L3VS 17 or Nor-β5 18 for 3 hours to label the proteasome. Additionally, we 
performed a dual labeling of the subunits by first incubating living cells with the β5 selective 
inhibitor 18 after which non-selective inhibitor 17 was added to label the residual unreacted β1 
and β2 subunits. As tetrazine 11 appeared not able to enter the cell, we added tetrazines 10 and 
11 simultaneously to the cell lysates in a 1:5 ratio, as similarly used to orthogonally label HSA-
VBA and GFP-norbornene in vitro.  
Fluorescent analysis of the SDS-PAGE gel after the tetrazine ligation showed that the VBA probe 
selectively reacted with dipyridyl tetrazine 10 when the ratio of tetrazines 10/11 was used (Figure 
6.5C). However, labeling with both tetrazines was observed when the tetrazines were added 
separately. The norbornene labeled β5 subunit reacted only slightly with dipyridyl tetrazine 10 
compared to pyrimidyl phenyl tetrazine 11 when the tetrazines were added separately, which is 
possibly caused by the higher concentration of 11 that has been employed. Consistently, when a 
1:5 ratio of the tetrazines 10/11 was used, norbornene reacted mainly with 11. The dual-labeled 
proteasome showed with pyridyl tetrazine 10 labeling of all three subunits, whereas pyrimidyl 
phenyl tetrazine 11 showed primarily labeling of the β5 subunit. Addition of the tetrazines 10/11 
Chapter 6128
in the ratio 1:5 showed a selective reaction of the β1 and β2 subunits with dipyridyl tetrazine 10, 
while the β5 subunit was labeled with both tetrazines. 
 
 
Figure 6.5 – A) Structures of the nonselective proteasome inhibitor VBA-Ahx3L3VS 17 and the β5-
selective inhibitor Nor-β5 18. B) The route used for the orthogonal labeling of the subunits of the 
proteasome with inhibitors 17 and 18 in living cells, followed by the tetrazine ligations with 10 and 11 in 
cell lysate. C) SDS-PAGE analysis of the tetrazine ligations with 10 and/or 11 of the proteasome subunits 
modified with 17 and/or 18, using a 1:5 ratio of 10/11. 
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Furthermore, we observed the formation of a single pyridazine after the reaction of 
phenylvinylboronic acid with the non-symmetric phenyl pyridyl tetrazine. These findings support 
our proposed role of the pyridyl nitrogen to coordinate to the boronic acid, explaining the high 
rate constants of VBAs towards pyridyl-substituted tetrazines.  
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in the ratio 1:5 showed a selective reaction of the β1 and β2 subunits with dipyridyl tetrazine 10, 
while the β5 subunit was labeled with both tetrazines. 
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proteasome with inhibitors 17 and 18 in living cells, followed by the tetrazine ligations with 10 and 11 in 
cell lysate. C) SDS-PAGE analysis of the tetrazine ligations with 10 and/or 11 of the proteasome subunits 
modified with 17 and/or 18, using a 1:5 ratio of 10/11. 
 
6.3 Conclusions and Outlook 
 
In summary, we explored the reactivity of VBAs towards a variety of tetrazines and 
compared these to the reactivity of non-boron containing alkenes norbornene and styrene. We 
observed that the VBAs are especially reactive towards pyridyl-substituted tetrazines and gave 
relatively low reaction rates with tetrazines that lack a potent Lewis base for boron coordination. 
Furthermore, we observed the formation of a single pyridazine after the reaction of 
phenylvinylboronic acid with the non-symmetric phenyl pyridyl tetrazine. These findings support 
our proposed role of the pyridyl nitrogen to coordinate to the boronic acid, explaining the high 
rate constants of VBAs towards pyridyl-substituted tetrazines.  
We exploited the reactivity difference of the VBAs towards tetrazines bearing different 
substituents in a dual orthogonal labeling strategy of proteins. Multiple labeling strategies are in 
high demand for studying, for example, two or more biomolecules in the same biological system. 
Our orthogonal bioorthogonal reactions of the VBA and norbornene moieties were based on 
dipyridyl tetrazine and phenyl pyrimidyl tetrazine, of which the latter is not reactive towards 
VBA. We modified two model proteins with a VBA or a norbornene moiety and subsequently 
visualized a mixture of these proteins using the two tetrazines bearing a different fluorophore. 
Dual labeling of the proteins was possible with tandem tetrazine ligations or with a simultaneous 
incubation of the tetrazines in an optimized ratio. Finally, we used our optimized ratio for the 
simultaneous labeling of the proteasome in living cells using a non-selective probe equipped with 
VBA and subunit-selective one bearing a norbornene.  
Although norbornene showed rate constants in the same order of magnitude as VBA with 
dipyridyl-s-tetrazine, we do not expect any difficulties with the dual labeling when other non-
boron containing alkenes, such as the highly reactive TCOs9,10 are used. We envision that the 
unique reactivity of VBAs provide ample possibilities for its use in multiple orthogonal 
bioorthogonal reactions as we and others have previously successfully shown the orthogonality of 
the tetrazine ligation to other bioorthogonal reactions, such as the SPAAC reaction between 
azides and cyclooctynes.18,19 
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6.5 Experimental Section 
 
6.5.1 Synthetic procedures 
General experimental for the synthesis of the small molecules is described in Sections 3.5.1 and 4.5.1. The 
synthesis of 3-methyl-6-phenyl-s-tetrazine 3b is described in Chapter 3, the synthesis of maleimide 
vinylboronic acid pinacol ester 8 and BODIPY-FL dipyridyl tetrazine 10 in Chapter 4. Furthermore, the 
synthesis of VBA-Ahx3L3VS 17 and the determination of concentration of 17 necessary for full 
proteasome inhibition in living cells is described in Chapter 5. 
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3-Phenyl-6-(pyridin-2-yl)-1,2,4,5-tetrazine (3c). Benzonitrile (200 μL, 1.94 mmol, 1.0 equiv.) and 
2-cyanopyridine (217 mg, 2.09 mmol, 1.1 equiv.) were dissolved in dioxane (2 mL) and 
Zn(OTf)2 (71 mg, 0.19 mmol, 0.1 equiv.) was added. Hydrazine monohydrate (300 μL, 5.80 
mmol, 3.0 equiv.) was added dropwise and the mixture was heated at 60 °C overnight. The 
reaction mixture was cooled on ice and a solution of NaNO2 (511 mg, 7.41 mmol, 3.8 equiv.) in 
water (5 mL) was added. HCl (2 M) was added dropwise until the mixture turned red, the pH < 3 
and the toxic gas evolution ceased. The reaction mixture was extracted with CH2Cl2 until the 
organic layer remained colorless and the combined organic layers were dried with Na2SO4. The 
volatiles were removed in vacuo and the product was purified by column chromatography (40% EtOAc in 
heptane) yielding tetrazine 3c (123 mg, 28%) as a purple solid. Rf = 0.38 (40% EtOAc in heptane). 1H 
NMR (500 MHz, CDCl3) δ 8.98 (d, J = 4.8 Hz, 1H), 8.74 – 8.68 (m, 3H), 8.01 (td, J = 7.9, 1.6 Hz, 
1H), 7.69 – 7.61 (m, 3H), 7.59 – 7.55 (m, 1H). 13C NMR (125 MHz, CDCl3) δ 164.6, 163.6, 151.1, 
150.5, 137.6, 133.2, 131.7, 129.5, 128.6, 126.5, 124.1. HRMS (ESI+) m/z calculated for C13H9N5 
[M+H]+ 236.09362, found 236.09318. 
 
3-Methyl-6-(pyridin-2-yl)-1,2,4,5-tetrazine (3d). MeCN (1.50 mL, 28.8 mmol, 10 equiv.) and 2-
cyanopyridine (277 μL, 2.88 mmol, 1.0 equiv.) were dissolved in dioxane (1.5 mL) and Zn(OTf)2 
(524 mg, 1.44 mmol, 0.5 equiv.) was added. Hydrazine monohydrate (6.9 mL, 144 mmol, 50 
equiv.) was added dropwise and the reaction mixture was heated at 60 °C overnight. After cooling 
to rt, a solution of NaNO2 (3.97 g, 57.6 mmol, 20 equiv.) in H2O (190 mL) was added. HCl (1 
M) was added slowly until the solution turned red, the pH < 3 and the toxic gas evolution ceased. 
The mixture was extracted with CH2Cl2 until the organic layer remained colorless. The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification by column chromatography (50 to 
60% EtOAc in heptane) provided tetrazine 3d (130 mg, 26%) as a pink solid. Rf = 0.15 (50% EtOAc in 
heptane). 1H NMR (400 MHz, CDCl3) δ 8.96 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.65 (dt, J = 7.9, 1.1 Hz, 
1H), 7.99 (td, J = 7.8, 1.7 Hz, 1H), 7.56 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 3.17 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 168.3, 163.8, 151.0, 137.6, 126.5, 124.0, 77.2, 21.5. HRMS (ESI+) m/z calcd. for 
C8H7N5 [M+H]+ 174.07797, found: 174.07807. The data agrees with literature.32  
 
3-Phenyl-6-(pyrimidin-2-yl)-1,2,4,5-tetrazine (3e). Benzonitrile (500 μL, 4.85 mmol, 1.0 equiv.) and 
2-cyanopyrimidine (510 mg, 4.85 mmol, 1.0 equiv.) were dissolved in dioxane (2 mL) and 
Zn(OTf)2 (176 mg, 0.48 mmol, 0.1 equiv.) was added. Hydrazine monohydrate (1.26 mL, 24.2 
mmol, 5.0 equiv.) was added dropwise and the mixture was heated at 60 °C overnight. The 
reaction mixture was cooled on ice, and NaNO2 (1.0 g, 14.6 mmol, 3.0 equiv.) in water (10 mL) 
was added. HCl (1 M) was added slowly until the reaction mixture turned red, the pH < 3 and 
the toxic gas evolution ceased. The reaction mixture was extracted with CH2Cl2 until the organic 
layer remained colorless and the combined organic layers were dried with Na2SO4. The volatiles 
were removed and the product was purified by column chromatography (40 to 80% EtOAc in heptane) 
and crystallized with i-Pr2O yielding tetrazine 3e (152 mg, 13%) as purple crystals. Rf = 0.24 (60% EtOAc 
in heptane). 1H NMR (500 MHz, CDCl3) δ 9.14 (d, J = 4.9 Hz, 2H), 8.77 – 8.73 (m, 2H), 7.71 – 7.62 
(m, 3H), 7.59 (t, J = 4.9 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 164.7, 163.3, 159.8, 158.6, 133.6, 
131.5, 129.6, 129.0, 122.6. Tetrazine 3e was not visible on mass spectrometry. 
 
3-Methyl-6-(pyrimidin-2-yl)-1,2,4,5-tetrazine (3f). MeCN (2.48 mL, 47.5 mmol, 10 equiv.) and 2-
cyanopyrimidine (500 mg, 4.75 mmol, 1.0 equiv.) were dissolved in dioxane (1.5 mL) and 
Zn(OTf)2 (865 mg, 2.38 mmol, 0.5 equiv.) was added. Hydrazine monohydrate (11.5 mL, 238 
mmol, 50 equiv.) was added dropwise and the mixture was stirred at 60 °C overnight. After 
cooling to rt, NaNO2 (6.56 g, 95.2 mmol, 20 equiv.) in H2O (50 mL) was added. HCl (1 M) was 
added dropwise until the toxic gas evolution ceased and the solution turned red (pH ~ 3). The 
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3-Phenyl-6-(pyridin-2-yl)-1,2,4,5-tetrazine (3c). Benzonitrile (200 μL, 1.94 mmol, 1.0 equiv.) and 
2-cyanopyridine (217 mg, 2.09 mmol, 1.1 equiv.) were dissolved in dioxane (2 mL) and 
Zn(OTf)2 (71 mg, 0.19 mmol, 0.1 equiv.) was added. Hydrazine monohydrate (300 μL, 5.80 
mmol, 3.0 equiv.) was added dropwise and the mixture was heated at 60 °C overnight. The 
reaction mixture was cooled on ice and a solution of NaNO2 (511 mg, 7.41 mmol, 3.8 equiv.) in 
water (5 mL) was added. HCl (2 M) was added dropwise until the mixture turned red, the pH < 3 
and the toxic gas evolution ceased. The reaction mixture was extracted with CH2Cl2 until the 
organic layer remained colorless and the combined organic layers were dried with Na2SO4. The 
volatiles were removed in vacuo and the product was purified by column chromatography (40% EtOAc in 
heptane) yielding tetrazine 3c (123 mg, 28%) as a purple solid. Rf = 0.38 (40% EtOAc in heptane). 1H 
NMR (500 MHz, CDCl3) δ 8.98 (d, J = 4.8 Hz, 1H), 8.74 – 8.68 (m, 3H), 8.01 (td, J = 7.9, 1.6 Hz, 
1H), 7.69 – 7.61 (m, 3H), 7.59 – 7.55 (m, 1H). 13C NMR (125 MHz, CDCl3) δ 164.6, 163.6, 151.1, 
150.5, 137.6, 133.2, 131.7, 129.5, 128.6, 126.5, 124.1. HRMS (ESI+) m/z calculated for C13H9N5 
[M+H]+ 236.09362, found 236.09318. 
 
3-Methyl-6-(pyridin-2-yl)-1,2,4,5-tetrazine (3d). MeCN (1.50 mL, 28.8 mmol, 10 equiv.) and 2-
cyanopyridine (277 μL, 2.88 mmol, 1.0 equiv.) were dissolved in dioxane (1.5 mL) and Zn(OTf)2 
(524 mg, 1.44 mmol, 0.5 equiv.) was added. Hydrazine monohydrate (6.9 mL, 144 mmol, 50 
equiv.) was added dropwise and the reaction mixture was heated at 60 °C overnight. After cooling 
to rt, a solution of NaNO2 (3.97 g, 57.6 mmol, 20 equiv.) in H2O (190 mL) was added. HCl (1 
M) was added slowly until the solution turned red, the pH < 3 and the toxic gas evolution ceased. 
The mixture was extracted with CH2Cl2 until the organic layer remained colorless. The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification by column chromatography (50 to 
60% EtOAc in heptane) provided tetrazine 3d (130 mg, 26%) as a pink solid. Rf = 0.15 (50% EtOAc in 
heptane). 1H NMR (400 MHz, CDCl3) δ 8.96 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.65 (dt, J = 7.9, 1.1 Hz, 
1H), 7.99 (td, J = 7.8, 1.7 Hz, 1H), 7.56 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 3.17 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 168.3, 163.8, 151.0, 137.6, 126.5, 124.0, 77.2, 21.5. HRMS (ESI+) m/z calcd. for 
C8H7N5 [M+H]+ 174.07797, found: 174.07807. The data agrees with literature.32  
 
3-Phenyl-6-(pyrimidin-2-yl)-1,2,4,5-tetrazine (3e). Benzonitrile (500 μL, 4.85 mmol, 1.0 equiv.) and 
2-cyanopyrimidine (510 mg, 4.85 mmol, 1.0 equiv.) were dissolved in dioxane (2 mL) and 
Zn(OTf)2 (176 mg, 0.48 mmol, 0.1 equiv.) was added. Hydrazine monohydrate (1.26 mL, 24.2 
mmol, 5.0 equiv.) was added dropwise and the mixture was heated at 60 °C overnight. The 
reaction mixture was cooled on ice, and NaNO2 (1.0 g, 14.6 mmol, 3.0 equiv.) in water (10 mL) 
was added. HCl (1 M) was added slowly until the reaction mixture turned red, the pH < 3 and 
the toxic gas evolution ceased. The reaction mixture was extracted with CH2Cl2 until the organic 
layer remained colorless and the combined organic layers were dried with Na2SO4. The volatiles 
were removed and the product was purified by column chromatography (40 to 80% EtOAc in heptane) 
and crystallized with i-Pr2O yielding tetrazine 3e (152 mg, 13%) as purple crystals. Rf = 0.24 (60% EtOAc 
in heptane). 1H NMR (500 MHz, CDCl3) δ 9.14 (d, J = 4.9 Hz, 2H), 8.77 – 8.73 (m, 2H), 7.71 – 7.62 
(m, 3H), 7.59 (t, J = 4.9 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 164.7, 163.3, 159.8, 158.6, 133.6, 
131.5, 129.6, 129.0, 122.6. Tetrazine 3e was not visible on mass spectrometry. 
 
3-Methyl-6-(pyrimidin-2-yl)-1,2,4,5-tetrazine (3f). MeCN (2.48 mL, 47.5 mmol, 10 equiv.) and 2-
cyanopyrimidine (500 mg, 4.75 mmol, 1.0 equiv.) were dissolved in dioxane (1.5 mL) and 
Zn(OTf)2 (865 mg, 2.38 mmol, 0.5 equiv.) was added. Hydrazine monohydrate (11.5 mL, 238 
mmol, 50 equiv.) was added dropwise and the mixture was stirred at 60 °C overnight. After 
cooling to rt, NaNO2 (6.56 g, 95.2 mmol, 20 equiv.) in H2O (50 mL) was added. HCl (1 M) was 
added dropwise until the toxic gas evolution ceased and the solution turned red (pH ~ 3). The 
solution was extracted with CH2Cl2 (3 ×), the combined organic layers were dried with Na2SO4 and the 
volatiles were removed. The solid was purified using column chromatography (50 to 100% EtOAc in 
heptane) yielding tetrazine 3f (65 mg, 8%) as a pink solid. Rf = 0.30 (EtOAc). 1H NMR (400 MHz, 
CDCl3) δ 9.12 (d, J = 4.9 Hz, 2H), 7.58 (t, J = 4.9 Hz, 1H), 3.22 (s, 3H). 13C NMR (100 MHz, CDCl3) 
δ 168.9, 163.4, 159.7, 158.6, 122.7, 21.7. GCMS 8.08 min, m/z = 174 (M+·, 3%, calcd. for C7H6N6 
174), 105 [(M-C2H3N3)+, 100%], 78 [(M-C3H3N4)+, 30%]. 
 
3,4-Diphenyl-6-(pyridin-2-yl)-1,4-dihydropyridazine (5). 3-Phenyl-6-(pyridin-2-yl)-s-tetrazine 3c 
(10.2 mg, 43 μmol, 1.0 equiv.) and (E)-2-phenylvinylboronic acid 1 (6.4 mg, 43 μmol, 
1.0 equiv.) were dissolved in MeOH (1 mL) at ambient atmosphere and stirred for 16 h. 
The volatiles were evaporated yielding dihydropyridazine 5 (12.9 mg, 96%) as a yellow 
solid. Rf = 0.60 (40% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 9.24 (br. s, 
1H), 8.55 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.80 – 7.71 (m, 2H), 7.65 (ddd, J = 8.1, 7.3, 
1.8 Hz, 1H), 7.60 (dt, J = 8.1, 1.2 Hz, 1H), 7.37 – 7.33 (m, 2H), 7.33 – 7.26 (m, 5H), 
7.23 – 7.16 (m, 2H), 5.70 (dd, J = 6.3, 2.2 Hz, 1H), 4.88 (d, J = 6.2 Hz, 1H). 13C NMR 
(125 MHz, CDCl3) δ 150.6, 148.5, 144.3, 140.8, 137.2, 136.6, 135.4, 129.2, 128.4, 128.4, 127.4, 
127.0, 126.4, 123.1, 119.0, 97.8, 40.0. HRMS (ESI+) m/z calculated for C21H17N3 [M+H]+ 312.15007, 
found 312.14851. 
 
3,4-Diphenyl-6-(pyridin-2-yl)pyridazine (6). To a solution of dihydropyridazine 5 (12.9 mg, 42 μmol, 
1.0 equiv.) in MeOH (1 mL) was added chloranil (22 mg, 89 μmol, 2.1 equiv.) at ambient 
atmosphere and the reaction mixture was stirred for 1 h. The volatiles were evaporated and 
the product was purified using column chromatography (40% EtOAc in heptane) yielding 
pyridazine 6 (12.6 mg, 98%) as a yellow solid. Rf = 0.33 (40% EtOAc in heptane). 1H 
NMR (500 MHz, CDCl3) δ 8.79 (dt, J = 8.0, 1.1 Hz, 1H, 6-C=CH), 8.72 (ddd, J = 4.9, 
1.8, 1.0 Hz, 1H, 6-N=CH), 8.59 (s, 1H, 5-CH), 7.91 (td, J = 7.8, 1.8 Hz, 1H, 6-C=CH-
CH), 7.58 – 7.49 (m, 2H, 3-C=CH-CH=CH), 7.41 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H, 6-
N=CH-CH), 7.38 – 7.27 (m, 8H, 3-C=CH-CH=CH and 4-C=CH-CH=CH). 13C NMR (125 MHz, 
CDCl3) δ 159.5 (3-C-C=N-N), 157.2 (6-C-C=N-N), 153.7 (6-C-C=N-N), 149.5 (6-N=CH), 139.9 (4-
C-C=CH), 137.4 (6-C=CH-CH), 137.2 (4-C-C=CH), 136.9 (3-C-C=CH), 130.2 (3-C=CH-CH=CH), 
129.3 (4-C=CH-CH=CH or 4-C=CH-CH=CH), 129.0 (3-C=CH-CH=CH), 128.79 (4-C=CH-
CH=CH), 128.76 (3-C=CH-CH=CH), 128.3 (4-C=CH-CH=CH or 4-C=CH-CH=CH), 125.6 (5-
CH), 124.8 (6-N=CH-CH), 121.9 (6-C=CH). HRMS (ESI+) m/z calculated for C21H15N3 [M+H]+ 
310.13442, found 310.13309.  
 
3,4-Diphenyl-6-(pyridin-2-yl)pyridazine (6) and 4,6-diphenyl-3-(pyridin-2-yl)pyridazine (7). 3-
Phenyl-6-(pyridin-2-yl)-s-tetrazine 3c (10.0 mg, 43 μmol, 1.0 equiv.) and 
styrene 4 (24.4 μL, 213 μmol, 5.0 equiv.) were mixed in MeOH (1 mL) at 
ambient atmosphere and stirred for 5 days. Chloranil (21 mg, 86 μmol, 2.0 
equiv.) was added and the mixture was stirred for 1 h. The volatiles were 
removed yielding 6 and 7 in a ratio of 70:30. The mixture was purified with 
column chromatography (10 to 50% EtOAc in heptane) to isolate the 
pyridazines, yielding 6 (7.5 mg, 57%) and 7 (3.0 mg, 23%) as off-white 
solids. Rf = 0.41 for 6 and 0.22 for 7 (30% EtOAc in heptane). See the reaction of 3c with 1 for the 
analytical data of 6. Isomer 7: 1H NMR (400 MHz, CDCl3) δ 8.46 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H, 3-
N=CH), 8.23 – 8.17 (m, 2H, 6-C=CH), 7.95 – 7.91 (m, 2H, 3-C=CH and 5-CH), 7.81 (td, J = 7.7, 1.8 
Hz, 1H, 3-C=CH-CH), 7.60 – 7.51 (m, 3H, 6-C=CH-CH=CH), 7.37 – 7.31 (m, 3H, 4-C=CH-
CH=CH), 7.29 – 7.22 (m, 3H, 3-N=CH-CH and 4-C=CH-CH=CH). 13C NMR (100 MHz, CDCl3) δ 
158.7 (6-C-C=N-N), 157.4 (3-C-C=N-N), 155.9 (3-C-C=N-N), 149.1 (3-N=CH), 140.4 (4-C-C=CH), 
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137.3 (4-C-C=CH), 136.8 (3-C=CH-CH), 136.2 (6-C-C=N-N), 130.4 (6-C=CH-CH=CH), 129.2 (6-
C=CH-CH), 128.9 (4-C=CH-CH=CH), 128.7 (4-C=CH-CH=CH), 128.6 (4-C=CH-CH=CH), 127.4 
(6-C=CH), 125.3 (5-CH), 125.0 (3-C=CH), 123.5 (3-N=CH-CH). HRMS (ESI+) m/z calculated for 
C21H15N3 [M+H]+ 310.13442, found 310.13449. 
 
N-Boc-2,2’-(ethylenedioxy)diethylamine (13). 2,2’-(Ethylenedioxy)diethylamine 12 (1.67 mL, 11.45 
mmol, 5.0 equiv.) was dissolved in dry CH2Cl2 (20 mL), di-tert-butyl 
dicarbonate (500 mg, 2.92 mmol, 1.0 equiv.) in dry CH2Cl2 (5 mL) was 
added and the mixture was stirred for 1 h. Additional CH2Cl2 was added and the organic layer was washed 
with H2O until the starting material was removed (5 × 20 mL). The organic layer was dried with Na2SO4 
and the solvent was removed under reduced pressure, yielding BOC-protected amine 13 (438 mg, 77%) 
as a colorless oil. 1H-NMR (500 MHz, CDCl3) δ 5.14 (br. s, 1H), 3.66 – 3.58 (m, 4H), 3.54 (t, J = 5.2 
Hz, 2H), 3.51 (t, J = 5.2 Hz, 2H), 3.31 (q, J = 5.3 Hz, 2H), 2.87 (t, J = 5.2 Hz, 2H), 1.53 – 1.36 (m, 
11H). 13C NMR (125 MHz, CDCl3) δ 156.1, 79.3, 73.6, 70.4, 41.9, 40.5, 28.6. LRMS (ESI+) m/z calcd. 
for C11H24N2O4 [M+H]+ 249.2, found: 248.9. The data agrees with the reported literature values.33 
 
5-Norbornene-2-methyl-(2-(2-(2-N-Boc-aminoethoxy)ethoxy)ethyl)carbamate (14). Amine 13 (281 
mg, 1.13 mmol, 1.5 equiv.) was dissolved in dry DMF (5 mL) 
and DIPEA (197 μL, 1.13 mmol, 1.5 equiv.) was added. Then 
norbornene-NHS (Section 4.5.1) (200 mg, 0.75 mmol, 1.0 
equiv.) in dry DMF (1 mL) was added dropwise to the solution, which was stirred for 1 h. The solvent 
was removed and the crude mixture was purified by column chromatography (60% EtOAc in heptane) 
yielding norbornene 14 (241 mg, 80%), an endo/exo mixture of 2:1 as a colorless oil. Rf = 0.31 (60% 
EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 6.17 (dd, J = 5.8, 3.0 Hz, 1H, Hendo-5), 6.14 – 6.06 
(m, 1H, Hexo-5 and 1H, Hexo-6), 5.97 (dd, J = 5.8, 2.9 Hz, 1H Hendo-6), 5.23 (s, 1H, NH), 5.08 (s, 1H, 
NH), 4.16 (dd, J = 10.7, 6.4 Hz, 1H, OCH2CHexo), 3.99 (t, J = 9.9 Hz, 1H, OCH2CHexo), 3.87 (dd, J = 
10.5, 6.7 Hz, 1H, OCH2CHendo), 3.72 – 3.53 (m, 8H OCH2CH2 and 1H OCH2CHendo), 3.46 – 3.28 (m, 
4H, CH2NH), 2.92 – 2.87 (m, 1H, Hendo-1), 2.87 – 2.80 (m, 1H, Hendo-4 and 1H, Hexo-4), 2.75 – 2.69 
(m, 1H, Hexo-1), 2.45 – 2.35 (m, 1H, Hendo-2), 1.84 (ddd, J = 11.8, 9.2, 3.8 Hz, 1H, Hendo-3), 1.76 – 1.69 
(m, 1H, Hexo-2), 1.54 – 1.41 (m, 9H, C(CH3)3 and 1H, Hendo-7), 1.39 – 1.14 (m, 1H, Hendo-7, 2H, Hexo-7 
and 2H, Hexo-3), 0.61 – 0.53 (m, 1H, Hendo-3). 13C NMR (125 MHz, CDCl3) δ 156.9 (C=O), 156.1 
(C=O), 137.5 (Cendo-5), 137.0, 136.3 (Cexo-5,6), 132.3 (Cendo-6), 79.4 (C(CH3)3), 70.4, 70.32, 70.27 
(CPEG), 69.1 (OCH2CHexo), 68.4 (OCH2CHendo), 49.4 (Cendo-7), 45.1 (Cexo-7), 43.9 (Cendo-1), 43.7 (Cexo-1), 
42.3 (Cendo-4), 41.7 (Cexo-4), 40.9, 40.5 (CH2NH), 38.4 (Cexo-2), 38.2 (Cendo-2), 29.6 (Cexo-3), 29.0 (Cendo-
3), 28.5 (C(CH3)3). HRMS (ESI+) m/z calcd. for C20H34N2O6 [M+Na]+ 421.23146, found: 421.23174. 
 
5-Norbornene-2-methyl-(2-(2-(2-maleimido)propanamido)ethoxy)ethoxy)ethyl)carbamate (9). 
Norbornene 14 (141 mg, 0.36 mmol, 1.2 equiv.) was 
dissolved in dry CH2Cl2 (6 mL) and 4 M HCl in dioxane 
(2.05 mL, 8.19 mmol, 28 equiv.) was dropwise added. 
The solution was stirred for 1 h at which the solvent was 
removed. The mixture was dissolved in dry DMF (5 mL) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (55 mg, 0.36 mmol, 1.2 equiv.), HOBt hydrate (48 mg, 0.36 mmol, 
1.2 equiv.), 3-maleimidopropionic acid (50 mg, 0.30 mmol, 1.0 equiv.) and DIPEA (97 μL, 0.55 mmol, 
1.8 equiv.) were added. The solution was stirred overnight at which the solvent was removed. The mixture 
was purified by column chromatography (0 to 4% MeOH in CH2Cl2) yielding maleimide norbornene 9 
(73 mg, 54%) as a slightly yellow oil in an endo/exo mixture of 2:1. Rf = 0.38 (10% MeOH in CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 6.68 (s, 2H, (CH=CH-C=O)), 6.27 (s, 1H, NH), 6.13 (dd, J = 5.7, 3.0 
Hz, 1H, Hendo-5), 6.08 – 6.03 (m, 1H, Hexo-5 and 1H, Hexo-6), 5.92 (dd, J = 5.7, 2.9 Hz, 1H, Hendo-6), 
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137.3 (4-C-C=CH), 136.8 (3-C=CH-CH), 136.2 (6-C-C=N-N), 130.4 (6-C=CH-CH=CH), 129.2 (6-
C=CH-CH), 128.9 (4-C=CH-CH=CH), 128.7 (4-C=CH-CH=CH), 128.6 (4-C=CH-CH=CH), 127.4 
(6-C=CH), 125.3 (5-CH), 125.0 (3-C=CH), 123.5 (3-N=CH-CH). HRMS (ESI+) m/z calculated for 
C21H15N3 [M+H]+ 310.13442, found 310.13449. 
 
N-Boc-2,2’-(ethylenedioxy)diethylamine (13). 2,2’-(Ethylenedioxy)diethylamine 12 (1.67 mL, 11.45 
mmol, 5.0 equiv.) was dissolved in dry CH2Cl2 (20 mL), di-tert-butyl 
dicarbonate (500 mg, 2.92 mmol, 1.0 equiv.) in dry CH2Cl2 (5 mL) was 
added and the mixture was stirred for 1 h. Additional CH2Cl2 was added and the organic layer was washed 
with H2O until the starting material was removed (5 × 20 mL). The organic layer was dried with Na2SO4 
and the solvent was removed under reduced pressure, yielding BOC-protected amine 13 (438 mg, 77%) 
as a colorless oil. 1H-NMR (500 MHz, CDCl3) δ 5.14 (br. s, 1H), 3.66 – 3.58 (m, 4H), 3.54 (t, J = 5.2 
Hz, 2H), 3.51 (t, J = 5.2 Hz, 2H), 3.31 (q, J = 5.3 Hz, 2H), 2.87 (t, J = 5.2 Hz, 2H), 1.53 – 1.36 (m, 
11H). 13C NMR (125 MHz, CDCl3) δ 156.1, 79.3, 73.6, 70.4, 41.9, 40.5, 28.6. LRMS (ESI+) m/z calcd. 
for C11H24N2O4 [M+H]+ 249.2, found: 248.9. The data agrees with the reported literature values.33 
 
5-Norbornene-2-methyl-(2-(2-(2-N-Boc-aminoethoxy)ethoxy)ethyl)carbamate (14). Amine 13 (281 
mg, 1.13 mmol, 1.5 equiv.) was dissolved in dry DMF (5 mL) 
and DIPEA (197 μL, 1.13 mmol, 1.5 equiv.) was added. Then 
norbornene-NHS (Section 4.5.1) (200 mg, 0.75 mmol, 1.0 
equiv.) in dry DMF (1 mL) was added dropwise to the solution, which was stirred for 1 h. The solvent 
was removed and the crude mixture was purified by column chromatography (60% EtOAc in heptane) 
yielding norbornene 14 (241 mg, 80%), an endo/exo mixture of 2:1 as a colorless oil. Rf = 0.31 (60% 
EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 6.17 (dd, J = 5.8, 3.0 Hz, 1H, Hendo-5), 6.14 – 6.06 
(m, 1H, Hexo-5 and 1H, Hexo-6), 5.97 (dd, J = 5.8, 2.9 Hz, 1H Hendo-6), 5.23 (s, 1H, NH), 5.08 (s, 1H, 
NH), 4.16 (dd, J = 10.7, 6.4 Hz, 1H, OCH2CHexo), 3.99 (t, J = 9.9 Hz, 1H, OCH2CHexo), 3.87 (dd, J = 
10.5, 6.7 Hz, 1H, OCH2CHendo), 3.72 – 3.53 (m, 8H OCH2CH2 and 1H OCH2CHendo), 3.46 – 3.28 (m, 
4H, CH2NH), 2.92 – 2.87 (m, 1H, Hendo-1), 2.87 – 2.80 (m, 1H, Hendo-4 and 1H, Hexo-4), 2.75 – 2.69 
(m, 1H, Hexo-1), 2.45 – 2.35 (m, 1H, Hendo-2), 1.84 (ddd, J = 11.8, 9.2, 3.8 Hz, 1H, Hendo-3), 1.76 – 1.69 
(m, 1H, Hexo-2), 1.54 – 1.41 (m, 9H, C(CH3)3 and 1H, Hendo-7), 1.39 – 1.14 (m, 1H, Hendo-7, 2H, Hexo-7 
and 2H, Hexo-3), 0.61 – 0.53 (m, 1H, Hendo-3). 13C NMR (125 MHz, CDCl3) δ 156.9 (C=O), 156.1 
(C=O), 137.5 (Cendo-5), 137.0, 136.3 (Cexo-5,6), 132.3 (Cendo-6), 79.4 (C(CH3)3), 70.4, 70.32, 70.27 
(CPEG), 69.1 (OCH2CHexo), 68.4 (OCH2CHendo), 49.4 (Cendo-7), 45.1 (Cexo-7), 43.9 (Cendo-1), 43.7 (Cexo-1), 
42.3 (Cendo-4), 41.7 (Cexo-4), 40.9, 40.5 (CH2NH), 38.4 (Cexo-2), 38.2 (Cendo-2), 29.6 (Cexo-3), 29.0 (Cendo-
3), 28.5 (C(CH3)3). HRMS (ESI+) m/z calcd. for C20H34N2O6 [M+Na]+ 421.23146, found: 421.23174. 
 
5-Norbornene-2-methyl-(2-(2-(2-maleimido)propanamido)ethoxy)ethoxy)ethyl)carbamate (9). 
Norbornene 14 (141 mg, 0.36 mmol, 1.2 equiv.) was 
dissolved in dry CH2Cl2 (6 mL) and 4 M HCl in dioxane 
(2.05 mL, 8.19 mmol, 28 equiv.) was dropwise added. 
The solution was stirred for 1 h at which the solvent was 
removed. The mixture was dissolved in dry DMF (5 mL) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (55 mg, 0.36 mmol, 1.2 equiv.), HOBt hydrate (48 mg, 0.36 mmol, 
1.2 equiv.), 3-maleimidopropionic acid (50 mg, 0.30 mmol, 1.0 equiv.) and DIPEA (97 μL, 0.55 mmol, 
1.8 equiv.) were added. The solution was stirred overnight at which the solvent was removed. The mixture 
was purified by column chromatography (0 to 4% MeOH in CH2Cl2) yielding maleimide norbornene 9 
(73 mg, 54%) as a slightly yellow oil in an endo/exo mixture of 2:1. Rf = 0.38 (10% MeOH in CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 6.68 (s, 2H, (CH=CH-C=O)), 6.27 (s, 1H, NH), 6.13 (dd, J = 5.7, 3.0 
Hz, 1H, Hendo-5), 6.08 – 6.03 (m, 1H, Hexo-5 and 1H, Hexo-6), 5.92 (dd, J = 5.7, 2.9 Hz, 1H, Hendo-6), 
5.28 – 5.15 (m, 1H, NH), 4.17 – 4.04 (m, 1H, OCH2CHexo), 3.98 – 3.90 (m, 1H, OCH2CHexo), 3.89 – 
3.71 (m, 1H, OCH2CHendo and 2H, ((C=O)-CH2-CH2-N), 3.67 – 3.47 (m, 1H, OCH2CHendo and 8H, 
OCH2CH2), 3.46 – 3.25 (m, 4H, CH2NH), 2.87 – 2.82 (m, 1H, Hendo-1), 2.82 – 2.77 (m, 1H, Hendo-4 
and 1H, Hexo-4), 2.69 – 2.65 (m, 1H, Hexo-1), 2.51 (t, J = 7.2 Hz, 2H, (C=O)-CH2-CH2-N), 2.42 – 2.29 
(m, 5H, Hendo-2), 1.85 – 1.75 (m, 1H, Hendo-3), 1.75 – 1.62 (m, 1H, Hexo-2), 1.46 – 1.37 (m, 1H, Hendo-7), 
1.36 – 1.26 (m, 2H, Hexo-7), 1.27 – 1.18 (m, 1H, Hendo-7 and 1H, Hexo-3), 1.18 – 1.08 (m, 1H, Hexo-3), 
0.57 – 0.46 (m, 1H, Hendo-3). 13C NMR (125 MHz, CDCl3) δ 170.6 (CH=CH-C=O), 169.8 (O-(C=O)-
N), 156.9 (N-(C=O)-C), 137.6 (Cendo-5), 137.1, 136.3 (Cexo-5 and 6), 134.3 (C=C-C=O), 132.3 (Cendo-6), 
70.4, 70.3, 69.9 (CPEG), 69.2 (OCH2CHexo), 68.5 (OCH2CHendo), 49.5 (Cendo-7), 45.1 (Cexo-7), 44.0 (Cendo-
1), 43.7 (Cexo-1), 42.3 (Cendo-4), 41.7 (Cexo-4), 40.8, 39.3 (CPEG), 38.4 (Cexo-2), 38.3 (Cendo-2), 34.7 ((C=O)-
CH2-CH2-N), 34.4 ((C=O)-CH2-CH2-N), 29.6 (Cexo-3), 29.0 (Cendo-3). HRMS (ESI+) m/z calcd. for 
C11H24N2O4 [M+Na]+ 472.20597, found: 472.20625. 
 
4-(6-(Pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid (15). 2-Cyanopyrimidine (1.0 g, 9.51 mmol, 
1.0 equiv.) and 4-cyanobenzoic acid (2.1 g, 14.3 mmol, 1.5 equiv.) were dissolved in ethanol 
(45 mL). Hydrazine monohydrate (5.9 mL, 263 mmol, 28 equiv.) was added and the mixture 
was refluxed overnight. The mixture was cooled to rt and the orange solid was collected by 
filtration and washed with acetone. The solid was dissolved in acetic acid (10 mL) and a solution 
of NaNO2 (2.9 g, 42.8 mmol, 4.5 equiv.) in water (4 mL) was added at 0 °C. The mixture was 
stirred for 1 h at rt (toxic gases evolve), whereupon the purple solid was collected by filtration 
and washed trice with water. The solid was added to nearly boiling DMF, filtrated and the 
residue was washed twice with nearly boiling DMF. The volatiles of the filtrate were removed 
under reduced pressure, yielding tetrazine 15 (800 mg, 30%) as a pink solid. 1H NMR (400 
MHz, (CD3)2SO) δ 9.21 (d, J = 4.9 Hz, 2H), 8.71 – 8.65 (m, 2H), 8.26 – 8.21 (m, 2H), 7.84 (t, J = 4.9 
Hz, 1H). 13C NMR (100 MHz, (CD3)2SO) δ 167.0, 163.3, 162.9, 159.1, 158.5, 134.7, 130.2, 128.2, 
123.0. LRMS (ESI-) m/z calcd. For C13H8N6O2 [M-H]- 279.1 found: 279.1. The data agrees with the 
reported literature values.29 
 
N-(2-(2-(2-N-Boc-aminoethoxy)ethoxy)ethyl)-4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-
yl)benzamide (16). Tetrazine 15 (75 mg, 0.267 mmol, 1.0 equiv.) was dissolved in 
dry DMF (2 mL) and HATU (122 mg, 0.321 mmol, 1.2 equiv.) and DIPEA (93 
μL, 0.535 mmol, 2.0 equiv.) were added. Next, amine 13 (80 mg, 0.321 mmol, 1.2 
equiv.) was added and the mixture was stirred overnight. Then, H2O was added and 
the mixture was extracted with EtOAc (3 ×). The combined organic layers were 
washed with brine, dried with Na2SO4 and the volatiles were evaporated. The crude 
mixture was purified using column chromatography (0 to 5% MeOH in EtOAc) 
yielding amide 16 (41 mg, 30%) as a pink solid. Rf = 0.32 (5% MeOH in EtOAc). 
1H NMR (500 MHz, CD3OD) δ 9.16 (d, J = 4.9 Hz, 2H), 8.83 – 8.77 (m, 2H), 
8.15 – 8.10 (m, 2H), 7.80 (t, J = 4.9 Hz, 1H), 3.72 (t, J = 5.3 Hz, 2H), 3.69 – 3.67 (m, 2H), 3.66 – 3.63 
(m, 4H), 3.53 (t, J = 5.7 Hz, 2H), 3.22 (t, J = 5.7 Hz, 2H), 1.42 (s, 9H). 13C NMR (125 MHz, CD3OD) 
δ 169.3, 165.7, 164.1, 160.3, 159.7, 158.5, 139.9, 135.8, 129.7, 129.4, 124.5, 80.1, 71.4, 71.3, 71.1, 
70.5, 41.2, 41.1, 28.8. LRMS (ESI+) m/z calcd. for C24H30N8O5 [M+H]+ 511.2, found: 511.8. The data 
agrees with the reported literature values.34  
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N-(2-(2-(2-(Lissamine rhodamine B sulfonamido)ethoxy)ethoxy)ethyl)-4-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzamide (11). Tetrazine 16 (21 mg, 42 
μmol, 1.2 equiv.) was dissolved in dry CH2Cl2 (1 mL) and 4 M 
HCl in dioxane (104 μL, 0.42 mmol, 12 equiv.) was added. The 
mixture was stirred for 1 h at which the volatiles were evaporated. 
The solid was then dissolved in dry DMF (1 mL) and Lissamine 
rhodamine B sulfonyl chloride (20 mg, 35 μL, 1.0 equiv.) and 
DIPEA (30 μL, 0.17 mmol, 5.0 equiv.) were added. The reaction 
was stirred overnight, whereupon the volatiles were removed. The 
crude product was purified using semi-preparative HPLC with a 
H2O/MeCN gradient containing 1% trifluoroacetic acid (5% MeCN for 5 min, to 40% in 2.5 min, to 
65% in 17.5 min then to 100% in 5 min), yielding tetrazine-rhodamine 11 (12 mg, 36%) as a purple 
solid. 1H NMR (500 MHz, (CD3)2SO) δ 9.21 (d, J = 4.9 Hz, 2H), 8.71 (t, J = 5.6 Hz, 1H), 8.63 – 8.55 
(m, 2H), 8.44 (d, J = 2.0 Hz, 1H), 8.12 – 8.05 (m, 3H), 7.96 (dd, J = 7.9, 1.9 Hz, 1H), 7.85 (t, J = 4.9 
Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.02 – 6.92 (m, 4H), 6.84 (d, J = 2.1 Hz, 2H), 3.66 – 3.53 (m, 12H), 
3.50 – 3.41 (m, 6H), 3.06 (q, J = 5.8 Hz, 2H), 1.19 (t, J = 7.1 Hz, 12H). 13C NMR (125 MHz, 
(CD3)2SO) δ 165.4, 163.2, 162.9, 159.1, 158.5, 157.4, 157.0, 155.0, 147.9, 141.9, 138.0, 133.7, 133.0, 
132.6, 130.6, 128.3, 128.0, 126.6, 125.8, 123.1, 113.6, 113.4, 95.4, 69.6, 69.4, 69.0, 68.9, 45.2, 42.6, 
39.4*, 12.5. * Visualized using HSQC, underneath the DMSO peak. HRMS (ESI+) m/z calcd. for 
C46H50N10O9S2 [M+Na]+ 973.31013, found: 973.30962. 
 
Norbornene-Phe-trans-BiCha-Phe-Ala-EK (18). LU-005c31 (3.8 mg, 5.5 μmol, 1.0 equiv.) and 
norbornene-alkyne21 (1.2 mg, 6.6 μmol, 1.2 equiv.) were 
dissolved in DMF (1 mL) at ambient atmosphere. An 
aqueous solution of sodium ascorbate (100 μL of 41.3 
mM, 4.13 μmol, 0.75 eq.) and an aqueous solution of 
CuSO4 (100 μL of 27.5 mM, 2.75 μmol, 0.5 eq.) were 
added and the reaction mixture was stirred overnight. The 
mixture was concentrated in vacuo and purified by HPLC 
(75 to 85% MeCN in H2O), yielding proteasome inhibitor 18 (1.2 mg, 22%). 1H NMR (600 MHz, 
CDCl3) δ 7.54 (d, J = 4.0 Hz, 1H), 7.28 – 7.14 (m, 8H), 7.03 – 6.96 (m, 2H), 6.91 (d, J = 7.4 Hz, 1H), 
6.56 (d, J = 7.6 Hz, 1H), 6.42 (d, J = 6.9 Hz, 1H), 6.22 – 6.12 (m, 2H), 5.88 – 5.79 (m, 1H), 5.28 – 
5.20 (m, 1H), 4.63 – 4.56 (m, 1H), 4.48 – 4.41 (m, 2H), 4.40 – 4.32 (m, 2H), 3.53 – 3.46 (m, 1H), 
3.38 – 3.32 (m, 1H), 3.16 – 3.11 (m, 1H), 3.12 – 3.07 (m, 1H), 2.99 (d, J = 7.0 Hz, 2H), 2.93 – 2.82 
(m, 3H), 1.96 – 1.87 (m, 1H), 1.67 – 1.58 (m, 6H), 1.58 – 1.52 (m, 1H), 1.51 (s, 3H), 1.44 – 1.34 (m, 
2H), 1.35 – 1.24 (m, 2), 1.22 (d, J = 7.1 Hz, 3H), 1.19 – 0.74 (m, 15H). 13C NMR (150 MHz, CDCl3) 
δ 207.8, 174.7, 171.2, 170.1, 167.4, 145.0, 138.01, 137.99, 136.4, 135.2, 132.3, 132.2, 129.4, 129.0, 
128.9, 128.8, 127.6, 127.2, 123.3, 123.1, 65.9, 59.0, 54.3, 52.5, 51.9, 50.2, 48.1, 46.3, 44.8, 43.3, 42.8, 
39.4, 39.0, 38.2, 34.9, 34.5, 33.7, 33.0, 30.4, 30.0, 29.9, 29.71, 29.65, 26.9, 17.3, 16.9. LCMS (ESI+) 
(linear gradient 10 to 90% MeCN/H2O, 0.1% TFA, 15.0 min): Rt = 9.68 min, m/z calcd. for 
C50H65N7O6 [M+H]+ 859.50 found: 860.20. HRMS (ESI+) m/z calcd. for C50H65N7O6 [M+H]+ 
860.50691, found: 860.50719. 
 
6.5.2 Determination of second-order rate constants 
The second-order rate constants described in this chapter were measured at a Spark M10 microplate reader 
(Tecan) at a controlled temperature of 20 °C, with no shaking performed before the start of the 
measurement. For this machine, the time between the addition of the tetrazine to the alkene and the start 
of the measurement was ±20 s. The k2 values of the reactions between the alkenes 1, 2 and 4 and tetrazines 
3b - f in 1:1 MeOH/PBS were determined as described in Section 3.5.3. Only the product of the reaction 
HN
O
O
NH O
O
NH
O
NN N
HN
O
6Orthogonal Bioorthogonal Tetrazine Ligations 135
N-(2-(2-(2-(Lissamine rhodamine B sulfonamido)ethoxy)ethoxy)ethyl)-4-(6-(pyrimidin-2-yl)-
1,2,4,5-tetrazin-3-yl)benzamide (11). Tetrazine 16 (21 mg, 42 
μmol, 1.2 equiv.) was dissolved in dry CH2Cl2 (1 mL) and 4 M 
HCl in dioxane (104 μL, 0.42 mmol, 12 equiv.) was added. The 
mixture was stirred for 1 h at which the volatiles were evaporated. 
The solid was then dissolved in dry DMF (1 mL) and Lissamine 
rhodamine B sulfonyl chloride (20 mg, 35 μL, 1.0 equiv.) and 
DIPEA (30 μL, 0.17 mmol, 5.0 equiv.) were added. The reaction 
was stirred overnight, whereupon the volatiles were removed. The 
crude product was purified using semi-preparative HPLC with a 
H2O/MeCN gradient containing 1% trifluoroacetic acid (5% MeCN for 5 min, to 40% in 2.5 min, to 
65% in 17.5 min then to 100% in 5 min), yielding tetrazine-rhodamine 11 (12 mg, 36%) as a purple 
solid. 1H NMR (500 MHz, (CD3)2SO) δ 9.21 (d, J = 4.9 Hz, 2H), 8.71 (t, J = 5.6 Hz, 1H), 8.63 – 8.55 
(m, 2H), 8.44 (d, J = 2.0 Hz, 1H), 8.12 – 8.05 (m, 3H), 7.96 (dd, J = 7.9, 1.9 Hz, 1H), 7.85 (t, J = 4.9 
Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.02 – 6.92 (m, 4H), 6.84 (d, J = 2.1 Hz, 2H), 3.66 – 3.53 (m, 12H), 
3.50 – 3.41 (m, 6H), 3.06 (q, J = 5.8 Hz, 2H), 1.19 (t, J = 7.1 Hz, 12H). 13C NMR (125 MHz, 
(CD3)2SO) δ 165.4, 163.2, 162.9, 159.1, 158.5, 157.4, 157.0, 155.0, 147.9, 141.9, 138.0, 133.7, 133.0, 
132.6, 130.6, 128.3, 128.0, 126.6, 125.8, 123.1, 113.6, 113.4, 95.4, 69.6, 69.4, 69.0, 68.9, 45.2, 42.6, 
39.4*, 12.5. * Visualized using HSQC, underneath the DMSO peak. HRMS (ESI+) m/z calcd. for 
C46H50N10O9S2 [M+Na]+ 973.31013, found: 973.30962. 
 
Norbornene-Phe-trans-BiCha-Phe-Ala-EK (18). LU-005c31 (3.8 mg, 5.5 μmol, 1.0 equiv.) and 
norbornene-alkyne21 (1.2 mg, 6.6 μmol, 1.2 equiv.) were 
dissolved in DMF (1 mL) at ambient atmosphere. An 
aqueous solution of sodium ascorbate (100 μL of 41.3 
mM, 4.13 μmol, 0.75 eq.) and an aqueous solution of 
CuSO4 (100 μL of 27.5 mM, 2.75 μmol, 0.5 eq.) were 
added and the reaction mixture was stirred overnight. The 
mixture was concentrated in vacuo and purified by HPLC 
(75 to 85% MeCN in H2O), yielding proteasome inhibitor 18 (1.2 mg, 22%). 1H NMR (600 MHz, 
CDCl3) δ 7.54 (d, J = 4.0 Hz, 1H), 7.28 – 7.14 (m, 8H), 7.03 – 6.96 (m, 2H), 6.91 (d, J = 7.4 Hz, 1H), 
6.56 (d, J = 7.6 Hz, 1H), 6.42 (d, J = 6.9 Hz, 1H), 6.22 – 6.12 (m, 2H), 5.88 – 5.79 (m, 1H), 5.28 – 
5.20 (m, 1H), 4.63 – 4.56 (m, 1H), 4.48 – 4.41 (m, 2H), 4.40 – 4.32 (m, 2H), 3.53 – 3.46 (m, 1H), 
3.38 – 3.32 (m, 1H), 3.16 – 3.11 (m, 1H), 3.12 – 3.07 (m, 1H), 2.99 (d, J = 7.0 Hz, 2H), 2.93 – 2.82 
(m, 3H), 1.96 – 1.87 (m, 1H), 1.67 – 1.58 (m, 6H), 1.58 – 1.52 (m, 1H), 1.51 (s, 3H), 1.44 – 1.34 (m, 
2H), 1.35 – 1.24 (m, 2), 1.22 (d, J = 7.1 Hz, 3H), 1.19 – 0.74 (m, 15H). 13C NMR (150 MHz, CDCl3) 
δ 207.8, 174.7, 171.2, 170.1, 167.4, 145.0, 138.01, 137.99, 136.4, 135.2, 132.3, 132.2, 129.4, 129.0, 
128.9, 128.8, 127.6, 127.2, 123.3, 123.1, 65.9, 59.0, 54.3, 52.5, 51.9, 50.2, 48.1, 46.3, 44.8, 43.3, 42.8, 
39.4, 39.0, 38.2, 34.9, 34.5, 33.7, 33.0, 30.4, 30.0, 29.9, 29.71, 29.65, 26.9, 17.3, 16.9. LCMS (ESI+) 
(linear gradient 10 to 90% MeCN/H2O, 0.1% TFA, 15.0 min): Rt = 9.68 min, m/z calcd. for 
C50H65N7O6 [M+H]+ 859.50 found: 860.20. HRMS (ESI+) m/z calcd. for C50H65N7O6 [M+H]+ 
860.50691, found: 860.50719. 
 
6.5.2 Determination of second-order rate constants 
The second-order rate constants described in this chapter were measured at a Spark M10 microplate reader 
(Tecan) at a controlled temperature of 20 °C, with no shaking performed before the start of the 
measurement. For this machine, the time between the addition of the tetrazine to the alkene and the start 
of the measurement was ±20 s. The k2 values of the reactions between the alkenes 1, 2 and 4 and tetrazines 
3b - f in 1:1 MeOH/PBS were determined as described in Section 3.5.3. Only the product of the reaction 
HN
O
O
NH O
O
NH
O
NN N
HN
O
between tetrazine 3c and VBA 1 did not dissolve at 500 μM in 1:1 MeOH/PBS, therefore the decay of 
the tetrazine during the reaction was followed at 305 nm at 100 μM, again with 10-20 equiv. alkene (1-2 
mM). The data is shown in Figure 6.2 and Table S1. 
 
6.5.3 Protein expression of GFP-cys 
Chemicals, antibiotics and human serum albumin (HSA) were purchased from Sigma Aldrich. Primers 
were purchased from Integrated DNA Technologies, Inc. and restriction enzymes were obtained from 
New England Biolabs (NEB). E. coli one shot Top 10 Chemically competent cells and E. coli Rosetta 
(DE3) pLysS cells were purchased from Thermo Fisher Scientific Inc. Protocols for the dialysis and 
characterization by ESI-TOF could be found in Section 4.5.4.  
 
Construction of the pEt30A-GFP-cys Expression Vector 
The cysteine codon was introduced by amplifying the coding region of GFP by PCR with the forward 
primer 5’-GCCATGGCTGATATCGGATCCATGAGCAAAGGAGAAGAACTTTT-3’, which includes 
a BamHI restriction site, and reverse primer  
5’-GGTGGTGCTCGAGTGCGGCCGCTTAACATTTGTAGAGCTCATCCATGCCAT-3’, which 
includes a cysteine codon, a stop codon and NotI restriction site. The PCR was conducted with 1 unit of 
Phusion polymerase, 30 ng of genomic DNA as a template, 100 μM dNTP, 10 pmol of the primers, and 
1 × HF Buffer (NEB) in a total volume of 50 μL. The reaction mixture was heated at 98 °C for 30 sec, 
followed by 25 cycles for 20 sec at 98 °C, 30 sec at 58 °C, and 2 min at 72 °C. To ensure complete 
extension, the reaction mixture was incubated at 72 °C for 4 min after the 25 cycles. The PCR product 
was purified with a QIAquick PCR purification kit (Qiagen). Subsequently, the PCR product and the 
plasmid vector pET30A (both 2 μg) were both digested with 20 units of BamHI and NotI for 1 h at 37 °C 
in 1 × NEB 3.1 (NEB) in a total volume of 50 μL. The digestion products were isolated with a QIAquick 
gel extraction kit (Qiagen). The vector DNA (50 ng) was ligated with the GFP-cys insert (10 ng) with T4 
ligase (NEB) overnight at 16 °C. After heat inactivation of T4 (20 min at 65 °C), supercompetent Top 10 
cells were transformed with the ligation mix (25 ng vector) and selected for kanamycin-resistance. The 
plasmids from positive colonies were isolated with the Miniprep DNA purification system (Qiagen) and 
sequences were verified by automated DNA sequencing (RadboudUMC sequence facility).  
 
Expression and purification of GFP-cys  
The pEt30A-GFP-cys expression vector was transformed into E. coli BL21 Rosetta(DE3) pLysS cells and 
selected for chloramphenicol (25 μg/mL) and kanamycin (50 μg/mL) resistance. A single colony was 
inoculated in LB medium (100 mL) supplemented with chloramphenicol (25 μg/mL) and kanamycin (50 
μg/mL) and grown overnight at 37 °C, 200 rpm. 20 mL of overnight culture was used to inoculate 2 × TY 
medium (1 L) supplemented with kanamycin (50 μg/mL). Cultures were incubated at 37 °C until the 
optical density at 600 nm (OD600) reached 0.6-0.8 (3-4 h). Protein expression was then induced by 
addition of 150 μL of 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) for 16 h at 20 °C. Cells were 
harvested at 5000 rpm for 20 min at 4 °C and the pellet was resuspended in 30 mL of lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl and 10 mM imidazole, pH 8.0) and stored at – 80 °C. After the GFP-cys cell 
lysate was thawed at 37 °C, cells were further lysed by ultrasonic disruption (5 × 30 s). The cell lysate was 
clarified by centrifugation (4 °C, 30 min, 13000 rpm) and the supernatant was incubated with 750 μL Ni-
NTA agarose beads (50% suspension, GE Healthcare) for 1 h at 4 °C. The suspension was loaded onto a 
column and washed three times with 3 mL of wash buffer (50 mM NaH2PO4, 300 mM NaCl and 20 mM 
imidazole, pH 8.0). Subsequently, the protein was eluted in six fractions of 1 mL using elution buffer (50 
mM NaH2PO4, 300 mM NaCl and 250 mM imidazole, pH 8.0). All fractions of the affinity purification 
were analyzed on SDS-PAGE gel (Figure S6.1). Finally, the elution fractions 1-5 were combined and 
dialyzed against 3 × 1 L of 1 × PBS buffer (2 × 1 h and 1 × 16 h, 4 °C). Finally, the protein concentration 
was determined at 488 nm (ε = 55 000 M-1 c-1) and concentrated to 50 μM using Amicon® Ultra-15 
Centrifugal Filters (10.000 NMWL). Fractions of GFP-cys were stored with 10% glycerol at -80 °C. The 
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protein yield was 7.2 mg GFP-cys/L bacterial culture. The mass and purity of the protein was confirmed 
by mass spectroscopy (HRMS (ESI+) calcd. 32316 Da, found 32294 Da (Figure S6.2).  
 
Amino-acid Sequence of GFP-cys 
MHHHHHHSSG LVPRGSGMKE TAAAKFERQH MDSPDLGTDD DDKAMADIGS MSKGEELFTG 
VVPILVELDG DVNGHKFSVR GEGEGDATNG KLTLKFICTT GKLPVPWPTL VTTLTYGVQC 
FSRYPDHMKR HDFFKSAMPE GYVQERTISF KDDGTYKTRA EVKFEGDTLV NRIELKGIDF 
KEDGNILGHK LEYNFNSHNV YITADKQKNG IKANFKIRHN VEDGSVQLAD HYQQNTPIGD 
GPVLLPDNHY LSTQSVLSKD PNEKRDHMVL LEFVTAAGIT HGMDELYKC STOP 
 
6.5.4 Dual labeling of HSA and GFP in vitro 
Protocols for the protein modification and SDS-PAGE gels (15%) could be found in Section 4.5.4. For 
the SDS-PAGE gels, the fluorescent signal of the BODIPY dye and the Lissamine rhodamine B dye were 
measured and the proteins on the gel were visualized by staining with colloidal staining. 
 
Protein modification of HSA and GFP separately  
Maleimide coupling of the proteins was performed as described in Section 4.5.4. In short, maleimide-VBA 
8 (5 μL, 10 mM in DMSO, 2 equiv.) was added to a solution of recombinant HSA-cys (50 μM, 500 μL) 
and maleimide-norbornene 9 was added to GFP-cys using the same conditions. The mixtures were 
incubated at 20 °C, 400 rpm for 2 h, whereupon the proteins were dialyzed to 1 × PBS (3 × 1 h). Next, 
HSA-cys, GFP-cys, HSA-VBA and GFP-norbornene (10 μM, 20 μL) were incubated with tetrazine 10 or 
11 (0.2 μL, 10 mM in DMSO, 10 equiv.) for 1 h at 20 °C, 400 rpm. Next, the samples were analyzed by 
SDS-PAGE (Figure 6.4A). For labeling of GFP we observed around 50% modification of the protein, 
which could not be improved by more equivalents of reagents or longer reaction times.  
 
Tandem protein modification of a mixture of HSA-VBA and GFP-norbornene with first tetrazine 11, then 
tetrazine 10 
For the protein modification in tandem, first tetrazine 11 (0.2 μL, 2 mM in DMSO, 2 equiv.) was added 
to a mixture of HSA-VBA and GFP-norbornene (20 μL, 10 μM of both proteins) and shaken for the 
specified time at 20 °C, 400 rpm. Next, tetrazine 10 (0.2 μL, 2 mM in DMSO, 2 equiv.) was added to the 
mixture and the reaction was shaken for 1 h. The positive control contained a mixture of HSA-VBA and 
GFP-norbornene and tetrazine 10 or 11 (0.2 μL, 2 mM in DMSO, 2 equiv.), that was shaken for 1 h. 
Next, the samples were analyzed by SDS-PAGE (Figure 6.4B). 
 
Protein modification using a ratio of tetrazines 10 and 11 
A mixture of HSA-VBA and GFP-norbornene (20 μL, 10 μM of both proteins) was incubated with 
tetrazine 10 or 11 (0.2 μL, 2 mM in DMSO, 2 equiv.) or a premix of 10/11 with increasing amount of 
tetrazine 11 (0.4 μL of 10/11 from 2:2 to 2:100 equiv.) for 60 min at 20 °C, 400 rpm. Next, the samples 
were analyzed by SDS-PAGE (Figure 6.4C). 
 
6.5.5 Dual labeling of the proteasome in living cells 
Protocols for the cell culture, cell lysis and SDS-PAGE analysis (15%) could be found in Section 5.5.2. 
 
Inhibition of the proteasome in living cells with 18 followed by competition in cell lysate 
To determine the concentration of 18 to fully inhibit the β5 subunit, a competition assay with BODIPY-
Ahx3L3VS (Section 5.5.1) was performed as described previously in Section 5.5.2. In short, HeLa cells 
were seeded in a 12-well plate (0.5 × 106 cells/well in 500 μL of growth medium) and directly incubated 
with the indicated concentration of inhibitor 18 (5 μL of 100 × stock in DMSO) for 3 h at 37 °C. The 
cells were washed twice with PBS, and then lysed as described in the general experimental (~30 μL 
digitonin lysis buffer for 1 mg/mL protein lysate). Finally, the lysate (10 μL of 1 mg/mL) was incubated 
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protein yield was 7.2 mg GFP-cys/L bacterial culture. The mass and purity of the protein was confirmed 
by mass spectroscopy (HRMS (ESI+) calcd. 32316 Da, found 32294 Da (Figure S6.2).  
 
Amino-acid Sequence of GFP-cys 
MHHHHHHSSG LVPRGSGMKE TAAAKFERQH MDSPDLGTDD DDKAMADIGS MSKGEELFTG 
VVPILVELDG DVNGHKFSVR GEGEGDATNG KLTLKFICTT GKLPVPWPTL VTTLTYGVQC 
FSRYPDHMKR HDFFKSAMPE GYVQERTISF KDDGTYKTRA EVKFEGDTLV NRIELKGIDF 
KEDGNILGHK LEYNFNSHNV YITADKQKNG IKANFKIRHN VEDGSVQLAD HYQQNTPIGD 
GPVLLPDNHY LSTQSVLSKD PNEKRDHMVL LEFVTAAGIT HGMDELYKC STOP 
 
6.5.4 Dual labeling of HSA and GFP in vitro 
Protocols for the protein modification and SDS-PAGE gels (15%) could be found in Section 4.5.4. For 
the SDS-PAGE gels, the fluorescent signal of the BODIPY dye and the Lissamine rhodamine B dye were 
measured and the proteins on the gel were visualized by staining with colloidal staining. 
 
Protein modification of HSA and GFP separately  
Maleimide coupling of the proteins was performed as described in Section 4.5.4. In short, maleimide-VBA 
8 (5 μL, 10 mM in DMSO, 2 equiv.) was added to a solution of recombinant HSA-cys (50 μM, 500 μL) 
and maleimide-norbornene 9 was added to GFP-cys using the same conditions. The mixtures were 
incubated at 20 °C, 400 rpm for 2 h, whereupon the proteins were dialyzed to 1 × PBS (3 × 1 h). Next, 
HSA-cys, GFP-cys, HSA-VBA and GFP-norbornene (10 μM, 20 μL) were incubated with tetrazine 10 or 
11 (0.2 μL, 10 mM in DMSO, 10 equiv.) for 1 h at 20 °C, 400 rpm. Next, the samples were analyzed by 
SDS-PAGE (Figure 6.4A). For labeling of GFP we observed around 50% modification of the protein, 
which could not be improved by more equivalents of reagents or longer reaction times.  
 
Tandem protein modification of a mixture of HSA-VBA and GFP-norbornene with first tetrazine 11, then 
tetrazine 10 
For the protein modification in tandem, first tetrazine 11 (0.2 μL, 2 mM in DMSO, 2 equiv.) was added 
to a mixture of HSA-VBA and GFP-norbornene (20 μL, 10 μM of both proteins) and shaken for the 
specified time at 20 °C, 400 rpm. Next, tetrazine 10 (0.2 μL, 2 mM in DMSO, 2 equiv.) was added to the 
mixture and the reaction was shaken for 1 h. The positive control contained a mixture of HSA-VBA and 
GFP-norbornene and tetrazine 10 or 11 (0.2 μL, 2 mM in DMSO, 2 equiv.), that was shaken for 1 h. 
Next, the samples were analyzed by SDS-PAGE (Figure 6.4B). 
 
Protein modification using a ratio of tetrazines 10 and 11 
A mixture of HSA-VBA and GFP-norbornene (20 μL, 10 μM of both proteins) was incubated with 
tetrazine 10 or 11 (0.2 μL, 2 mM in DMSO, 2 equiv.) or a premix of 10/11 with increasing amount of 
tetrazine 11 (0.4 μL of 10/11 from 2:2 to 2:100 equiv.) for 60 min at 20 °C, 400 rpm. Next, the samples 
were analyzed by SDS-PAGE (Figure 6.4C). 
 
6.5.5 Dual labeling of the proteasome in living cells 
Protocols for the cell culture, cell lysis and SDS-PAGE analysis (15%) could be found in Section 5.5.2. 
 
Inhibition of the proteasome in living cells with 18 followed by competition in cell lysate 
To determine the concentration of 18 to fully inhibit the β5 subunit, a competition assay with BODIPY-
Ahx3L3VS (Section 5.5.1) was performed as described previously in Section 5.5.2. In short, HeLa cells 
were seeded in a 12-well plate (0.5 × 106 cells/well in 500 μL of growth medium) and directly incubated 
with the indicated concentration of inhibitor 18 (5 μL of 100 × stock in DMSO) for 3 h at 37 °C. The 
cells were washed twice with PBS, and then lysed as described in the general experimental (~30 μL 
digitonin lysis buffer for 1 mg/mL protein lysate). Finally, the lysate (10 μL of 1 mg/mL) was incubated 
with BODIPY-Ahx3L3VS (0.1 μL of 30 μM stock in DMSO, 0.3 μM final concentration) for 1 h at 37 °C 
and the samples were analyzed by SDS-PAGE (Figure S6.3).  
 
Dual protein modification in living cells and subsequent tetrazine ligation in cell lysate 
HeLa cells were seeded in a 6 well plate (~1.5 × 106 cells/well in 750 L of growth medium) and dual 
labeling was performed by incubation of the cells with first with inhibitor 18 (7.5 L of 3 mM stock in 
DMSO, 30 M final concentration) for 3 h, after which inhibitor 17 (7.5 μL of 30 mM stock in DMSO, 
300 M final concentration) was added for an additional 3 h at 37 °C. Labeling of cells with only 17 or 
18 was performed following the dual labeling protocol above and instead replacing the omitted probe with 
a DMSO sample. After removal of the medium, the cells were washed with PBS (3 ×) and the cells were 
lysed as described in the general experimental (50 μL digitonin lysis buffer for a 2 mg/mL protein lysate). 
Next, the HeLa lysate samples (5 L of 2 mg/mL) were incubated with tetrazine 10 (0.5 L of 0.3 mM 
stock in DMSO, 30 μM final concentration), tetrazine 11 (0.5 L of 1.5 mM stock in DMSO, 150 μM 
final concentration) or a 1:5 ratio of 10 and 11 (0.5 L of 0.3:1.5 mM stock of 10/11 in DMSO, 30:150 
μM of 10/11 final concentration) for 1 h at 37 °C. The excess of the tetrazines was removed by 
precipitating the proteins using a standard chloroform/methanol precipitation protocol35. In short, 40 L 
MeOH, 10 L of CHCl3 and 30 L of H2O was added to the samples, and the samples were subsequent 
vortexed and centrifuged for 2 min at 9000 rcf. The upper layer was removed and 100 L MeOH was 
added. The sample was vortexed and centrifuged for 2 min at 9000 rcf. The liquid was removed and the 
pellet was washed twice with 100 L MeOH and air-dried for 10 min. The pellet was taken up in 16 L 
MilliQ and 4 L loading buffer and the samples were analyzed by 12% SDS-PAGE (Figure 6.5C). 
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6.7 Supplementary Table and Figures 
 
Table S6.1 – Second-order rate constants in M-1 s-1 of tetrazines 3a - f with VBA 1, 
norbornene 2 and styrene 4 
 
Tetrazine 
 
1 
 
1.4 ± 0.1[a] 1.4 ± 0.1[a] 0.0094 ± 0.0010[a] 
2 
 
0.00029 ± 0.00005 0.025 ± 0.001 0.00069 ± 0.00009 
3 
 
0.18 ± 0.01 0.18 ± 0.01 0.0017 ± 0.0001 
4 
 
0.011 ± 0.001 0.14 ± 0.01 0.0032 ± 0.0002 
5 
 
0.0052 ± 0.0006 0.70 ± 0.01 0.020 ± 0.002 
6 
 
0.0017 ± 0.0001 0.51 ± 0.02 0.0087 ± 0.0004 
[a] Previously reported in Chapter 3.
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Figure S6.1 – SDS-PAGE gel of His-tag affinity purification of GFP-cys. 
 
 
Figure S6.2 – ESI-TOF mass spectrometry of GFP-cys. A) Deconvoluted total mass spectrum, B) 
Multiply charged ion series. 
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Figure S6.3 – Labeling of the proteasome in living cells with different concentrations of β5-selective 
inhibitor 18, followed by cell lysis and fluorescent modification of the unlabeled proteasome using 
BODIPY-Ahx3L3VS (Section 5.5.1). 
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Figure S6.3 – Labeling of the proteasome in living cells with different concentrations of β5-selective 
inhibitor 18, followed by cell lysis and fluorescent modification of the unlabeled proteasome using 
BODIPY-Ahx3L3VS (Section 5.5.1). 
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Abstract 
 
In Chapter 6, we reported the bioorthogonal inverse electron-demand Diels-Alder (iEDDA) 
reaction of vinylboronic acids (VBAs) that gave exceptionally high reaction rates with tetrazines 
bearing a boron-coordinating pyridyl moiety compared to tetrazines lacking such a substituent. 
Here, we investigated the VBA reactivity in more detail and showed that the reaction rate of the 
tetrazine ligation with VBAs was improved by shifting the equilibrium from the boronic acid to 
the boronate anion. In addition, we explored the second-order rate constants of several tetrazines 
containing potential VBA-coordinating hydroxyl substituents. We observed an increase in rate 
constants of several orders of magnitude compared to tetrazines lacking a hydroxyl substituent. 
Furthermore, the hydroxyl-substituted tetrazines appeared more selective towards VBAs 
compared to the commonly used reactant norbornene and were more stable in an aqueous 
environment than the previously studied tetrazines containing a pyridyl substituent.  
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Abstract 
 
In Chapter 6, we reported the bioorthogonal inverse electron-demand Diels-Alder (iEDDA) 
reaction of vinylboronic acids (VBAs) that gave exceptionally high reaction rates with tetrazines 
bearing a boron-coordinating pyridyl moiety compared to tetrazines lacking such a substituent. 
Here, we investigated the VBA reactivity in more detail and showed that the reaction rate of the 
tetrazine ligation with VBAs was improved by shifting the equilibrium from the boronic acid to 
the boronate anion. In addition, we explored the second-order rate constants of several tetrazines 
containing potential VBA-coordinating hydroxyl substituents. We observed an increase in rate 
constants of several orders of magnitude compared to tetrazines lacking a hydroxyl substituent. 
Furthermore, the hydroxyl-substituted tetrazines appeared more selective towards VBAs 
compared to the commonly used reactant norbornene and were more stable in an aqueous 
environment than the previously studied tetrazines containing a pyridyl substituent.  
 
 
7.1 Introduction 
 
The development of bioorthogonal reactions has advanced tremendously as it allows 
selective modification of biomolecules without interfering with any naturally occurring 
biochemical functionality.1–4 The tetrazine ligation is one of the most popular bioorthogonal 
reactions due to its selectivity and high reaction rates.5–8 So far, several bioorthogonal reactants 
have been developed for this inverse electron-demand Diels-Alder (iEDDA) reaction, such as 
strained alkynes (e.g. bicyclo[6.1.0]nonyne (BCN)),9,10 strained alkenes (e.g. trans-cyclooctene 
(TCO),11,12 norbornene,13 and cyclopropene)14,15 and non-strained alkenes (e.g. primary 
alkenes).16,17 During our efforts to improve the reaction rates of the slow reacting non-strained 
alkenes, we found that vinylboronic acids (VBAs) show impressive second-order rate constants 
(k2) with 3,6-dipyridiyl-s-tetrazines of up to 27 M-1 s-1 in 5% MeOH/PBS (see Chapters 3 and 4). 
The VBAs are readily accessible, biocompatible with cellular components, and suitable for protein 
modification. In Chapter 5, we showed that vinylboronic acids are also suitable for bioorthogonal 
application in living cells. 
 Boronic acids are considered weak electron-donors, due to the inductive effect that is 
caused by the electronegativity difference between boron and carbon, the electronic deficiency of 
boron and the electron-donating oxygens attached to boron.18 Furthermore, boronic acids possess 
a vacant p orbital and are mild organic Lewis acids that form the more electron-rich boronate 
complex after coordination by a Lewis base. In aqueous media, the boronic acids are in 
equilibrium with their negatively charged boronate anion, although the VBAs have high pKa 
values and therefore reside mainly in the trivalent boronic acid form at physiological pH (pH 7.4) 
(Figure 7.1A).18  
 
 
Figure 7.1 – A) The equilibrium between boronic acid 1a and boronate anion 1b in aqueous 
environment. B) Coordination of the nitrogen of the pyridyl ring of tetrazine 2a to the boronic acid of 
VBA 1, affording dihydropyridazine 3 as a single isomer. 
 
In Chapter 6, we reported that VBAs are much more reactive towards pyridyl-substituted 
tetrazines than towards tetrazines lacking a Lewis basic substituent (Figure 7.1B). We observed 
that the high reaction rates of the VBAs towards the pyridyl-substituted tetrazines are caused by 
coordination of the nitrogen of the pyridyl ring to the boron of the VBA, which favors the 
reaction due to the induced proximity and the inductive effect. We used this unique reactivity of 
the VBA to develop two orthogonal tetrazine ligations and perform a simultaneous dual labeling 
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of two proteins containing a VBA and a norbornene moiety. In this chapter, we describe the 
reactivity of the boronic acids and their tetravalent boronate counterparts towards tetrazines in 
more detail by altering the pH of the reaction mixture. In addition, we discuss the reactivity of a 
set of tetrazines bearing conceivable boron-coordinating hydroxyl substituents. We hypothesize 
that the hydroxyl moiety may favor coordination to the VBA and increase the rate constants of 
the tetrazine-VBA ligation. Furthermore, we anticipate that orthogonality of these tetrazines 
towards VBAs could be established as more electron-rich tetrazines react less favorably in the 
general iEDDA reaction with unsubstituted (strained) alkenes. 
 
7.2 Results and Discussion 
 
7.2.1 pH effect on the tetrazine ligation with VBAs 
First, we examined the difference in reactivity of a vinylboronic acid and its boronate 
anion analogue in the iEDDA reaction with a tetrazine (Figure 7.2A). As formation of the 
boronate anion is favored upon increasing pH, we expected that this would also advance the 
tetrazine ligation. We examined the reaction of (E)-phenylvinylboronic acid 1 with 3-phenyl-s-
tetrazine 2b, lacking a boron-coordinating atom, between pH 8 and 11. Indeed, the rate of the 
reaction of VBA 1 with tetrazine 2b increased at higher pH, indicating that the boronate anion is 
more reactive than the boronic acid (Figure 7.2B). As a control experiment, we examined the 
reaction of tetrazine 2b with norbornene 5 in the same buffers and observed that the rate is 
 
 
Figure 7.2 – A) Schematic overview of the pH effect on the reaction of tetrazine 2b with VBA 1 yielding 
dihydropyridazine 4. B) The reactions of tetrazine 2c with VBA 1 (left) and norbornene 5 (right) in 50% 
MeOH and 50% Na2B4O7 buffer, ranging from pH 8 until 11. The reactions were measured at 20 °C by 
following the decay of the tetrazine at 540 nm. [a] Endo/exo 2:1.  
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of two proteins containing a VBA and a norbornene moiety. In this chapter, we describe the 
reactivity of the boronic acids and their tetravalent boronate counterparts towards tetrazines in 
more detail by altering the pH of the reaction mixture. In addition, we discuss the reactivity of a 
set of tetrazines bearing conceivable boron-coordinating hydroxyl substituents. We hypothesize 
that the hydroxyl moiety may favor coordination to the VBA and increase the rate constants of 
the tetrazine-VBA ligation. Furthermore, we anticipate that orthogonality of these tetrazines 
towards VBAs could be established as more electron-rich tetrazines react less favorably in the 
general iEDDA reaction with unsubstituted (strained) alkenes. 
 
7.2 Results and Discussion 
 
7.2.1 pH effect on the tetrazine ligation with VBAs 
First, we examined the difference in reactivity of a vinylboronic acid and its boronate 
anion analogue in the iEDDA reaction with a tetrazine (Figure 7.2A). As formation of the 
boronate anion is favored upon increasing pH, we expected that this would also advance the 
tetrazine ligation. We examined the reaction of (E)-phenylvinylboronic acid 1 with 3-phenyl-s-
tetrazine 2b, lacking a boron-coordinating atom, between pH 8 and 11. Indeed, the rate of the 
reaction of VBA 1 with tetrazine 2b increased at higher pH, indicating that the boronate anion is 
more reactive than the boronic acid (Figure 7.2B). As a control experiment, we examined the 
reaction of tetrazine 2b with norbornene 5 in the same buffers and observed that the rate is 
 
 
Figure 7.2 – A) Schematic overview of the pH effect on the reaction of tetrazine 2b with VBA 1 yielding 
dihydropyridazine 4. B) The reactions of tetrazine 2c with VBA 1 (left) and norbornene 5 (right) in 50% 
MeOH and 50% Na2B4O7 buffer, ranging from pH 8 until 11. The reactions were measured at 20 °C by 
following the decay of the tetrazine at 540 nm. [a] Endo/exo 2:1.  
independent of the pH, as expected. In the absence of an alkene, tetrazine 2b slowly degrades, 
especially in the basic aqueous solutions (Figure S7.1). 
 
7.2.2 Second-order rate constants of VBAs with tetrazines bearing a hydroxyl-substituent 
As we established that the tetrazine ligation proceeds faster when the VBA adopts the 
boronate anion configuration, we next explored the reactivity of a set of tetrazines bearing 
hydroxyl substituents. The coordination of the hydroxyl to the VBA could at physiological pH 
promote the rate of the iEDDA reaction by making the VBA more reactive and favor the 
cycloaddition due to the induced proximity. In addition, as the tested hydroxyl substituents are 
more electron-rich than the pyridine substituent, we expect that the hydroxyl-tetrazines react less 
favorably in the iEDDA cycloaddition with unsubstituted alkenes, such as norbornene, and 
thereby become more selective for reactions with VBAs. 
We synthesized several tetrazines possessing a hydroxyl substituent and compared the k2 
values of the tetrazine ligations of VBA 1 with norbornene 5 (Figure 7.3, Table S1). As previously 
shown in Chapter 3, VBA 1 and norbornene 5 have a comparable rate constant of 1.4 M-1 s-1 
with dipyridyl-s-tetrazine 2a in 50% MeOH/PBS at 20 °C. Methyl pyridyl tetrazine 2c still 
possesses a boron-coordinating atom, although a 10-fold lower k2 value was found for VBA 1 
than for norbornene 5. Phenyl-s-tetrazine 2b also showed a lower rate constant for VBA 1 than 
 
 
Figure 7.3 – The second-order rate constants of tetrazines 2a - i with VBA 1 and norbornene 5 measured 
in 1:1 MeOH/PBS (pH 7.4) at 20 °C, shown on a logarithmic scale. [a] Previously reported in Chapter 3. 
[b] Previously reported in Chapter 6. [c] Endo/exo = 2:1.  
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for norbornene 5. Phenyl methyl tetrazine 2d, the derivative of 2c lacking a coordination atom, 
gave a 100-fold lower rate constant with VBA 1 than with norbornene 5. 
Introducing an aliphatic hydroxyl substituent, as in tetrazine 2e, resulted in a tremendous 
increase in reaction rate compared to the non-hydroxyl-containing tetrazine 2d, giving a k2 value 
of VBA 1 with 2e that is almost 500-fold higher than with 2d. The rate constant of norbornene 5 
with tetrazine 2e slightly dropped compared to the constant with 2d and was 10-fold lower than 
the k2 of 2e with VBA, demonstrating that this hydroxylated tetrazine is more selective towards 
vinylboronic acids. The reaction of VBA 1 with disubstituted hydroxyethyl-substituted tetrazine 
2f and the hydroxyethyl-methyl-substituted tetrazine 2g showed lower rate constants than with 
tetrazine 2e, possibly due to lack of an aromatic substituent on the tetrazine for stacking. Both 
tetrazines 2f and 2g gave again a slightly lower k2 value with norbornene 5 than tetrazine 2d. 
Next, we investigated tetrazines bearing a hydroxyl substituent on the phenyl ring in the 
reaction with VBA and norbornene. The o-hydroxyphenyl tetrazine 2h gave a high rate constant 
of 0.28 M-1 s-1 for VBA 1, almost 1000-fold higher than the k2 of phenyl methyl tetrazine 2d. 
Moreover, the reactivity of 2h with norbornene 5 was 23-fold lower, making this tetrazine very 
selective for VBA. In contrast, m-hydroxyphenyl tetrazine 2i gave a more than 3 orders of 
magnitude decrease in reaction rate compared to the o-hydroxy-substituted 2h, possibly due to 
unfavorable positioning of the hydroxyl for coordination. Important to emphasize is that the 
hydroxyl substitution pattern is not relevant for the tetrazine ligations with norbornene as m-
hydroxy-substituted tetrazine 2i gave a comparable rate constant as the o-hydroxy-substituted 
tetrazine 2h. 
The results above indicate that coordination of a hydroxyl-substituent on the tetrazine to 
the boronic acid has a positive influence on the rate of the iEDDA cycloaddition. Furthermore, 
the hydroxyl-substituted tetrazines are much more selective for VBA than for norbornene. While 
dipyridyl-s-tetrazine gives comparable rate constants for both alkenes, tetrazine 2h gives for 
example a 23-fold higher k2 for VBA 1 than for norbornene 5. To validate that the increase in 
reactivity of the VBAs towards the hydroxyl-substituted tetrazines is indeed caused by 
coordination, we isolated the product of VBA 1 and tetrazine 2h (Scheme 7.1). Since the reaction 
of VBA 1 with tetrazine 2h gave several tautomers of the dihydropyridazine, we oxidized the 
product to the corresponding pyridazine to facilitate characterization of the product. This two-
step reaction gave pyridazine 6 as a single isomer in quantitative yield with the phenyl substituent 
on the 5-position of the pyridazine ring, demonstrating the coordination of the boronic acid to 
the o-hydroxyphenyl ring of tetrazine 2h. 
 
 
Scheme 7.1 – Product formation of the reaction of tetrazine 2h with VBA 1 and subsequent oxidation 
with chloranil, yielding pyridazine 6 as a single isomer in quantitative yield (determined by 1H NMR). i) 
a) 1:1 MeOH/PBS (pH 7.4), 16 h. b) Chloranil, 1:1 MeOH/PBS (pH 7.4), 2 h, quant. (95% isolated 
yield). 
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for norbornene 5. Phenyl methyl tetrazine 2d, the derivative of 2c lacking a coordination atom, 
gave a 100-fold lower rate constant with VBA 1 than with norbornene 5. 
Introducing an aliphatic hydroxyl substituent, as in tetrazine 2e, resulted in a tremendous 
increase in reaction rate compared to the non-hydroxyl-containing tetrazine 2d, giving a k2 value 
of VBA 1 with 2e that is almost 500-fold higher than with 2d. The rate constant of norbornene 5 
with tetrazine 2e slightly dropped compared to the constant with 2d and was 10-fold lower than 
the k2 of 2e with VBA, demonstrating that this hydroxylated tetrazine is more selective towards 
vinylboronic acids. The reaction of VBA 1 with disubstituted hydroxyethyl-substituted tetrazine 
2f and the hydroxyethyl-methyl-substituted tetrazine 2g showed lower rate constants than with 
tetrazine 2e, possibly due to lack of an aromatic substituent on the tetrazine for stacking. Both 
tetrazines 2f and 2g gave again a slightly lower k2 value with norbornene 5 than tetrazine 2d. 
Next, we investigated tetrazines bearing a hydroxyl substituent on the phenyl ring in the 
reaction with VBA and norbornene. The o-hydroxyphenyl tetrazine 2h gave a high rate constant 
of 0.28 M-1 s-1 for VBA 1, almost 1000-fold higher than the k2 of phenyl methyl tetrazine 2d. 
Moreover, the reactivity of 2h with norbornene 5 was 23-fold lower, making this tetrazine very 
selective for VBA. In contrast, m-hydroxyphenyl tetrazine 2i gave a more than 3 orders of 
magnitude decrease in reaction rate compared to the o-hydroxy-substituted 2h, possibly due to 
unfavorable positioning of the hydroxyl for coordination. Important to emphasize is that the 
hydroxyl substitution pattern is not relevant for the tetrazine ligations with norbornene as m-
hydroxy-substituted tetrazine 2i gave a comparable rate constant as the o-hydroxy-substituted 
tetrazine 2h. 
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dipyridyl-s-tetrazine gives comparable rate constants for both alkenes, tetrazine 2h gives for 
example a 23-fold higher k2 for VBA 1 than for norbornene 5. To validate that the increase in 
reactivity of the VBAs towards the hydroxyl-substituted tetrazines is indeed caused by 
coordination, we isolated the product of VBA 1 and tetrazine 2h (Scheme 7.1). Since the reaction 
of VBA 1 with tetrazine 2h gave several tautomers of the dihydropyridazine, we oxidized the 
product to the corresponding pyridazine to facilitate characterization of the product. This two-
step reaction gave pyridazine 6 as a single isomer in quantitative yield with the phenyl substituent 
on the 5-position of the pyridazine ring, demonstrating the coordination of the boronic acid to 
the o-hydroxyphenyl ring of tetrazine 2h. 
 
 
Scheme 7.1 – Product formation of the reaction of tetrazine 2h with VBA 1 and subsequent oxidation 
with chloranil, yielding pyridazine 6 as a single isomer in quantitative yield (determined by 1H NMR). i) 
a) 1:1 MeOH/PBS (pH 7.4), 16 h. b) Chloranil, 1:1 MeOH/PBS (pH 7.4), 2 h, quant. (95% isolated 
yield). 
 
7.2.3 Stability of tetrazines in aqueous environment 
The bioorthogonal application of tetrazines requires that these moieties are stable in 
aqueous solution or biological environment. However, some tetrazines slowly decompose in 
aqueous environment with especially electron-withdrawing substituents destabilizing the aromatic 
ring.19,20 As we expect that the hydroxyl-containing tetrazines described above are more electron-
rich than the pyridyl-substituted tetrazines 2a and 2c, we predicted that the former also have 
superior stability. Therefore, we tested the stability of tetrazines 2a – i in aqueous environment at 
37 °C by measuring the decrease in absorbance of the tetrazines at 540 nm (Figure 7.4, Table 
S2). In addition, we included and evaluated the stability of the tetrazines 2j – l employed in 
Chapter 6. 
As expected, we observed that dipyridyl-s-tetrazines 2a as well as pyrimidyl-substituted 
tetrazines 2j and 2k were rather unstable, with 60 - 85% of the tetrazines being degraded after 12 
hours in 1:9 DMSO/PBS. In contrast, the more electron-rich pyridyl tetrazines 2l and 2c and 
phenyl tetrazines 2b and 2d were more stable, with at least 75% of the tetrazines remaining after 
12 hours. To our delight, all hydroxyl-substituted tetrazines 2e – i were similarly stable and only 
slight degradation was visible after 12 hours. 
 
 
Figure 7.4 – The decrease of absorbance at 540 nm of tetrazines 2a - l in 1:9 DMSO/PBS (pH 7.4) at 37 
°C. The normalized mean with SD is plotted. [a] Measured in 1:1 DMSO/PBS (pH 7.4) as tetrazines 2i 
and 2l were insoluble in 1:9 DMSO/PBS. 
 
7.3 Conclusions and Outlook 
 
To conclude, we compared the reactivity of vinylboronic acids with their negatively 
charged boronate anions in the tetrazine ligation by changing the pH of the reaction buffer. As 
expected, the more electron-rich boronate anion gave a faster reaction with tetrazines. Previously, 
we reported that VBAs are also reactive towards tetrazines containing a pyridine substituent, of 
which the nitrogen coordinates to the boronic acid of the VBA. Here, we synthesized several 
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hydroxyl-substituted tetrazines and showed that the hydroxyl substituent can coordinate to the 
boronic acid and increase the rate constants of the tetrazine ligation with VBAs. Furthermore, 
these new tetrazines were more electron-rich than the pyridyl-substituted tetrazines and gave 
lower rate constants with norbornene compared to VBA. In addition, the hydroxyl-substituted 
tetrazines were found to be more stable in aqueous media and therefore more suitable for 
bioorthogonal application requiring long incubation times compared to the pyridyl-substituted 
tetrazines.  
While the reaction rate of dipyridyl-s-tetrazine with the tested VBA is still a magnitude 
faster, we argue that the developed hydroxyl-substituted tetrazines are a valuable asset for 
bioorthogonal conjugation due to their small size, stability and hydrophilic character. 
Furthermore, the selectivity of the hydroxyl tetrazines towards VBAs renders them potential 
candidates for use in orthogonal bioorthogonal tetrazine ligations for dual labeling of two 
biomolecules, when combined with the reaction of a strained alkene and a tetrazine lacking a 
boron-coordinating substituent.  
 
7.4 Acknowledgements 
 
We would like to thank Jurriaan Heming for the initial experiments on the effect of pH 
on the tetrazine ligation.  
 
7.5 Experimental Section 
 
7.5.1 Synthetic procedures 
General experimental for the synthesis of the small molecules is described in Sections 3.5.1 and 4.5.1. The 
synthesis of 3-phenyl-1,2,4,5-tetrazine 2b and 3-methyl-6-phenyl-1,2,4,5-tetrazine 2d is described in 
Chapter 3, the synthesis of 3-methyl-6-(pyridin-2-yl)-1,2,4,5-tetrazine 2c, 3-phenyl-6-(pyrimidin-2-yl)-
1,2,4,5-tetrazine 2j, 3-methyl-6-(pyrimidin-2-yl)-1,2,4,5-tetrazine 2k and of 3-phenyl-6-(pyridin-2-yl)-
1,2,4,5-tetrazine 2l is reported in Chapter 6. 
 
2-(6-Phenyl-1,2,4,5-tetrazin-3-yl)ethan-1-ol (2e). Benzonitrile (250 μL, 2.42 mmol, 1.0 equiv.) and 3-
hydroxypropionitrile (497 μL, 7.27 mmol, 3.0 equiv.) were added to dioxane and Zn(OTf)2 (176 
mg, 0.48 mmol, 0.2 equiv.) was added. Hydrazine hydrate (1.26 mL, 24.2 mmol, 10.0 equiv.) 
was added dropwise, and the mixture was stirred at 60 °C overnight. After the reaction had cooled 
to rt, NaNO2 (1.0 g, 14.7 mmol, 6.0 equiv.) in H2O (10 mL) was added. Then, the mixture was 
cooled with ice and 1 M HCl was added until the mixture turned pink, the pH < 3 and the 
(toxic) gas evolution stopped. Then, the mixture was extracted with EtOAc until the organic layer 
no longer became a pink color. The combined organic layers were dried over Na2SO4 and the 
volatiles were removed under reduced pressure. The mixture was purified by column chromatography (20 
to 40% EtOAc in heptane), and after the volatiles were removed under reduced pressure the solid was 
dissolved in toluene and filtered. Again, the volatiles were removed under reduced pressure yielding 
tetrazine 2e (158 mg, 32%) as a pink solid. Rf = 0.28 (40% EtOAc in heptane). 1H NMR (400 MHz, 
CDCl3) δ 8.64 – 8.57 (m, 2H), 7.68 – 7.56 (m, 3H), 4.32 (t, J = 5.8 Hz, 2H), 3.64 (t, J = 5.8 Hz, 2H). 
13C NMR (100 MHz, CDCl3) δ 168.4, 164.8, 132.9, 131.8, 129.5, 128.2, 60.2, 37.6. GCMS (9.98 min) 
m/z calcd. for C10H10N4O 202, found = 103 [(M-C3H5N3O)+, 100%], 76 [(M-C4H5N4O)+, 40%]. The 
data agrees with literature.21 
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hydroxyl-substituted tetrazines and showed that the hydroxyl substituent can coordinate to the 
boronic acid and increase the rate constants of the tetrazine ligation with VBAs. Furthermore, 
these new tetrazines were more electron-rich than the pyridyl-substituted tetrazines and gave 
lower rate constants with norbornene compared to VBA. In addition, the hydroxyl-substituted 
tetrazines were found to be more stable in aqueous media and therefore more suitable for 
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7.5.1 Synthetic procedures 
General experimental for the synthesis of the small molecules is described in Sections 3.5.1 and 4.5.1. The 
synthesis of 3-phenyl-1,2,4,5-tetrazine 2b and 3-methyl-6-phenyl-1,2,4,5-tetrazine 2d is described in 
Chapter 3, the synthesis of 3-methyl-6-(pyridin-2-yl)-1,2,4,5-tetrazine 2c, 3-phenyl-6-(pyrimidin-2-yl)-
1,2,4,5-tetrazine 2j, 3-methyl-6-(pyrimidin-2-yl)-1,2,4,5-tetrazine 2k and of 3-phenyl-6-(pyridin-2-yl)-
1,2,4,5-tetrazine 2l is reported in Chapter 6. 
 
2-(6-Phenyl-1,2,4,5-tetrazin-3-yl)ethan-1-ol (2e). Benzonitrile (250 μL, 2.42 mmol, 1.0 equiv.) and 3-
hydroxypropionitrile (497 μL, 7.27 mmol, 3.0 equiv.) were added to dioxane and Zn(OTf)2 (176 
mg, 0.48 mmol, 0.2 equiv.) was added. Hydrazine hydrate (1.26 mL, 24.2 mmol, 10.0 equiv.) 
was added dropwise, and the mixture was stirred at 60 °C overnight. After the reaction had cooled 
to rt, NaNO2 (1.0 g, 14.7 mmol, 6.0 equiv.) in H2O (10 mL) was added. Then, the mixture was 
cooled with ice and 1 M HCl was added until the mixture turned pink, the pH < 3 and the 
(toxic) gas evolution stopped. Then, the mixture was extracted with EtOAc until the organic layer 
no longer became a pink color. The combined organic layers were dried over Na2SO4 and the 
volatiles were removed under reduced pressure. The mixture was purified by column chromatography (20 
to 40% EtOAc in heptane), and after the volatiles were removed under reduced pressure the solid was 
dissolved in toluene and filtered. Again, the volatiles were removed under reduced pressure yielding 
tetrazine 2e (158 mg, 32%) as a pink solid. Rf = 0.28 (40% EtOAc in heptane). 1H NMR (400 MHz, 
CDCl3) δ 8.64 – 8.57 (m, 2H), 7.68 – 7.56 (m, 3H), 4.32 (t, J = 5.8 Hz, 2H), 3.64 (t, J = 5.8 Hz, 2H). 
13C NMR (100 MHz, CDCl3) δ 168.4, 164.8, 132.9, 131.8, 129.5, 128.2, 60.2, 37.6. GCMS (9.98 min) 
m/z calcd. for C10H10N4O 202, found = 103 [(M-C3H5N3O)+, 100%], 76 [(M-C4H5N4O)+, 40%]. The 
data agrees with literature.21 
 
2,2'-(1,2,4,5-Tetrazine-3,6-diyl)bis(ethan-1-ol) (2f). 3-Hydroxypropionitrile (325 μL, 4.76 mmol, 1.0 
equiv.) and 2-pyrimidinecarbonitrile (100 mg, 0.95 mmol, 0.2 equiv.) were dissolved in dioxane 
(2 mL) and Zn(OTf)2 (86 mg, 0.24 mmol, 0.05 equiv.) was added. Hydrazine hydrate (1.15 
mL, 24.8 mmol, 5.0 equiv.) was added dropwise, and the mixture was stirred at 60 °C overnight. 
After the reaction had cooled to rt, NaNO2 (656 mg, 9.51 mmol, 2.0 equiv.) in H2O (5 mL) 
was added. 1 M HCl was added until the mixture turned pink, the pH < 3 and the (toxic) gas 
evolution stopped. Then, the mixture was extracted with EtOAc (ca. 15 ×), the combined 
organic layers were dried over Na2SO4 and the volatiles were removed under reduced pressure. 
The mixture was purified by column chromatography (0 to 5% MeOH in EtOAc), yielding 2f (138 mg, 
17%) as a pink solid. Rf = 0.41 (5% MeOH in EtOAc). 1H NMR (400 MHz, CDCl3) δ 4.28 (t, J = 5.8 
Hz, 2H), 3.59 (t, J = 5.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 169.0, 60.1, 37.6. Tetrazine 2f was 
not visible on mass spectrometry. The data agrees with literature.21 
 
2-(6-Methyl-1,2,4,5-tetrazin-3-yl)ethan-1-ol (2g). 3-Hydroxypropionitrile (342 μL, 5.00 mmol, 1.0 
equiv.) and acetonitrile (783 μL, 15.0 mmol, 3.0 equiv.) were added to dioxane (2 mL) and 
Zn(OTf)2 (363 mg, 1.00 mmol, 0.2 equiv.) was added. Hydrazine hydrate (2.6 mL, 50 mmol, 
10.0 equiv.) was added dropwise and the mixture was stirred at 60 °C overnight. After the 
reaction had cooled to rt, NaNO2 (2.76 g, 40.0 mmol, 8.0 equiv.) in H2O (20 mL) was added. 
The mixture was cooled with ice and 1 M HCl was added until the mixture turned pink, the pH 
< 3 and the (toxic) gas evolution stopped. Then, the aqueous mixture was saturated with HCl and 
extracted with EtOAc (ca. 15 ×). The combined organic layers were dried over Na2SO4, the volatiles were 
removed under reduced pressure. The mixture was purified by column chromatography (40 to 60% 
EtOAc in heptane), yielding tetrazine 2g (184 mg, 26%) as a pink oil. Rf = 0.29 (60% EtOAc in heptane). 
1H NMR (400 MHz, CDCl3) δ 4.25 (t, J = 5.8 Hz, 2H), 3.56 (t, J = 5.7 Hz, 2H), 3.05 (s, 2H), 2.19 (br. 
s, 1H). 13C NMR (100 MHz, CDCl3) δ 168.4, 168.0, 60.1, 37.5, 21.3. GCMS 4.80 min, m/z = 140 
(M+·, 2%, calcd. for C5H8N4O 140), 41 [(M-C3H5N3O)+, 70%]. The data agrees with literature.22  
 
2-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenol (2h). 2-Hydroxybenzonitrile (596 mg, 5.00 mmol, 1.0 
equiv.) was dissolved in dioxane (2 mL) and acetonitrile (783 μL, 15.0 mmol, 3.0 equiv.) and 
Zn(OTf)2 (363 mg, 1.0 mmol, 0.2 equiv.) were added. Hydrazine hydrate (2.6 mL, 50 mmol, 
10.0 equiv.) was added dropwise, and the mixture was stirred at 60 °C overnight. After the 
reaction had cooled to rt, NaNO2 (2.76 g, 40.0 mmol, 8.0 equiv.) in H2O (20 mL) was 
added. The mixture was cooled with ice and 1 M HCl was added until the mixture turned 
pink, the pH < 3 and the (toxic) gas evolution stopped. Then, the mixture was extracted with EtOAc (3 
×), the combined organic layers were washed with brine, dried over Na2SO4, and the volatiles were 
removed under reduced pressure. The mixture was purified by column chromatography (10% EtOAc in 
heptane), yielding tetrazine 2h (147 mg, 16%) as a red solid. Rf = 0.28 (10% EtOAc in heptane). 1H 
NMR (400 MHz, CDCl3) δ 11.11 (s, 1H), 8.65 (dd, J = 8.1, 1.7 Hz, 1H), 7.52 (ddd, J = 8.3, 7.2, 1.7 
Hz, 1H), 7.12 (dd, J = 8.4, 1.1 Hz, 1H), 7.09 (ddd, J = 8.1, 7.2, 1.2 Hz, 1H), 3.12 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 166.8, 165.1, 160.1, 135.2, 128.7, 120.4, 118.9, 114.2, 21.4. GCMS (8.33 min) 
m/z = 188 (M+·, 20%, calcd. for C9H8N4O 188), 119 [(M-C2H3N3)+, 100%]. 
 
3-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenol (2i). 3-Hydroxybenzonitrile (596 mg, 5.00 mmol, 1.0 equiv.) 
was dissolved in dioxane (2 mL) and acetonitrile (783 μL, 15.0 mmol, 3.0 equiv.) and 
Zn(OTf)2 (363 mg, 1.00 mmol, 0.2 equiv.) were added. Hydrazine hydrate (2.6 mL, 50 
mmol, 10.0 equiv.) was added dropwise, and the mixture was stirred at 60 °C overnight. After 
the reaction had cooled to rt, NaNO2 (2.76 g, 40.0 mmol, 8.0 equiv.) in H2O (20 mL) was 
added. The mixture was cooled with ice and 1 M HCl was added until the mixture turned 
pink, the pH < 3 and the (toxic) gas evolution stopped. Then, the mixture was extracted with 
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EtOAc (2 ×), the combined organic layers were washed with brine, dried over Na2SO4, and the volatiles 
were removed under reduced pressure. The mixture was purified by column chromatography (10 to 50% 
EtOAc in heptane), yielding tetrazine 2i (406 mg, 43%) as a red solid. Rf = 0.32 (30% EtOAc in heptane). 
1H NMR (500 MHz, (CD3)2SO) δ 9.93 (s, 1H), 7.91 (ddd, J = 7.7, 1.5, 1.0 Hz, 1H), 7.88 (dd, J = 2.5, 
1.6 Hz, 1H), 7.46 (app. t, J = 7.9 Hz, 1H), 7.06 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 2.99 (s, 3H). 13C NMR 
(125 MHz, (CD3)2SO) δ 167.1, 163.2, 158.1, 133.0, 130.6, 119.5, 118.2, 113.8, 20.8. Tetrazine 2j was 
not visible on mass spectrometry. 
 
2-(6-Methyl-5-phenylpyridazin-3-yl)phenol (6). Tetrazine 2h (10 mg, 53 μmol, 1.0 equiv.) and VBA 1 
(7.9 mg, 53 μmol, 1.0 equiv.) were mixed in MeOH (1.0 mL) and PBS (0.5 mL, pH 7.4) 
and the reaction was stirred for 24 h. Next, chloranil (26 mg, 0.11 mmol, 2.0 equiv.) was 
added and the mixture was stirred for 2 h. H2O was added and the solution was extracted 
with EtOAc (3 ×). The combined organic layers were washed with brine, dried over 
Na2SO4, and the volatiles were removed under reduced pressure. 1H NMR spectroscopy 
indicated that the pyridazine was formed as a single isomer in quantitative yield. The solid 
was purified by column chromatography (20% EtOAc in heptane), yielding pyridazine 6 (13 mg, 95%) as 
a slightly yellow solid. Rf = 0.22 (20% EtOAc in heptane). 1H NMR (500 MHz, CDCl3) δ 7.89 (s, 1H, 
4’-H), 7.74 (dd, J = 8.1, 1.6 Hz, 1H, 6-H), 7.57 – 7.50 (m, 3H, m-Ph and p-Ph), 7.44 – 7.39 (m, 2H, o-
Ph), 7.37 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H, 4-H), 7.12 (dd, J = 8.3, 1.2 Hz, 1H, 3-H), 6.94 (ddd, J = 8.2, 
7.2, 1.3 Hz, 1H, 5-H), 2.71 (s, 3H, CH3). 13C NMR (125 MHz, CDCl3) δ 160.1 (2-C), 159.3 (3’-C), 
156.8 (6’-C), 142.3 (5’-C), 136.6 (1’’-C), 132.4 (4-C), 129.4 (p-Ph), 129.2 (m-Ph), 128.6 (o-Ph), 126.3 
(6-C), 123.1 (4’-C), 119.3 (5-C), 119.1 (3-C), 116.8 (1-C), 21.2 (CH3). HRMS (ESI+) m/z calcd. for 
C17H14N2O [M+H]+ 263.11844, found 263.11728. 
 
7.5.2 Kinetic and stability experiments 
The kinetic experiments described in this chapter were measured at a Spark M10 microplate reader 
(Tecan) at a controlled temperature, with no shaking performed before the start of the measurement. The 
compounds were dissolved in the organic solvent and diluted with the aqueous solution before the 
measurement. The time delay between the addition of the tetrazine and the start of the measurement was 
ca. 20 s. All reactions were performed in triplo or in quadruplo. The kinetic data was analyzed using Prism 
(GraphPad Software, Inc). 
 
pH effect of the tetrazine ligation with vinylboronic acid 
Tetrazine 2b (2.00 mM in MeOH) and alkenes 1 or 5 (20.0 mM in MeOH) were diluted with Na2B4O7 
buffer (50 μM of Na2B4O7, ranging from pH = 8 till pH = 11). After addition of the tetrazine to the 
alkene, the solution had a final concentration of 500 μM tetrazine (1.0 equiv.) and 5.00 mM of alkene (10 
equiv.). The reactions between tetrazines 2b and the alkenes 1 and 5 in 50% MeOH/PBS (pH 7.4) were 
followed on the plate reader at 20 °C, by measuring the absorbance decay of the tetrazine at 540 nm. The 
kinetics were normalized by setting the plateau at the end of the reaction as 0% and the calculated Y0 value 
as 100%. If the reactions did not end in a plateau after the set time, the plateau was set equal to the 
background absorbance of the dihydropyridazine absorption. The normalized decay of the absorbance of 
the tetrazine was plotted against time (min) (Figure 7.2 and S7.1). 
 
Determination of second-order rate constants 
The k2 values of the reactions between the alkenes 1 and 5 and tetrazines 2a – i in 1:1 MeOH/PBS were 
determined as described in Section 3.5.3. The data is shown in Figure 7.3 and Table S7.1. 
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EtOAc (2 ×), the combined organic layers were washed with brine, dried over Na2SO4, and the volatiles 
were removed under reduced pressure. The mixture was purified by column chromatography (10 to 50% 
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not visible on mass spectrometry. 
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(6-C), 123.1 (4’-C), 119.3 (5-C), 119.1 (3-C), 116.8 (1-C), 21.2 (CH3). HRMS (ESI+) m/z calcd. for 
C17H14N2O [M+H]+ 263.11844, found 263.11728. 
 
7.5.2 Kinetic and stability experiments 
The kinetic experiments described in this chapter were measured at a Spark M10 microplate reader 
(Tecan) at a controlled temperature, with no shaking performed before the start of the measurement. The 
compounds were dissolved in the organic solvent and diluted with the aqueous solution before the 
measurement. The time delay between the addition of the tetrazine and the start of the measurement was 
ca. 20 s. All reactions were performed in triplo or in quadruplo. The kinetic data was analyzed using Prism 
(GraphPad Software, Inc). 
 
pH effect of the tetrazine ligation with vinylboronic acid 
Tetrazine 2b (2.00 mM in MeOH) and alkenes 1 or 5 (20.0 mM in MeOH) were diluted with Na2B4O7 
buffer (50 μM of Na2B4O7, ranging from pH = 8 till pH = 11). After addition of the tetrazine to the 
alkene, the solution had a final concentration of 500 μM tetrazine (1.0 equiv.) and 5.00 mM of alkene (10 
equiv.). The reactions between tetrazines 2b and the alkenes 1 and 5 in 50% MeOH/PBS (pH 7.4) were 
followed on the plate reader at 20 °C, by measuring the absorbance decay of the tetrazine at 540 nm. The 
kinetics were normalized by setting the plateau at the end of the reaction as 0% and the calculated Y0 value 
as 100%. If the reactions did not end in a plateau after the set time, the plateau was set equal to the 
background absorbance of the dihydropyridazine absorption. The normalized decay of the absorbance of 
the tetrazine was plotted against time (min) (Figure 7.2 and S7.1). 
 
Determination of second-order rate constants 
The k2 values of the reactions between the alkenes 1 and 5 and tetrazines 2a – i in 1:1 MeOH/PBS were 
determined as described in Section 3.5.3. The data is shown in Figure 7.3 and Table S7.1. 
 
  
Stability of the tetrazines  
The tetrazines 2a – h, 2j and 2k (10 mM in DMSO) were diluted with a preheated solution of 1 × PBS 
(pH 7.4)for a final solution of 1 mM in 1:9 DMSO/PBS at 37 °C. Tetrazines 2i and 2l (10 mM in 
DMSO) were diluted with a preheated solution of DMSO and 1 × PBS for a final solution of 1 mM in 
1:1 DMSO/PBS at 37 °C. The stability of the tetrazines was followed over time at 37 °C, by measuring 
the absorbance decay of the tetrazine at 540 nm. The data was normalized by setting the background 
absorption of 1:9 or 1:1 DMSO/PBS as 0% and the calculated Y0 value as 100%. The data is shown in 
Figure 7.4 and Table S7.2. 
 
7.6 References 
 
[1] Shih, H.-W.; Kamber, D. N.; Prescher, J. A.; Building Better Bioorthogonal Reactions. Curr. 
Opin. Chem. Biol. 2014, 21, 103–111. 
[2] Shieh, P.; Bertozzi, C. R.; Design Strategies for Bioorthogonal Smart Probes. Org. Biomol. Chem. 
2014, 12 (46), 9307–9320. 
[3] King, M.; Wagner, A.; Developments in the Field of Bioorthogonal Bond Forming Reactions - 
Past and Present Trends. Bioconjug. Chem. 2014, 25, 825–839. 
[4] Chen, X.; Wu, Y.-W.; Selective Chemical Labeling of Proteins. Org. Biomol. Chem. 2016, 14 (24), 
5417–5439. 
[5] Šečkutė, J.; Devaraj, N. K.; Expanding Room for Tetrazine Ligations in the in Vivo Chemistry 
Toolbox. Curr. Opin. Chem. Biol. 2013, 17 (5), 761–767. 
[6] Knall, A.-C.; Slugovc, C.; Inverse Electron Demand Diels-Alder (iEDDA)-Initiated Conjugation: 
A (High) Potential Click Chemistry Scheme. Chem. Soc. Rev. 2013, 42 (12), 5131–5142. 
[7] Kozma, E.; Demeter, O.; Kele, P.; Bioorthogonal Fluorescent Labelling of Biopolymers via Inverse 
Electron Demand Diels-Alder Reactions. ChemBioChem 2017, 18, 486–501. 
[8] Oliveira, B. L.; Guo, Z.; Bernardes, G. J. L.; Inverse Electron Demand Diels-Alder Reactions in 
Chemical Biology. Chem. Soc. Rev. 2017, 46 (16), 4895–4950. 
[9] Borrmann, A.; Milles, S.; Plass, T.; Dommerholt, J.; Verkade, J. M. M.; Wiessler, M.; Schultz, C.; 
van Hest, J. C. M.; van Delft, F. L.; Lemke, E. A.; Genetic Encoding of a Bicyclo[6.1.0]nonyne-
Charged Amino Acid Enables Fast Cellular Protein Imaging by Metal-Free Ligation. 
ChemBioChem 2012, 13 (14), 2094–2099. 
[10] Lang, K.; Davis, L.; Wallace, S.; Mahesh, M.; Cox, D. J.; Blackman, M. L.; Fox, J. M.; Chin, J. 
W.; Genetic Encoding of Bicyclononynes and Trans-Cyclooctenes for Site-Specific Protein 
Labeling in Vitro and in Live Mammalian Cells via Rapid Fluorogenic Diels-Alder Reactions. J. 
Am. Chem. Soc. 2012, 134 (25), 10317–10320. 
[11] Blackman, M. L.; Royzen, M.; Fox, J. M.; Tetrazine Ligation: Fast Bioconjugation Based on 
Inverse-Electron-Demand Diels-Alder Reactivity. J. Am. Chem. Soc. 2008, 130 (41), 13518–
13519. 
[12] Selvaraj, R.; Fox, J. M.; Trans-Cyclooctene - a Stable, Voracious Dienophile for Bioorthogonal 
Labeling. Curr. Opin. Chem. Biol. 2013, 17 (5), 753–760. 
[13] Devaraj, N. K.; Weissleder, R.; Hilderbrand, S. A.; Tetrazine-Based Cycloadditions: Application to 
Pretargeted Live Cell Imaging. Bioconjug. Chem. 2008, 19 (12), 2297–2299. 
[14] Patterson, D. M.; Nazarova, L. A.; Xie, B.; Kamber, D. N.; Prescher, J. A.; Functionalized 
Cyclopropenes as Bioorthogonal Chemical Reporters. J. Am. Chem. Soc. 2012, 134 (45), 18638–
18643. 
[15] Yang, J.; Šečkutė, J.; Cole, C. M.; Devaraj, N. K.; Live-Cell Imaging of Cyclopropene Tags with 
Fluorogenic Tetrazine Cycloadditions. Angew. Chem. Int. Ed. 2012, 51 (30), 7476–7479. 
[16] Niederwieser, A.; Späte, A.-K.; Nguyen, L. D.; Jüngst, C.; Reutter, W.; Wittmann, V.; Two-Color 
Glycan Labeling of Live Cells by a Combination of Diels-Alder and Click Chemistry. Angew. 
Chapter 7156
Chem. Int. Ed. 2013, 52 (15), 4265–4268. 
[17] Lee, Y.-J.; Kurra, Y.; Yang, Y.; Torres-Kolbus, J.; Deiters, A.; Liu, W. R.; Genetically Encoded 
Unstrained Olefins for Live Cell Labelling with Tetrazine Dyes. Chem. Commun. 2014, 50, 
13085–13088. 
[18] Hall, D. G.; Boronic Acids, Preparation and Applications in Organic Synthesis, Medicine and 
Materials; WILEY-VCH, Weinheim, 2011. 
[19] Versteegen, R. M.; Rossin, R.; Ten Hoeve, W.; Janssen, H. M.; Robillard, M. S.; Click to Release: 
Instantaneous Doxorubicin Elimination upon Tetrazine Ligation. Angew. Chem. Int. Ed. 2013, 52 
(52), 14112–14116. 
[20] Karver, M. R.; Weissleder, R.; Hilderbrand, S. A.; Synthesis and Evaluation of a Series of 1,2,4,5-
Tetrazines for Bioorthogonal Conjugation. Bioconjug. Chem. 2011, 22 (11), 2263–2270. 
[21] Wu, H.; Yang, J.; Šečkutė, J.; Devaraj, N. K.; In Situ Synthesis of Alkenyl Tetrazines for Highly 
Fluorogenic Bioorthogonal Live-Cell Imaging Probes. Angew. Chem. Int. Ed. 2014, 53 (23), 
5805–5809. 
[22] Yang, J.; Karver, M. R.; Li, W.; Sahu, S.; Devaraj, N. K.; Metal-Catalyzed One-Pot Synthesis of 
Tetrazines Directly from Aliphatic Nitriles and Hydrazine. Angew. Chem. Int. Ed. 2012, 51 (21), 
5222–5225. 
 
  
7Highly Stable and Selective Hydroxyl-Substituted Tetrazines 157
Chem. Int. Ed. 2013, 52 (15), 4265–4268. 
[17] Lee, Y.-J.; Kurra, Y.; Yang, Y.; Torres-Kolbus, J.; Deiters, A.; Liu, W. R.; Genetically Encoded 
Unstrained Olefins for Live Cell Labelling with Tetrazine Dyes. Chem. Commun. 2014, 50, 
13085–13088. 
[18] Hall, D. G.; Boronic Acids, Preparation and Applications in Organic Synthesis, Medicine and 
Materials; WILEY-VCH, Weinheim, 2011. 
[19] Versteegen, R. M.; Rossin, R.; Ten Hoeve, W.; Janssen, H. M.; Robillard, M. S.; Click to Release: 
Instantaneous Doxorubicin Elimination upon Tetrazine Ligation. Angew. Chem. Int. Ed. 2013, 52 
(52), 14112–14116. 
[20] Karver, M. R.; Weissleder, R.; Hilderbrand, S. A.; Synthesis and Evaluation of a Series of 1,2,4,5-
Tetrazines for Bioorthogonal Conjugation. Bioconjug. Chem. 2011, 22 (11), 2263–2270. 
[21] Wu, H.; Yang, J.; Šečkutė, J.; Devaraj, N. K.; In Situ Synthesis of Alkenyl Tetrazines for Highly 
Fluorogenic Bioorthogonal Live-Cell Imaging Probes. Angew. Chem. Int. Ed. 2014, 53 (23), 
5805–5809. 
[22] Yang, J.; Karver, M. R.; Li, W.; Sahu, S.; Devaraj, N. K.; Metal-Catalyzed One-Pot Synthesis of 
Tetrazines Directly from Aliphatic Nitriles and Hydrazine. Angew. Chem. Int. Ed. 2012, 51 (21), 
5222–5225. 
 
  
7.7 Supplementary Figure and Tables 
 
 
 
Figure S7.1 – The degradation of tetrazine 2b in 50% MeOH and 50% Na2B4O7 buffer, ranging from 
pH 8 until 11. The reactions were measured at 20 °C by following the decay of the tetrazine at 540 nm. 
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Table S7.1 – Second-order rate constants in M-1 s-1 of tetrazines 2a - i with VBA 1 and norbornene 5.
 
Entry Tetrazine 
 
1 
 
1.4 ± 0.1[a] 1.4 ± 0.1[a] 
2 
 
0.011 ± 0.001[b] 0.14 ± 0.01[b] 
3 
 
0.064 ± 0.06 0.30 ± 0.02 
4 
 
0.00029 ± 0.00005[b] 0.025 ± 0.001[b] 
5 
 
0.12 ± 0.01 0.010 ± 0.001 
6 
 
0.013 ± 0.001 0.0031 ± 0.0004 
7 
 
0.010 ± 0.001 0.0062 ± 0.0002 
8 
 
0.28 ± 0.01 0.012 ± 0.001 
9 
 
0.00012 ± 0.00002 0.026 ± 0.001 
[a] Previously reported in Chapter 3. [b] Previously reported in Chapter 6. [c] Endo/exo 2:1. 
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Table S7.2 – Stability of tetrazines 2a – l in 1:9 DMSO/PBS (pH 7.4) over time measured at 540 
nm. Mean with SD of proportion intact (%) at 0, 4 and 12 h. 
Entry Tetrazine 0 h 4 h 12 h 
1 
 
100 ± 1 73.6 ± 1.1 41.9 ± 1.6 
2 
 
100 ± 1 70.0 ± 0.4 36.2 ± 0.2 
3 
 
100 ± 1 56.0 ± 0.5 17.4 ± 0.4 
4[a] 
 
100 ± 1 92.6 ± 1.6 88.6 ± 1.0 
5 
 
100 ± 2 93.7 ± 1.0 89.8 ± 1.4 
6 
 
100 ± 1 92.5 ± 0.7 78.8 ± 3.6 
7 
 
100 ± 1 92.9 ± 1.3 83.6 ± 4.3 
8 97.7 ± 0.9 104 ± 1 100 ± 1 
9 
 
100 ± 1 97.3 ± 1.3 92.0 ± 1.0 
10 
 
100 ± 1 88.5 ± 0.5 82.6 ± 0.5 
11 
 
100 ± 1 96.4 ± 1.5 92.0 ± 2.3 
12[a] 
 
100 ± 2 97.0 ± 1.2 96.3 ± 0.7 
[a] Measured in 1:1 DMSO/PBS as the tetrazines 2i and 2l were insoluble in 1:9 DMSO/PBS.
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8.1 Summary 
 
 The research described in this thesis aims to explore non-strained and hydrophilic 
vinylboronic acids (VBAs) as bioorthogonal reactants in the inverse electron-demand Diels-Alder 
(iEDDA) reaction with tetrazines. As reactants are given the name bioorthogonal when they are 
not perturbing the biological systems,1–6 we aimed to explore the reactivity of VBAs towards any 
biological functional group, the stability in aqueous media and toxicity to the biological system. 
Furthermore, as reactions are especially suitable for bioconjugation when they are fast and high 
yielding, we determined the kinetics of the VBA-tetrazine ligations and investigated the unique 
reactivity of the VBAs in more detail.  
 In Chapter 1, an overview of the previously developed bioorthogonal reactants for the 
tetrazine ligation is provided and their biocompatibility and reactivity is discussed. In addition, 
we briefly describe the applications of the tetrazine ligation and highlight their use in orthogonal 
bioorthogonal reactions and in click-to-release reactions. In Chapter 2, we review the recent 
developments in non-catalyzed and metal-catalyzed bioconjugation reactions involving boronic 
acids as well as the biocompatibility of the reactants. We additionally discuss several points of 
attention when using boronic acids in living systems, such as their sensitivity towards oxidation 
and their potential to condensate with naturally occurring diols.  
In Chapter 3, we report our initial studies on the reactivity of several non-strained 
alkenes in the tetrazine ligation with 3,6-dipyridyl-s-tetrazine that led to the discovery of the 
highly reactive vinylboronic acids. The reaction of dipyridyl-s-tetrazine with the fastest VBA 
tested, (E)-(4-methoxyphenyl)vinylboronic acid, showed the formation of a single 
dihydropyridazine, lacking the boronic acid. In Chapter 4, we established that this VBA gave a 
second-order rate constant (k2) of 27 M-1 s-1 with dipyridyl tetrazine derivative in 5% MeOH in 
PBS (pH 7.4). In addition, we showed that this VBA was stable in the presence of common 
biological functionalities and acceptably stable in cell lysate (85% present after 24 hours). We 
demonstrated that the reactants and products of the VBA-tetrazine ligation were not or only 
slightly toxic to living cells at relevant bioconjugation concentrations. In addition, derivatives of 
the VBA were used for the modification and visualization of human serum albumin (HSA) in 
PBS as well as in cell lysate using a fluorescent tetrazine. The clear fluorescent signal on SDS-
PAGE and full conversion of the VBA to the dihydropyridazine, displayed by ESI-TOF, showed 
the biocompatibility of the VBA to the protein and the lysate.  
As complexation of boronic acids to carbohydrates diols on the cell membrane may 
hamper cellular uptake we examined the biocompatibility and the use of VBA in living cells in 
Chapter 5. By comparing covalent inhibitors of the proteasome containing a VBA or the widely 
applied norbornene moiety,7 we observed that only a slightly higher concentration of the VBA-
probe was necessary for complete inhibition of the proteasome. However, this difference was also 
observed in cell lysate, indicating that the vinylboronic acid handle does not significantly hamper 
uptake of the probes into the cell. In addition, the subsequent tetrazine ligation was slightly faster 
for the VBA than the norbornene probe, as expected by the difference in rate constants, 
suggesting that the VBA moiety was intact. It should be noted that the potential condensation of 
the VBAs to biological diols could not be visualized using the tetrazine ligation, as the boronic 
acid is released instantly after the conjugation. Therefore, we cannot demonstrate whether the 
boronic acid gives slight background condensation with biomolecules in and on the cell. 
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PAGE and full conversion of the VBA to the dihydropyridazine, displayed by ESI-TOF, showed 
the biocompatibility of the VBA to the protein and the lysate.  
As complexation of boronic acids to carbohydrates diols on the cell membrane may 
hamper cellular uptake we examined the biocompatibility and the use of VBA in living cells in 
Chapter 5. By comparing covalent inhibitors of the proteasome containing a VBA or the widely 
applied norbornene moiety,7 we observed that only a slightly higher concentration of the VBA-
probe was necessary for complete inhibition of the proteasome. However, this difference was also 
observed in cell lysate, indicating that the vinylboronic acid handle does not significantly hamper 
uptake of the probes into the cell. In addition, the subsequent tetrazine ligation was slightly faster 
for the VBA than the norbornene probe, as expected by the difference in rate constants, 
suggesting that the VBA moiety was intact. It should be noted that the potential condensation of 
the VBAs to biological diols could not be visualized using the tetrazine ligation, as the boronic 
acid is released instantly after the conjugation. Therefore, we cannot demonstrate whether the 
boronic acid gives slight background condensation with biomolecules in and on the cell. 
During our initial studies on the scope of the VBA-tetrazine reaction, we observed that 
vinylboronic acids were especially reactive towards 3,6-dipyridyl-s-tetrazine compared to the 
tested 3-phenyl-s-tetrazine and 3-methyl-6-phenyl-s-tetrazine. These results encouraged us to 
investigate whether we could develop a new set of orthogonal tetrazine ligations using VBA 5 and 
the widely used norbornene 6. Therefore, we investigated the reactivity of VBA 5 with a set of 
other tetrazines containing methyl, phenyl, pyridyl and pyrimidyl substituents as described in 
Chapter 6. We found high k2 values for VBA only with pyridyl-substituted tetrazines and 
demonstrated that coordination of the pyridyl nitrogen to the boronic acid caused this unique 
reactivity. We postulate that the low reactivity of methyl, phenyl and pyrimidyl tetrazines is 
caused by the absence or the lower Lewis basicity of the tetrazine substituents. 
The above observation was of especial interest as some of these tetrazines remain highly 
reactive towards norbornene 6 (Figure 8.1). The difference in rate constant of pyrimidyl phenyl 
tetrazine 2 with norbornene and VBA, for example, was more than 100-fold. We expected this to 
be adequate for a selective reaction of tetrazine 2 with norbornene in the presence of molecules 
containing a VBA moiety. Therefore we performed the dual labeling of two proteins, modified 
with norbornene and VBA, using pyrimidyl phenyl tetrazine 2 and dipyridyl tetrazine 1. As 
dipyridyl tetrazine 1 is equally reactive towards both VBA 5 and norbornene 6, the tetrazine 
ligations could not be performed simultaneously using an equimolar amount of the tetrazines. 
However, by using the tetrazine ligations in tandem or with an optimized ratio of the two 
tetrazines, clear dual labeling could be observed. 
 
 
Figure 8.1 – Color-coded second-order rate constants of tetrazines 1 – 4 with VBA 5 and norbornene 6 
in 1:1 MeOH/PBS, as reported in Chapters 3, 6 and 7, and the ratio between the constants of 5 and 6 is 
given underneath. [a] Endo/exo 2:1. 
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that tetrazines could become more selective towards vinylboronic acids by exchanging the 
electron-poor pyridyl substituents of 1 for more electron-rich substituents still containing a 
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towards VBA 5 than to norbornene 6, while the m-hydroxyphenyl tetrazine 4 was at least three 
orders of magnitude less reactive (Figure 8.1).  
 
8.2 Future Perspectives 
 
8.2.1 New reagents for a faster and more selective VBA-tetrazine ligation 
 One of the challenges in the development of bioorthogonal reactions is the fast kinetics 
needed for in vivo applications.8 The second-order rate constant of the fastest VBA tested, (E)-(4-
methoxyphenyl)vinylboronic acid, with a dipyridyl tetrazine derivative was 27 M-1 s-1, which is a 
medium rate compared to the wide-span of rate constants reported for other bioorthogonal 
tetrazine ligations (k2 between 10-2 and 106).9–11 It is expected that the reactivity of VBA is suitable 
for both in vitro and in vivo applications, as e.g. the equally reactive cyclopropene showed clear 
labeling in mice.12 However, it should be emphasized that trans-cyclooctenes13,14 will presumably 
be more suitable for bioorthogonal reactions in vivo, due to their exceptionally high rate constants 
with tetrazines (k2 between 104 and 106), although their stability in vivo has also been 
challenged.15 
 The reaction rate of the tetrazine ligation with VBAs is especially high when coordination 
between the boronic acid and a Lewis base substituent on the tetrazine is possible, making the 
VBA more reactive and the reaction favorable due to the induced proximity. We expect that the 
discovery of this unique coordination-dependent reactivity of the VBAs opens up the way for 
exciting new tetrazine-VBA reactions with fast kinetics. It would be interesting to explore the 
reactivity of VBAs that allow intramolecular coordination of the boronic acid, such as present in 
7 and 8 (Figure 8.2A). Otherwise, tetrazines with alternative substituents bearing a boron-
coordinating atom could potentially increase the kinetics of the VBA-tetrazine reaction, as in 
tetrazines 9 – 14, whereof 9 was previously employed in a coordination-mediated reaction with 
an alkynyldifluoroborane in organic solvents (Figures 8.2B, C). 
 
 
Figure 8.2 – Proposed structures of new reagents for a VBA-tetrazine ligation with high rate constants. 
 
  In addition to high kinetics, tetrazines that are especially reactive towards VBAs compared 
to other bioorthogonal dienophiles are especially of interest (Chapter 7). So far, the most VBA-
selective tetrazine we developed is o-hydroxyphenyl tetrazine 3, which gave a k2 value that was 23-
fold faster with VBA 5 than with norbornene 6. We expect that the reactivity as well as the 
selectivity of the tetrazines could be further improved when alternative electron-rich substituents 
that can still coordinate to boron, as in tetrazine 12, or multiple coordination sites, as in tetrazine 
13 or 14, are used (Figure 8.2C). 
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  In addition to high kinetics, tetrazines that are especially reactive towards VBAs compared 
to other bioorthogonal dienophiles are especially of interest (Chapter 7). So far, the most VBA-
selective tetrazine we developed is o-hydroxyphenyl tetrazine 3, which gave a k2 value that was 23-
fold faster with VBA 5 than with norbornene 6. We expect that the reactivity as well as the 
selectivity of the tetrazines could be further improved when alternative electron-rich substituents 
that can still coordinate to boron, as in tetrazine 12, or multiple coordination sites, as in tetrazine 
13 or 14, are used (Figure 8.2C). 
 
8.2.2 Incorporation of VBA probes by the endogenous cellular machinery 
In this thesis, we have established that vinylboronic acids are suitable as bioorthogonal 
reactant for the tetrazine ligation in vitro and in living cells. Many applications using 
bioorthogonal chemistry to study the role of biomolecules require the introduction of the 
functional handle directly into the biomolecule of interest. To this end, the endogenous cellular 
machinery has been used to incorporate unnatural substrates bearing the bioorthogonal handle 
into proteins,16 glycans17 and DNA/RNA.18 As the incorporation of a reactive group directly into 
the biomolecules has led to many interesting biological insights, we evaluated whether our VBAs 
could be used for this application.16–18 We presume that the smaller aliphatic VBAs, although they 
possess reduced rate constants, would be more suitable for this incorporation than the frequently 
applied larger aromatic VBAs. In this section, we describe our efforts and future perspectives on 
the incorporation of both aliphatic and aromatic VBAs by the endogenous cellular machinery. 
We initially explored the incorporation of carbohydrates containing a VBA moiety by 
metabolic glycoengineering, which has proved itself useful as tool to study the mechanism of 
incorporation of sugar derivatives into the cell surface and the interactions of cells with other 
cells, viruses and bacteria.17 In this method, functionalized sialic acids or mannosamines, the latter 
being intracellularly converted to sialic acid derivatives, are incorporated in the cell membrane by 
the enzymes of the sialic acid biosynthetic pathway. These enzymes tolerate small alterations of 
the carbohydrate structures allowing the incorporation of certain bioorthogonal reagents, 
including an azide and an alkyne, which were subsequently labeled using the CuAAC, SPAAC or 
Staudinger ligation.19–21 In addition, carbohydrates containing a primary alkene,22,23 
cyclopropene,24,25 or norbornene26 were metabolically incorporated and visualized using the 
tetrazine ligation. 
We investigated the incorporation of sialic acid 17, containing a VBA moiety, by the 
sialic acid biosynthetic pathway onto the cell surface. We further included sialic acid derivatives 
15 and 16 containing a norbornene or a primary alkene as positive controls, as these reactive 
handles were previously successfully employed in glycoengineering (Figure 8.3A). The derivatives 
were added to live cells allowing the incorporation of the sialic acids on the cell surface. 
Subsequently, the tetrazine ligation was performed using a fluorescent tetrazine or biotinylated 
tetrazine, the latter being subsequently labeled with a fluorescent streptavidin in a second step. 
Cell sorting by flow cytometry indicated that incorporation was slightly successful, as low levels of 
labeling by the tetrazines was observed (data not shown). Unfortunately, our results were not 
reproducible, including the experiments with the previously reported carbohydrate derivatives 
containing a norbornene 15 and a primary alkene 16. Furthermore, the fluorescent signal after 
the tetrazine ligations was much lower than the signal after the CuAAC or SPAAC reaction of the 
incorporated azide-containing sialic acid. As we could not reproduce the previously published 
method to incorporate and visualize the norbornene and primary alkene carbohydrates 15 and 16 
onto the cell surface we did not pursue this line of research further.  
Possibly, the incorporation of non-natural amino acids containing a VBA moiety in 
proteins using genetic code expansion of living cells would be a suitable alternative. In this 
approach, an orthogonal tRNA/synthetase pair is used to incorporate unnatural amino acids into 
a protein in response to an amber stop codon on the mRNA.27,28 Two tRNA/synthetase pairs are 
frequently applied, which incorporate a tyrosyl derivative (MjTyrRS/MjtRNATyr) or a pyrrolysine 
derivative (PylRS/tRNAPyl). So far, several non-natural amino acids containing bioorthogonal 
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Figure 8.3 – A) Structures of the synthesized sialic acids 15 – 17 modified with a norbornene, alkene or 
VBA moiety. B) Designed structures of non-natural amino acids 18 – 20 containing a VBA moiety. [a] 
Endo/exo 2:1. 
 
reactants for the tetrazine ligation have been inserted, including norbornene, cyclopropene, TCO, 
BCN and a tetrazine.16 In addition, an unnatural amino acid containing a phenylboronic acid 
moiety has been previously incorporated into several proteins.29–31 We propose that the structures 
of the unnatural amino acid VBA 18 as tyrosyl derivative and the amino acids 19 and 20 as 
pyrrolysine derivatives are suitable for insertion into a protein (Figure 8.3B). Especially the latter 
two are in our interest, as we could use them to investigate the bioorthogonality of the aliphatic 
VBA and compare it to our frequently applied aromatic VBA. 
 
8.2.3 Click-to-release reactions of tetrazines with vinylboronic acids  
The interest in bioorthogonal click-to-release reactions for activation of protected 
biologically relevant molecules in vivo has increased significantly in the last years.32 During the 
iEDDA with VBAs, we observed direct release of the boronic acid and suspected that we could 
use this mechanism as promising starting point for a VBA-based click-to-release strategy. We 
evaluated the reactivity and stability of a set of vinylboronic esters, as shown in Chapter 3, which 
would liberate the boronic ester after the iEDDA. We hypothesized that this boronic ester would 
quickly hydrolyze to boric acid and, possibly by means of a cleavable linker, could liberate an 
activated moiety (Figure 8.4A). Unfortunately, all vinylboronic esters and vinylboronates tested 
so far were not fully stable in aqueous media and gave hydrolysis to the free boronic acid over 
time. We therefore examined an alternative click-to-release method using VBAs by directly 
attaching the leaving group onto the alkene bond (Figure 8.4B).  
As discussed in Chapter 1, the iEDDA of tetrazines with alkenes gives release when a 
leaving group is attached directly, or to the allylic position of the alkene. So far, three different 
classes of dienophiles have been developed for an iEDDA click-to-release reaction, namely 
TCO*,33 vinyl ethers34,35 and oxa/azabenzonorbornadienes36,37 The vinyl ethers are interesting due 
to their small size, however, disappointingly low rate constants were observed with tetrazines.34 
We expected that, by addition of a boronic acid moiety on the vinyl ethers, we would increase the 
reaction rates of these click-to-release reactions. In addition, similar to the vinyl ethers,34,35 we 
expect that the VBA ethers give full release of the alcohol after the iEDDA, of which the 
preliminary results are discussed below. 
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pyrrolysine derivatives are suitable for insertion into a protein (Figure 8.3B). Especially the latter 
two are in our interest, as we could use them to investigate the bioorthogonality of the aliphatic 
VBA and compare it to our frequently applied aromatic VBA. 
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The interest in bioorthogonal click-to-release reactions for activation of protected 
biologically relevant molecules in vivo has increased significantly in the last years.32 During the 
iEDDA with VBAs, we observed direct release of the boronic acid and suspected that we could 
use this mechanism as promising starting point for a VBA-based click-to-release strategy. We 
evaluated the reactivity and stability of a set of vinylboronic esters, as shown in Chapter 3, which 
would liberate the boronic ester after the iEDDA. We hypothesized that this boronic ester would 
quickly hydrolyze to boric acid and, possibly by means of a cleavable linker, could liberate an 
activated moiety (Figure 8.4A). Unfortunately, all vinylboronic esters and vinylboronates tested 
so far were not fully stable in aqueous media and gave hydrolysis to the free boronic acid over 
time. We therefore examined an alternative click-to-release method using VBAs by directly 
attaching the leaving group onto the alkene bond (Figure 8.4B).  
As discussed in Chapter 1, the iEDDA of tetrazines with alkenes gives release when a 
leaving group is attached directly, or to the allylic position of the alkene. So far, three different 
classes of dienophiles have been developed for an iEDDA click-to-release reaction, namely 
TCO*,33 vinyl ethers34,35 and oxa/azabenzonorbornadienes36,37 The vinyl ethers are interesting due 
to their small size, however, disappointingly low rate constants were observed with tetrazines.34 
We expected that, by addition of a boronic acid moiety on the vinyl ethers, we would increase the 
reaction rates of these click-to-release reactions. In addition, similar to the vinyl ethers,34,35 we 
expect that the VBA ethers give full release of the alcohol after the iEDDA, of which the 
preliminary results are discussed below. 
 
 
Figure 8.4 – Possible click-to-release reactions of vinylboronic acids using tetrazines. A) Protected boronic 
ester that releases boric acid and the diol after the tetrazine ligation. B) VBA ether elimination releasing 
boric acid and an alcohol after the tetrazine ligation. 
 
We synthesized VBA 26 containing the ether moiety and its primary alkene derivative 27, 
the latter by following a literature procedure38 (Scheme 8.1). The synthesis of VBA 26 started 
with the etherification of 4-hydroxybenzyl alcohol 21 with trichloroethylene and subsequent 
protection of the aliphatic alcohol of 22. Next, dichlorovinyl ether 23 was treated with n-BuLi 
for elimination of hydrogen chloride and a halogen-lithium exchange that yielded, after 
quenching with water, alkyne 24. Deprotection of the aliphatic alcohol and hydroboration of 
alkyne 25 with pinacolborane yielded VBA pinacol ester 26. In our kinetic experiments, we used 
the pinacol ester as precursor for the free boronic acid as it hydrolyzes quickly in aqueous media 
(see Section 4.2.3).  
 
 
Scheme 8.1 – Synthesis of VBA ether 26 and structure of vinyl ether 27. i) Trichloroethylene, K2CO3, 
DMF, 70 °C, 16 h, 87%. ii) TBSCl, imidazole, DMF, 2 h, quant. iii) n-BuLi, Et2O, -78 °C to -40 °C, 
87%. iv) TBAF, THF, 0 °C, 91%. v) Pinacolborane, RuHClCO(PPh3)3, toluene, 50 °C, 16 h, 76%.  
 
We examined the second-order rate constants of the synthesized alkenes 26 and 27 with 
3,6-dipyridyl-s-tetrazine 1 in 75% MeOH in PBS. As we used the pinacol ester as precursor, we 
incubated ester 26 for 2 h in the solvent mixture for full hydrolysis to the free boronic acid VBA 
ether before measuring its k2 value. VBA 26 gave a 4-fold higher rate constant than vinyl ether 
27, clearly indicating a positive effect of the boronic acid on the reactivity of the alkene (Figure 
8.5A). Unfortunately, the effect of the boronic acid on the reaction of the vinyl ethers is much 
smaller than on styrene and its derivatives, where a 100-fold increase in rate constants was found 
(Chapters 3 and 4). Next, we looked in more detail into the click-to-release reaction of 3,6-
dipyridyl-s-tetrazine 7 and the alkenes 26 and 27 by 1H NMR over time (Figures 8.5B, C). A 
near to complete conversion of VBA ether 26 was observed after 7 days, whereas vinyl ether 27 
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gave around 50% conversion. Both reactions yielded the formation of pyridazine 28 and 4-
hydroxybenzyl alcohol 21, while no intermediates were observed, showing that the release 
reaction is fast for both vinyl ether 27 as well as VBA ether 26. 
The results above provide a promising starting point to use VBAs as reagents in the click-
to-release strategy. We hypothesize that the relatively moderate rate enhancement after addition 
of the boronic acid substituent on the vinyl ether is caused by an increase in electron density of 
the alkene bond, thereby lowering the Lewis acidity of the boronic acid and making it less 
favorable for coordination. We expect, however, that altering the ether substituent to a less 
electron-donating leaving group, such as a carbamate, would benefit the reactivity of the VBA 
towards pyridyl-substituted tetrazines.  
  
 
Figure 8.5 – A) Scheme of the reaction of 3,6-dipyridyl-s-tetrazine 1 with VBA ether 26 and vinyl ether 
27. k2 values are measured in 3:1 MeOH/PBS. B) 1H-NMR study of the reaction between tetrazine 1 (∎) 
and VBA ether 26 (▲) yielding pyridazine 28 () and 4-hydroxybenzyl alcohol 21 (♦) in 3:1 
CD3OD/deuterated PBS. C) Same as B, but then the reaction of 1 with vinyl ether 27 (▼). 
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gave around 50% conversion. Both reactions yielded the formation of pyridazine 28 and 4-
hydroxybenzyl alcohol 21, while no intermediates were observed, showing that the release 
reaction is fast for both vinyl ether 27 as well as VBA ether 26. 
The results above provide a promising starting point to use VBAs as reagents in the click-
to-release strategy. We hypothesize that the relatively moderate rate enhancement after addition 
of the boronic acid substituent on the vinyl ether is caused by an increase in electron density of 
the alkene bond, thereby lowering the Lewis acidity of the boronic acid and making it less 
favorable for coordination. We expect, however, that altering the ether substituent to a less 
electron-donating leaving group, such as a carbamate, would benefit the reactivity of the VBA 
towards pyridyl-substituted tetrazines.  
  
 
Figure 8.5 – A) Scheme of the reaction of 3,6-dipyridyl-s-tetrazine 1 with VBA ether 26 and vinyl ether 
27. k2 values are measured in 3:1 MeOH/PBS. B) 1H-NMR study of the reaction between tetrazine 1 (∎) 
and VBA ether 26 (▲) yielding pyridazine 28 () and 4-hydroxybenzyl alcohol 21 (♦) in 3:1 
CD3OD/deuterated PBS. C) Same as B, but then the reaction of 1 with vinyl ether 27 (▼). 
 
8.3 Concluding Remarks 
  
In this thesis, we introduced vinylboronic acids as bioorthogonal reactants in the tetrazine 
ligation and demonstrated their biocompatibility by using them for protein modification in vitro 
and in living cells. The non-strained VBAs are easily accessible and because of their hydrophilicity, 
low toxicity and stability attractive reactants for bioorthogonal applications. Furthermore, due to 
the unique reactivity of the VBAs, which give especially high rate constants with tetrazines 
bearing a boron-coordinating atom, they are applicable in orthogonal tetrazine ligations for dual 
labeling of two biomolecules in the same system.  
The outlook and scope of the VBA-tetrazine ligation is promising. There is ample room to 
find and explore more selective or faster reactants, to investigate VBA-incorporation into 
biomolecules using the endogenous cellular machinery and to expand on the VBA-based click-to-
release reaction, to name some examples. Over the last years, several bioconjugation reactions 
using boronic acid moieties have been reported and used for chemical modification of 
biomolecules in vitro and in vivo. Developing these boronic acid-based bioconjugation methods is 
challenging as many reactions suffer from reversibility (e.g. boronate ester formation) or toxicity 
of one of the reagents (e.g. metal catalysts). The covalent and catalyst-free reaction between 
vinylboronic acids and tetrazines is therefore a promising new addition for the bioconjugation 
toolbox and provides excellent opportunities of the VBA-tetrazine ligation for future 
bioorthogonal applications. 
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8.5 Experimental Section 
 
8.5.1 Synthetic procedures 
General experimental for the synthesis of the small molecules is described in Sections 3.5.1 and 4.5.1. 
 
(Z)-(4-((1,2-Dichlorovinyl)oxy)phenyl)methanol (22). 4-Hydroxybenzyl alcohol 21 (2.0 g, 16.1 
mmol, 1.0 equiv.) was dissolved in DMF (16 mL) under ambient atmosphere and 
K2CO3 (2.7 g, 19.3 mmol, 1.2 equiv.) was added. Next, the mixture was heated at 
70°C and trichloroethylene (1.8 mL, 19.3 mmol, 1.2 equiv.) was added dropwise. 
After the mixture was stirred at 70 °C overnight, it was cooled down to rt, H2O (20 mL) was added and 
the mixture was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine, 
dried over Na2SO4, and the volatiles were removed under reduced pressure. As there was still water 
present, the product was resuspended in H2O and extracted with Et2O (3 × 15 mL). The combined 
organic layers were washed with brine and dried over Na2SO4. The volatiles were removed under reduced 
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pressure yielding vinyl ether 22 (3.1 g, 87%) as a dark orange oil. Rf = 0.57 (50% EtOAc in heptane). 1H 
NMR (400 MHz, CDCl3) δ 7.40 – 7.34 (m, 2H), 7.09 – 7.04 (m, 2H), 5.96 (s, 1H), 4.67 (s, 2H). 13C 
NMR (100 MHz, CDCl3) δ 153.3, 140.0, 137.1, 128.6, 117.2, 103.8, 64.7. GCMS 6.68 min, m/z = 218 
(M+, calcd. for C9H8Cl2O2 = 218, 100%), 107 [(M-C7H7O)+, 55%], 77 [(M-C6H5)+, 85%]. 
 
(Z)-t-Butyl((4-((1,2-dichlorovinyl)oxy)benzyl)oxy)dimethylsilane (23). Alcohol 22 (2.0 g, 9.1 mmol, 
1.0 equiv.) was dissolved in dry DMF (16 mL) and the mixture was cooled to 0 
°C. Then, imidazole (750 mg, 11.0 mmol, 1.2 equiv.) and TBSCl (1.7 g, 11.0 
mmol, 1.2 equiv.) were added and the reaction was stirred for 2 h at rt. The 
mixture was diluted with Et2O (20 mL), washed with sat. NH4Cl and brine and dried over Na2SO4. The 
volatiles were removed under reduced pressure yielding TBS ether 23 (3.1 g, quant.) as a slightly yellow 
oil. Rf = 0.32 (10% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H), 7.06 – 6.99 
(m, 2H), 5.94 (s, 1H), 4.72 (s, 2H), 0.94 (s, 9H), 0.10 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 152.7, 
140.2, 137.8, 127.4, 116.9, 103.5, 64.4, 25.9, 18.4, -5.3. GCMS 8.36 min, m/z = 332 (M+, calcd. for 
C15H22Cl2O2Si = 332, <1%), 275 [(M-C11H13O2Si)+, 65%]. 
 
t-Butyl((4-(ethynyloxy)benzyl)oxy)dimethylsilane (24). Dichlorovinyl ether 23 (2.0 g, 5.95 mmol, 1.0 
equiv.) was dissolved in dry Et2O (50 mL) and n-BuLi (15 mL of 1.6 M in hexanes, 
23.8 mmol, 4.0 equiv.) was added dropwise to the mixture. The solution was then 
stirred for 1 h at -78 °C, before the mixture was warmed to -40 °C over the course 
of 1 h and stirred for another 1 h at -40 °C. Next, the mixture was quenched with H2O (10 mL) and 
extracted with Et2O (3 × 15 mL). The combined organic layers were washed with sat. NH4Cl and brine 
and dried over Na2SO4. The volatiles were removed under reduced pressure and the crude product was 
purified using column chromatography (1% EtOAc in heptane), yielding alkyne 24 (1.4 g, 87%) as a dark 
brown oil. Rf = 0.33 (1% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.26 
– 7.23 (m, 2H), 4.71 (s, 2H), 2.07 (s, 1H), 0.94 (s, 9H), 0.09 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 
154.5, 137.9, 127.4, 114.7, 84.7, 64.3, 33.2, 25.9, 18.4, -5.2. GCMS 6.71 min, m/z = 262 (M+, calcd. for 
C15H22O2Si = 262, < 1%), 205 [(M-C11H13O2Si)+, 100%], 131 [(M-C9H7O)+, 100%], 77 [(M-C6H5)+, 
30%]. 
 
(4-(Ethynyloxy)phenyl)methanol (25). TBS ether 24 (1.0 g, 3.8 mmol, 1.0 equiv.) was dissolved in dry 
THF (20 mL) and the mixture was cooled to 0 °C. 1 M TBAF in THF (4.2 mL, 4.2 
mmol, 1.1 equiv.) was added and the mixture was stirred for 30 mins at 0 °C before 
the reaction was quenched with H2O (15 mL). The product was extracted with 
EtOAc (3 × 15 mL) and the combined organic layers were washed with brine and dried over MgSO4. The 
volatiles were removed under reduced pressure and the crude product was purified using column 
chromatography (30% EtOAc in heptane), yielding alcohol 24 (506 mg, 91%) as a dark green solid. Rf = 
0.30 (30% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.36 (m, 2H), 7.30 – 7.27 (m, 
2H), 4.68 (s, 2H), 2.10 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 155.0, 137.3, 128.5, 115.1, 84.5, 64.6, 
33.5. GCMS 4.64 min, m/z = 148 (M+, calcd. for C9H8O2 = 148, 100%), 77 [(M- C6H5)+, 70%]. 
 
(E)-(2-(4-(Hydroxymethyl)phenoxy)vinyl)boronic acid pinacol ester (26). Alkyne 25 (100 mg, 0.68 
mmol, 1.0 equiv.) was dissolved in dry toluene (2 mL) and sparged with N2 
for 10 minutes. Pinacolborane (490 μL, 3.38 mmol, 5.0 equiv.) and 
RuHClCO(PPh3)3 (38 mg, 34 μmol, 0.05 equiv.) were added and the mixture 
was stirred at 50 °C overnight. The mixture was cooled down to rt before the volatiles were removed under 
reduced pressure. The crude product was dissolved in Et2O (10 mL) and washed with sat. NaHCO3 and 
brine, and dried over Na2SO4. The volatiles were removed under reduced pressure and the crude product 
was purified using column chromatography (1 to 10% EtOAc in heptane), yielding VBA 26 (141 mg, 
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pressure yielding vinyl ether 22 (3.1 g, 87%) as a dark orange oil. Rf = 0.57 (50% EtOAc in heptane). 1H 
NMR (400 MHz, CDCl3) δ 7.40 – 7.34 (m, 2H), 7.09 – 7.04 (m, 2H), 5.96 (s, 1H), 4.67 (s, 2H). 13C 
NMR (100 MHz, CDCl3) δ 153.3, 140.0, 137.1, 128.6, 117.2, 103.8, 64.7. GCMS 6.68 min, m/z = 218 
(M+, calcd. for C9H8Cl2O2 = 218, 100%), 107 [(M-C7H7O)+, 55%], 77 [(M-C6H5)+, 85%]. 
 
(Z)-t-Butyl((4-((1,2-dichlorovinyl)oxy)benzyl)oxy)dimethylsilane (23). Alcohol 22 (2.0 g, 9.1 mmol, 
1.0 equiv.) was dissolved in dry DMF (16 mL) and the mixture was cooled to 0 
°C. Then, imidazole (750 mg, 11.0 mmol, 1.2 equiv.) and TBSCl (1.7 g, 11.0 
mmol, 1.2 equiv.) were added and the reaction was stirred for 2 h at rt. The 
mixture was diluted with Et2O (20 mL), washed with sat. NH4Cl and brine and dried over Na2SO4. The 
volatiles were removed under reduced pressure yielding TBS ether 23 (3.1 g, quant.) as a slightly yellow 
oil. Rf = 0.32 (10% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H), 7.06 – 6.99 
(m, 2H), 5.94 (s, 1H), 4.72 (s, 2H), 0.94 (s, 9H), 0.10 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 152.7, 
140.2, 137.8, 127.4, 116.9, 103.5, 64.4, 25.9, 18.4, -5.3. GCMS 8.36 min, m/z = 332 (M+, calcd. for 
C15H22Cl2O2Si = 332, <1%), 275 [(M-C11H13O2Si)+, 65%]. 
 
t-Butyl((4-(ethynyloxy)benzyl)oxy)dimethylsilane (24). Dichlorovinyl ether 23 (2.0 g, 5.95 mmol, 1.0 
equiv.) was dissolved in dry Et2O (50 mL) and n-BuLi (15 mL of 1.6 M in hexanes, 
23.8 mmol, 4.0 equiv.) was added dropwise to the mixture. The solution was then 
stirred for 1 h at -78 °C, before the mixture was warmed to -40 °C over the course 
of 1 h and stirred for another 1 h at -40 °C. Next, the mixture was quenched with H2O (10 mL) and 
extracted with Et2O (3 × 15 mL). The combined organic layers were washed with sat. NH4Cl and brine 
and dried over Na2SO4. The volatiles were removed under reduced pressure and the crude product was 
purified using column chromatography (1% EtOAc in heptane), yielding alkyne 24 (1.4 g, 87%) as a dark 
brown oil. Rf = 0.33 (1% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.26 
– 7.23 (m, 2H), 4.71 (s, 2H), 2.07 (s, 1H), 0.94 (s, 9H), 0.09 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 
154.5, 137.9, 127.4, 114.7, 84.7, 64.3, 33.2, 25.9, 18.4, -5.2. GCMS 6.71 min, m/z = 262 (M+, calcd. for 
C15H22O2Si = 262, < 1%), 205 [(M-C11H13O2Si)+, 100%], 131 [(M-C9H7O)+, 100%], 77 [(M-C6H5)+, 
30%]. 
 
(4-(Ethynyloxy)phenyl)methanol (25). TBS ether 24 (1.0 g, 3.8 mmol, 1.0 equiv.) was dissolved in dry 
THF (20 mL) and the mixture was cooled to 0 °C. 1 M TBAF in THF (4.2 mL, 4.2 
mmol, 1.1 equiv.) was added and the mixture was stirred for 30 mins at 0 °C before 
the reaction was quenched with H2O (15 mL). The product was extracted with 
EtOAc (3 × 15 mL) and the combined organic layers were washed with brine and dried over MgSO4. The 
volatiles were removed under reduced pressure and the crude product was purified using column 
chromatography (30% EtOAc in heptane), yielding alcohol 24 (506 mg, 91%) as a dark green solid. Rf = 
0.30 (30% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.36 (m, 2H), 7.30 – 7.27 (m, 
2H), 4.68 (s, 2H), 2.10 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 155.0, 137.3, 128.5, 115.1, 84.5, 64.6, 
33.5. GCMS 4.64 min, m/z = 148 (M+, calcd. for C9H8O2 = 148, 100%), 77 [(M- C6H5)+, 70%]. 
 
(E)-(2-(4-(Hydroxymethyl)phenoxy)vinyl)boronic acid pinacol ester (26). Alkyne 25 (100 mg, 0.68 
mmol, 1.0 equiv.) was dissolved in dry toluene (2 mL) and sparged with N2 
for 10 minutes. Pinacolborane (490 μL, 3.38 mmol, 5.0 equiv.) and 
RuHClCO(PPh3)3 (38 mg, 34 μmol, 0.05 equiv.) were added and the mixture 
was stirred at 50 °C overnight. The mixture was cooled down to rt before the volatiles were removed under 
reduced pressure. The crude product was dissolved in Et2O (10 mL) and washed with sat. NaHCO3 and 
brine, and dried over Na2SO4. The volatiles were removed under reduced pressure and the crude product 
was purified using column chromatography (1 to 10% EtOAc in heptane), yielding VBA 26 (141 mg, 
76%) as a dark brown oil. Rf = 0.27 (1% EtOAc in heptane). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.31 
(m, 2H), 7.23 (d, J = 13.8 Hz, 1H), 7.07 – 7.02 (m, 2H), 4.88 (d, J = 13.9 Hz, 1H), 4.66 (d, J = 5.7 Hz, 
2H), 1.60 (t, J = 5.9 Hz, 1H), 1.27 (s, 12H). 13C NMR (100 MHz, CDCl3) δ 159.4, 136.6, 128.5, 
118.4, 83.0, 64.8, 24.7, 21.1. No signal was observed for the carbon attached to boron. GCMS 8.90 min, 
m/z = 275 (M+, calcd. for C15H21BO4 = 275, 100%), 77 [(M- C6H5)+, 28%]. 
 
8.5.2 Kinetic experiments 
Determination of second-order rate constants 
The reactions between tetrazine 1 (500 μM) and the alkenes 26 and 27 (10 – 20 equiv.) in 3:1 
MeOH/PBS were followed at 540 nm using a Spark M10 microplate reader (Tecan) at a controlled 
temperature of 20 °C as described in Section 6.5.2. Only the VBA ether 26 was incubated for 2 h in 3:1 
MeOH/PBS prior to the measurement to hydrolyze the pinacol ester. The k2 values were calculated with 
the method described in Section 3.5.3.  
 
1H NMR study of the click-to-release reaction 
The reactions between tetrazine 1 and the alkenes 26 and 27 in 3:1 CD3OD/deuterated PBS were 
followed using 1H NMR (500 MHz). Prior to the start of the tetrazine ligation, pinacol ester 26 (5 mM) 
was incubated in 3:1 CD3OD/deuterated PBS. The hydrolysis of the pinacol ester was followed over time 
and showed full conversion to the free boronic acid within 2 h (data not shown). Next, tetrazine 1 (5.0 
mM) and the deprotected VBA 26 or the vinyl ether 27 (5.0 mM) were mixed 1:1 for a final 
concentration of 2.5 mM and the reactions were followed over time up to 14 days.  
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Chemische biologie is een relatief nieuw veld dat chemie gebruikt om biologische 
systemen te bestuderen en te manipuleren. Een groot deel van het veld richt zich op de 
modificatie van biomoleculen om zo hun rol in hun eigen cellulaire omgeving te kunnen 
bestuderen. Een vrij nieuwe, maar populaire strategie dat geschikt is voor het modificeren van 
verschillende typen biomoleculen, zoals eiwitten, lipiden, (poly)sacharides en nucleïnezuren, 
maakt gebruik van zo-genoemde ‘bio-orthogonale’ chemie. Deze strategie is gebaseerd op het 
inbouwen van een unieke functionele groep in het biomolecuul van belang, dat in een tweede 
stap covalent reageert met een detectie- of affiniteitshandvat door middel van de selectieve 
chemische reactie. Een reactie is bio-orthogonaal als het toegepast kan worden in een biologisch 
systeem zonder deze te beïnvloeden. Zo moeten de reagentia niet-natuurlijke moleculen zijn die 
enkel met elkaar reageren, en dus niet met functionele groepen die voorkomen in biologische 
systemen, en moeten de reagentia en het product niet-toxisch zijn.  Verder moet deze chemische 
modificatie een hoge opbrengst hebben en snel onder fysiologische omstandigheden verlopen. 
Bio-orthogonale reacties worden veel toegepast, bijvoorbeeld om de rol van een biomolecuul te 
onderzoeken in zijn natuurlijke cellulaire omgeving of om bioconjugaten te ontwikkelen voor 
verbeterde medicinale en diagnostische toepassingen. 
Het onderzoek beschreven in dit proefschrift is gericht op het verkennen van 
vinylboorzuren (in het Engels vinylboronic acids, afgekort als VBA's) als bio-orthogonale 
reagentia in de tetrazineligatie (Figuur 9.1). De tetrazineligatie is een reactie tussen de tetrazine en 
een alkyn of een alkeen, dat een covalent verbonden product oplevert. Ondanks het feit dat de 
tetrazineligaties vaak worden toegepast als bio-orthogonale reacties, voldoen veel reactanten niet 
aan de vereisten om ze als volledig bio-orthogonaal te laten gelden. Nieuwe reagentia voor de 
tetrazineligatie die stabieler, beter oplosbaar en/of toegankelijker zijn, vormen aantrekkelijke 
aanvullingen op de bio-orthogonale moleculaire toolbox. In dit werk hebben we vastgesteld dat 
nieuwe hydrofiele vinylboorzuren geschikte, snel reagerende, bio-orthogonale reagentia zijn.  
 
 
Figuur 9.1 – Schematisch overzicht van een bio-orthogonale reactie tussen een vinylboorzuur-
gemodificeerd eiwit en een tetrazine dat gefunctionaliseerd is met een fluorofoor.  
 
Om het onderzoek in de thesis in te leiden, wordt in hoofdstuk 1 een kort overzicht 
gegeven van de meest gebruikte bio-orthogonale reacties. Verder worden de eerder ontwikkelde 
bio-orthogonale reagentia voor de tetrazineligatie geïntroduceerd en hun reactiviteit en 
geschiktheid voor gebruik in biologische systemen beschreven. Daarnaast noemen we de 
toepassingen van de tetrazineligatie in het kort en benadrukken we het gebruik ervan in systemen 
waarbij meerdere bio-orthogonale reacties tegelijkertijd gebruikt kunnen worden. In hoofdstuk 2 
beschrijven we de recente ontwikkelingen van reacties met biomoleculen waarbij (vinyl)boorzuren 
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betrokken zijn. We bediscussiëren de geschiktheid van de boorzuren voor gebruik in biologische 
systemen en hun mogelijke ongewilde nevenreacties in biologische systemen.  
In hoofdstuk 3 rapporteren we onze initiële studies naar de reactiviteit van verschillende 
alkenen in de tetrazineligatie die leidde tot de ontdekking van de zeer reactieve vinylboorzuren. 
Omdat reacties vooral geschikt zijn voor bioconjugatie wanneer ze snel en hoogproductief zijn, 
hebben we de kinetiek van de VBA-tetrazineligaties bepaald en de unieke reactiviteit van de 
VBA's in meer detail onderzocht. De snelste reactie, tussen een tetrazine met pyridyl-
substituenten en een vinylboorzuur met een 4-methoxyfenyl-substituent op het alkeen, gaf een 
enkel dihydropyridazine-product, zonder de boorzuur. In hoofdstuk 4 hebben we de bio-
orthogonaliteit van de vinylboorzuren verder onderzocht. De VBA's zijn stabiel in waterige media 
en reageren niet met algemene biologische functionele groepen. Bovendien zijn de reactanten en 
producten van de VBA-tetrazineligatie niet, of slechts in lichte mate, toxisch, voor levende cellen 
bij de relevante concentraties. Uiteindelijk hebben we aangetoond dat de VBA-tetrazineligatie 
geschikt is om een eiwit te modificeren en visualiseren. 
Omdat vinylboorzuren mogelijke ongewilde nevenreacties kunnen geven in biologische 
systemen, zoals complexvorming met polysachariden op het celmembraan, hebben we de 
toepasbaarheid van VBA's in levende cellen in hoofdstuk 5 onderzocht. Hiervoor vergeleken we 
de eigenschappen van gesynthetiseerde enzymremmers van het proteasoom die een VBA of een 
andere veel toegepaste bio-orthogonale groep bevatten. Het enzym kon gevisualiseerd worden in 
de cellen door een fluorescente tetrazine toe te voegen. Tot onze tevredenheid namen we waar dat 
de VBA na uren in de cel nog intact was en de opname van de enzymremmer niet significant 
werd belemmerd door de boorzuur.  
Tijdens ons onderzoek beschreven in hoofdstuk 3-5 merkten we op dat VBA's 
voornamelijk snel reageren met pyridyl-gesubstitueerde tetrazines en minder reactief zijn met 
tetrazines zonder een pyridyl substituent. Om dit verder te onderzoeken hebben we in hoofdstuk 
6 de snelheid van de reacties van VBA's met een set andere tetrazines onderzocht. Van de geteste 
tetrazines, reageerden VBA's echter enkel snel met de pyridyl-gesubstitueerde tetrazines. We 
hebben aangetoond dat de hoge reactiviteit tussen deze twee moleculen kan worden 
toegeschreven aan coördinatie van de pyridyl-stikstof aan de boorzuur. De unieke reactiviteit van 
de VBA's hebben we vervolgens gebruikt om twee verschillende eiwitten te visualiseren in één 
biologisch systeem. Hoewel deze dubbele tetrazineligatie uitgevoerd kon worden door te variëren 
in de verhoudingen en incubatietijden van de verschillende tetrazine reagentia, was het nadelig 
dat de pyridyl-gesubstitueerde tetrazines ook snel reageren met de gebruikte gespannen alkeen. 
Daarom hebben we in hoofdstuk 7 nieuwe tetrazines ontwikkeld die selectiever zijn voor VBA's 
door de tetrazine te functionaliseren met elektronenrijke substituenten en functionele groepen die 
aan de boorzuur kunnen coördineren. Elektronenrijke tetrazines reageren minder snel met 
gespannen alkenen waardoor selectiviteit voor VBAs kan worden verkregen. De meest selectieve 
tetrazine, met een o-hydroxyfenyl substituent, reageerde bijna net zo snel met de VBA als de 
tetrazine met pyridylsubstituenten, terwijl het 23 maal sneller reageerde met de VBA dan met het 
andere geteste bio-orthogonale reagens. In hoofdstuk 8 worden, naast de Engelse samenvatting, 
de reikwijdte en de veelbelovende vooruitzichten van de VBA-tetrazineligatie beschreven.  
 
De Nederlandse samenvatting van het onderzoek beschreven in deze thesis is op enkele punten 
gesimplificeerd omwille van de begrijpelijkheid voor niet-chemici. Zie voor meer details de Engelse 
samenvatting in hoofdstuk 8 en natuurlijk de andere hoofdstukken van dit proefschrift. 
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betrokken zijn. We bediscussiëren de geschiktheid van de boorzuren voor gebruik in biologische 
systemen en hun mogelijke ongewilde nevenreacties in biologische systemen.  
In hoofdstuk 3 rapporteren we onze initiële studies naar de reactiviteit van verschillende 
alkenen in de tetrazineligatie die leidde tot de ontdekking van de zeer reactieve vinylboorzuren. 
Omdat reacties vooral geschikt zijn voor bioconjugatie wanneer ze snel en hoogproductief zijn, 
hebben we de kinetiek van de VBA-tetrazineligaties bepaald en de unieke reactiviteit van de 
VBA's in meer detail onderzocht. De snelste reactie, tussen een tetrazine met pyridyl-
substituenten en een vinylboorzuur met een 4-methoxyfenyl-substituent op het alkeen, gaf een 
enkel dihydropyridazine-product, zonder de boorzuur. In hoofdstuk 4 hebben we de bio-
orthogonaliteit van de vinylboorzuren verder onderzocht. De VBA's zijn stabiel in waterige media 
en reageren niet met algemene biologische functionele groepen. Bovendien zijn de reactanten en 
producten van de VBA-tetrazineligatie niet, of slechts in lichte mate, toxisch, voor levende cellen 
bij de relevante concentraties. Uiteindelijk hebben we aangetoond dat de VBA-tetrazineligatie 
geschikt is om een eiwit te modificeren en visualiseren. 
Omdat vinylboorzuren mogelijke ongewilde nevenreacties kunnen geven in biologische 
systemen, zoals complexvorming met polysachariden op het celmembraan, hebben we de 
toepasbaarheid van VBA's in levende cellen in hoofdstuk 5 onderzocht. Hiervoor vergeleken we 
de eigenschappen van gesynthetiseerde enzymremmers van het proteasoom die een VBA of een 
andere veel toegepaste bio-orthogonale groep bevatten. Het enzym kon gevisualiseerd worden in 
de cellen door een fluorescente tetrazine toe te voegen. Tot onze tevredenheid namen we waar dat 
de VBA na uren in de cel nog intact was en de opname van de enzymremmer niet significant 
werd belemmerd door de boorzuur.  
Tijdens ons onderzoek beschreven in hoofdstuk 3-5 merkten we op dat VBA's 
voornamelijk snel reageren met pyridyl-gesubstitueerde tetrazines en minder reactief zijn met 
tetrazines zonder een pyridyl substituent. Om dit verder te onderzoeken hebben we in hoofdstuk 
6 de snelheid van de reacties van VBA's met een set andere tetrazines onderzocht. Van de geteste 
tetrazines, reageerden VBA's echter enkel snel met de pyridyl-gesubstitueerde tetrazines. We 
hebben aangetoond dat de hoge reactiviteit tussen deze twee moleculen kan worden 
toegeschreven aan coördinatie van de pyridyl-stikstof aan de boorzuur. De unieke reactiviteit van 
de VBA's hebben we vervolgens gebruikt om twee verschillende eiwitten te visualiseren in één 
biologisch systeem. Hoewel deze dubbele tetrazineligatie uitgevoerd kon worden door te variëren 
in de verhoudingen en incubatietijden van de verschillende tetrazine reagentia, was het nadelig 
dat de pyridyl-gesubstitueerde tetrazines ook snel reageren met de gebruikte gespannen alkeen. 
Daarom hebben we in hoofdstuk 7 nieuwe tetrazines ontwikkeld die selectiever zijn voor VBA's 
door de tetrazine te functionaliseren met elektronenrijke substituenten en functionele groepen die 
aan de boorzuur kunnen coördineren. Elektronenrijke tetrazines reageren minder snel met 
gespannen alkenen waardoor selectiviteit voor VBAs kan worden verkregen. De meest selectieve 
tetrazine, met een o-hydroxyfenyl substituent, reageerde bijna net zo snel met de VBA als de 
tetrazine met pyridylsubstituenten, terwijl het 23 maal sneller reageerde met de VBA dan met het 
andere geteste bio-orthogonale reagens. In hoofdstuk 8 worden, naast de Engelse samenvatting, 
de reikwijdte en de veelbelovende vooruitzichten van de VBA-tetrazineligatie beschreven.  
 
De Nederlandse samenvatting van het onderzoek beschreven in deze thesis is op enkele punten 
gesimplificeerd omwille van de begrijpelijkheid voor niet-chemici. Zie voor meer details de Engelse 
samenvatting in hoofdstuk 8 en natuurlijk de andere hoofdstukken van dit proefschrift. 
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